<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>384</serviceExecutionTime><Trial id="10166"><TitleDisplay>Dose Study of ACAM-2000 Smallpox Vaccine in Previously Vaccinated Adults</TitleDisplay><TitleOfficial>The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM-2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">H-400-003</Identifier><Identifier type="NCT">NCT00053482</Identifier></Identifiers><Indications><Indication id="1270">Variola virus infection</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ACAM-2000</Name><Drug id="41400">ACAM-2000</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Dryvax</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="41400">ACAM-2000</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18751">Acambis plc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="41400" type="Drug"><TargetEntity id="328985" type="siDrug">Smallpox (Vaccinia) Vaccine, Live</TargetEntity></SourceEntity><SourceEntity id="18751" type="Company"><TargetEntity id="5000002676" type="organizationId">Sanofi Pasteur Holding Ltd</TargetEntity></SourceEntity><SourceEntity id="1270" type="ciIndication"><TargetEntity id="B03" type="ICD10"></TargetEntity><TargetEntity id="050.9" type="ICD9"></TargetEntity><TargetEntity id="10041197" type="MEDDRA"></TargetEntity><TargetEntity id="D012899" type="MeSH"></TargetEntity><TargetEntity id="-1532547108" type="omicsDisease"></TargetEntity><TargetEntity id="868" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="18751">Acambis plc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="12364">Live attenuated viral vaccine</Class><Class id="12378">Prophylactic vaccine</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="596">Injectable formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Dose Comparison</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>357</PatientCountEnrollment><DateStart>2003-01-31T00:00:00Z</DateStart><DateEnd type="actual">2003-03-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-15T04:23:33Z</DateChangeLast><DateAdded>2008-04-21T13:35:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Sanofi Pasteur Inc.</Affiliation><Name>Medical Director</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Have a history of previous smallpox vaccination more than 10 years previous to the date of screening and presence of a vaccination scar&lt;/li&gt;&lt;li&gt;Females must not be pregnant, lactating and must agree to use an effective form of birth control for the 30 days following vaccination or  unable to bear children&lt;/li&gt;&lt;li&gt;Agree to be available for the entire study and agree to comply with all requirements&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Children of one year of age or younger in the household or be in close contact&lt;/li&gt;&lt;li&gt;Smallpox vaccination within 10 years&lt;/li&gt;&lt;li&gt;Known or suspected HIV infection, primary immunodeficiency disorder, leukemia, lymphoma, or current radiation treatment or use of immunosuppressive or anti-neoplastic drugs or have a household member or intimate contact with the conditions listed above&lt;/li&gt;&lt;li&gt;Renal disease&lt;/li&gt;&lt;li&gt;Current or past history of eczema or a household member or direct contact who has eczema&lt;/li&gt;&lt;li&gt;Known allergy or past allergic reactions to latex gloves or to antibiotics which include neomycin, streptomycin, chlortetracycline, and polymyxin B&lt;/li&gt;&lt;li&gt;Known allergy or past allergic reaction to blood products&lt;/li&gt;&lt;li&gt;Known allergy to cidofovir or sulfa-containing drugs&lt;/li&gt;&lt;li&gt;History of allergic phenomena following smallpox vaccination in the past, including urticaria, erythema multiforme, or Stevens-Johnson syndrome&lt;/li&gt;&lt;li&gt;Transfusion of blood or treatment with any blood product&lt;/li&gt;&lt;li&gt;Current or history of drug or alcohol abuse&lt;/li&gt;&lt;li&gt;Innoculation with any other live vaccine or participating in another drug or vaccine trial within 30 days of enrollment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax Smallpox Vaccine</Description><Timeframe>Days 0 to 30 post-vaccination</Timeframe></Measure><Measure><Description>Participants With &gt;/= four-fold Increase in Plaque-Reduction Neutralization Test (PRNT50) Titers Post-vaccination With ACAM2000 or Dryvax Smallpox Vaccine</Description><Timeframe>Days 0 to 30 post-vaccination</Timeframe></Measure><Measure><Description>Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax Smallpox Vaccine</Description><Timeframe>Days 0 to 30 post-vaccination</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a phase II study to determine the minimum dose of &lt;ulink linkType="Drug" linkID="41400"&gt;ACAM-2000&lt;/ulink&gt; needed to produce a cutaneous reaction in at least 90% of a population of healthy adults who were previously vaccinated against smallpox.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The main objectives of this study were to compare the safety and tolerability of four dose levels of &lt;ulink linkType="Drug" linkID="41400"&gt;ACAM-2000&lt;/ulink&gt; and a standard dose of Dryvax in healthy adults at least 28 years of age and previously vaccinated to smallpox. Safety and tolerability was to be determined by examination of the local cutaneous reaction, adverse events, physical examinations, vital signs, structured interviews, and laboratory analysis.
The study was designed also to determine the immunogenicity by comparing the following:
&lt;br/&gt;The proportion of subjects at each dose level who developed a major cutaneous reaction.&lt;br/&gt;The proportion of subjects in each treatment group who developed neutralizing antibodies, including the fold-increase in antibody titer between baseline and day-30 sera; and the geometric mean vaccinia neutralizing antibody titer on day-30.&lt;br/&gt;Determine the minimum dose of &lt;ulink linkType="Drug" linkID="41400"&gt;ACAM-2000&lt;/ulink&gt; that is calculated to produce a major cutaneous reaction in at least 90% of a population of healthy adults who had a history of smallpox vaccination.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>PRA International</Name><Address1>Lenexa</Address1><Address2>Kansas</Address2><Address3>66219</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Bio-Kinetic Clinical Applications</Name><Address1>Springfield</Address1><Address2>Missouri</Address2><Address3>65802</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Memorial Hospital of Rhode Island Division of Infectious Diseases</Name><Address1>Pawtucket</Address1><Address2>Rhode Island</Address2><Address3>02860</Address3><CountrySubDivision code="RI">Rhode Island</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00053482</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2003-04-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2003-01-30T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-04-21T13:35:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="119687"><TitleDisplay>Therapeutic Effects of Telmisartan and Irbesartan on Hypertensive Patients With Overt Diabetic Nephropathy</TitleDisplay><TitleOfficial>Therapeutic effects of telmisartan and irbesartan on hypertensive patients with overt diabetic nephropathy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000001470</Identifier></Identifiers><Indications><Indication id="178">Hypertension</Indication></Indications><BiomarkerNames><BiomarkerName id="118" role="Therapeutic effect marker" type="Genomic;Proteomic">Albumin</BiomarkerName><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="153" role="Therapeutic effect marker" type="Biochemical">High-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="429" role="Therapeutic effect marker" type="Biochemical">N,N-dimethylarginine</BiomarkerName><BiomarkerName id="442" role="Therapeutic effect marker" type="Biochemical">Malondialdehyde</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2083" role="Therapeutic effect marker" type="Genomic;Proteomic">Protein S100-A6</BiomarkerName><BiomarkerName id="2358" role="Therapeutic effect marker" type="Biochemical">Urea nitrogen</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="12516" role="Therapeutic effect marker" type="Proteomic">Urinary protein</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>irbesartan</Name><Drug id="4469">irbesartan</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>telmisartan</Name><Drug id="5051">telmisartan</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4469">irbesartan</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1007327">Yokohama City University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="5051">telmisartan</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1007327">Yokohama City University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4469" type="Drug"><TargetEntity id="176436" type="siDrug">Irbesartan</TargetEntity></SourceEntity><SourceEntity id="5051" type="Drug"><TargetEntity id="195173" type="siDrug">Telmisartan</TargetEntity></SourceEntity><SourceEntity id="1007327" type="Company"><TargetEntity id="4296562607" type="organizationId">Public University Corporation Yokohama City University</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"></TargetEntity><TargetEntity id="D006973" type="MeSH"></TargetEntity><TargetEntity id="-369992864" type="omicsDisease"></TargetEntity><TargetEntity id="240" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="64" type="Action"><TargetEntity id="3578" type="Mechanism">Anti-Angiotensin II</TargetEntity></SourceEntity><SourceEntity id="788" type="Action"><TargetEntity id="67" type="Mechanism">Angiotensin AT1 Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1007327">Yokohama City University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="64">Angiotensin II receptor antagonist</Action><Action id="788">Angiotensin II AT-1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2657">Antihypertensive</Class><Class id="2659">Cardioprotectant</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2008-11-01T00:00:00Z</DateStart><DateEnd type="actual">2014-03-01T00:00:00Z</DateEnd><DateChangeLast>2015-09-19T03:03:21Z</DateChangeLast><DateAdded>2013-04-09T06:16:28Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Yokohama City University Graduate School of Medicine Department of Cardiorenal Medicine; 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, JAPAN</Affiliation><Email>tamukou@med.yokohama-cu.ac.jp</Email><Name>Kouichi Tamura</Name></Contact><Contact type="Public contact"><Affiliation>Yokohama City University Graduate School of Medicine Department of Medical Science; 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, JAPAN</Affiliation><Name>Kazukai Uchino</Name><Phone>045-787-2634</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Type 2 diabetes&lt;/li&gt;&lt;li&gt;Mild-to-moderate hypertension (clinic systolic BP &gt; 130 mmHg, clinic diastolic BP &gt; 80 mmHg or on antihypertensive drugs)&lt;/li&gt;&lt;li&gt;Urinary protein excretion &gt; 0.3 g daily, or urinary protein concentartion &gt; 300 mg/g urinary creatinine on spot urine examination&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pregnant women, or women suspected of being pregnant&lt;/li&gt;&lt;li&gt;Hyperkalemia&lt;/li&gt;&lt;li&gt;History of hypersensitivity to&lt;ulink linkType="Drug" linkID="5051"&gt;telmisartan&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="4469"&gt;irbesartan&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Severe liver disorder, or severe biliary atresia&lt;/li&gt;&lt;li&gt;Severe hypertension (clinic BP &gt; 180/100 mmHg)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Clinical blood pressure</Description></Measure><Measure><Description>Ambulatory blood pressure monitoring: mean blood pressure, day-night variation, short-term blood pressure/heart rate variability, LF/HF</Description></Measure><Measure><Description>Renal function: eGFR, urinary protein/albuminon excretion, urinary urea nitrogen, urinary type 4 collagen</Description></Measure><Measure><Description>Glucose metabolism: fasting blood glucose, fasting insulin resistance index (IRI), Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR)</Description></Measure><Measure><Description>Lipid metabolism: total cholesterol, LDL, HDL, triglycerides (TG)</Description></Measure><Measure><Description>Renin-angiotensin system, inflammatory and oxidative stress markers: plasma renin activity (PRA), urinary angiotensinigen, HMW-adiponectin, advanced glycation end product (AGE), malondialdehyde (MDA)- linear discriminant analyses (LDA), asymmetric dimethylarginine (ADMA), cathecholamine</Description></Measure><Measure><Description>Vascular function: ankle-brachial index/brachial-ankle pulse wave velocity (ABI/baPWV)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to compare &lt;ulink linkType="Drug" linkID="5051"&gt;telmisartan&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="4469"&gt;irbesartan&lt;/ulink&gt; concerning blood pressure profile including short-term blood pressure variability and metabolic profile in 60 patients with hypertension with type 2 overt diabetic nephropathy [&lt;ulink linkType="Reference" linkID="1400675"&gt;1400675&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would include two groups:&lt;br/&gt;Group A: patients would receive  qd &lt;ulink linkType="Drug" linkID="5051"&gt;telmisartan&lt;/ulink&gt; 20 mg    for 24 weeks, and dosage may be modulated accroding to the clinical parameters (&lt;ulink linkType="Drug" linkID="5051"&gt;telmisartan&lt;/ulink&gt; 20 to 80 mg daily). &lt;br/&gt;Group B: patients would receive qd  &lt;ulink linkType="Drug" linkID="4469"&gt;irbesartan&lt;/ulink&gt; 50 mg   for 24 weeks, and dosage may be modulated accroding to the clinical parameters (&lt;ulink linkType="Drug" linkID="4469"&gt;irbesartan&lt;/ulink&gt; 50 to 200 mg daily).&lt;br/&gt;Target blood pressure level would be  below 130/80 mmHg in both groups  [&lt;ulink linkType="Reference" linkID="1400675"&gt;1400675&lt;/ulink&gt;]. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hypertension</Disease><PatientSegments><PatientSegment><PatientSegment id="1">Subjects with Primary/Essential Hypertension</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="14">Subjects with comorbid conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="104">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="107">Subjects with hypertension</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="113">Subjects with diabetic nephropathy</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7708">Subjects with Diabetes/Diabetic Nephropathy</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7709">Subjects with Hypertensive Nephropathy</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11420">Subjects with Proteinuria/Albuminuria</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Diabetic complication</Disease><PatientSegments><PatientSegment><PatientSegment id="8443">Subjects with Diabetic Nephropathy</PatientSegment><SubSegments><SubSegment id="8445">Subjects with overt nephropathy</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8468">Hypertensive diabetic subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000001470</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="5">Clinic/office BP</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="141"><Endpoint>Assessment of Arterial Stiffness &amp; Antiatherogenic Markers</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="142">Ankle-brachial index (ABI) [Ankle-Arm Blood Pressure Test]</SubEndpoint><SubEndpoint disease="Hypertension" id="145">Brachial-ankle pulse wave velocity (baPWV)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="165"><Endpoint>Assessment of Insulin Levels</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="166">Assessment of fasting insulin</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="171"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="173">Adiponectin</SubEndpoint><SubEndpoint disease="Hypertension" id="192">Malondialdehyde (MDA)</SubEndpoint><SubEndpoint disease="Hypertension" id="199">Asymmetric dimethylarginine [ADMA]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="211"><Endpoint>Assessment of Insulin Sensitivity</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="215">Homeostatic model assessment (HOMA) Index</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="222"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="223">Assessment of Total Cholesterol</SubEndpoint><SubEndpoint disease="Hypertension" id="224">Triglyceride levels (TG)</SubEndpoint><SubEndpoint disease="Hypertension" id="225">HDL-C (High-density lipoprotein cholesterol)</SubEndpoint><SubEndpoint disease="Hypertension" id="226">LDL-C (Low-density lipoprotein cholesterol)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="237"><Endpoint>Assessment of Renin, Angiotensin, Aldosterone (RAS) Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="241">Angiotensin II</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="242"><Endpoint>Assessment of Renal Function</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="243">Assessment of Blood Urea Nitrogen (BUN)</SubEndpoint><SubEndpoint disease="Hypertension" id="251">Urinary albumin excretion/albuminuria</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="245"><Endpoint>Assessment of Glomerular Filtration Rate (GFR)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="255"><Endpoint>Assessment of Urinary Protein Excretion/Proteinuria</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1362"><Endpoint>Assessment of Insulin Levels</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1363">Assessment of fasting insulin</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1412"><Endpoint>Assessment of Insulin Sensitivity</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1416">Homeostasis model assessment (HOMA)- insulin sensitivity index (HOMA-I, HOMA-IR)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1423"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1451"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1452">Assessment of Total Cholesterol</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1453">Triglyceride levels (TG)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1454">HDL-C (High-density lipoprotein cholesterol)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1455">LDL-C (Low-density lipoprotein cholesterol)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1514"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1345">Assessment of fasting blood glucose</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1566"><Endpoint>Assessment of Arterial Stiffness &amp; Antiatherogenic Markers</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1567">Ankle-brachial index (ABI) [Ankle-Arm Blood Pressure Test]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1579"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="6734">Assessment of heart rate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1580"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1581">Ambulatory Blood Pressure (ABP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1606"><Endpoint>Assessment of Renal Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1609"><Endpoint>Assessment of Glomerular Filtration Rate (GFR)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Diabetic complication" id="11200"><Endpoint>Assessment of Insulin Sensitivity</Endpoint><SubEndpoints><SubEndpoint disease="Diabetic complication" id="11202">Homeostasis model assessment (HOMA)- insulin sensitivity index (HOMA-I, HOMA-IR)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Diabetic complication" id="11216"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Diabetic complication" id="11219">Adiponectin/adipokines</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Diabetic complication" id="11247"><Endpoint>Assessment of Vascular Endothelial Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Diabetic complication" id="11251"><Endpoint>Assessment of Renal Function</Endpoint><SubEndpoints><SubEndpoint disease="Diabetic complication" id="11261">Urinary albumin excretion/albuminuria</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Diabetic complication" id="11254"><Endpoint>Assessment of Glomerular Filtration Rate (GFR)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Diabetic complication" id="11278"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Diabetic complication" id="11279">Assessment of Total Cholesterol</SubEndpoint><SubEndpoint disease="Diabetic complication" id="11280">Triglyceride levels (TG)</SubEndpoint><SubEndpoint disease="Diabetic complication" id="11281">HDL-C (High-density lipoprotein cholesterol)</SubEndpoint><SubEndpoint disease="Diabetic complication" id="11282">LDL-C (Low-density lipoprotein cholesterol)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Diabetic complication" id="11338"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Diabetic complication" id="11180">Assessment of fasting blood glucose</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Diabetic complication" id="11379"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Diabetic complication" id="11380">Ambulatory Blood Pressure (ABP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="43878"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="6836">RAAS biomarkers</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="45104"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1571">Assessment of pulse wave velocity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hypertension" id="45431"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="161">Assessment of fasting blood glucose</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="End stage renal disease" id="22509"><Endpoint>Assessment of Urinary Protein Excretion/Proteinuria</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22511">Assessment of proteinuria/albuminuria/macroalbuminuria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22514"><Endpoint>Assessment of Renal Function</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22508">Assessment of Blood Urea Nitrogen (BUN)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22521"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22522">Assessment of asymmetric dimethylarginine(ADMA)</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22532">Assessment of other inflammatory/oxidative stress markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22534"><Endpoint>Assessment of Immune Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22535"><Endpoint>Assessment of Blood Glucose Levels</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22538">Assessment of insulin</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22539"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22540">Assessment of blood pressure</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22541">Assessment of renin-angiotensin aldosterone system(RAAS)</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22542">Assessment of vascular structure/function</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22543"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="45626"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22536">Assessment of glucose level</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="46155"><Endpoint>Assessment of Glomerular Filtration Rate (GFR)</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22506">Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hypertension" id="1"><Criterion>Subjects with Primary/Essential Hypertension</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="5">Subjects with mild/stage 1 (JNC 6) hypertension</SubCriterion><SubCriterion disease="Hypertension" id="6">Subjects with moderate/stage 2 (JNC 6) hypertension</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hypertension" id="79"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion><Inclusion disease="Hypertension" id="126"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="134">Subjects with macroalbuminuria/proteinuria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="587"><Criterion>Subjects with Diabetic Complications</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="588">Subjects with diabetic nephropathy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="619"><Criterion>Subjects with Hypertension</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="620">Primary/essential hypertension</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="647"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="654">Subjects with macroalbuminuria/proteinuria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="683"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="687">Subjects on/treated with other antihypertensives</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Diabetic complication" id="6952"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="6954">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Diabetic complication" id="6963"><Criterion>Subjects with Overt Nephropathy</Criterion></Inclusion><Inclusion disease="Diabetic complication" id="6981"><Criterion>Hypertensive Diabetic Subjects</Criterion></Inclusion><Inclusion disease="End stage renal disease" id="17664"><Criterion>Subjects with Diabetes/Diabetic Nephropathy</Criterion></Inclusion><Inclusion disease="End stage renal disease" id="17665"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17666">Subjects with hypertensive nephropathy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17687"><Criterion>Subjects with Proteinuria/Albuminuria</Criterion></Inclusion><Inclusion disease="Hypertension" id="33436"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="55">Subjects co-morbid with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33962"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="648">Subjects with abnormal serum creatinine</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hypertension" id="1"><Criterion>Subjects with Primary/Essential Hypertension</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="6">Subjects with stage 2 (JNC 6) hypertension</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="125"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Hypertension" id="222"><Criterion>Subjects with Electrolyte Imbalances</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="223">Hyperkalemia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="225"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="911"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="928"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="930">Subjects co-morbid with electrolyte/metabolic imbalance</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="983"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="990">Hypersensitivity/contraindications to study medication/device</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diabetic complication" id="8529"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="8530">Subjects co-morbid with biliary disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diabetic complication" id="8587"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="8588">Subjects co-morbid with electrolyte/metabolic imbalance</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diabetic complication" id="8618"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="8619">Hypersensitivity/contraindications to study medication/device</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17519"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17522"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17527"><Criterion>Subjects with Fluid/Electrolyte Imbalance</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17531"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17553"><Criterion>Subjects with Contraindications to Study Procedure</Criterion></Exclusion><Exclusion disease="Diabetic complication" id="26280"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Diabetic complication" id="8559">Subjects with severe hypertension</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="26281"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1577">Subjects with severe hypertension</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-09T06:16:28Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="123047"><TitleDisplay>Comparative Study of Efficacy of Osveral and Desferal</TitleDisplay><TitleOfficial>Comparative study of efficacy of Osveral and Desferal in major thalassemia patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT201112118370N1</Identifier></Identifiers><Indications><Indication id="2371">Thalassemia major</Indication></Indications><BiomarkerNames><BiomarkerName id="1051" role="Therapeutic effect marker" type="Genomic;Proteomic">Ferritin</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>deferasirox</Name><Drug id="19300">deferasirox</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>deferoxamine mesylate</Name><Drug id="45417">deferoxamine mesylate</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="19300">deferasirox</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1057376">Kermanshah University of Medical Sciences</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="45417">deferoxamine mesylate</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1057376">Kermanshah University of Medical Sciences</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="19300" type="Drug"><TargetEntity id="280627" type="siDrug">Deferasirox</TargetEntity></SourceEntity><SourceEntity id="1057376" type="Company"><TargetEntity id="5035551657" type="organizationId">Kermanshah University of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="2371" type="ciIndication"><TargetEntity id="2433" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="47096" type="Action"><TargetEntity id="2881" type="Mechanism">Anti-Ferritin</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1057376">Kermanshah University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="47096">Ferritin inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="105">Chelating agent</Class><Class id="1545">Anticancer</Class><Class id="1546">Blood system agent</Class><Class id="1748">Fungicide</Class><Class id="2557">Iron chelator</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="743">Granule</Technology><Technology id="596">Injectable formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>202</PatientCountEnrollment><DateStart>2010-12-22T00:00:00Z</DateStart><DateChangeLast>2017-05-10T12:02:51Z</DateChangeLast><DateAdded>2013-04-26T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Imam Reza Hospital, Kermanshah Kermanshah Kermanshah 00988314276334</Affiliation><Name>Reza Akramipoor</Name></Contact><Contact type="Public contact"><Affiliation>Kermanshah University Of Medical Sciences; Shahid Beheshti Blvd Kermanshah Kermanshah Iran, Islamic Republic Of</Affiliation><Email>Hkawosi@kums.acir</Email><Name>Farid Najafi</Name><Phone>988318375424</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age  &gt; 2 years&lt;/li&gt;&lt;li&gt;Type of disease, major thalassemia or intermediate that have complete medical file&lt;/li&gt;&lt;li&gt;Serum ferritin, when reaches upper than 1000&lt;/li&gt;&lt;li&gt;Number of injections, if patient has injected more than 10 times or volume of blood injection is more than 100 cc/kg&lt;/li&gt;&lt;li&gt;Creatinin, should not be more than normal range&lt;/li&gt;&lt;li&gt;Patients should be negative of HIV, HBV, HCV&lt;/li&gt;&lt;li&gt;Liver enzymes should be less than 5 times of normal range&lt;/li&gt;&lt;li&gt;Cellular blood count (CBC) should be in normal range&lt;/li&gt;&lt;li&gt;Patients should not have any cardiac problem and should not use any cardiac drugs and patients should have EF &gt; 55% and LVEDE&amp;lt; 40cc/m2 in echocardiography&lt;/li&gt;&lt;li&gt;Patients should not have visual and auditory problems&lt;/li&gt;&lt;li&gt;Patients should not have any proteinuria in urine analysis (Pr/Cr should not be more than 0.6 mg in random urine sampling&lt;/li&gt;&lt;li&gt;Preferentiality, pregnant or lactiferous women should not take part in this study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Increase of creatinine, if creatinine gets upper normal range (for age) in study or gets more than 33% of basic creatinin rate (before beginning of study)&lt;/li&gt;&lt;li&gt;Occurrence of cardiac diseases according to annual checking (control)&lt;/li&gt;&lt;li&gt;Occurrence of visual and auditory problems according to annual checking&lt;/li&gt;&lt;li&gt;If serologic tests of HIV or hepatitis gets positive according to annual checking; Increase of liver enzymes more than 5 times of the normal range&lt;/li&gt;&lt;li&gt;Occurrence of pancytopenia, including platelet count less than 150000/mm3 or exact count of PMN less than1500/ mm -In conditions of nausea, sever vomiting   and  irresponseness to antiemetics  and hydration by physicians; In occurrences of sever dermal rashes  and  lack of recovery or progressive increase of them&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Serum ferritin by blood test</Description><Timeframe>1 month</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Dermatological, gastrointestinal, liver and renal complications: blood test and examination by physician</Description><Timeframe>Monthly</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to compare  the efficacy of &lt;ulink linkType="Drug" linkID="19300"&gt;Osveral&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="45417"&gt;Desferal&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1407726"&gt;1407726&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive Osveral 10 to 40 mg/kg/day or  Desferal 20 to 40 mg/kg/day [&lt;ulink linkType="Reference" linkID="1407726"&gt;1407726&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Dr. Mohammad Kermanshahi Hospital</Name><Address1>Kermanshah</Address1><Address2>Kermanshah</Address2><CountrySubDivision>Kermanshah</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Dr. Reza Akramipour</Name></Contact></Contacts></Site><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Anemia</Disease><PatientSegments><PatientSegment><PatientSegment id="7527">Subjects with Thalassemia</PatientSegment><SubSegments><SubSegment id="7530">Subjects with beta thalassemia major/cooley's anemia</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT201112118370N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Anemia" id="17205"><Endpoint>Assessment of iron status</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17206">Assessment of serum ferritin</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Anemia" id="17263"><Endpoint>Assessment of Co-morbidity</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Anemia" id="14374"><Criterion>Subjects with Thalassemia</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14377">Subjects with beta thalassemia major/cooley's anemia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="14408"><Criterion>Subjects co-morbid with cardiovascular disease/disorder</Criterion></Inclusion><Inclusion disease="Anemia" id="14431"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14432">Subjects with normal/acceptable iron levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="33342"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14433">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="33976"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14429">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Anemia" id="11815"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Anemia" id="11817"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11824"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="26321"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11844">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Anemia" id="11845">Subjects with abnormal/unacceptable renal function</SubCriterion><SubCriterion disease="Anemia" id="11847">Subjects with abnormal/unacceptable hematological functions</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2012-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>13.32 Months</EnrollmentPeriod><EnrollmentRate>15.17 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2017-05-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="12782"><TitleDisplay>A Study to Evaluate Tapentadol (CG-5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine</TitleDisplay><TitleOfficial>A Randomized, Withdrawal, Active- and Placebo-controlled, Double-blind, Multicenter, Phase III Trial Assessing Safety and Efficacy of Oral CG-5503 (Tapentadol) PR in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">761101</Identifier><Identifier type="NCT">NCT00472303</Identifier><Identifier type="Other">2006-004997-28</Identifier><Identifier type="Other">KF5503/15</Identifier><Identifier type="Other">KF5503/15-R331333-PAI-3013</Identifier></Identifiers><Indications><Indication id="3211">Cancer pain</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tapentadol (sustained release, pain) J&amp;J PRD/Grunenthal</Name><Drug id="56791">tapentadol (sustained release, pain) J&amp;J PRD/Grunenthal</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>morphine</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="56791">tapentadol (sustained release, pain) J&amp;J PRD/Grunenthal</Drug><IndicationsPioneer><Indication id="3211">Cancer pain</Indication></IndicationsPioneer><Companies><Company><Company id="16587">Grunenthal GmbH</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="29481">Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="16587" type="Company"><TargetEntity id="4296790654" type="organizationId">Gruenenthal GmbH</TargetEntity></SourceEntity><SourceEntity id="29481" type="Company"><TargetEntity id="5037652982" type="organizationId">Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</TargetEntity></SourceEntity><SourceEntity id="3211" type="ciIndication"><TargetEntity id="G89.3" type="ICD10"></TargetEntity><TargetEntity id="10058019" type="MEDDRA"></TargetEntity><TargetEntity id="-301829128" type="omicsDisease"></TargetEntity><TargetEntity id="6" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="293" type="Action"><TargetEntity id="271" type="Mechanism">mu-Opioid Agonists</TargetEntity><TargetEntity id="5725" type="Mechanism">mu-Opioid Positive Allosteric Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>65</NumberOfSites><CompaniesSponsor><Company id="16587">Grunenthal GmbH</Company></CompaniesSponsor><CompaniesCollaborator><Company id="29481">Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="293">Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="285">Norepinephrine uptake inhibitor</Class><Class id="2946">Analgesic</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="660">Oral sustained release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>622</PatientCountEnrollment><DateStart>2007-07-31T00:00:00Z</DateStart><DateEnd type="actual">2012-06-30T00:00:00Z</DateEnd><DateChangeLast>2019-03-25T07:07:38Z</DateChangeLast><DateAdded>2008-06-03T15:35:30Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Clinic of Anaesthesiology and Pain Management, AKH Vienna</Affiliation><Name>Hans Georg Kress, Dr</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male and non-pregnant, non-lactating female subjects. Sexually active women must be post menopausal, surgically sterile, or practicing an effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization) before entry and throughout the trial. Female subjects of childbearing potential must have a negative pregnancy test at screening&lt;/li&gt;&lt;li&gt;Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the trial and are willing to participate in the trial&lt;/li&gt;&lt;li&gt;Of at least 18 years of age with chronic malignant tumor-related pain with a mean pain intensity (NRS) of &gt;/= 5 points&lt;/li&gt;&lt;li&gt;Subjects who are opioid-naive or pretreated with an equianalgesic dose range equivalent of up to 160 mg  morphine po per day and are dissatisfied with prior treatment&lt;/li&gt;&lt;li&gt;Women must be postmenopausal, surgically sterile, or practicing or agree to practice an effective method of birth control throughout the trial&lt;/li&gt;&lt;li&gt;Expected course of the disease and the pain that would permit compliance with the trial protocol over the entire trial period&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;General:&lt;ul&gt;&lt;li&gt;Subjects will be excluded from the study if they have a history of seizure disorder or epilepsy&lt;/li&gt;&lt;li&gt;History of alcohol or drug abusein the investigators judgment, based on patient history and physical examination&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension&lt;/li&gt;&lt;li&gt;Clinical laboratory values reflecting severe renal insufficiency&lt;/li&gt;&lt;li&gt;Moderate or severe hepatic impairment&lt;/li&gt;&lt;li&gt;Hepatitis B or C, HIV&lt;/li&gt;&lt;li&gt;Inadequate bone marrow reserve&lt;/li&gt;&lt;li&gt;Currently treated with radiotherapy&lt;/li&gt;&lt;li&gt;Pain inducing chemotherapy&lt;/li&gt;&lt;li&gt;Anti-parkinsonian drugs, neuroleptics, monoamine oxidase inhibitors, serotonin norepinephrine reuptake inhibitor (SNRI) or any other analgesic therapy than investigational medication or rescue medication during the trial.&lt;/li&gt;&lt;li&gt;Selective serotonin reuptake inhibitor (SSRI) treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose&lt;/li&gt;&lt;li&gt;The subject has a clinically significant disease other than cancer which in the investigators opinion may affect efficacy or safety assessments eg, significant unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatrical (resulting in disorientation, memory impairment or inability to report accurately) or metabolic disturbances&lt;/li&gt;&lt;li&gt;Any scheduled surgery during the trial&lt;/li&gt;&lt;li&gt;Any painful procedure during the trial that may, in the opinion of the Investigator, affect the efficacy or safety assessments&lt;/li&gt;&lt;li&gt;Employees of the investigator or trial center, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial center, as well as family members of the employees or the investigator&lt;/li&gt;&lt;li&gt;Known to or suspected of not being able to comply with the protocol and the use of tapentadol or morphine&lt;/li&gt;&lt;li&gt;Have received an experimental drug or used an experimental medical device within 30 days before the planned start of treatment&lt;/li&gt;&lt;li&gt;Participation in another trial concurrently&lt;/li&gt;&lt;li&gt;Subjects who have participated in previous trials of tapentadol&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Trial specific:&lt;ul&gt;&lt;li&gt;Life-long history of seizure disorder or epilepsy, or any of the following within one year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or severe traumatic brain injury within 15 years (consisting of &gt;/= 1 of the following: brain contusion, intracranial hematoma, either unconsciousness or post-traumatic amnesia lasting for more than 24 h) or with residual sequelae suggesting transient changes in consciousness&lt;/li&gt;&lt;li&gt;Known history and/or presence of cerebral tumor or cerebral metastases&lt;/li&gt;&lt;li&gt;Subjects with moderately or severely impaired hepatic function, or subjects with an ALT and/or AST greater than three-fold the upper limit of normal&lt;/li&gt;&lt;li&gt;Inadequate baseline bone marrow reserve with WBC count&amp;lt;/= 3 500/microl, platelet count &amp;lt;/= 100000/microl, and hemoglobin level &amp;lt;/= 9.5 g/dl&lt;/li&gt;&lt;li&gt;Subjects with severely impaired renal function&lt;/li&gt;&lt;li&gt;Subjects with hypercalcemia,  ie corrected total serum calcium levels &gt;  3.0 mmol/l&lt;/li&gt;&lt;li&gt;Subjects taking any prohibited concomitant medications (as specified below)&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension (repeated measurements of systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt; 95 mmHg)&lt;/li&gt;&lt;li&gt;Clinically relevant history of hypersensitivity, allergy or contraindications to tapentadol or morphine or any of the excipients&lt;/li&gt;&lt;li&gt;Chronic hepatitis B or C, or HIV, or presence of active hepatitis B or C within the past 3 months. [For Switzerland (amendment 1 to 2) the exclusion criterion reads: chronic hepatitis B or C, or HIV (known by history) , or presence of active hepatitis B or C within the past 3 months]&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of participants scored as responder in maintenance phase: a 'responder' is a participant in the study that: completed 28 days of the maintenance phase, had a numeric rating scale score below 5 on the 11 point scale (where 0 indicates no pain and 10 indicates worst possible pain. This twice daily current pain score was averaged over Day 18 to Day 43, did not use more than 20 mg of rescue medication per day on average in the 28 day maintenance period (from Day 18 to Day 43). A participant that met all 3 of the above-mentioned criteria is counted as a responder, in other words the participant benefited from the assigned drug treatment. A participant that failed to meet only 1 of the 3 criteria is not counted as a responder</Description><Timeframe>Day 18 through Day 43 (end of maintenance phase)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Titration Phase in the Tapentadol Treatment Arm: Participants were asked to record their 'average pain over the last 24 h' pain intensity each evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated 'no pain' and a score of 10 indicated 'pain as bad as you can imagine'</Description><Timeframe>Day 1 through Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Titration Phase in the Morphine Treatment Arm: participants were asked to record their 'average pain over the last 24 h' pain intensity each evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated 'no pain' and a score of 10 indicated 'pain as bad as you can imagine'</Description><Timeframe>Day 1 through Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Maintenance Phase: participants were asked to record their 'average pain over the last 24 h' pain intensity each evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated 'no pain' and a score of 10 indicated 'pain as bad as you can imagine'</Description><Timeframe>Day 18 through Day 43 (end of maintenance phase)</Timeframe></Measure><Measure><Description>Current Pain Intensity Scores, Averaged Per Week, During the Titration Phase in the Tapentadol Arm: participants were asked to record their current pain intensity in the morning and evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated 'no pain' and a score of 10 indicated 'pain as bad as you can imagine'</Description><Timeframe>Day 1 through Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Current Pain Intensity Scores, Averaged Per Week, During the Titration Phase in the Morphine Arm: participants were asked to record their current pain intensity in the morning and evening. Average pain scores are the averages of all scores recorded during the during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated 'no pain' and a score of 10 indicated 'pain as bad as you can imagine'</Description><Timeframe>Day 1 through Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Current Pain Intensity Scores, Averaged Per Week by Treatment, During the Maintenance Phase: participants were asked to record their current pain intensity in the morning and evening. Average pain scores are the averages of all scores recorded during the 3 days prior to re-randomization or during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated 'no pain' and a score of 10 indicated 'pain as bad as you can imagine'</Description><Timeframe>Day 15 through Day 43 (end of maintenance phase)</Timeframe></Measure><Measure><Description>Use of Rescue Medication in the Titration Phase: the number of participants using rescue medication morphine sulfate immediate release 10 mg tablets in the titration phase were counted. This data was captured in an electronic diary. During the trial, morphine immediate release 10 mg was allowed as required without a maximum dose defined. However, participants were only re-randomized if their mean consumption of rescue medication was less or equal to 2 doses (20 mg) per day during the last 3 days of the titration phase)</Description><Timeframe>Day 1 through Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Number of Participants Using Immediate Release Morphine Rescue Medication in the Maintenance Phase: participants were issued morphine 10 mg immediate release medication. The number of participants using rescue medication morphine sulfate immediate release 10 mg tablets in the maintenance phase were counted. This use of morphine immediate release was captured in each participant's electronic diary</Description><Timeframe>Day 15 through Day 43 (end of maintenance phase)</Timeframe></Measure><Measure><Description>The Average Mean Total Daily Dose of Rescue Medication: mean total daily dose of rescue medication morphine sulphate immediate release tablets in milligrams per day (mg/day)</Description><Timeframe>Day 1 (start of titration phase) through Day 43 (end of maintenance phase)</Timeframe></Measure><Measure><Description>Changes in the Short Form 36 Health Survey (SF-36) During the Titration Phase: the Short Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. Low scores on the Physical Component Summary measure indicate limitations in physical functioning, e.g. a high degree of bodily pain and physical limitations etc. For the Mental Component Summary measure, a low score is indicative of frequent psychological distress, social and role disability due to emotional problems etc. The theoretical range for the physical component score is 12.3279 to 59.6503. The theoretical range for the mental component score is 13.5313 to 59.6503. Positive values for changes in the component scores indicate an improvement</Description><Timeframe>Day 1 (start of titration phase); Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Changes in the Short Form 36 Health Survey (SF-36) During the Maintenance Phase: the Short Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. Low scores on the Physical Component Summary measure indicate limitations in physical functioning, eg, a high degree of bodily pain and physical limitations etc. For the Mental Component Summary measure, a low score is indicative of frequent psychological distress, social and role disability due to emotional problems etc. The theoretical range for the physical component score is 12.3279 to 59.6503. The theoretical range for the mental component score is 13.5313 to 59.6503. Positive values for changes in the component scores indicate an improvement</Description><Timeframe>Day 15 (start of maintenance); Day 43 (end of maintenance phase)</Timeframe></Measure><Measure><Description>Change in the EuroQoL (EQ-5D) Health Status Index (United Kingdom Time Trade-off Value Set) Change From Start of Titration to Endpoint Titration: the participant scores the EuroQol-5D. The EuroQoL-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1 = no problems, 2 = some problems, 3 = extreme problems). The responses to the five EQ-5D dimensions are scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating 'full health' and 0 representing dead. A positive change in the mean indicates that during this phase the health status improved. A positive change indicates an improvement in health. The minimal important difference is 0.074 (range -0.011 to 0.140)</Description><Timeframe>Day 1 (start of titration); Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) Titration Phase: EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate better health. The values indicated represent the change from Day 1, a positive value indicates an improvement since the start of treatment</Description><Timeframe>Day 1 (start of titration); Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Change in the EuroQoL (EQ-5D) Health Status Index (United Kingdom Time Trade-off Value Set) Over Time in the Maintenance Phase for Tapentadol and the Placebo Randomized Withdrawal Treatment Arms: The participant scores the EuroQol-5D. The EuroQoL-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1 = no problems, 2 = some problems, 3 = extreme problems). The responses to the five EQ-5D dimensions are scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating 'full health' and 0 representing dead. A negative change in the mean indicates a worsening in health status since the beginning of the maintenance phase. A positive change indicates an improvement in health. The minimal important difference in the Health Status Index is 0.074 (range -0.011 to 0.140)</Description><Timeframe>Day 15 (start of maintenance); Day 43 (end of maintenance phase)</Timeframe></Measure><Measure><Description>Changes in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) Maintenance Phase: EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The values indicated represent the change from Day 15, a negative mean value indicates a worsening of health-related quality of life since the start of the maintenance phase</Description><Timeframe>Day 15 (start of maintenance); Day 43 (end of maintenance phase)</Timeframe></Measure><Measure><Description>Patient Global Impression of Change: in the Patient Global Impression of Change (PGIC) the participant is asked 'Since I began study treatment, my overall status is'. The participant is asked to circle one of seven categories. Scores range from very much improved to very much worse. The question was asked at the end of the maintenance phase with reference to the start of the maintenance phase where the participant continued at the dose that was effective at the end of the Titration Phase</Description><Timeframe>Day 43 (end of maintenance phase)</Timeframe></Measure><Measure><Description>Quality of Sleep (Sleep Questionnaire) in the Titration Phase: participants were asked the following question: 'Please rate the overall quality of your sleep last night?' The quality of sleep from the start of the titration phase to the end of the titration phase was measured. The participant could choose one of the following options: Excellent, good, fair and poor</Description><Timeframe>Day 1 (start of titration); Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Quality of Sleep (Sleep Questionnaire) During the Maintenance Phase of the Trial: participants were asked the following question: 'Please rate the overall quality of your sleep last night?' The quality of sleep from the start of maintenance to the completion of treatment is reported. The participant could choose one of the following options: Excellent, good, fair and poor</Description><Timeframe>Day 15 (start of maintenance); Day 43 (end of maintenance phase)</Timeframe></Measure><Measure><Description>Clinical Opioid Withdrawal Scale (COWS) at the End of the Titration Phase: this instrument was developed by the National Institute on Drug Abuse. The physical components of withdrawal are primarily evaluated and based on questions and clinical observations. The possible opioid withdrawal effects are assessed using the Clinical Opioid Withdrawal Score (COWS). The COWS is a clinician rated 11-item scale that primarily evaluates the physical components of opioid withdrawal and is based on questions and clinical observations</Description><Timeframe>Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Clinical Opioid Withdrawal Score (COWS) at the End of the Maintenance Phase: this instrument was developed by the National Institute on Drug Abuse. The physical components of withdrawal are primarily evaluated and based on questions and clinical observations. The possible opioid withdrawal effects are assessed using the Clinical Opioid Withdrawal Score (COWS). The COWS is a clinician rated 11-item scale that primarily evaluates the physical components of opioid withdrawal and is based on questions and clinical observations. Responses are rated on a Likert-type scale ranging from 0 to 4 or 5 depending on the item</Description><Timeframe>Day 43 (end of maintenance phase)</Timeframe></Measure><Measure><Description>Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) During the Titration Phase: the Constipation Assessment (PAC-SYM) is a 12-item self-report questionnaire that assesses the severity of symptoms of constipation. Participants are asked 'How severe have each of these symptoms been in the last two weeks?' eg, 'Pain in your stomach'. There are 3 subscales: 4 questions on Abdominal symptoms, 3 questions on rectal symptoms and 5 questions on stool symptoms. Responses are rated on a 5-point Likert Scale ranging from 0 (absence of symptom) to 4 (very severe symptoms). The changes in overall mean and in each of the mean sub-scores vary theoretically from -4 to +4 (where a change of +4 would indicate a change from not present to very severe symptom). If the changes in the overall or subscale mean scores are positive then there is a worsening in symptoms associated with constipation from the start to the end of the titration phase</Description><Timeframe>Day 1 (start of titration); Day 14 (end of titration phase)</Timeframe></Measure><Measure><Description>Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) During the maintenance Phase:the Constipation Assessment (PAC-SYM) is a 12-item self-report questionnaire that assesses the severity of symptoms of constipation. Participants are asked "How severe have each of these symptoms been in the last two weeks?' eg,'Pain in your stomach'. There are 3 subscales: 4 questions on Abdominal symptoms, 3 questions on rectal symptoms and 5 questions on stool symptoms. Responses are rated on a 5-point Likert Scale ranging from 0 (absence of symptom) to 4 (very severe symptoms). The changes in overall mean and in each of the mean sub-scores vary theoretically from -4 to +4 (where a change of +4 would indicate a change from not present to very severe symptom). If the changes in the overall or subscale mean scores are positive then there is a worsening in symptoms associated with constipation from the start to the end of the maintenance phase.A negative mean change indicates an improvement</Description><Timeframe>Day 15 (start of maintenance); Day 43 (end of maintenance phase)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to determine whether &lt;ulink linkType="Drug" linkID="56791"&gt;CG-5503 PR&lt;/ulink&gt; was effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition, CG-5503 would also be compared to morphine controlled release, also referred to as slow release (SR).&lt;/para&gt;&lt;para&gt;The primary objective of this trial  was to evaluate the safety and efficacy of orally administered tapentadol PR tablets BID over 4 weeks (Maintenance phase) in subjects with moderate to severe chronic malignant tumor-related pain in comparison with placebo.&lt;/para&gt;&lt;para&gt;Secondary objectives of this trial : &lt;br/&gt;To compare efficacy and safety of tapentadol PR with morphine sulfate PR during the Titration phase as well as over the whole treatment phase. &lt;br/&gt;To collect pharmacokinetic information for dose verification and population pharmacokinetic analyses.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2016, results of direct conversion from tramadol to tapentadol prolonged release were published. In tramadol/tapentadol PR subgroup, the responder rates (responders: completed titration, mean pain intensity &amp;lt; 5 [0 to 10 scale] and &amp;lt;/= 20mg/day rescue medication during last 3days) were slightly better   (69.8% [90/129]) compared to the overall CG-5503 PR group (63.9%). In both the groups tolerability profiles were comparable [&lt;ulink linkType="Reference" linkID="1869455"&gt;1869455&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Arm 1: po Tapentadol 100 mg to 250 mg  bid. Subjects randomized to placebo in the maintenance phase would receive 100 mg tapentadol prolonged release  bid for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all Subjects  would receive matching placebo in the maintenance (ie, randomized withdrawal) phase.&lt;br/&gt;Arm 2: po Morphine 40 to 100 mg  bid. Capsule taken po,  bid, morning and evening with preferably 12 h (not &amp;lt; 6 h) between doses. Maintenance phase: continuing on dose level established in titration phase.&lt;br/&gt;Arm 3: po Tapentadol 100  to 250 mg  bid. Tablet taken po,  bid, morning and evening with preferably 12 h (not &amp;lt; 6 h) between doses.&lt;/para&gt;&lt;para&gt;Subjects would be issued with an electronic diary (eDiary) to capture Numeric Rating Scale (NRS) pain intensities.&lt;/para&gt;&lt;para&gt;Assessments of pain relief would include the pain intensity numeric rating scale (NRS), patient global impression of change scale (PGIC). Safety evaluations would include monitoring of adverse events, physical examinations, and clinical laboratory tests. Venous blood samples would be collected for the determination of serum concentrations of CG-5503 PR.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were  randomized (2 : 1) and titrated to their optimal dose of CG-5503 PR (100 to 250mg bid) or morphine sulphate-controlled release (40  to 100mg bid) over 2weeks [&lt;ulink linkType="Reference" linkID="1869455"&gt;1869455&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="23807">morphine</Intervention><Treatments><Treatment><Dose>40 milligram</Dose><Route></Route></Treatment><Treatment><Dose>100 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="23806">tapentadol (sustained release, pain) J&amp;J PRD/Grunenthal</Intervention><Treatments><Treatment><Dose>100 milligram</Dose><Route></Route></Treatment><Treatment><Dose>250 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Austria"><Sites><Site><Name>Site 043001</Name><Address1>Vienna</Address1><Address3>1090</Address3><Contacts></Contacts></Site><Site><Name>Site 043002</Name><Address1>Vienna</Address1><Address3>1020</Address3><Contacts></Contacts></Site><Site><Name>Site 043004</Name><Address1>Klagenfurt</Address1><Address3>9020</Address3><Contacts></Contacts></Site><Site><Name>Site 043005</Name><Address1>Vienna</Address1><Address3>1100</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Bulgaria"><Sites><Site><Name>Site 359004</Name><Address1>Shoumen</Address1><Address3>9700</Address3><Contacts></Contacts></Site><Site><Name>Site 359008</Name><Address1>Sofia</Address1><Address3>1784</Address3><Contacts></Contacts></Site><Site><Name>Site 359011</Name><Address1>Pleven</Address1><Address3>5800</Address3><Contacts></Contacts></Site><Site><Name>Site 359012</Name><Address1>Varna</Address1><Address3>9003</Address3><Contacts></Contacts></Site><Site><Name>Site 359013</Name><Address1>Gabrovo</Address1><Address3>5300</Address3><Contacts></Contacts></Site><Site><Name>Site 359014</Name><Address1>Plovdiv</Address1><Address3>4004</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Czech Republic"><Sites><Site><Name>Site 420001</Name><Address1>Pilsen</Address1><Address3>30460</Address3><Contacts></Contacts></Site><Site><Name>Site 420002</Name><Address1>Ceske Budejovice</Address1><Address3>37087</Address3><Contacts></Contacts></Site><Site><Name>Site 420004</Name><Address1>Prague</Address1><Address3>18181</Address3><Contacts></Contacts></Site><Site><Name>Site 420005</Name><Address1>Brno</Address1><Address3>62500</Address3><Contacts></Contacts></Site><Site><Name>Site 420006</Name><Address1>Hradec Kralove</Address1><Address3>50005</Address3><Contacts></Contacts></Site><Site><Name>Site 420007</Name><Address1>Liberec</Address1><Address3>46063</Address3><Contacts></Contacts></Site><Site><Name>Site 420008</Name><Address1>Olomouc</Address1><Address3>77520</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Name>Site 049002</Name><Address1>Wiesbaden</Address1><Address3>65185</Address3><Contacts></Contacts></Site><Site><Name>Site 049006</Name><Address1>Waldkirch</Address1><Address3>79183</Address3><Contacts></Contacts></Site><Site><Name>Site 049007</Name><Address1>Loewenstein</Address1><Address3>74245</Address3><Contacts></Contacts></Site><Site><Name>Site 049009</Name><Address1>Berlin</Address1><Address3>12627</Address3><Contacts></Contacts></Site><Site><Name>Site 049012</Name><Address1>Kln</Address1><Address3>50996</Address3><Contacts></Contacts></Site><Site><Name>Site 049014</Name><Address1>Essen</Address1><Address3>45122</Address3><Contacts></Contacts></Site><Site><Name>Site 049020</Name><Address1>Potsdam</Address1><Address3>14467</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><Name>Site 034002</Name><Address1>Valencia</Address1><Address3>46014</Address3><Contacts></Contacts></Site><Site><Name>Site 034004</Name><Address1>Sevilla</Address1><Address3>1013</Address3><Contacts></Contacts></Site><Site><Name>Site 034005</Name><Address1>Barcelona</Address1><Address3>08221</Address3><Contacts></Contacts></Site><Site><Name>Site 034006</Name><Address1>Mahon Menorca</Address1><Address3>07703</Address3><Contacts></Contacts></Site><Site><Name>Site 034009</Name><Address1>Barcelona</Address1><Address3>08208</Address3><Contacts></Contacts></Site><Site><Name>Site 034012</Name><Address1>Pamplona</Address1><Address3>31008</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>Site 033101</Name><Address1>Tarbes</Address1><Address3>65000</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Croatia"><Sites><Site><Name>Site 385001</Name><Address1>Slavonski Brod</Address1><Address3>35000</Address3><Contacts></Contacts></Site><Site><Name>Site 385002</Name><Address1>Zagreb</Address1><Address3>10000</Address3><Contacts></Contacts></Site><Site><Name>Site 385003</Name><Address1>Zagreb</Address1><Address3>10000</Address3><Contacts></Contacts></Site><Site><Name>Site 385004</Name><Address1>Varazdin</Address1><Address3>42000</Address3><Contacts></Contacts></Site><Site><Name>Site 385006</Name><Address1>Zabok</Address1><Address3>49210</Address3><Contacts></Contacts></Site><Site><Name>Site 385007</Name><Address1>Osijek</Address1><Address3>31000</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Hungary"><Sites><Site><Name>Site 036001</Name><Address1>Debrecen</Address1><Address3>4043</Address3><Contacts></Contacts></Site><Site><Name>Site 036002</Name><Address1>Nyiregyhaza</Address1><Address3>4412</Address3><Contacts></Contacts></Site><Site><Name>Site 036003</Name><Address1>Mtrahza</Address1><Address3>3233</Address3><Contacts></Contacts></Site><Site><Name>Site 036005</Name><Address1>Komrom</Address1><Address3>2900</Address3><Contacts></Contacts></Site><Site><Name>Site 036006</Name><Address1>Szkesfehrvr</Address1><Address3>8000</Address3><Contacts></Contacts></Site><Site><Name>Site 036009</Name><Address1>Szkesfehrvr</Address1><Address3>8000</Address3><Contacts></Contacts></Site><Site><Name>Site 036010</Name><Address1>Szekszard</Address1><Address3>7100</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Name>Site 039001</Name><Address1>Napoli</Address1><Address3>80131</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Moldova, Republic of"><Sites><Site><Name>Site 373001</Name><Address1>Chisinau</Address1><Address3>2025</Address3><Contacts></Contacts></Site><Site><Name>Site 373002</Name><Address1>Chisinau</Address1><Address3>2025</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Poland"><Sites><Site><Name>Site 048001</Name><Address1>Warszawa</Address1><Address3>02781</Address3><Contacts></Contacts></Site><Site><Name>Site 048004</Name><Address1>Bydgoszcz</Address1><Address3>85796</Address3><Contacts></Contacts></Site><Site><Name>Site 048005</Name><Address1>Gdanks</Address1><Address3>80286</Address3><Contacts></Contacts></Site><Site><Name>Site 048007</Name><Address1>Poznan</Address1><Address3>60355</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Romania"><Sites><Site><Name>Site 040001</Name><Address1>Iasi</Address1><Address3>700106</Address3><Contacts></Contacts></Site><Site><Name>Site 040002</Name><Address1>Bucharest</Address1><Address3>022328</Address3><Contacts></Contacts></Site><Site><Name>Site 040003</Name><Address1>Bucharest</Address1><Address3>022328</Address3><Contacts></Contacts></Site><Site><Name>Site 040004</Name><Address1>Bucharest</Address1><Address3>022328</Address3><Contacts></Contacts></Site><Site><Name>Site 040005</Name><Address1>Cluj-Napoca</Address1><Address3>400015</Address3><Contacts></Contacts></Site><Site><Name>Site 040006</Name><Address1>Brasov</Address1><Address3>500074</Address3><Contacts></Contacts></Site><Site><Name>Site 040007</Name><Address1>Timisoara</Address1><Address3>300239</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Serbia"><Sites><Site><Name>Site 381001</Name><Address1>Sremska Kamenica</Address1><Address3>21204</Address3><Contacts></Contacts></Site><Site><Name>Site 381002</Name><Address1>Nis</Address1><Address3>18000</Address3><Contacts></Contacts></Site><Site><Name>Site 381003</Name><Address1>Belgrade</Address1><Address3>11000</Address3><Contacts></Contacts></Site><Site><Name>Site 381004</Name><Address1>Belgrade</Address1><Address3>11000</Address3><Contacts></Contacts></Site><Site><Name>Site 381005</Name><Address1>Belgrade</Address1><Address3>11000</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Russian Federation"><Sites><Site><Name>Site 007003</Name><Address1>Moscow</Address1><Address3>125284</Address3><Contacts></Contacts></Site><Site><Name>Site 007005</Name><Address1>Yaroslavl</Address1><Address3>150054</Address3><Contacts></Contacts></Site><Site><Name>Site 007007</Name><Address1>Nizhniy Novgorod</Address1><Address3>603140</Address3><Contacts></Contacts></Site><Site><Name>Site 007010</Name><Address1>Arkhangels</Address1><Address3>163045</Address3><Contacts></Contacts></Site><Site><Name>Site 007012</Name><Address1>Vladikavkaz</Address1><Address3>362007</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Sweden"><Sites><Site><Name>Site 046001</Name><Address1>Stockholm</Address1><Address3>17176</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Slovakia"><Sites><Site><Name>Site 421001</Name><Address1>Kosice</Address1><Address3>04191</Address3><Contacts></Contacts></Site><Site><Name>Site 421005</Name><Address1>Banska Bystrica</Address1><Address3>97517</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cancer supportive care</Disease><PatientSegments><PatientSegment><PatientSegment id="8977">Cancer/Treatment-related Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8387">Subjects with Chronic Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8389">Subjects with Moderate to Severe Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8426">Subjects with Cancer Related Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00472303</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2006-004997-28</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cancer supportive care" id="19266"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19270">Assessment of Complete Response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19428"><Endpoint>Assessment of Pain</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25894"><Endpoint>Assessment of Response Rates (RR)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cancer supportive care" id="19282"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19411"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19412">Assessment of Other Treatment or Procedure Related Outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19428"><Endpoint>Assessment of Pain</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26042">Assessment of drop-out rate/withdrawal rate</SubEndpoint><SubEndpoint disease="Pain" id="26044">Assessment of analgesic use/rescue medication</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cancer supportive care" id="13361"><Criterion>Subjects with History of Use of Non-chemotherapeutic Drugs</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13369"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13382">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22087"><Criterion>Subjects Based on Duration of Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22090">Subjects with chronic pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22144"><Criterion>Subjects with Cancer Related Pain</Criterion></Inclusion><Inclusion disease="Pain" id="22148"><Criterion>Subjects Based on Pain Scale Ratings</Criterion><SubCriteria><SubCriterion disease="Pain" id="22150">Based on Numerical Rating Scale [NRS]</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="33243"><Criterion>Subjects with disease complications</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13306">Subjects with cancer/treatment-related pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34061"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="22211">Subjects with history/scheduled to receive opioids</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="34100"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13383">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cancer supportive care" id="10881"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10882"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10883">Subjects co-morbid with HIV infection</SubCriterion><SubCriterion disease="Cancer supportive care" id="10884">Subjects co-morbid with hepatitis virus infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cancer supportive care" id="10908"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10913">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cancer supportive care" id="10916"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Pain" id="20023"><Criterion>Subjects with Neuropathic Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="20034">Subjects with cancer related neuropathy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20071"><Criterion>Subjects with Cancer Related Pain</Criterion></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20117"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Pain" id="20119"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20147">Subjects with history/scheduled to receive serotonin agonists</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20174">Subjects with history/scheduled to receive other drug therapies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="25893"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pain" id="20124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26044"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Pain" id="20116">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2007-05-10T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-06-03T15:35:30Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2016-11-03T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2019-03-22T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-22T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-03-22T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-03-25T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="142839"><TitleDisplay>Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Depigoid Grass Mix in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis with or without Mild Intermittent Asthma</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">EudarCT 2007-004255-10</Identifier><Identifier type="Secondary Organisational">6078-PG-PSC-164</Identifier></Identifiers><Indications><Indication id="1107">Allergic rhinitis</Indication><Indication id="2438">Allergic conjunctivitis</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Depigoid</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1030298" type="Company"><TargetEntity id="4297726368" type="organizationId">Laboratorios Leti SLU</TargetEntity></SourceEntity><SourceEntity id="1107" type="ciIndication"><TargetEntity id="10039085" type="MEDDRA"></TargetEntity><TargetEntity id="-600684678" type="omicsDisease"></TargetEntity><TargetEntity id="298" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2438" type="ciIndication"><TargetEntity id="10010744" type="MEDDRA"></TargetEntity><TargetEntity id="D003233" type="MeSH"></TargetEntity><TargetEntity id="-26844943" type="omicsDisease"></TargetEntity><TargetEntity id="764" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1030298">Laboratorios Leti SL</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2007-11-12T00:00:00Z</DateStart><DateEnd type="actual">2008-09-22T00:00:00Z</DateEnd><DateChangeLast>2017-07-06T16:14:11Z</DateChangeLast><DateAdded>2013-06-28T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Prior to study specific examinations the patient has to give his/her written informed consent&lt;/li&gt;&lt;li&gt;Patients &gt;/= 18 years old&lt;/li&gt;&lt;li&gt;History of clinical relevant allergic rhinitis and/or rhinoconjunctivitis to grass pollen and a positive skin prick test for Dactylis glomerata pollen at or within 12 months prior to the screening visit&lt;/li&gt;&lt;li&gt;Symptoms more than two years prior to study start&lt;/li&gt;&lt;li&gt;Subject must exhibit a moderate response upon 4000 Dactylis glomerata pollen grains/m3 within 2 h in the Environmental Challenge Chamber at visit 4 and at the baseline visit (V6) which is defined as to have at least 30% of the maximum possible TNSS score (ie, 120) of at least one of four records during the pollen exposure&lt;/li&gt;&lt;li&gt;FEV1/FVC &gt;/= 70% predicted&lt;/li&gt;&lt;li&gt;Absence of any structural nasal abnormalities or nasal polyps, absence of a history of frequent nose bleeding or recent nasal surgery&lt;/li&gt;&lt;li&gt;Absence of conditions or factors, which would make the subject unlikely to be able to stay in the Fraunhofer EEC for 2 h&lt;/li&gt;&lt;li&gt;Non smokers or smokers with a history of less than ten pack years&lt;/li&gt;&lt;li&gt;Able and willing to give written informed consent to take part in the study&lt;/li&gt;&lt;li&gt;Available to complete all study measurements&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Disease specific criteria:&lt;ul&gt;&lt;li&gt;History of significant clinical manifestations of allergy as a result of sensitization against tree pollen allergens, weed allergens and perennial allergens (eg, Aspergillus spores, animal dander, house dust mite)&lt;/li&gt;&lt;li&gt;Persistent asthma (GINA &gt;/= II)&lt;/li&gt;&lt;li&gt;Intermittent asthma having been treated with steroids within two years prior to screening&lt;/li&gt;&lt;li&gt;History of a respiratory tract infection and/or exacerbation of asthma within 4 weeks before the screening and during the study&lt;/li&gt;&lt;li&gt;Any history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients with other known previous/concomitant diseases:&lt;ul&gt;&lt;li&gt;Active tuberculosis&lt;/li&gt;&lt;li&gt;Acute and chronic inflammatory or infectious diseases at the target organ (not including intermittent asthma, rhinitis and rhinoconjunctivities)&lt;/li&gt;&lt;li&gt;Advanced secondary changes at the target organ (eg, emphysema or bronchiectasis)&lt;/li&gt;&lt;li&gt;Autoimmune disorders (eg, of the liver, kidney, the nervous system, thyroid gland, rheumatic diseases)&lt;/li&gt;&lt;li&gt;Immune deficiencies&lt;/li&gt;&lt;li&gt;Any disease which prohibits the use of adrenaline (eg, hyperthyroidism)&lt;/li&gt;&lt;li&gt;Cardiovascular insufficiency or any severe or unstable pulmonary, or endocrine disease, clinically significant renal or hepatic disease or dysfunction, hematological disorder, any other clinically significant medical condition that could increase the risk to the study participant&lt;/li&gt;&lt;li&gt;Malignant disease of any kind during the previous five years&lt;/li&gt;&lt;li&gt;Abnormal laboratory parameters and vital signs that could increase the risk to the study participant&lt;/li&gt;&lt;li&gt;Alcohol, drug or medication abuse within the past year&lt;/li&gt;&lt;li&gt;Severe psychiatric/psychological or neurological disorders&lt;/li&gt;&lt;li&gt;Patients with other known previous/concomitant treatments&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;The following therapy is not allowed within the specified period prior to screening as well as during the study and will prevent the patient from being included into the study:&lt;ul&gt;&lt;li&gt;SIT with grass pollen extract within the last five years&lt;/li&gt;&lt;li&gt;The 7 days prior and 14 days post an immunization with vaccines&lt;/li&gt;&lt;li&gt;Anti-allergic treatment within the last 4 weeks prior to screening, apart from rescue medication (ie, nasal/ocular H1-blocking agents and salbutamol) right after each pollen chamber visit and rescue medication for the use during the grass pollen season for symptoms of grass pollen allergic rhinitis and/or rhinoconjunctivitis and/or asthma (ie, systemic and topical antihistaminic and salbutamol)&lt;/li&gt;&lt;li&gt;Locally and systemically treatment with beta-blocker is not allowed during the entire study and will lead to the patient being withdrawn&lt;/li&gt;&lt;li&gt;Treatment with substances interfering with the immune system are not allowed during the entire study and will lead to the patient being withdrawn&lt;/li&gt;&lt;li&gt;Treatment with tranquillizer or psychoactive drugs&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Others:&lt;ul&gt;&lt;li&gt;Patients who are expected to be non-compliant and/or not cooperative&lt;/li&gt;&lt;li&gt;Participation in the treatment phase of any other clinical study within the last 30 days prior to the start of the study&lt;/li&gt;&lt;li&gt;Patients who have already participated in this study&lt;/li&gt;&lt;li&gt;Patients who are employees at the investigational site, relatives or spouses of the investigator&lt;/li&gt;&lt;li&gt;Any donation of germ cells, blood, organs, or bone marrow during the course of the study&lt;/li&gt;&lt;li&gt;Patients who are not contractually capable&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Special restrictions for female patients:&lt;ul&gt;&lt;li&gt;Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation&lt;/li&gt;&lt;li&gt;Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, unless they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels&amp;gt; 40 mIU/ml or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or hysterectomy or are using one or more of the following acceptable methods of contraception: surgical sterilization (eg, bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean Total Nasal Symptom Score (TNSS) at visit (V) 14 for the symptoms nasal obstruction, rhinorrhea, nasal itching and sneezing, each scored on a 100 mm visual analog scale (VAS) ranging from 'none' to 'severe'</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of the study was the comparison of the efficacy and safety of &lt;ulink linkType="Drug" linkID="68284"&gt;Depigoid&lt;/ulink&gt; grass mix versus placebo starting with the pre-seasonal immunotherapy under standardized pollen chamber conditions and proceeding with the grass pollen season immunotherapy over the following grass pollen season in patients with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma caused by clinical relevant sensitization against grass pollen. &lt;br/&gt;The secondary objectives were to evaluate:&lt;br/&gt;Single symptoms of TNSS during Environmental Challenge Chamber.&lt;br/&gt;TNSS at Visit 20.&lt;br/&gt;Symptom items as assessed by the patient questionnaire.&lt;br/&gt;Difference of the distributed weight and the collected weight of paper tissues.&lt;br/&gt;Use of rescue medication during pollen season as assessed by the patient diary (leaving out the time window of +/- 3 days around the last pollen chamber visit).&lt;br/&gt;Single symptoms of TNSS during pollen season as assessed by the patient diary (leaving out the time window of +/- 3 days around the last pollen chamber visit).&lt;br/&gt;Laboratory.&lt;br/&gt;Adverse events.&lt;br/&gt;Global evaluation of safety [&lt;ulink linkType="Reference" linkID="1445490"&gt;1445490&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="68284"&gt;Depigoid&lt;/ulink&gt;  or placebo [&lt;ulink linkType="Reference" linkID="1445490"&gt;1445490&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Allergic rhinitis</Disease><PatientSegments><PatientSegment><PatientSegment id="10203">Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10213">Subjects with comorbid conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Allergic rhinitis" id="14322"><Endpoint>Assessment of Total Nasal Symptom Score</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Allergic rhinitis" id="14331"><Endpoint>Assessment of Rhinitis Visual-Analogue Score</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Allergic rhinitis" id="14338"><Endpoint>Assessment of Nasal Symptoms/Symptom scores</Endpoint><SubEndpoints><SubEndpoint disease="Allergic rhinitis" id="14339">Assessment of rhinorrhoea</SubEndpoint><SubEndpoint disease="Allergic rhinitis" id="14340">Assessment of nasal congestion</SubEndpoint><SubEndpoint disease="Allergic rhinitis" id="14341">Assessment of sneezing</SubEndpoint><SubEndpoint disease="Allergic rhinitis" id="14342">Assessment of nasal itching</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Allergic rhinitis" id="14351"><Endpoint>Assessment of use of Rescue Medication</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Allergic rhinitis" id="14322"><Endpoint>Assessment of Total Nasal Symptom Score</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14365"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14366"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14392"><Endpoint>Assessment of Organ Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Allergic rhinitis" id="14506"><Criterion>Subjects with Seasonal Allergic Rhinitis(Hay Fever)</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="14507">Subjects sensitive to grass pollens</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Allergic rhinitis" id="14516"><Criterion>Patient Diagnosed with Allergic Rhinitis Based on Positive Skin Prick Test</Criterion></Inclusion><Inclusion disease="Allergic rhinitis" id="14534"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="14536">Subjects co-morbid with rhinoconjunctivitis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Allergic rhinitis" id="14541"><Criterion>Subjects Diagnosed with Allergic Rhinitis by Other Tests</Criterion></Inclusion><Inclusion disease="Allergic rhinitis" id="14546"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="14551">Based on lung function/forced expiratory volume in 1 second values</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Allergic rhinitis" id="33762"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="14526">Subjects enrolled based on TNSS(Total nasal symptom score)</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Allergic rhinitis" id="11928"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11931">Subjects excluded based on sensitivity/exposure to specific allergens</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="11933"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11935">Subjects co-morbid with asthma</SubCriterion><SubCriterion disease="Allergic rhinitis" id="11936">Subjects with history of respiratory infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="11940"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11944">Subjects with history of / current bacterial infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="11945"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11946">Subjects co-morbid with CNS/neuropsychiatric disorder</SubCriterion><SubCriterion disease="Allergic rhinitis" id="11952">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Allergic rhinitis" id="11955">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="11947"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Allergic rhinitis" id="11948"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Allergic rhinitis" id="11949"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Allergic rhinitis" id="11950"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Allergic rhinitis" id="11956"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11959">Subjects excluded due to contraindication to adrenaline</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="11960"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11961">Subjects with a history/current use of protocol prohibited antihistamines</SubCriterion><SubCriterion disease="Allergic rhinitis" id="11962">Subjects with history of/requiring immunotherapy</SubCriterion><SubCriterion disease="Allergic rhinitis" id="11964">Subjects with history of/requiring prohibited beta blockers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="11967"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Allergic rhinitis" id="11968"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Allergic rhinitis" id="25861"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11951">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="26297"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11970">Subjects with abnormal vital signs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="28373"><Criterion>Subjects with history of respiratory disease/disorder</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11937">Subjects with history of nasal/paranasal disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-06-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="16001"><TitleDisplay>An open-labelled, parallel design, pharmacokinetic interaction study between voriconazole and indinavir</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>indinavir</Name><Drug id="5321">indinavir</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>voriconazole</Name><Drug id="8714">voriconazole</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="5321">indinavir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18862">Pfizer Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8714">voriconazole</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18862">Pfizer Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8714" type="Drug"><TargetEntity id="179738" type="siDrug">Voriconazole</TargetEntity></SourceEntity><SourceEntity id="5321" type="Drug"><TargetEntity id="199183" type="siDrug">Indinavir sulfate</TargetEntity></SourceEntity><SourceEntity id="18862" type="Company"><TargetEntity id="4296676890" type="organizationId">Pfizer Ltd</TargetEntity></SourceEntity><SourceEntity id="204" type="Action"><TargetEntity id="436" type="Mechanism">HIV Protease Inhibitors</TargetEntity></SourceEntity><SourceEntity id="768" type="Action"><TargetEntity id="4056" type="Mechanism">HIV-1 Protease Inhibitors</TargetEntity></SourceEntity><SourceEntity id="777" type="Action"><TargetEntity id="444" type="Mechanism">Lanosterol 14alpha-demethylase Inhibitors</TargetEntity><TargetEntity id="5607" type="Mechanism">Sterol 14-alpha Demethylase (CYP51) (Trypanosoma cruzi) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="18862">Pfizer Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="204">HIV protease inhibitor</Action><Action id="768">HIV-1 protease inhibitor</Action><Action id="777">Lanosterol-14 demethylase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15178">Systemic dermatological antifungal product</Class><Class id="161">Ergosterol synthesis inhibitor</Class><Class id="1748">Fungicide</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="751">Film coating</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>18</PatientCountEnrollment><PatientCountEvaluable>18</PatientCountEvaluable><DateStart>2000-09-17T00:00:00Z</DateStart><DateChangeLast>2011-12-16T11:19:26Z</DateChangeLast><DateAdded>2008-06-03T16:13:38Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy male subjects&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Pharmacokinetics</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This open, parallel group, placebo-controlled, randomized study was designed to determine the effect of &lt;ulink linkType="Drug" linkID="5321"&gt;indinavir&lt;/ulink&gt;  on &lt;ulink linkType="Drug" linkID="8714"&gt;voriconazole&lt;/ulink&gt;  pharmacokinetics [&lt;ulink linkType="Reference" linkID="381925"&gt;381925&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;One subject   withdrew from the study. The pharmacokinetics of   &lt;ulink linkType="Drug" linkID="8714"&gt;voriconazole&lt;/ulink&gt;  and   &lt;ulink linkType="Drug" linkID="5321"&gt;indinavir&lt;/ulink&gt;  were not significantly different when the drugs were administered per se compared to when they were co-administered . There were no significant drug interactions between    &lt;ulink linkType="Drug" linkID="8714"&gt;voriconazole&lt;/ulink&gt;   and  &lt;ulink linkType="Drug" linkID="5321"&gt;indinavir&lt;/ulink&gt;   [&lt;ulink linkType="Reference" linkID="381925"&gt;381925&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;All subjects (n = 18) received  &lt;ulink linkType="Drug" linkID="8714"&gt;voriconazole&lt;/ulink&gt; (200 mg bid) on days 1 to 17. Subjects were randomized to receive &lt;ulink linkType="Drug" linkID="5321"&gt;indinavir&lt;/ulink&gt; (800 mg tid) or placebo on days 8 to 17.  Maximum plasma concentration (Cmax), area under plasma concentration-time curve within a dosing interval (AUCt) and time to occurrence of Cmax (Tmax) were calculated. These parameters were compared, using ANOVA, within treatment groups at days 7 and 17 [&lt;ulink linkType="Reference" linkID="381925"&gt;381925&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="23093">indinavir</Intervention><Treatments><Treatment><Dose>800 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="23094">voriconazole</Intervention><Treatments><Treatment><Dose>200 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-06-03T16:13:38Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="163852"><TitleDisplay>TSO for Plaque Psoriasis</TitleDisplay><TitleOfficial>A Randomized, Blinded, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02011269</Identifier><Identifier type="Organisational Study">CNDO 201-201</Identifier><Identifier type="Secondary Organisational">CNDO 201-201</Identifier></Identifiers><Indications><Indication id="281">Psoriasis</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Trichuris suis ova, OvaMed/Dr Falk/Fortress Biotech</Name><Drug id="59730">Trichuris suis ova, OvaMed/Dr Falk/Fortress Biotech</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="59730">Trichuris suis ova, OvaMed/Dr Falk/Fortress Biotech</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1032809">Fortress Biotech Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="59730" type="Drug"><TargetEntity id="475065" type="siDrug">ASP-1002</TargetEntity><TargetEntity id="737177" type="siDrug">CNDO-201</TargetEntity></SourceEntity><SourceEntity id="1032809" type="Company"><TargetEntity id="5035420209" type="organizationId">Fortress Biotech Inc</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1032809">Fortress Biotech Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="1596">Immunomodulator</Class><Class id="2953">Anti-inflammatory</Class><Class id="399">Hypoglycemic agent</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="570">Cell therapy</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateStart>2014-03-31T00:00:00Z</DateStart><DateEnd type="estimated">2015-01-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-25T17:34:30Z</DateChangeLast><DateAdded>2013-12-17T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Coronado Biosciences</Affiliation><Name>Michael Ryan</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Males or females, 18 to 75 years old&lt;/li&gt;&lt;li&gt;Diagnosis of stable plaque type psoriasis for at least 6 months prior to baseline&lt;/li&gt;&lt;li&gt;Baseline moderate to severe psoriasis, defined as both of the following:&lt;ul&gt;&lt;li&gt;Psoriasis covering a body surface area (BSA) &gt;/= 10%, and&lt;/li&gt;&lt;li&gt;PGA &gt;/= 3, and&lt;/li&gt;&lt;li&gt;PASI &gt;/= 12&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who are currently taking or have taken in the past 30 days, for any reason, any medication that, in the opinion of the investigator, suppressed the immune response. This may include but is not limited to systemic steroids, azathioprine, methotrexate, cyclosporine, FK506, mycophenolate mofetil, mycophenolic acid, etanercept, adalimumab, infliximab, ustekinumab, cimzia, or any other biological agent targeted to any cell or cytokine in the immune system.  Patients who are on inhaled or ophthalmic steroids are allowed&lt;/li&gt;&lt;li&gt;Patients who have demonstrated a primary lack of response to any one of the following biological agents: etanercept, adalimumab, infliximab or ustekinumab. Patients who initially responded to one of these agents but subsequently lost response (secondary lack of response) are eligible for study entry; however, secondary lack of response to more than one of these agents will exclude the patient from study entry&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean percent change in Psoriasis Area and Severity Index (PASI) score: mean percent change in Psoriasis Area and Severity Index (PASI) score from pre-treatment at week 0 to week 12</Description><Timeframe>12 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a randomized, doulbe-blind, multicenter study to assess the safety and treatment effect      of 12 weeks of &lt;ulink linkType="Drug" linkID="59730"&gt;Trichuris suis ova&lt;/ulink&gt;  in subjects diagnosed with moderate to severe chronic      plaque psoriasis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would consist of three arms.&lt;br/&gt;Arm I: patients would receive 7500 active &lt;ulink linkType="Drug" linkID="59730"&gt;Trichuris suis ova&lt;/ulink&gt; which would be provided in a 15 ml of aqueous suspension (supplied in 30 ml glass containers) po q2w for 10 weeks.&lt;br/&gt;Arm II: patients would receive  15000 active &lt;ulink linkType="Drug" linkID="59730"&gt;Trichuris suis ova&lt;/ulink&gt; which would be provided in two 15 ml of aqueous suspension (supplied in 30 ml glass containers) po q2w for 10 weeks.&lt;br/&gt;Arm III: patients would receive placebo&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;The study was not conducted.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02011269</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Anticipated">2015-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2013-12-10T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-12-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-05-20T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="168115"><TitleDisplay>Open, crossover, randomized, single dose, two-treatments, two-periods, two-sequences, pilot bioequivalence study of two pharmaceutical preparations for soft gelatin capsules of Isotretinoin 20mg in fed subjects (breakfast)</TitleDisplay><TitleOfficial>Open, crossover, randomized, single dose, two-treatments, two-periods, two-sequences, pilot bioequivalence study of two pharmaceutical preparations for soft gelatin capsules of Isotretinoin 20mg in fed subjects (breakfast)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">/A260-13</Identifier></Identifiers><Indications><Indication id="3">Acne</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>isotretinoin (Gelpharma)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>isotretinoin</Name><Drug id="44318">isotretinoin</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1083043" type="Company"><TargetEntity id="5039730602" type="organizationId">Gelpharma SA de CV</TargetEntity></SourceEntity><SourceEntity id="1090881" type="Company"><TargetEntity id="5040760646" type="organizationId">Ipharma SA de CV</TargetEntity></SourceEntity><SourceEntity id="3" type="ciIndication"><TargetEntity id="L70" type="ICD10"></TargetEntity><TargetEntity id="706.1" type="ICD9"></TargetEntity><TargetEntity id="10000496" type="MEDDRA"></TargetEntity><TargetEntity id="443" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1083043">Gelpharma SA</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1090881">IPharma SA DE CV</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioavailability</Term><Term>Bioequivalence</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><DateChangeLast>2018-01-16T22:09:17Z</DateChangeLast><DateAdded>2014-01-20T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>IPharma, SA de CV</Affiliation><Email>bioequivalencia@i-pharma.com.mx</Email><Name>Everardo Pieyro Garza</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Were included in the study of male volunteers.&lt;/li&gt;&lt;li&gt;Aged 18 to 45 years.&lt;/li&gt;&lt;li&gt;A BMI (Body Mass Index) between 20 to 26 kg/m2.&lt;/li&gt;&lt;li&gt;Negative results in doping tests.&lt;/li&gt;&lt;li&gt;Negative test results Ac HIV, HBsAg and RPR (Syphilis test).&lt;/li&gt;&lt;li&gt;Values of clinical biochemical tests: blood count, urinalysis, Biochemical Profile (Glucose, Urea Nitrogen, Urea, Creatinine, Uric Acid, Cholesterol, triglycerides, total protein, albumin, globulin, bilirubin (total, direct and indirect), alkaline phosphatase , Lactic dehydrogenase, AST, ALT, calcium, phosphorus, sodium, potassium, chlorine and iron) are in a range between the minimum and maximum reference values accepted for these tests.&lt;/li&gt;&lt;li&gt;Electrocardiogram and normal chest radiograph.&lt;/li&gt;&lt;li&gt;Signing the informed consent for the bioequivalence study.&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Radiological, electrocardiographic abnormalities.&lt;/li&gt;&lt;li&gt;Positive results in drug tests.&lt;/li&gt;&lt;li&gt;Positive results of RPR; Achiv and HBsAg.&lt;/li&gt;&lt;li&gt;History of psychiatric disorder (eg, Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar Disorder (I or II) or Schizophrenia.&lt;/li&gt;&lt;li&gt;Habit of smoking.&lt;/li&gt;&lt;li&gt;People undergoing medical treatment.&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Area under the plasma concentration curve from administration to time t (AUC 0 to t)</Description></Measure><Measure><Description>Area under the plasma concentration curve from 0 to infinity (AUC 0 to inf)</Description></Measure><Measure><Description>Maximum plasma concentration (Cmax)</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this  study will to determine the  bioequivalence of Isotretinoin 20 mg soft gelatin capsule of Gelpharma as test drug versus &lt;ulink linkType="Drug" linkID="44318"&gt;Isotretinoin&lt;/ulink&gt; 20 mg soft gelatin capsule as reference drug in healthy volunteers.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects wwill receive a single dose of one of the two following formulations:&lt;br/&gt;&lt;br/&gt;- Isotretinoin 20 mg soft gelatin capsule of Gelpharma [test]&lt;br/&gt;&lt;br/&gt;- &lt;ulink linkType="Drug" linkID="44318"&gt;Isotretinoin&lt;/ulink&gt; 20 mg soft gelatin capsule [reference]&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Mexico"><Sites><Site><Name>IPharma, SA de CV</Name><Address1>MONTERREY</Address1><Address2>Nuevo Leon</Address2><CountrySubDivision>Nuevo Leon</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1033">Federal Commission for Protection against Health Risks (COFEPRIS) Clinical Trials Registry
</Name><Identifiers><Identifier></Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-11-23T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="172452"><TitleDisplay>Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder</TitleDisplay><TitleOfficial>Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00216723</Identifier><Identifier type="Organisational Study">KOREA ABILIFY PMS</Identifier></Identifiers><Indications><Indication id="299">Schizophrenia</Indication><Indication id="653">Bipolar disorder</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>aripiprazole</Name><Drug id="7781">aripiprazole</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="7781">aripiprazole</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1071456">Korea Otsuka Pharmaceuticals</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="7781" type="Drug"><TargetEntity id="162295" type="siDrug">Aripiprazole</TargetEntity></SourceEntity><SourceEntity id="1071456" type="Company"><TargetEntity id="4297066919" type="organizationId">Korea Otsuka Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"></TargetEntity><TargetEntity id="10039626" type="MEDDRA"></TargetEntity><TargetEntity id="D012559" type="MeSH"></TargetEntity><TargetEntity id="-729613619" type="omicsDisease"></TargetEntity><TargetEntity id="65" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="653" type="ciIndication"><TargetEntity id="F31" type="ICD10"></TargetEntity><TargetEntity id="296" type="ICD9"></TargetEntity><TargetEntity id="10057667" type="MEDDRA"></TargetEntity><TargetEntity id="D001714" type="MeSH"></TargetEntity><TargetEntity id="-1667300745" type="omicsDisease"></TargetEntity><TargetEntity id="47" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="11842" type="Action"><TargetEntity id="905" type="Mechanism">5-HT1A Receptor Partial Agonists</TargetEntity></SourceEntity><SourceEntity id="11845" type="Action"><TargetEntity id="1685" type="Mechanism">Dopamine D2 Receptor Partial Agonists</TargetEntity></SourceEntity><SourceEntity id="585" type="Action"><TargetEntity id="210" type="Mechanism">5-HT2A Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1071456">Korea Otsuka Pharmaceuticals</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="11842">5-HT 1a receptor partial agonist</Action><Action id="11845">Dopamine D2 receptor partial agonist</Action><Action id="585">5-HT 2a receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2941">Antidepressant</Class><Class id="2943">Antipsychotic</Class></Class><Technologies><Technology id="898">Formulation powder</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>3000</PatientCountEnrollment><DateStart>2004-04-30T00:00:00Z</DateStart><DateEnd type="actual">2009-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-04-01T22:06:51Z</DateChangeLast><DateAdded>2014-02-12T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Korea Otsuka Pharmaceutical Co.,Ltd.</Affiliation><Name>Jieun Kwon</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient with a schizophrenia or schizoaffective disorder or bipolar disorder according to DSM-IV criteria&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Unqualified patients judged by study investigator(s)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Efficacy</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of the study was to evaluate the safety and efficacy of &lt;ulink linkType="Drug" linkID="7781"&gt;aripiprazole&lt;/ulink&gt; in patients with      schizophrenia and bipolar disorder.  Qualified schizophrenia patients were enrolled to a 12-week treatment   and qualified bipolar disorder patients were enrolled to an 8-week treatment phase of      &lt;ulink linkType="Drug" linkID="7781"&gt;aripiprazole&lt;/ulink&gt; by physician's assessment. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive 10 or 15 mg/day &lt;ulink linkType="Drug" linkID="7781"&gt;aripiprazole&lt;/ulink&gt; qd schedule without regard to meals. This study would  continue for six years. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Asan Medical Center</Name><Address1>Seoul</Address1><Contacts></Contacts></Site><Site><Name>Samsung Medical Center</Name><Address1>Seoul</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Schizophrenia</Disease><PatientSegments><PatientSegment><PatientSegment id="7142">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="7146">Subjects with schizophrenia spectrum disorder</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7167">Subjects with Other Neuro-psychiatric Diseases/Disorders</PatientSegment><SubSegments><SubSegment id="7168">Subjects with other psychotic disorders</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00216723</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><OtherEndpoints><OtherEndpoint disease="Bipolar disorder" id="9921"><Endpoint>Assessment of Bipolar Disorder Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9923">Assessment of mania</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10001"><Endpoint>Assessment of Co-morbidity</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9922">Assessment of depression</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10011"><Endpoint>Assessment of Organ Function</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10025"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="10027">Assessment of extra pyramidal symptoms</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10026"><Endpoint>Assessment of adverse events</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10045"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></OtherEndpoint><OtherEndpoint disease="Schizophrenia" id="10108"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Schizophrenia" id="10111">Assessment of efficacy</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Schizophrenia" id="10116"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Schizophrenia" id="10117">Assessment of adverse events(AEs)/side effects</SubEndpoint><SubEndpoint disease="Schizophrenia" id="10118">Assessment of serious adverse events</SubEndpoint><SubEndpoint disease="Schizophrenia" id="10119">Assessment of extra pyramidal symptoms</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Schizophrenia" id="10162"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="44859"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9926">Assessment of symptom improvement</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Schizophrenia" id="45341"><Endpoint>Assessment of Co-morbidity</Endpoint><SubEndpoints><SubEndpoint disease="Schizophrenia" id="10068">Assessment of depression</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Schizophrenia" id="5450"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="5454">Subjects with schizophrenia spectrum disorder</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Schizophrenia" id="5492"><Criterion>Subjects co-morbid with psychiatric disease/disorders</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="5493">Subjects with other psychotic disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5787"><Criterion>Subjects with Bipolar Disorder</Criterion></Inclusion><Inclusion disease="Bipolar disorder" id="5795"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5796">Diagnosed by Diagnostic and Statistical Manual (DSM IV) criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5822"><Criterion>Subjects co-morbid with psychiatric disease/disorders</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5825">Subjects with psychotic disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Schizophrenia" id="33285"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="5457">Diagnosed by Diagnostic and Statistical Manual (DSM IV) criteria</SubCriterion></SubCriteria></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><DateFirstReceived>2005-09-14T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-02-12T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="174081"><TitleDisplay>Electromyostimulation and Strength Walking for Knee Injuries (KI)</TitleDisplay><TitleOfficial>Electromyostimulation and Strength Walking for Knee Injuries</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02065518</Identifier><Identifier type="Organisational Study">HU0001-10-1-TS04</Identifier><Identifier type="Secondary Organisational">TSNRP GRANT HU0001-10-1-TS04</Identifier></Identifiers><Indications><Indication id="3754">Knee injury</Indication></Indications><BiomarkerNames><BiomarkerName id="19714" role="Therapeutic effect marker" type="Physiological">Muscle strength</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>EMPI 300PV neuromuscular stimulator (NEMS)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>strength walking</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>standard rehabilitation protocol</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1108899" type="Company"><TargetEntity id="5045944323" type="organizationId">Malcolm Grow Medical Clinics and Surgery Center</TargetEntity></SourceEntity><SourceEntity id="23005" type="Company"><TargetEntity id="5035523764" type="organizationId">Walter Reed National Military Medical Center</TargetEntity></SourceEntity><SourceEntity id="26292" type="Company"><TargetEntity id="4296604797" type="organizationId">University of Tennessee</TargetEntity></SourceEntity><SourceEntity id="3754" type="ciIndication"><TargetEntity id="5599" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="26292">University of Tennessee</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1108899">Malcolm Grow Medical Clinics and Surgery Center</Company><Company id="23005">US Naval Medical Research Center</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Factorial Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>132</PatientCountEnrollment><DateStart>2014-03-31T00:00:00Z</DateStart><DateEnd type="estimated">2017-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-06-02T06:30:12Z</DateChangeLast><DateAdded>2014-02-21T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>ltalbot@uthsc.edu</Email><Name>Laura A Talbot</Name><Phone>901-448-6113</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of Tennessee Health Sciences Center</Affiliation><Name>Laura A Talbot</Name></Contact><Contact type="Public contact"><Name>Michelle Kane</Name><Phone>301-400-1237</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;A diagnosis of knee injury (internal derangement of the knee with new effusion, including knee sprain or strains, meniscal tear, cruciate ligamentous tear, and chondral flap or injury)&lt;/li&gt;&lt;li&gt;A diagnosis of knee pain that is anterior knee pain, overuse pain, patella-femoral pain, and chronic pain (&amp;lt; 6 months) associated with overuse syndromes which negatively impacts performance by&lt;ul&gt;&lt;li&gt;Pain in one or both knees on most days of the month&lt;/li&gt;&lt;li&gt;Self reported difficulty performing at least one or more tasks due to pain: stair climbing, rising from a chair, walking or running a quarter mile, repetitive movements such as kneeling or squatting or stooping, pain that inhibits job performance and daily activities&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Military service member at the time of injury (active duty military and Reserve/ National Guard in active duty status)&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 and&amp;lt;/= 50 years&lt;/li&gt;&lt;li&gt;Ability to provide freely given informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Fracture or injury to external knee structures such that knee extension or flexion is impaired&lt;/li&gt;&lt;li&gt;Evidence of a fracture on radiographs or clinical evidence of unstable tendon tear/rupture&lt;/li&gt;&lt;li&gt;A significant co-morbid medical condition (such as severe hypertension or neurological disorder in which NMES strength training or unsupervised exercise is contraindicated and would pose a safety threat or impair ability to participate&lt;/li&gt;&lt;li&gt;Inability or unwillingness to participate in a walking or strengthening program&lt;/li&gt;&lt;li&gt;Inability to speak and/or read English&lt;/li&gt;&lt;li&gt;Reduced sensory perception in the lower extremities&lt;/li&gt;&lt;li&gt;Inability to walk on a treadmill without an assistive device&lt;/li&gt;&lt;li&gt;Vision impairment, where patient is classified as legally blind&lt;/li&gt;&lt;li&gt;Unwillingness to accept random assignment&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;A Score &gt;/= 23 on the center for epidemiological studies- depression scale (CES-D)&lt;/li&gt;&lt;li&gt;If the person has a demand type implanted pacemaker or defibrillator&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in lower extremity muscle strength across six time periods: Investigators are examining the outcome measure to determine if: the four treatment groups differ significantly in lower extremity muscle strength over time; Lower extremity muscle strength differs significantly across the six time periods; Is there an interaction between treatment and time in relation to lower extremity muscle strength</Description><Timeframe>0, 3, 6, 9, 12, and 18 weeks</Timeframe></Measure><Measure><Description>Change in mobility across four time periods: Investigators are examining the outcome measure to determine if: the four treatment groups differ significantly in mobility over time; Mobility differs significantly across the 4 time periods; Is there an interaction between treatment and time in relation to mobility</Description><Timeframe>0, 6, 12, and 18 weeks</Timeframe></Measure><Measure><Description>Change in work efficiency across four time periods: Investigators are examining the outcome measure to determine if: the four treatment groups differ significantly in work efficiency over time; Work efficiency differs significantly across the 4 time periods; Is there an interaction between treatment and time in relation to work efficiency</Description><Timeframe>0, 6,12, and 18 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in quality of life (QOL) across four time periods: Investigators are examining  the outcome measure to determine if: the four treatment groups differ significantly in quality of life (QOL) over time; Quality of life (QOL) differs significantly across the 4 time periods; Is there an interaction between treatment and time in relation to quality of life (QOL)</Description><Timeframe>0, 6, 12, and 18 weeks</Timeframe></Measure><Measure><Description>Change in symptoms/pain across six time periods: Investigators are examining the outcome measure to determine if: the four treatment groups differ significantly in symptoms/pain over time; Symptoms/pain differs significantly across the 6 time periods; Is there an interaction between treatment and time in relation to symptoms/pain</Description><Timeframe>0, 3, 6, 9, 12, and 18 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this project is to compare three treatment regimens for knee injury to the      standard rehabilitation protocol: NMES, graduated strength walking (via a      weighted vest), and NMES combined with graduated strength walking.  Each treatment group      will be supplemented by the  standard of care and compared to a group who receive the      standard rehabilitation only.&lt;/para&gt;&lt;para&gt;The study will compare the effects of NMES, strength walking and combined NMES/strength      walking on strength, mobility, symptomatology, and quality of Life (QOL) in military patients      with knee injury to a standard rehabilitation protocol program only.  All groups will      participate in  standard rehabilitation protocol.  The groups will be assessed over 18      weeks to compare main and interactive effects over time.&lt;/para&gt;&lt;para&gt;The overall objective of this project is to compare three treatment regimens for      knee injury to the standard rehabilitation protocol as potential treatments for      improving strength, work efficiency, and mobility in active duty military personnel with a      knee injury.  The central hypothesis is that the combination of NMES and walking while      wearing a weighted vest will demonstrate greater improvements in muscle strength, work      efficiency, and mobility, as compared to the usual care alone.  &lt;/para&gt;&lt;para&gt;The specific aims are to compare      the effectiveness of three treatment regimens to the usual care in improving: muscle      strength,  work efficiency,  mobility,  symptoms/pain, and  quality of life.      After baseline testing, they propose to randomly assign male and female patients (n = 132) ages      18 to 50 years with a knee injury to one of four groups: NMES, strength walking, NMES and strength walking, or usual care.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study will consist of following groups:&lt;br/&gt;Group I: standard rehabilitation protocol (SRP). Patients  will receive the current standard of care, the Walter Reed National Military Medical Center (WRNMMC) rehabilitation protocol for knee injuries. This  will include treatment with a physical therapist at the WRNMMC physical therapy clinic.&lt;br/&gt;Group II: in addition to the standard  rehabilitation protocol, patients in two treatment groups will receive a portable lightweight device (300 PV unit) that provides clearly defined electrical stimuli. NMES training will consist of performing four 30-min stimulation sessions per week for 12 weeks; each 30-min session will entail 15 min/leg with 15 contractions per leg. Each contraction will be elicited by an electrical impulse (300 PV) generated by a battery-operated device.&lt;br/&gt;Group III: patients in the strength walking groups will participate in a home-based pedometer-driven walking program. All patients in this group will be given a pedometer to monitor their daily steps and, at week 7. In addition to the standard WRNMMC rehabilitation protocol, a series of 10-min lessons focused on increasing physical activity through lifestyle education and the use of a pedometer as a motivational tool and personal fitness tracker will be incorporated into their testing sessions for the first 6 weeks. At week 7, patients will be given a vest to begin the strengthening component.&lt;br/&gt;Group IV: in addition to the standard rehabilitation protocol, one group of patients will receive NMES training and will participate in a home-based pedometer-driven walking program. This group will follow the protocol for both the NMES training and strength walking. &lt;/para&gt;&lt;para&gt;NEMS: patients  will be trained at 15 to 20% of maximal voluntary contraction (MVC) during weeks 1 to 3, 20 to 30% of MVC during weeks 3 to 6 and 30 to 40% of MVC during weeks 6 to 9, 40 to 50% of MVC during weeks 9 to 12, then sustain 50% of MVC during weeks 12 to 18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.&lt;/para&gt;&lt;para&gt;Patients in all groups will receive 12-weeks of the      intervention and 6-weeks of follow-up.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Malcolm Grow Medical Clinics and Surgery Center</Name><Address1>Andrews AFB</Address1><Address2>Maryland</Address2><Address3>20762</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Walter Reed National Military Medical Cener</Name><Address1>Bethesda</Address1><Address2>Maryland</Address2><Address3>20889</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02065518</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2016-08-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2016-05-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>26.03 Months</EnrollmentPeriod><EnrollmentRate>5.07 Patients/Month</EnrollmentRate><DateFirstReceived>2014-02-12T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-02-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-06-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-06-27T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="174673"><TitleDisplay>N-acetytlcysteine Versus Placebo for the Prevention of Acute Reduction in Renal Function after Primary Angioplasty (NoVARA)</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">EudraCT 2010-022952-22</Identifier><Identifier type="Secondary Organisational">GIU-LU-RO</Identifier><Identifier type="Trial Acronym">NoVARA</Identifier></Identifiers><Indications><Indication id="69">Renal failure</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>N-acetylcysteine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="69" type="ciIndication"><TargetEntity id="10038435" type="MEDDRA"></TargetEntity><TargetEntity id="346" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1081124">AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA DI NOVARA</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>300</PatientCountEnrollment><DateStart>2010-10-22T00:00:00Z</DateStart><DateChangeLast>2014-03-13T05:57:49Z</DateChangeLast><DateAdded>2014-02-27T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with age 18 to 90 years&lt;/li&gt;&lt;li&gt;Admitted in hospital for acute coronary syndrome with persistent ST elevation and chest pain&amp;lt; 12 h &lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Shock cardiogenic&lt;/li&gt;&lt;li&gt;Chronic dialysis&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Allergy to N-acetylcysteine&lt;/li&gt;&lt;li&gt;Inability to obtain informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Assess the development of contrast induced acute renal failure</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to determine the effects of N-acetylcysteine versus placebo to prevent acute reduction in renal function after primary angioplasty.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized to receive either N-acetylcysteine or placebo.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Italy"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="173">Subjects with Unstable Coronary Artery Disease</PatientSegment><SubSegments><SubSegment id="178">ST elevation myocardial infarction (STEMI)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Acute coronary syndrome</Disease><PatientSegments><PatientSegment><PatientSegment id="302">ST Segment Elevation Myocardial Infarction(STEMI) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="321">Subjects with History of Cardiac Intervention</PatientSegment><SubSegments><SubSegment id="323">PTCA alone </SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Renal failure</Disease><PatientSegments><PatientSegment><PatientSegment id="8113">Subjects with Intrarenal Causes for Acute Renal Failure(ARF)</PatientSegment><SubSegments><SubSegment id="8116">Subjects with contrast induced nephropathy(CIN)/exposed to contrast agent</SubSegment><SubSegment id="8117">Subjects exposed to nephrotoxins</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">EudraCT 2010-022952-22</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2634"><Endpoint>Assessment of Adverse Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2649">Renal dysfunction/Complications/Requirement for dialysis</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Acute coronary syndrome" id="2999"><Endpoint>Assessment of Co-morbidity</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Renal failure" id="22943"><Endpoint>Assessment of Acute Renal Failure</Endpoint><SubEndpoints><SubEndpoint disease="Renal failure" id="22944">Assessment of contrast induced nephropathy(CIN)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1068"><Criterion>Subjects with Coronary Artery Disease (CAD)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1072">Time course of chest pain as symptom</SubCriterion><SubCriterion disease="Coronary artery disease" id="3871">Subjects with acute coronory syndrome</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1078"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1082">ST segment elevation myocardial infarction (STEMI)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1171">PTCA (percutaneous transluminal coronary angioplasty)/Stent placement</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Acute coronary syndrome" id="1285"><Criterion>ST Segment Elevation Myocardial Infarction(STEMI) Subjects</Criterion></Inclusion><Inclusion disease="Acute coronary syndrome" id="1296"><Criterion>Subjects with Coronary Artery Disease (CAD)</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="1293">The time course of the onset of chest pain (Angina)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Acute coronary syndrome" id="1321"><Criterion>Subjects with History of/Scheduled for Cardiac Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="1326">Percutaneous transluminal coronary angioplasty  (PTCA) alone</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Renal failure" id="20161"><Criterion>Subjects with Intrarenal Causes for Acute Renal Failure(ARF)</Criterion><SubCriteria><SubCriterion disease="Renal failure" id="20170">Subjects with contrast induced nephropathy(CIN)/exposed to contrast agent</SubCriterion><SubCriterion disease="Renal failure" id="20171">Subjects exposed to nephrotoxins</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1651"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1657">Subjects co-morbid with cardiogenic shock</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2179"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2181">Study medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2195"><Criterion>Subjects with History of Other Procedure/Intervention</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2206">Renal dialysis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Renal failure" id="17906"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Renal failure" id="17933"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Renal failure" id="17939"><Criterion>Subjects with History of Renal Replacement Therapy(RRT)</Criterion><SubCriteria><SubCriterion disease="Renal failure" id="17940">Subjects with history of/scheduled for dialysis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="25834"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1701">Subjects on hemodialysis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="26243"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2000">Subjects co-morbid with cardiogenic shock</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><ChangeHistory><Change type="added"><Date>2014-02-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="182320"><TitleDisplay>Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging</TitleDisplay><TitleOfficial>Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01174056</Identifier><Identifier type="Organisational Study">DDCF-2010060</Identifier></Identifiers><Indications><Indication id="646">Lung inflammation</Indication></Indications><BiomarkerNames><BiomarkerName id="172" role="Therapeutic effect marker" type="Genomic;Proteomic">Adiponectin</BiomarkerName><BiomarkerName id="237" role="Therapeutic effect marker" type="Biochemical">Leukotriene E4</BiomarkerName><BiomarkerName id="1925" role="Therapeutic effect marker" type="Cellular">Neutrophils</BiomarkerName><BiomarkerName id="46731" role="Therapeutic effect marker" type="Structural (imaging)">Standardized uptake value</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pioglitazone</Name><Drug id="4126">pioglitazone</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>zileuton</Name><Drug id="4718">zileuton</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>pioglitazone</Name><Drug id="4126">pioglitazone</Drug></Intervention><Intervention type="InterventionPrimary"><Name>zileuton</Name><Drug id="4718">zileuton</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4126">pioglitazone</Drug><IndicationsPioneer><Indication id="646">Lung inflammation</Indication></IndicationsPioneer><Companies><Company><Company id="1039210">Doris Duke Charitable Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="26113">Washington University in St Louis</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4126">pioglitazone</Drug><IndicationsPioneer><Indication id="646">Lung inflammation</Indication></IndicationsPioneer><Companies><Company><Company id="1039210">Doris Duke Charitable Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="26113">Washington University in St Louis</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4718">zileuton</Drug><IndicationsPioneer><Indication id="646">Lung inflammation</Indication></IndicationsPioneer><Companies><Company><Company id="1039210">Doris Duke Charitable Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="26113">Washington University in St Louis</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4718">zileuton</Drug><IndicationsPioneer><Indication id="646">Lung inflammation</Indication></IndicationsPioneer><Companies><Company><Company id="1039210">Doris Duke Charitable Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="26113">Washington University in St Louis</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4126" type="Drug"><TargetEntity id="126029" type="siDrug">Pioglitazone</TargetEntity><TargetEntity id="126029" type="siDrug">Pioglitazone</TargetEntity><TargetEntity id="164965" type="siDrug">Pioglitazone hydrochloride</TargetEntity><TargetEntity id="164965" type="siDrug">Pioglitazone hydrochloride</TargetEntity></SourceEntity><SourceEntity id="4718" type="Drug"><TargetEntity id="145060" type="siDrug">Zileuton</TargetEntity><TargetEntity id="145060" type="siDrug">Zileuton</TargetEntity></SourceEntity><SourceEntity id="1039210" type="Company"><TargetEntity id="5034763914" type="organizationId">Doris Duke Charitable Foundation</TargetEntity></SourceEntity><SourceEntity id="26113" type="Company"><TargetEntity id="4296303116" type="organizationId">Washington University</TargetEntity></SourceEntity><SourceEntity id="646" type="ciIndication"><TargetEntity id="2881" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1919" type="Action"><TargetEntity id="605" type="Mechanism">Insulin Sensitizers</TargetEntity></SourceEntity><SourceEntity id="247" type="Action"><TargetEntity id="1296" type="Mechanism">5-Lipoxygenase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2480" type="Action"><TargetEntity id="895" type="Mechanism">PPARgamma Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 0 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="26113">Washington University in St Louis</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1039210">Doris Duke Charitable Foundation</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1919">Insulin sensitizer</Action><Action id="247">5-Lipoxygenase inhibitor</Action><Action id="2480">PPAR gamma agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1615">Neuroprotectant</Class><Class id="237">Leukotriene B4 synthesis inhibitor</Class><Class id="2953">Anti-inflammatory</Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Placebo Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Factorial Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>39</PatientCountEnrollment><PatientCountEvaluable>18</PatientCountEvaluable><DateStart>2011-07-31T00:00:00Z</DateStart><DateEnd type="actual">2014-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-11-13T07:41:06Z</DateChangeLast><DateAdded>2014-04-18T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Washington University School of Medicine</Affiliation><Name>Delphine L Chen, MD</Name></Contact><Contact type="Public contact"><Email>salamond@mir.wustl.edu</Email><Name>Diane Salamon</Name><Phone>314) 362-7011</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy man or woman, any race or ethnicity, age 19 to 44 years old&lt;/li&gt;&lt;li&gt;Screening FEV1 and FVC&amp;gt; 90% of predicted&lt;/li&gt;&lt;li&gt;Screening oxygen saturation by pulse oximetry&amp;gt; 97% on room air&lt;/li&gt;&lt;li&gt;Capable of lying still and supine within the PET/CT scanner for ~1.5 h&lt;/li&gt;&lt;li&gt;Capable of following instructions for breathing protocol during CT portion of PET/CT&lt;/li&gt;&lt;li&gt;Able and willing to give informed consent&lt;/li&gt;&lt;li&gt;BMI&amp;lt; 35&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pregnancy (confirmed by qualitative urine hCG pregnancy test)&lt;/li&gt;&lt;li&gt;Lactation&lt;/li&gt;&lt;li&gt;Active menstruation&lt;/li&gt;&lt;li&gt;History of cardiopulmonary disease&lt;/li&gt;&lt;li&gt;Currently taking any prescription medications&lt;/li&gt;&lt;li&gt;History of tobacco use or illicit drug use within the past year&lt;/li&gt;&lt;li&gt;Presence of implanted electronic medical device&lt;/li&gt;&lt;li&gt;Enrollment in another research study of an investigational drug&lt;/li&gt;&lt;li&gt;Known allergy to rosiglitazone or&lt;ulink linkType="Drug" linkID="4718"&gt;zileuton&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Known allergy to both trimethoprim/sulfamethoxazole and amoxicillin&lt;/li&gt;&lt;li&gt;Known allergy to drugs routinely used during bronchoscopy&lt;/li&gt;&lt;li&gt;History of chronic active liver disease or acute liver disease within the past 3 months&lt;/li&gt;&lt;li&gt;SGOT&amp;gt; 47 IU/l, SGPT  &amp;gt; 53 IU/l, or bilirubin &amp;gt; 1.1 mg/dl&lt;/li&gt;&lt;li&gt;Inability lie flat for 1.5 h for PET/CT scans or follow breathing protocol instructions for the CT portion of the PET/CT&lt;/li&gt;&lt;li&gt;Prior research-related radiation exposure within the past year such that participation in this study would result in exposures that exceed the limits as defined by the FDA RDRC regulations (21 CFR 361.1)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Ki, measure of FDG uptake: Ki will be measured before and after endotoxin. Primary outcome measure is change in Ki (post- minus pre-endotoxin value) and absolute Ki after endotoxin</Description><Timeframe>Before and after endotoxin</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The mean standard uptake value (SUVmean)</Description></Measure><Measure><Description>Blood adiponectin and urinary leukotriene E4 (LTE4) levels, determined by enzyme-linked immunosorbent assay, to verify treatment compliance</Description></Measure><Measure><Description>Bronchoalveolar lavage (BAL) fluid cell counts: total and neutrophil cell counts obtained by bronchoalveolar lavage after endotoxin</Description><Timeframe>After endotoxin</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this research study was to gain understanding of the basic responses of the      lung to inflammation and specifically if a certain medication (&lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;) can reduce the inflammation      alone or in combination with another.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In February 2018, results were published. After endotoxin instillation ki and SUV mean increased in placebo,pioglitazone, andzileutoncohorts (Ki increased by 0.0021 +/- 0.0019, 0.0023 +/- 0.0017, and 0.0024 +/- 0.0020 and SUVmean by 0.47 +/- 0.14, 0.55 +/- 0.15, and 0.54 +/- 0.38, respectively p &amp;lt; 0.001) with no differences among treatment cohorts (p = 0.933). Pioglitazone treatment shows an increase in expected adiponectin levels but in zileutontreatment no expected urinary LTE4 levels was seen. In treatment cohorts BAL cell counts (p = 0.442) and neutrophil percentage (p = 0.773)was similar [&lt;ulink linkType="Reference" linkID="2021063"&gt;2021063&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study has four arms:&lt;br/&gt;Arm A: subjects would receive &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; 45 mg qd for 2 weeks prior to endotoxin instillation, stopping at 24 h after endotoxin instillation and Zileuton placebo, two tablets orally, twice daily x 5 days prior to endotoxin instillation until 24 h after endotoxin.&lt;br/&gt;Arm B: subjects would receive &lt;ulink linkType="Drug" linkID="4718"&gt;zileuton&lt;/ulink&gt; 600 mg tablets po  qid for 5 days prior to endotoxin, stopping 24 h after endotoxin instillation and pioglitazone placebo, one tablet, orally, twice daily  x 2 weeks prior to endotoxin instillation until 24 h after endotoxin.&lt;br/&gt;Arm C:  subjects would receive  pioglitazone placebo and Zileuton placebo.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received pioglitazoneplusplacebo,zileutonplusplacebo, or dualplaceboprior to bronchoscopic endotoxin instillation [&lt;ulink linkType="Reference" linkID="202163"&gt;202163&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="415909">pioglitazone</Intervention><Treatments><Treatment><Dose>45 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="415911">zileuton</Intervention><Treatments><Treatment><Dose>600 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Washington University School of Medicine</Name><Address1>St Louis</Address1><Address2>Missouri</Address2><Address3> 63110</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Washington University / Barnes Jewish Hospital</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3>63110</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01174056</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Asthma" id="6049"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Asthma" id="6011"><Endpoint>Assessment of Bronchial Biopsy/Bronchoalveolar Lavage (BAL) Markers</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6012">BAL fluid cell count</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Asthma" id="2773"><Criterion>Subjects with FEV1 Measurement</Criterion><SubCriteria><SubCriterion disease="Asthma" id="2779">Subjects with FEV1 &gt;=80% predicted</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Asthma" id="20242"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Asthma" id="20247"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Asthma" id="20252"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Asthma" id="20255"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Asthma" id="25070"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Asthma" id="3954">Smokers</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2010-07-30T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-04-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-04-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-04-16T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="183370"><TitleDisplay>A Randomized, Clinical Trial To Determine The Effectiveness The Motivational Interviewing In Stroke (Mist) To Reduce The Recurrent Stroke</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ACTRN12610000715077</Identifier><Identifier type="Other">U1111-1116-7462</Identifier><Identifier type="Trial Acronym">MIST</Identifier></Identifiers><Indications><Indication id="3676">Ischemic stroke</Indication></Indications><BiomarkerNames><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="153" role="Therapeutic effect marker" type="Biochemical">High-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="330" role="Therapeutic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Motivational interviewing</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1004479" type="Company"><TargetEntity id="4297143031" type="organizationId">Auckland University of Technology</TargetEntity></SourceEntity><SourceEntity id="3676" type="ciIndication"><TargetEntity id="10061256" type="MEDDRA"></TargetEntity><TargetEntity id="96" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1004479">Auckland University of Technology</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>430</PatientCountEnrollment><DateChangeLast>2019-06-03T10:05:48Z</DateChangeLast><DateAdded>2014-04-25T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>National Institute for Stroke &amp; Applied Neurosciences AUT University</Affiliation><Email>valery.feigin@aut.ac.nz</Email><Name>Valery Feigin</Name><Phone>+64 9 921 9166</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Discharged from hospital&lt;/li&gt;&lt;li&gt;Age above 45 years&lt;/li&gt;&lt;li&gt;First-ever stroke&lt;/li&gt;&lt;li&gt;Consented to participate in the trial&lt;/li&gt;&lt;li&gt;Able to converse fluently in English&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Recurrent stroke (excluding clinically silent previous strokes)&lt;/li&gt;&lt;li&gt;A diagnosis of subarachnoid haemorrhage&lt;/li&gt;&lt;li&gt;Significant impairments precluding participation (eg, aphasia, psychiatric conditions or cognitive impairment [defined as Mini Mental State Examination (MMSE)&amp;lt; 23])&lt;/li&gt;&lt;li&gt;Inability to give informed consent&lt;/li&gt;&lt;li&gt;Another condition likely to impact their participation in the trial (eg life-threatening condition other than cardiovascular disease)&lt;/li&gt;&lt;li&gt;Expected discharge to hospital/nursing home setting where adherence to lifestyle recommendations and medications is beyond participant control&lt;/li&gt;&lt;li&gt;Receiving psychiatric or clinical psychology treatment that can contaminate the study intervention&lt;/li&gt;&lt;li&gt;Are likely to move out of the study area after discharge&lt;/li&gt;&lt;li&gt;Are unable to converse in English, which would impact assessment and intervention delivery&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Adherence to medication and lifestyle changes recommended by treating physicians at and after hospital discharge in stroke patients 12 months post-randomisation, indicated by change in systolic blood pressure (BP) and low-density cholesterol (LDL) levels</Description><Timeframe>Baseline and 12 months post-randomization</Timeframe></Measure><Measure><Description>To examine change in systolic BP levels at 3, 6 and 9 months follow-up, and LDL-cholesterol levels at 6 months follow-up</Description><Timeframe>Baseline, 3, 6 and 9 months post-randomization</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Self-reported adherence (self-reported use of anti-platelet, statin and BP lowering therapy as prescribed)</Description><Timeframe>Baseline, 3, 6 and 9 months post-randomization</Timeframe></Measure><Measure><Description>Self-reported barriers to adherence</Description><Timeframe>Baseline, 3, 6 and 9 months post-randomization</Timeframe></Measure><Measure><Description>Cardiovascular events (new stroke or coronary heart disease, both fatal and non-fatal). This outcome will be assessed by means of questionnaire and extraction of data from medical records</Description><Timeframe>Baseline, 3, 6 and 9 months post-randomization</Timeframe></Measure><Measure><Description>Quality of life as measured by the Short Form 36 (SF-36) questionnaire</Description><Timeframe>Baseline, 3, 6 and 9 months post-randomization</Timeframe></Measure><Measure><Description>Change in other lipid fractions high-density cholesterol, total cholesterol, triglycerides. This outcome will be assessed by means of blood test and extraction of relevant data from medical records</Description><Timeframe>6 and 12 months post-randomization</Timeframe></Measure><Measure><Description>Healthcare resource consumption and cost-effectiveness. The resourse consumption will be estimated from the investigators' point of view. Costs will assessed by means of questionnaires and data from medical records (health service databases) and will include all rehabilitative and medical services, General Medical Service benefit (or other Primary Health Organisation reimbursement), private prescription charges, co-payments, costs for hospitalisations, and resource utilisation costs</Description><Timeframe>12 months after randomization</Timeframe></Measure><Measure><Description>Mood as measured by the Hospital Anxiety and Depression Scale</Description><Timeframe>Baseline, 3, 6 and 9 months post-randomization</Timeframe></Measure><Measure><Description>Physical disability as measured by the Barthel Index</Description><Timeframe>Baseline</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of thestudy was to determine the effectiveness of motivational interviewing in improving adherence to medication and lifestyle changes recommended by treating physicians at and after hospital discharge in strokepatients12 months poststroke to reduce risk factors for recurrent stroke [&lt;ulink linkType="Reference" linkID="1549360"&gt;1549360&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients  would  be randomized to either motivational interviews or usual care groups [&lt;ulink linkType="Reference" linkID="1549360"&gt;1549360&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="New Zealand"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stroke</Disease><PatientSegments><PatientSegment><PatientSegment id="11631">Subjects with Ischemic Stroke</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11635">Subjects with First Stroke</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1004">WHO ICTRP</Name><Identifiers><Identifier>U1111-1116-7462</Identifier></Identifiers></Registry><Registry><Name id="1011">Australian New Zealand Clinical Trials Registry (ANZCTR)</Name><Identifiers><Identifier>ACTRN12610000715077</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Stroke" id="45013"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24246">Assessment of blood pressure</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Stroke" id="24185"><Endpoint>Assessment of Cardiovascular Events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24223"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24090">Assessment by Barthel Activities of Daily Living Index</SubEndpoint><SubEndpoint disease="Stroke" id="27532">Assessment by Short Form Health Survey (SF-36)</SubEndpoint><SubEndpoint disease="Stroke" id="27557">Assessment by Hospital Anxiety and Depression Scale (HADS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24257"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="27908"><Endpoint>Health Economic Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="27909">Assessment of cost effectiveness</SubEndpoint><SubEndpoint disease="Stroke" id="27914">Health care resource utilization</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stroke" id="20936"><Criterion>Stroke Subjects</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20938">Subjects with ischemic stroke</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stroke" id="20941"><Criterion>Subjects with Other Types of Stroke</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20942">Subjects with first stroke</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stroke" id="18676"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-04-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="18566"><TitleDisplay>A Phase II, Open-Label Study To Evaluate The Safety And Efficacy Of Elvucitabine In Combination With Kaletra In Treatment-Naive HIV Patients</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">ACH443-012</Identifier></Identifiers><Indications><Indication id="158">HIV infection</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>elvucitabine</Name><Drug id="12738">elvucitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>lopinavir + ritonavir</Name><Drug id="14681">lopinavir + ritonavir</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12738">elvucitabine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="27226">Achillion Pharmaceuticals Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="14681">lopinavir + ritonavir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="27226">Achillion Pharmaceuticals Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="12738" type="Drug"><TargetEntity id="236929" type="siDrug">Elvucitabine</TargetEntity></SourceEntity><SourceEntity id="14681" type="Drug"><TargetEntity id="291602" type="siDrug">Lopinavir/ritonavir</TargetEntity></SourceEntity><SourceEntity id="27226" type="Company"><TargetEntity id="4295902590" type="organizationId">Achillion Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"></TargetEntity><TargetEntity id="042" type="ICD9"></TargetEntity><TargetEntity id="10020161" type="MEDDRA"></TargetEntity><TargetEntity id="D015658" type="MeSH"></TargetEntity><TargetEntity id="-841965209" type="omicsDisease"></TargetEntity><TargetEntity id="862" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="204" type="Action"><TargetEntity id="436" type="Mechanism">HIV Protease Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="27226">Achillion Pharmaceuticals Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1832">Nucleoside reverse transcriptase inhibitor</Action><Action id="204">HIV protease inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="175">Drug combination</Technology><Technology id="590">Enteric coated formulation</Technology><Technology id="751">Film coating</Technology><Technology id="102">Nucleotide and derivatives</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="742">Pellet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>24</PatientCountEnrollment><PatientCountEvaluable>24</PatientCountEvaluable><DateStart>2005-12-31T00:00:00Z</DateStart><DateEnd type="actual">2006-05-31T00:00:00Z</DateEnd><DateChangeLast>2011-12-05T05:18:44Z</DateChangeLast><DateAdded>2008-07-14T14:39:40Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Treatment-naive HIV patients&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure><Measure><Description>Tolerability</Description></Measure><Measure><Description>Reduction in viral load</Description><Timeframe>Over 21 days</Timeframe></Measure><Measure><Description>Plasma RNA levels</Description><Timeframe>Over 28 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;All three doses also showed similar safety profiles without the occurrence of any serious adverse events, particularly white or red blood cell reduction [&lt;ulink linkType="Reference" linkID="1232535"&gt;1232535&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This phase II,  open-label, 21-day study was designed to evaluate the safety and efficacy of &lt;ulink linkType="Drug" linkID="12738"&gt;elvucitabine&lt;/ulink&gt; in combination with &lt;ulink linkType="Drug" linkID="14681"&gt;Kaletra&lt;/ulink&gt; in treatment-naive HIV patients [&lt;ulink linkType="Reference" linkID="641157"&gt;641157&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232535"&gt;1232535&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results showed that by day 21, HIV RNA copies had decreased by 1.8, 12.9 and 2.0 log for 5, 10 and 20 mg doses, respectively. &lt;ulink linkType="Drug" linkID="12738"&gt;Elvucitabine&lt;/ulink&gt; was well-tolerated and its half-life of around 100 h facilitates less frequent dosing regimens [&lt;ulink linkType="Reference" linkID="641157"&gt;641157&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232535"&gt;1232535&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients were administered with &lt;ulink linkType="Drug" linkID="12738"&gt;elvucitabine&lt;/ulink&gt; 5 or 10 mg qd or 20 mg q48h for 21 days in combination with &lt;ulink linkType="Drug" linkID="14681"&gt;Kaletra&lt;/ulink&gt; . Plasma samples were collected over 35 days and plasma RNA was measured over 28 days [&lt;ulink linkType="Reference" linkID="641157"&gt;641157&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232535"&gt;1232535&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="27639">elvucitabine</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>10 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>20 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-07-14T14:39:40Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="190832"><TitleDisplay>Sirolimus-Eluting Versus Zotarolimus-Eluting Stents For Chronic Total Coronary Occlusions</TitleDisplay><TitleOfficial>A Randomized, Comparison Of Sirolimus-Eluting Stent Implantation With Zotarolimus-Eluting Stent Implantation For The Treatment Of Chronic Total Coronary Occlusions. The PRISON III Trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00428454</Identifier><Identifier type="Organisational Study">RDC-2006-02</Identifier><Identifier type="Trial Acronym">PRISON III</Identifier></Identifiers><Indications><Indication id="80">Coronary artery disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sirolimus-eluting stent</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>zotarolimus-eluting stent</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1055008" type="Company"><TargetEntity id="5035549999" type="organizationId">R &amp; D Cardiologie</TargetEntity></SourceEntity><SourceEntity id="23012" type="Company"><TargetEntity id="4295909551" type="organizationId">Cordis Corp</TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"></TargetEntity><TargetEntity id="D003327" type="MeSH"></TargetEntity><TargetEntity id="-1572475765" type="omicsDisease"></TargetEntity><TargetEntity id="221" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>5</NumberOfSites><CompaniesSponsor><Company id="1055008">R &amp; D Cardiologie</Company></CompaniesSponsor><CompaniesCollaborator><Company id="23012">Cordis Corp</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>301</PatientCountEnrollment><DateStart>2007-01-31T00:00:00Z</DateStart><DateEnd type="actual">2015-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-06-22T10:32:21Z</DateChangeLast><DateAdded>2014-05-30T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>St. Antonius Hospital</Affiliation><Name>Maarten J. Suttorp, MD, PhD</Name></Contact><Contact type="Public contact"><Affiliation>University of Ottawa Heart Institute</Affiliation><Email>bchow@ottawaheart.ca</Email><Name>Benjamin Chow</Name><Phone>613-761-4044</Phone></Contact><Contact type="Public contact"><Affiliation>Instituto de Cardiologia; Sao Paulo; 01323-900; Brazil</Affiliation><Email>mangi@terra.com.br</Email><Name>Jose Mangione</Name><Phone>55 11 3505-3252</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The estimated duration of the occlusion is at least 2 weeks&lt;/li&gt;&lt;li&gt;Signs of ischemia related to the occluded coronary artery&lt;/li&gt;&lt;li&gt;Successful recanalization of the occluded artery is achieved&lt;/li&gt;&lt;li&gt;Reference diameter is &gt; 2.5 mm&lt;/li&gt;&lt;li&gt;Written informed consent obtained&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Primary or rescue PCI for acute myocardial infarction&lt;/li&gt;&lt;li&gt;The lesion could not be crossed&lt;/li&gt;&lt;li&gt;Lesions with complex anatomy making successful stent deployment unlikely&lt;/li&gt;&lt;li&gt;The guide wire is not in the true lumen distal to the occlusion&lt;/li&gt;&lt;li&gt;&lt;ulink linkType="Drug" linkID="4200"&gt;Sirolimus&lt;/ulink&gt; or zotarolimus allergy&lt;/li&gt;&lt;li&gt;Venous or arterial bypass grafts&lt;/li&gt;&lt;li&gt;Pregnant or nursing women&lt;/li&gt;&lt;li&gt;Participation in an other trial&lt;/li&gt;&lt;li&gt;Factors making long-term follow-up difficult or unlikely&lt;/li&gt;&lt;li&gt;Life expectancy  less than  one year&lt;/li&gt;&lt;li&gt;Contraindications for ASA or clopidogrel or heparin&lt;/li&gt;&lt;li&gt;Use of coumadins that could not be stopped before the procedure&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>In-segment late luminal loss at 8 months as assessed by an independent angiographic core lab</Description><Timeframe>8 month</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>A composite of major adverse cardiac events (MACE: death, myocardial infarction and clinically driven target lesion revascularization)</Description><Timeframe>8 month</Timeframe></Measure><Measure><Description>In-stent and in-segment MLD</Description><Timeframe>8 month</Timeframe></Measure><Measure><Description>In-stent and in-segment binary restenosis rate</Description><Timeframe>8 month</Timeframe></Measure><Measure><Description>In-stent late luminal loss</Description><Timeframe>8 month</Timeframe></Measure><Measure><Description>Percentage diameter stenosis</Description><Timeframe>8 month</Timeframe></Measure><Measure><Description>Stent thrombosis (acute, &lt; 1 day; subacute, 1 to 30 days; and late, &gt; 30 days)</Description><Timeframe>30 days</Timeframe></Measure><Measure><Description>Target vessel failure up to five year of clinical follow-up</Description><Timeframe>Five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In      this prospective, randomized trial, &lt;ulink linkType="Drug" linkID="4200"&gt;sirolimus&lt;/ulink&gt;-stent implantation would be compared with      zotarolimus-eluting stent implantation for the treatment of chronic total coronary      occlusions.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The      PRISON III study would address the  issues of   PRISON IItrial (&lt;ulink linkType="Protocol" linkID="105407"&gt;NCT00258596&lt;/ulink&gt;) and would provide information about two      different drug-eluting stents. It would be a prospective, randomized, single-blinded trial      that would compare the relative safety, clinical efficacy and angiographic outcomes of &lt;ulink linkType="Drug" linkID="4200"&gt;sirolimus&lt;/ulink&gt; and      zotarolimus-eluting stents in patients undergoing successful recanalization of CTO.&lt;/para&gt;&lt;para&gt;A total of 300 patients would be clinically followed up for 1, 6, 12 months, two, three, four and five years with angiographic follow-up at 8 months. Quantitative coronary analysis would be      performed by an independent core laboratory. The primary end point would be in-segment late      luminal loss at 8 month angiographical follow-up.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Belgium"><Sites><Site><Name>AZ Middelheim</Name><Address1>Antwerpen</Address1><Address3>2020</Address3><Contacts></Contacts></Site><Site><Name>A.Z. Middelheim</Name><Address1>Antwerpen</Address1><Address3> 2020</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Name>AMC</Name><Address1>Amsterdam</Address1><Address3>1105AZ</Address3><Contacts></Contacts></Site><Site><Name>Catharina Ziekenhuis</Name><Address1>Eindhoven</Address1><Address3>5602ZA</Address3><Contacts></Contacts></Site><Site><Name>Onze Lieve Vrouwe Gasthuis</Name><Address1>Amsterdam</Address1><Address3>1090HM</Address3><Contacts></Contacts></Site><Site><Name>St Antonius Hospital</Name><Address1>Nieuwegein</Address1><Address3>3435CM</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="207">Subjects Undergoing /Underwent Major Cardiac Intervention</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="243">Subjects with Abnormal Angiographic Findings</PatientSegment><SubSegments><SubSegment id="251">Stenosis/Narrowing of vessel</SubSegment><SubSegment id="253">Target lesion measurements by visual estimation in coronary angiogram</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="368">Subjects with Myocardial Ischemia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00428454</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2542"><Endpoint>Assessment of Stenosis/Restenosis</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2554">Minimal luminal diameter</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Coronary artery disease" id="2491"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2492">Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2619">Assessment of major adverse cardiac events (MACEs)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2512"><Endpoint>Assessment of Thrombotic/Thromboembolic Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2565">Stent thrombosis</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2542"><Endpoint>Assessment of Stenosis/Restenosis</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2545">Binary restenosis rates</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2554">Minimal luminal diameter</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2571"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2703">Assessment of target lesion revascularization (TLR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2621"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2689"><Endpoint>Assessment of Reperfusion/Revascularization</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2706">Target vessel failure after stent placement</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1068"><Criterion>Subjects with Coronary Artery Disease (CAD)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1069">Subejcts with coronary artery stenosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="1201"><Criterion>Coronary Angiogram Findings Suggestive of/Confirmed CAD/CHD</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1224">Target reference vessel dimensions suitable for stent placement</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="3873"><Criterion>Subjects with Ischemic Heart Diseases</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="3875">Subjects with symptomatic ischemia</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1609"><Criterion>Subjects with Specific Coronary Angiographic Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1617">Chronic total occlusion/TIMI flow 0 or TIMI flow 1 prior to wire crossing</SubCriterion><SubCriterion disease="Coronary artery disease" id="1620">Excessive tortuosity/angulation proximal to or within the lesion</SubCriterion><SubCriterion disease="Coronary artery disease" id="1625">Lesion located with in a bypassgraft</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1842"><Criterion>Subjects with History of/Scheduled for Diagnostic/Therapeutic Procedures</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1851">Percutaneous coronary intervention (PCI) - Angioplasty</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26158"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1805">Anticoagulant therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>41.03 Months</EnrollmentPeriod><EnrollmentRate>7.34 Patients/Month</EnrollmentRate><DateFirstReceived>2007-01-29T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-06-22T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="191258"><TitleDisplay>Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation</TitleDisplay><TitleOfficial>Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00626626</Identifier><Identifier type="Organisational Study">25223</Identifier><Identifier type="Secondary Organisational">PSU25223</Identifier></Identifiers><Indications><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="161">Hodgkins disease</Indication><Indication id="1727">Acute leukemia</Indication><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1735">Chronic myelocytic leukemia</Indication><Indication id="1744">Mantle cell lymphoma</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="203">Lymphoma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>alemtuzumab</Name><Drug id="2716">alemtuzumab</Drug></Intervention><Intervention type="InterventionPrimary"><Name>clofarabine</Name><Drug id="23624">clofarabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>hydrocortisone</Name></Intervention><Intervention type="InterventionPrimary"><Name>non-myeloablative allogeneic hematopoietic transplant</Name></Intervention><Intervention type="InterventionPrimary"><Name>ondansetron</Name><Drug id="3750">ondansetron</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="duo"><Interventions><Intervention type="InterventionControl"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionControl"><Name>fludarabine</Name><Drug id="6156">fludarabine</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="23624">clofarabine</Drug><IndicationsPioneer><Indication id="161">Hodgkins disease</Indication><Indication id="1744">Mantle cell lymphoma</Indication></IndicationsPioneer><Companies><Company><Company id="1062187">Milton S. Hershey Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2716">alemtuzumab</Drug><IndicationsPioneer><Indication id="1727">Acute leukemia</Indication></IndicationsPioneer><Companies><Company><Company id="1062187">Milton S. Hershey Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3750">ondansetron</Drug><IndicationsPioneer><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="161">Hodgkins disease</Indication><Indication id="1727">Acute leukemia</Indication><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1735">Chronic myelocytic leukemia</Indication><Indication id="1744">Mantle cell lymphoma</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="203">Lymphoma</Indication></IndicationsPioneer><Companies><Company><Company id="1062187">Milton S. Hershey Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2716" type="Drug"><TargetEntity id="130761" type="siDrug">Alemtuzumab</TargetEntity></SourceEntity><SourceEntity id="3750" type="Drug"><TargetEntity id="130944" type="siDrug">Ondansetron hydrochloride</TargetEntity></SourceEntity><SourceEntity id="23624" type="Drug"><TargetEntity id="154861" type="siDrug">Clofarabine</TargetEntity></SourceEntity><SourceEntity id="1062187" type="Company"><TargetEntity id="5035553622" type="organizationId">Milton S Hershey Medical Center</TargetEntity></SourceEntity><SourceEntity id="1272" type="ciIndication"><TargetEntity id="D46" type="ICD10"></TargetEntity><TargetEntity id="10028533" type="MEDDRA"></TargetEntity><TargetEntity id="D011289" type="MeSH"></TargetEntity><TargetEntity id="-376765165" type="omicsDisease"></TargetEntity><TargetEntity id="711" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="161" type="ciIndication"><TargetEntity id="C81" type="ICD10"></TargetEntity><TargetEntity id="201" type="ICD9"></TargetEntity><TargetEntity id="10020206" type="MEDDRA"></TargetEntity><TargetEntity id="D006689" type="MeSH"></TargetEntity><TargetEntity id="98293" type="ORPHANET"></TargetEntity><TargetEntity id="-1008729809" type="omicsDisease"></TargetEntity><TargetEntity id="701" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1727" type="ciIndication"><TargetEntity id="10000830" type="MEDDRA"></TargetEntity><TargetEntity id="684" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"></TargetEntity><TargetEntity id="690" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1735" type="ciIndication"><TargetEntity id="C93.1" type="ICD10"></TargetEntity><TargetEntity id="10009013" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1744" type="ciIndication"><TargetEntity id="C83.1" type="ICD10"></TargetEntity><TargetEntity id="10061275" type="MEDDRA"></TargetEntity><TargetEntity id="D020522" type="MeSH"></TargetEntity><TargetEntity id="52416" type="ORPHANET"></TargetEntity><TargetEntity id="-1332546842" type="omicsDisease"></TargetEntity><TargetEntity id="1384" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"></TargetEntity><TargetEntity id="D008223" type="MeSH"></TargetEntity><TargetEntity id="-386134440" type="omicsDisease"></TargetEntity><TargetEntity id="698" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="138" type="Action"><TargetEntity id="416" type="Mechanism">DNA-Directed DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="1065" type="Mechanism">DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="3618" type="Mechanism">Nucleic Acid Polymerase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="15" type="Action"><TargetEntity id="213" type="Mechanism">5-HT3 Antagonists</TargetEntity></SourceEntity><SourceEntity id="346" type="Action"><TargetEntity id="487" type="Mechanism">Ribonucleoside-Diphosphate Reductase Inhibitors</TargetEntity><TargetEntity id="5552" type="Mechanism">Ribonucleoside-Diphosphate Reductase Inhibitors (bacterial)</TargetEntity></SourceEntity><SourceEntity id="5218" type="Action"><TargetEntity id="1622" type="Mechanism">Anti-CD52</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1062187">Milton S. Hershey Medical Center</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="138">DNA polymerase inhibitor</Action><Action id="15">5-HT 3 receptor antagonist</Action><Action id="346">Ribonucleotide reductase inhibitor</Action><Action id="5218">CD52 antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="1589">Apoptosis stimulator</Class><Class id="2953">Anti-inflammatory</Class><Class id="2970">Anti-emetic</Class><Class id="55685">Anticancer monoclonal antibody</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="751">Film coating</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="102">Nucleotide and derivatives</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>8</PatientCountEnrollment><DateStart>2007-05-31T00:00:00Z</DateStart><DateEnd type="actual">2010-01-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-24T17:40:23Z</DateChangeLast><DateAdded>2014-05-28T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Penn State College of Medicine</Affiliation><Name>David F Claxton, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Phase I&lt;ul&gt;&lt;li&gt;Acute leukemia - secondary or beyond first remission or in CR with poor risk cytogenetics, myelodysplastic syndrome IPPS Int-2 or high risk, chronic myelogenous leukemia in accelerated or blast crisis and imatinib refractory or lymphoma having failed second line therapy or relapsed mantle cell lymphoma&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Phase II&lt;ul&gt;&lt;li&gt;Acute leukemia secondary or at high risk for relapse, myelodysplastic syndrome IPPS Int-2 or high risk or having failed other therapy, chronic myelogenous leukemia, lymphoma having failed first line therapy or at high risk, relapsed Hodgkin's, CCL progressed beyond initial therapy, multiple myeloma beyond initial response or with high risk features&lt;/li&gt;&lt;li&gt;Must have an HLA matched or 5/6 matched related donor at at least a 5/6 matched unrelated donor available&lt;/li&gt;&lt;li&gt;Have adequate renal and hepatic functions&lt;/li&gt;&lt;li&gt;Capable of understanding the investigational nature, potential risk and benefits of the study and able to provide valid informed consent&lt;/li&gt;&lt;li&gt;Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment&lt;/li&gt;&lt;li&gt;Male and female patients of childbearing potential must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Current concomitant chemotherapy, radiation therapy or immunotherapy other than as specified in the protocol&lt;/li&gt;&lt;li&gt;Use of investigational agents within 30 days and no cytotoxic anticancer agents within 2 weeks before study entry with the exception of hydroxyurea.  The patient must have recovered from all non-hematological acute toxicities from any previous therapy&lt;/li&gt;&lt;li&gt;Other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo treatment&lt;/li&gt;&lt;li&gt;Patients with systemic fungal, bacterial, viral, or other infection not controlled&lt;/li&gt;&lt;li&gt;Pregnant or lactating patients&lt;/li&gt;&lt;li&gt;Any significant concurrent disease, illness or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow-up or interpretation of study results&lt;/li&gt;&lt;li&gt;Age&amp;gt; 70 (for phase I) or 75 (for phase II)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Engraftment of Allogeneic Blood Cells: establish the safety of clofarabine and cyclophosphamide preceding allogeneic hematopoietic engraftment. Assess the efficacy of Clofarabine and cyclophosphamide as conditioning for promoting allogeneic hematopoietic engraftment. Adequacy of engraftment will be assessed via assessment of chimerism (percent donor engraftment). A total of &lt;  20% engraftment by day 30 is then failure of engraftment. Safety is defined per common toxicity criteria - Non-Hematological and non renal toxicities of &gt;/= grade 3 or &gt;/= grade 4 up to day 30 are scored as toxicity</Description><Timeframe>Two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Disease-Free Survival: observe disease free survivals in acute leukemia and lymphoma patients receiving allogeneic hematopoietic transplant after Clofarabine and cyclophosphamide conditioning</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Overall Survival: observe overall survival in leukemia and lymphoma patients receiving transplant after clofarabine and cyclophosphamide conditioning</Description><Timeframe>Two years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this atudy was  to  assess the safety and      efficacy of cyclophosphamide and &lt;ulink linkType="Drug" linkID="23624"&gt;clofarabine&lt;/ulink&gt; in promoting hematopoietic engraftment after      allogeneic transplant of blood stem cells.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be divided into two phases. In phase I of the study 9 to 12 patients will be treated in order to establish      cyclophosphamide and clofarabine dose, and to confirm reasonable safety and engraftment      efficacy. Phase II would treat at total of 20 patients at the selected dose level of      clofarabine and cyclophosphamide.  &lt;/para&gt;&lt;para&gt;This study consist of two treatment arms:&lt;br/&gt;Am 1 (experimental: 'clofarabine, cyclophosphamide , &lt;ulink linkType="Drug" linkID="2716"&gt;alemtuzumab&lt;/ulink&gt;'): patients would receive hydrocortisone 100 mg iv 30 min prior to each dose of clofarabine, &lt;ulink linkType="Drug" linkID="3750"&gt;ondansetron&lt;/ulink&gt; 16 mg po or iv or another comparable antiemetic  would be given prior to each dose of clofarabine. An additional similar dose would be given prior to cyclophosphamide dose. Clofarabine 30 mg/m2 - 8 through - 4 (five doses) infusion wlould be administred. Alemtuzumab (20 mg over 2 h on day - 8 only and after clofarabine. Cyclophosphamide 500 mg/m2 days - 8 and - 7 (two doses) would be given over 1 h beginning 4 h after the beginning of clofarabine infusion.&lt;br/&gt;Arm 2 (experimental: 'clofarabine, cyclophosphamide , alemtuzumab' {phase II]): patients would receive hydrocortisone 100 mg iv 30 min prior to each dose of clofarabine, ondansetron 16 mg  po or iv or another comparable antiemetic will be be given prior to each dose of Clofarabine. An additional similar dose will be given prior to cyclophosphamide dose. Clofarabine 30 mg/m2 - 8 through - 4 (five doses) infusion. Alemtuzumab 20 mg would be administered on day - 8 only and after clofarabine. Cyclophosphamide 1000 mg/m2 days - 8 and - 7 (two doses) would be given over 1 h beginning 4 h after the beginning of clofarabine infusion (patients 4 to 9).&lt;/para&gt;&lt;para&gt;Results would be compared to extensive Penn State Milton S. Hershey Medical Center experience using &lt;ulink linkType="Drug" linkID="6156"&gt;fludarabine&lt;/ulink&gt; and cyclophosphamide in a similar patient population. Supportive care, including graft versus host disease prophylaxis would be be similar to that recently used at Hershey Medical Center. Primary endpoints would include survival and engraftment as compared to historical results at Hershey Medical Center. Disease specific outcomes for frequent diagnoses such as acute leukemia and non-hodgkin's lymphoma would be assessed as secondary endpoints.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;The trial was terminated because of investigator decision.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</Name><Address1>Hershey</Address1><Address2>Pennsylvania</Address2><Address3>17033</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Penn State College of Medicine - Penn State Milton S. Hershey Medical Center</Name><Address1>Hershey</Address1><Address2>Pennsylvania</Address2><Address3> 17033</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cancer supportive care</Disease><PatientSegments><PatientSegment><PatientSegment id="9001">Transplantation for Cancers</PatientSegment><SubSegments><SubSegment id="9002">Stem-cell/bone marrow transplantation for cancers</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9009">Hematological cancer subjects for supportive care</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Multiple myeloma</Disease><PatientSegments><PatientSegment><PatientSegment id="3878">Subjects with Protocol Specified Risk Stratification</PatientSegment><SubSegments><SubSegment id="3881">Subjects with high risk stratification</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3467">Subjects with Hodgkin's Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3489">Subjects with B Cell Non Hodgkin's Lymphoma</PatientSegment><SubSegments><SubSegment id="3475">Subjects with mantle cell lymphoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3525">Subjects with Relapse/Recurrent Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3530">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="23734">Subjects with Specific Grade of Lymphoma</PatientSegment><SubSegments><SubSegment id="3501">Subjects with Moderately Aggressive (intermediate grade) Lymphoma</SubSegment><SubSegment id="3502">Subjects with Aggressive (high grade) Lymphoma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3973">Subjects at risk of developing disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3975">Subjects with Acute Leukemia Unspecified Type</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3976">Subjects with Chronic Leukemia Unspecified Type</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3978">Subjects with Chronic Myeloid Leukemia (CML)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3987">Subjects with Secondary Leukemia</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3999">Subjects with Treatment Resistant Disease</PatientSegment><SubSegments><SubSegment id="4000">Subjects with chemotherapy resistant disease</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="4003">Subjects with Relapsed/Recurrent Leukemia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Myelodysplastic syndrome</Disease><PatientSegments><PatientSegment><PatientSegment id="8708">Subjects at Risk of Developing Myelodysplastic Syndrome</PatientSegment><SubSegments><SubSegment id="8727">Subjects with Intermediate Risk-2 Myelodysplastic Syndrome</SubSegment><SubSegment id="8728">Subjects with High Risk Myelodysplastic Syndrome</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8735">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Myeloproliferative disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="8754">Subjects with Chronic Myelogenous Leukemia</PatientSegment><SubSegments><SubSegment id="8755">Subjects with blast-crisis chronic myelogenous leukemia</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8763">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00626626</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Multiple myeloma" id="7374"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Multiple myeloma" id="7388"><Endpoint>Assessment of Transplant Response</Endpoint><SubEndpoints><SubEndpoint disease="Multiple myeloma" id="7389">Assessment of successful engraftment</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Multiple myeloma" id="7488"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7679"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7845"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7868">Assessment of Efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8136"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8140">Assessment of Clinical Efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myelodysplastic syndrome" id="11903"><Endpoint>Assessment of Engraftment</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Myelodysplastic syndrome" id="11912"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Myelodysplastic syndrome" id="11937"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Myelodysplastic syndrome" id="11938">Assessment of Efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myeloproliferative disorder" id="14279"><Endpoint>Assessment of Engraftment</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19374"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19419"><Endpoint>Assessment of Engraftment</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lymphoma" id="7538"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7544"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7879"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7885"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11812"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myeloproliferative disorder" id="14198"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myeloproliferative disorder" id="14199"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19255"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3442"><Criterion>Subjects with Hodgkin's Lymphoma</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3464"><Criterion>Subjects with B Cell Non Hodgkin's Lymphoma</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3450">Subjects with mantle cell lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3491"><Criterion>Subjects Having Protocol Specified Donors</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3492">Subjects with related donor</SubCriterion><SubCriterion disease="Lymphoma" id="3493">Subjects with unrelated donor</SubCriterion><SubCriterion disease="Lymphoma" id="3496">Subjects with HLA matched donor</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3518"><Criterion>Subjects with other hematological malignancies</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3519"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3609"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3614"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3621"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3622">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="4609"><Criterion>Subjects with Risk Stratified Multiple Myeloma</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4612">Subjects with high risk stratification</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="4642"><Criterion>Subjects Having Protocol Specified Donors</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4644">Subjects with HLA matched donor</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="4738"><Criterion>Subjects with Response to Therapy</Criterion></Inclusion><Inclusion disease="Leukemia" id="4961"><Criterion>Subjects at Risk of Developing Disease</Criterion></Inclusion><Inclusion disease="Leukemia" id="4973"><Criterion>Subjects with Acute Leukemia Unspecified Type</Criterion></Inclusion><Inclusion disease="Leukemia" id="4974"><Criterion>Subjects with Chronic Leukemia Unspecified Type</Criterion></Inclusion><Inclusion disease="Leukemia" id="4977"><Criterion>Subjects with Secondary Leukemia</Criterion></Inclusion><Inclusion disease="Leukemia" id="4982"><Criterion>Subjects with Chronic Myeloid Leukemia (CML)</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5003">Subjects with accelerated phase of CML</SubCriterion><SubCriterion disease="Leukemia" id="5004">Subjects with blast phase of CML</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5031"><Criterion>Subjects with Other Bone Marrow Disorders</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5032">Subjects with myelodysplastic syndromes</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5036"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5037">Subjects with other hematologic malignancies</SubCriterion><SubCriterion disease="Leukemia" id="5042">Subjects co-morbid with hodgkin's lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5071"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5073">Subjects with normal/adequate liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5157"><Criterion>Subjects with Response to Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5159">Subjects in second remission</SubCriterion><SubCriterion disease="Leukemia" id="5160">Subjects in third remission</SubCriterion><SubCriterion disease="Leukemia" id="5163">Subjects in complete response/remission</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5164"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5165">Subjects with progressive/refractory leukemia to chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5173"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Multiple myeloma" id="5228"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4675">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="7092"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5119">Subjects with history of targeted therapy for leukemia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7597"><Criterion>Subjects with Intermediate Risk-2 Myelodysplastic Syndrome</Criterion></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7603"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7604"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7630"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8741"><Criterion>Subjects with Chronic Myelogenous Leukemia</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="8742">Subjects with blast-crisis chronic myelogenous leukemia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8750"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8791"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13331"><Criterion>Transplantation for Cancers</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13332">Stem-cell/bone marrow transplantation for cancers</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="13354"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13359">Subjects with history of anti-cancer radiotherapy</SubCriterion><SubCriterion disease="Cancer supportive care" id="13360">Subjects with history of surgery/procedure for protocol specified cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="13362"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13364">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="13369"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13382">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myeloproliferative disorder" id="13446"><Criterion>Protocol Specified Inclusion Criteria for Donors</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="33320"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="8776">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="33739"><Criterion>Subjects with risk of disease recurrence</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7598">Subjects with High Risk Myelodysplastic Syndrome</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="34012"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3628">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34013"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5074">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="34024"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13365">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="34054"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4676">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="34100"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13383">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="34403"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13377">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="34876"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13379">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4702"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4761"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4762">Subject with history of radiotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="4769">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="4777">Subject with history of biologics therapy</SubCriterion><SubCriterion disease="Lymphoma" id="4783">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Multiple myeloma" id="6065"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Multiple myeloma" id="6124"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="6125">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Multiple myeloma" id="6133">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Multiple myeloma" id="6181"><Criterion>Subjects with Adverse Effects to Therapy</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="6184">Subjects with drug related toxicity due to myeloma therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Leukemia" id="6660"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Leukemia" id="8709"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6618">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Leukemia" id="6645">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9161"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9188"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9189">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9193">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9195">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10302"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="10303">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10308"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10311"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10335"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="10336">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10340">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10342">Subjects with history of/scheduled to receive an investigational drug</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10945">Patient with history of immunotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10344"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10882"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10908"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10909">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cancer supportive care" id="26825"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10911">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="26833"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9191">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2008-02-20T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="211636"><TitleDisplay>Effects of High-Dose Resveratrol in Non-Diabetic Obese Males</TitleDisplay><TitleOfficial>Effects of High-Dose Resveratrol on Resting Energy Expenditure and HOMA in Non-Diabetic Obese Males</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02247596</Identifier><Identifier type="Organisational Study">2009/00454</Identifier></Identifiers><Indications></Indications><BiomarkerNames><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="153" role="Therapeutic effect marker" type="Biochemical">High-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>resveratrol</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1042211" type="Company"><TargetEntity id="5035543949" type="organizationId">National Medical Research Council (Nmrc)  Singapore</TargetEntity></SourceEntity><SourceEntity id="1072668" type="Company"><TargetEntity id="5001001212" type="organizationId">Khoo Teck Puat Hospital</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1072668">Khoo Teck Puat Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1042211">National Medical Research Council (NMRC), Singapore</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>36</PatientCountEnrollment><DateStart>2009-07-31T00:00:00Z</DateStart><DateEnd type="actual">2012-10-31T00:00:00Z</DateEnd><DateChangeLast>2015-05-28T10:29:36Z</DateChangeLast><DateAdded>2014-09-26T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Khoo Teck Puat Hospital</Affiliation><Name>Kian Peng Goh</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Ability to give informed consent&lt;/li&gt;&lt;li&gt;Obese Chinese Male&lt;/li&gt;&lt;li&gt;Age 21 to 55 yrs old&lt;/li&gt;&lt;li&gt;No diabetes mellitus&lt;/li&gt;&lt;li&gt;BMI of 30 kg/m2 or more during screening&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Unwilling to abstain from ingesting large quantities of resveratrol-containing foods (eg, red wine, nuts)&lt;/li&gt;&lt;li&gt;Cancer diagnosis that is currently under treatment, is clinically detectable, or that has been treated within the past five years&lt;/li&gt;&lt;li&gt;Terminal disease or on palliative care&lt;/li&gt;&lt;li&gt;Current excessive alcohol intake (&amp;gt; 21 units per week for men; 14 units per week for women)&lt;/li&gt;&lt;li&gt;Known  diabetes mellitus&lt;/li&gt;&lt;li&gt;Past history of unexplained hypoglycemia&lt;/li&gt;&lt;li&gt;Past or current history of strokes&lt;/li&gt;&lt;li&gt;History of any grape allergy&lt;/li&gt;&lt;li&gt;On alternative or traditional medications&lt;/li&gt;&lt;li&gt;Treated with another investigational drug within last 6 months&lt;/li&gt;&lt;li&gt;Poorly controlled hypertension (SBP&amp;gt;/= 160 or DBP &amp;gt;/= 100) within last 1 month&lt;/li&gt;&lt;li&gt;ALT and/or AST&amp;gt; 1.5 x above upper limit of normal within last 6 months&lt;/li&gt;&lt;li&gt;GFR&amp;lt; 50 ml/min/1.73m2 (MDRD equation) within last 6 months&lt;/li&gt;&lt;li&gt;Staff of Department of Medicine, Khoo Teck Puat Hospital&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change from baseline in resting energy expenditure via indirect calorimetry at 2 weeks: measured in Kcal/day using a metabolic cart</Description><Timeframe>2 weeks (pre and post intervention)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change from baseline in Blood pressure at 2 weeks: systolic and diastolic blood pressure in mmHg</Description><Timeframe>2 weeks (pre and post intervention)</Timeframe></Measure><Measure><Description>Change from baseline in Glycated hemoglobin at 2 weeks: HbA1c in %</Description><Timeframe>2 weeks (pre and post intervention)</Timeframe></Measure><Measure><Description>Change from baseline in insulin resistance via Homeostasis Model Assessment (HOMA) 2 calculator at 2 weeks: beta cell function, B (%),insulin sensitivity, S (%), Insulin resistance, IR</Description><Timeframe>2 weeks (pre and post intervention)</Timeframe></Measure><Measure><Description>Change from baseline in lipid subfractions at 2 weeks: LDL, HDL and triglycerides in mmol/l</Description><Timeframe>2 weeks (pre and post intervention)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary aim of study was to examine the effects of 2 weeks of oral resveratrol on      resting energy expenditure and insulin sensitivity in non-diabetic obese male subjects.      Secondary variables included plasma lipid subfraction, blood pressure and glycated      hemoglobin (HbA1c).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be recruited between July 2009 and July 2012 from a single hospital in Singapore.      &lt;/para&gt;&lt;para&gt;The study would be a randomized, double-blind, parallel group trial consisting of a screening      visit, a two-week treatment period and a post-treatment visit.&lt;/para&gt;&lt;para&gt;Randomization would be centrally performed during treatment assignment with a 2-digit reference      code placed in sealed opaque envelopes maintained by the person responsible for the      preparation of the intervention drug and placebo.  Trans-resveratrol extract from Polygonum      Cuspidatum (Mega Resveratrol, Danbury, USA) was used in the trial. The placebo was not      distinguishable by color, form, or taste from the active drug. The randomization code would be      unblinded only after all predefined data were recorded.&lt;br/&gt;Subjects would receive 1g tid of either resveratrol or placebo for 2 weeks and      instructed to abstain from foods with high resveratrol content during the entire duration of      the trial. Compliance would be determined by pill counting at the end of the trial period.      Subjects in both arms were not allowed to commence on an exercise regimen or supplements      during the study period. Subjects who dropped out of the trial would not be replaced. All      variables would be measured at baseline and at the end of the treatment period.&lt;/para&gt;&lt;para&gt;RMR would be measured by indirect calorimetry using a breath-by-breath metabolic gas analyser via      the face-mask method.&lt;/para&gt;&lt;para&gt;The investigators estimated that a sample size of 18 patients per group (Total n = 36) was      needed to provide 80% power and two-sided 5% to detect a difference in a Cohen's effect size      of 1.0 between the two groups.&lt;/para&gt;&lt;para&gt;All analyses would be performed using SPSS 21.0 (IBM) with statistical significance set at p &amp;lt;      0.05 and with the percentage change from baseline as the unit of analysis. All data would be      analyzed according to the intention-to-treat principle. MANOVA would be performed to compare the      intervention and placebo groups for the unadjusted and adjusted p-values on the study      variables of interest. Normal distribution would be verified with the Kolmogorov-Smirnov test and      data would be presented as mean +/- standard deviation (SD).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Singapore"><Sites><Site><Name>Khoo Teck Puat Hospital</Name><Address1>Singapore</Address1><Address3>768828</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02247596</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20414"><Endpoint>Assessment of Metabolic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20416">Assessment of energy expenditure</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20406"><Endpoint>Assessment of HbA1c levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20407"><Endpoint>Assessment of Beta Cell Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20412"><Endpoint>Assessment of Insulin Sensitivity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20432"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20411">Assessment of insulin resistance</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20446"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20452">Assessment of Triglycerides</SubEndpoint><SubEndpoint disease="Obesity" id="20455">Assessment of LDL-C</SubEndpoint><SubEndpoint disease="Obesity" id="20456">Assessment of HDL</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20599"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20554">Assessment of blood pressure</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion></Inclusion><Inclusion disease="Obesity" id="19678"><Criterion>Subjects with Protocol Specified BMI</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19682">Subjects with BMI&gt;30</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19790"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19723">Non-Diabetic Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="34455"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19791">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15293"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15294">Subjects co-morbid with stroke</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15295"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15401">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15311"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15312">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15316"><Criterion>Subjects co-morbid with hypertension</Criterion></Exclusion><Exclusion disease="Obesity" id="15325"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15331">Subjects with neoplasm/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15336"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15338">Subjects with abnormal glycemic parameters</SubCriterion><SubCriterion disease="Obesity" id="15340">Abnormal liver function test</SubCriterion><SubCriterion disease="Obesity" id="15341">Subjects with abnormal renal function tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Obesity" id="15354"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-10-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-09-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="22451"><TitleDisplay>The Use of Rosiglitazone to Treat Asthma</TitleDisplay><TitleOfficial>The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">07-14592</Identifier><Identifier type="NCT">NCT00614874</Identifier></Identifiers><Indications><Indication id="31">Asthma</Indication></Indications><BiomarkerNames><BiomarkerName id="2713" role="Therapeutic effect marker" type="Physiological">Forced expiratory volume</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rosiglitazone</Name><Drug id="8976">rosiglitazone</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8976">rosiglitazone</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="21233">Creighton University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8976" type="Drug"><TargetEntity id="210057" type="siDrug">Rosiglitazone maleate</TargetEntity><TargetEntity id="284437" type="siDrug">Rosiglitazone</TargetEntity></SourceEntity><SourceEntity id="21233" type="Company"><TargetEntity id="4297259109" type="organizationId">Creighton University</TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1919" type="Action"><TargetEntity id="605" type="Mechanism">Insulin Sensitizers</TargetEntity></SourceEntity><SourceEntity id="2480" type="Action"><TargetEntity id="895" type="Mechanism">PPARgamma Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21233">Creighton University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1919">Insulin sensitizer</Action><Action id="2480">PPAR gamma agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>16</PatientCountEnrollment><DateStart>2008-12-31T00:00:00Z</DateStart><DateEnd type="actual">2010-03-31T00:00:00Z</DateEnd><DateChangeLast>2013-11-22T08:55:20Z</DateChangeLast><DateAdded>2008-08-04T13:03:32Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Creighton University Medical Center</Affiliation><Name>Tammy Wichman</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Able to comprehend and grant a witnessed, written informed consent&lt;/li&gt;&lt;li&gt;Must be &gt; 19 years old&lt;/li&gt;&lt;li&gt;Must be able to swallow a tablet&lt;/li&gt;&lt;li&gt;Female participants must have a negative urine pregnancy test at visit 1 and
             throughout duration of the study&lt;/li&gt;&lt;li&gt;Must have a history of physician diagnosed asthma&lt;/li&gt;&lt;li&gt;Must have a baseline forced expiratory volume in 1 s (FEV1)&amp;gt; 60% predicted&lt;/li&gt;&lt;li&gt;Must be able to perform pulmonary function testing&lt;/li&gt;&lt;li&gt;Must have methacholine-induced decrease in FEV1 of 20%&lt;/li&gt;&lt;li&gt;Must be capable of withholding medications that may affect the methacholine challenge
             test&lt;/li&gt;&lt;li&gt;Must be able to withstand a 30 day washout period for all inhaled corticosteroids&lt;/li&gt;&lt;li&gt;Must be able to attend all office visits, 4 weeks apart for 12 weeks.  Each visit will
             last approximately 2 to 3 h&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Age 18 or younger&lt;/li&gt;&lt;li&gt;FEV1&amp;lt; 60% predicted value&lt;/li&gt;&lt;li&gt;History or presence of significant renal, hepatic,neurological, cardiovascular,
             hematological, cerebrovascular, respiratory, endocrine, gastrointestinal, or collagen
             vascular disorder that in the investigator's opinion could interfere with the study or
             require medical attention that would interfere with the study&lt;/li&gt;&lt;li&gt;History of cancer other than basal cell skin cancer&lt;/li&gt;&lt;li&gt;History of hypoglycemia&lt;/li&gt;&lt;li&gt;Current smokers, greater than ten pack year history, or patients quitting less than one
             year prior to screening&lt;/li&gt;&lt;li&gt;History within the past year of excessive alcohol intake or drug addiction&lt;/li&gt;&lt;li&gt;History of respiratory infection requiring treatment with an antibiotic within 2 week
             prior to visit 1&lt;/li&gt;&lt;li&gt;Chronic intermittent use of inhaled, oral, intra-muscular, topical or intravenous
             corticosteroids within 4 weeks of visit 1&lt;/li&gt;&lt;li&gt;Inability to perofrm consistent spirometry or nitric oxide exhalation&lt;/li&gt;&lt;li&gt;Treatment with an experimental, non-approved drug, or investigational drug within the
             past 30 days&lt;/li&gt;&lt;li&gt;Known hypersensitivity to&lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;History of noncompliance to medical regimens and participants who are considered to be
             potentially unreliable&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Methacholine Responsiveness as Assessed by PC20 : PC20 is the concentration of methacholine at which patients had a decrease in Forced Expiratory Volume in one second (FEV1) of 20%</Description><Timeframe>Patients were assessed at baseline and at 12 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Exhaled Nitric Oxide in Parts Per Billion (Ppb), Parts Per Billion : Fraction Exhaled Nitric oxide was measured on each visit prior to bronchoprovocation by chemiluminescence using an analyzer</Description><Timeframe>Patients were assessed at baseline and 12 weeks</Timeframe></Measure><Measure><Description>Forced Expiratory Volume in 1 Second (FEV1) : FEV1 in liters</Description><Timeframe>Patients were assessed at baseline and 12 weeks</Timeframe></Measure><Measure><Description>Forced Expiratory Volume in One Second (FEV1) Percent Predicted : Spirometry was performed on each visit according to American Thoracic Society guidelines. FEV1 percent predicted was measured.</Description><Timeframe>Patients were assessed at baseline and 12 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study utilized the drug &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; (Avandia) to treat the
      effects of airway inflammation in patients with asthma.
The study would be conducted on 14 adult steroid naive patients with asthma. Patients with
      qualifying pulmonary function testing values would be eligible for enrollment.  Enrolled
      subjects would be treated with &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; po at 2 mg dose for 4 weeks. Patients would be
      reassessed and dosing will increase in 4 week increments up to 12 mg.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will take &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; 2 mg for 4 weeks, then 4 mg for 4 weeks, then 8 mg for 4 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Creighton University Medical Center, Department of Pulmonology and Critical Care</Name><Address1>Omaha</Address1><Address2>Nebraska</Address2><Address3>68131</Address3><CountrySubDivision code="NE">Nebraska</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Asthma</Disease><PatientSegments><PatientSegment><PatientSegment id="11959">Subjects with Persistent Asthma</PatientSegment><SubSegments><SubSegment id="11960">Subjects with mild persistent asthma</SubSegment><SubSegment id="11961">Subjects with moderate persistent asthma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00614874</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Asthma" id="5918"><Endpoint>Assessment of Pulmonary Function</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="5919">Change in lung function after challenge test</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Asthma" id="5962"><Endpoint>Assessments of Airway Status/Obstruction</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="5964">Airway reactivity/hyperreactivity</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Asthma" id="5918"><Endpoint>Assessment of Pulmonary Function</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="5924">Impulse oscillometry measurements</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="5997"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6005">Assessment of exhaled nitric oxide</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6139"><Endpoint>Spirometry Unspecified</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Asthma" id="2773"><Criterion>Subjects with FEV1 Measurement</Criterion><SubCriteria><SubCriterion disease="Asthma" id="2779">Subjects with FEV1 &gt;=80% predicted</SubCriterion><SubCriterion disease="Asthma" id="4274">Subjects with FEV1 60% to 79% predicted</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Asthma" id="2801"><Criterion>Bronchial Hyper Responsiveness by Methacholine Challenge Test</Criterion></Inclusion><Inclusion disease="Asthma" id="4322"><Criterion>Subjects with Diagnosis of Asthma</Criterion></Inclusion><Inclusion disease="Asthma" id="22363"><Criterion>Subjects with Persistent Asthma</Criterion><SubCriteria><SubCriterion disease="Asthma" id="22364">Subjects with mild persistent asthma</SubCriterion><SubCriterion disease="Asthma" id="22365">Subjects with moderate persistent asthma</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Asthma" id="3839"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Asthma" id="3855"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Asthma" id="3877"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Asthma" id="20239"><Criterion>Subjects with Protocol Specified Pulmonary Funtion Findings</Criterion></Exclusion><Exclusion disease="Asthma" id="20241"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Asthma" id="20242"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Asthma" id="20243"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Asthma" id="20244"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Asthma" id="20246"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Asthma" id="20247"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Asthma" id="20248"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Asthma" id="20249">Subjects with history of/scheduled for asthma drugs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Asthma" id="20252"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Asthma" id="20263"><Criterion>Subjects with contraindication to imaging/diagnostic procedures</Criterion></Exclusion><Exclusion disease="Asthma" id="25070"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Asthma" id="3954">Smokers</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-02-28T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-08-04T13:03:32Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="226066"><TitleDisplay>Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology</TitleDisplay><TitleOfficial>Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Treatment</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02401880</Identifier><Identifier type="Organisational Study">EMLIN-001</Identifier><Identifier type="Other">2014-004895-48</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="435" role="Therapeutic effect marker" type="Genomic;Proteomic">Glucagon</BiomarkerName><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="28765" role="Therapeutic effect marker" type="Cellular">Pancreatic alpha cells</BiomarkerName><BiomarkerName id="28800" role="Therapeutic effect marker" type="Cellular">Pancreatic beta cells</BiomarkerName><BiomarkerName id="46480" role="Therapeutic effect marker" type="Proteomic">Glucagon/Insulin ratio</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>empagliflozin</Name><Drug id="58762">empagliflozin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>empagliflozin</Name><Drug id="58762">empagliflozin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>linagliptin</Name><Drug id="55852">linagliptin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>metformin hydrochloride</Name><Drug id="6050">metformin hydrochloride</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="55852">linagliptin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039637">Profil Institut fr Stoffwechselforschung GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22546">Boehringer Ingelheim GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="58762">empagliflozin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039637">Profil Institut fr Stoffwechselforschung GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22546">Boehringer Ingelheim GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="58762">empagliflozin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039637">Profil Institut fr Stoffwechselforschung GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22546">Boehringer Ingelheim GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6050">metformin hydrochloride</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039637">Profil Institut fr Stoffwechselforschung GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22546">Boehringer Ingelheim GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6050" type="Drug"><TargetEntity id="220882" type="siDrug">Metformin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="55852" type="Drug"><TargetEntity id="365734" type="siDrug">Linagliptin</TargetEntity></SourceEntity><SourceEntity id="58762" type="Drug"><TargetEntity id="470491" type="siDrug">Empagliflozin</TargetEntity><TargetEntity id="470491" type="siDrug">Empagliflozin</TargetEntity></SourceEntity><SourceEntity id="1039637" type="Company"><TargetEntity id="5001364237" type="organizationId">Profil Institut fuer Stoffwechselforschung GmbH</TargetEntity></SourceEntity><SourceEntity id="22546" type="Company"><TargetEntity id="4295869234" type="organizationId">Boehringer Ingelheim GmbH</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4020" type="Action"><TargetEntity id="1251" type="Mechanism">SGLT-2 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="5537" type="Action"><TargetEntity id="415" type="Mechanism">Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors</TargetEntity><TargetEntity id="3328" type="Mechanism">Anti-CD26 (Anti-Dipeptidyl Peptidase IV; DPPIV)</TargetEntity><TargetEntity id="5399" type="Mechanism">Dipeptidyl peptidase 4 (DPP4) antagonists</TargetEntity></SourceEntity><SourceEntity id="8805" type="Action"><TargetEntity id="2375" type="Mechanism">AMP-Activated Protein Kinase (AMPK) Activators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1039637">Profil Institut fr Stoffwechselforschung GmbH</Company></CompaniesSponsor><CompaniesCollaborator><Company id="22546">Boehringer Ingelheim GmbH</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4020">Sodium glucose transporter-2 inhibitor</Action><Action id="5537">Dipeptidyl peptidase IV inhibitor</Action><Action id="8805">AMP activated protein kinase stimulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="38206">Biguanide antidiabetic product</Class><Class id="38439">DPP IV inhibitor antidiabetic product</Class><Class id="399">Hypoglycemic agent</Class><Class id="7292">Vulnerary agent</Class></Class><Technologies><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>89</PatientCountEnrollment><PatientCountEvaluable>83</PatientCountEvaluable><DateStart>2015-05-31T00:00:00Z</DateStart><DateEnd type="actual">2015-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-04-25T12:01:51Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Hellersbergstr. 9, Neuss, 41460 Germany</Affiliation><Email>christoph.kapitza@profil.com</Email><Extension>157</Extension><Name>Christoph Kapitza</Name><Phone>+4921314018</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male or female subject with diabetes mellitus type 2&lt;/li&gt;&lt;li&gt;Diabetes mellitus type 2 on stable treatment with metformin (daily dose at least 1000 mg) for at least 6 months&lt;/li&gt;&lt;li&gt;HbA1c 7.0 to 9.9%, both inclusive&lt;/li&gt;&lt;li&gt;Diabetes duration of at least 24 months&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of diabetes mellitus type 1&lt;/li&gt;&lt;li&gt;GFR (as calculated by the Cockcroft-Gault equation)&amp;lt; 60 ml/min at screening&lt;/li&gt;&lt;li&gt;Systolic blood pressure outside the range of 100 to 160 mmHg or diastolic blood pressure &gt; 95 mmHg at screening&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in glucagon/insulin ratio (AUC 0 to 180 min) during LMT from V3 to V4 between the two treatment groups (linagliptin versus placebo)</Description><Timeframe>0 to 180 min after trial drug administration as given above</Timeframe></Measure><Measure><Description>Change in first phase glucagon/insulin ratio during hyperglycemic clamp investigation (AUC 0 to 10 min) from V3 to V4 between the two treatment groups (linagliptin versus placebo)</Description><Timeframe>0 to 10 min after trial drug administration as given above</Timeframe></Measure><Measure><Description>Change in intact proinsulin release (AUC 0 to 180 min) during LMT from V3 to V4 between the two treatment groups (linagliptin versus placebo)</Description><Timeframe>0 to 180 min after trial drug administration as given</Timeframe></Measure><Measure><Description>Change in glucagon release (AUC 0 to 180 min) during Liquid Meal Test (LMT) from V3 to V4 between the two treatment groups (linagliptin versus placebo) (glucagon release was basis for sample size calculation)</Description><Timeframe>30 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Treatment-emergent hypoglycemic episodes, changes in clinical variables, incidence of adverse events</Description><Timeframe>Ongoing during the trial</Timeframe></Measure><Measure><Description>Alpha and beta cell function assessed using a standardized liquid meal test and an intravenous (iv) glucose challenge</Description></Measure><Measure><Description>Efficacy measures comprised proinsulin and glucagon after the liquid meal test</Description></Measure><Measure><Description>Assessment of fast and late-phase insulin release after an iv glucose load with a subsequent hyperglycemic clamp</Description></Measure><Measure><Description>Change in glucagon release (AUC 0 to 180 min) during LMT from V2 to V3 during treatment with empagliflozin (V2 versus V3)</Description><Timeframe>30 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary aim of this exploratory mechanistic study was to investigate the effects of      &lt;ulink linkType="Drug" linkID="58762"&gt;empagliflozin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="55852"&gt;linagliptin&lt;/ulink&gt; on alpha- and beta cell physiology in type 2 diabetes mellitus (T2DM) subjects.&lt;/para&gt;&lt;para&gt;This study aimed evaluate the effect of the DPP-IV inhibitor linagliptin (as compared to      placebo) in addition to the SGLT-2 inhibitor empagliflozin on pancreatic alpha and beta cell      function, as well as several markers of metabolic control.&lt;br/&gt;The primary objective of this study was to evaluate the effect of empagliflozin treatment on alpha- and beta-cell function in subjects with T2DM on stable &lt;ulink linkType="Drug" linkID="66865"&gt;metformin&lt;/ulink&gt; background therapy and  to evaluate insulin resistance during treatment with empagliflozin plus linagliptin compared to empagliflozin alone in  subjects with T2DM on stable metformin background therapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2017, results were published. During TP1, empagliflozinreduced postprandial plasma glucose levels and fasting, associated with a significant improvement in the conversion rate of proinsulin and reduction in postprandial insulin levels. During TP2, the addition oflinagliptinfurther improved postprandial glucose levels, probably as a result of a marked reduction in postprandial glucagon concentrations (TP2). During TP1 withempagliflozin, the insulin response to an iv glucose load increased and further improved after the addition oflinagliptin(TP2) [&lt;ulink linkType="Reference" linkID="1919506"&gt;1919506&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would be performed as a multicenter study which includes two centres and a total of 44 subjects      with T2DM would be included according to the defined inclusion and exclusion criteria.&lt;/para&gt;&lt;para&gt;Subjects have to be on a stable &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; therapy and would receive in a first step      empagliflozin for 30 days. Both therapies (metformin and empagliflozin) would be continued      for another 30 days and subjects would be randomized to three arms. Subjects in arms 1 and 2 would receive  either 5 mg of linagliptin or      placebo in addition to stable metformin and empagliflozin therapy for 30 days. Subjects in arm 3 would receive  empagliflozin 25 mg for 30 days. Subjects in arm 1,2 and 3 would receive empagliflozin for 60 days.&lt;/para&gt;&lt;para&gt;Subjects would come for two inhouse periods  to their corresponding study center and would      undergo an hyperglycemic clamp test as well as a meal test in each of the periods.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects in treatment period 1 (TP1) received 25 mgempagliflozinfor a duration of 1month.  In treatment period 2 (TP2), subjects were randomized to receive linagliptin5 mg or placebo for 1 additional month [&lt;ulink linkType="Reference" linkID="1919506"&gt;1919506&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="516680">empagliflozin</Intervention><Treatments><Treatment><Dose>25 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="516681">linagliptin</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Profil Institut fr Stoffwechselforschung GmbH</Name><Address1>Neuss</Address1><Address3>41460</Address3><Contacts></Contacts></Site><Site><Name>Profil Mainz GmbH &amp; Co. KG</Name><Address1>Mainz</Address1><Address3>55116</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="97">Subjects on Monotherapy</PatientSegment><SubSegments><SubSegment id="98">Subjects only on metformin</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="103">Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="145">Subjects with Moderate Glycemic Control</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02401880</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2014-004895-48</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1385"><Endpoint>Assessment of Glucagon Secretion/Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1650"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1663">Clinical laboratory tests/biochemical analysis</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1385"><Endpoint>Assessment of Glucagon Secretion/Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1650"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1663">Clinical laboratory tests/biochemical analysis</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="639"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="670"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="905">Subjects on/agreeing to maintain stable dose of oral hypoglycemic agents</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33510"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="607">Subjects with Poor/Inadequate Glycemic Control</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="901">Subjects with Moderate Glycemic Control</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="837"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="849"><Criterion>Subjects  with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="851">Subjects with type 1 diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5078"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5080">Abnormal lab test</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-12-11T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-03-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-04-27T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="233321"><TitleDisplay>Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer</TitleDisplay><TitleOfficial>Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02483767</Identifier><Identifier type="Organisational Study">PUMCH-BC-OVARIAN SUPPRESSION</Identifier><Identifier type="Trial Acronym">POF</Identifier></Identifiers><Indications><Indication id="49">Breast tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="3" role="Disease marker" type="Genomic;Proteomic">HER2</BiomarkerName><BiomarkerName id="5" role="Disease marker" type="Genomic;Proteomic">Estrogen receptor</BiomarkerName><BiomarkerName id="1688" role="Therapeutic effect marker" type="Biochemical">Follicle-stimulating hormone</BiomarkerName><BiomarkerName id="5326" role="Therapeutic effect marker" type="Biochemical">Estradiol</BiomarkerName><BiomarkerName id="8291" role="Therapeutic effect marker" type="Genomic;Proteomic">Anti-Muellerian hormone type-2 receptor</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>anthracycline</Name></Intervention><Intervention type="InterventionPrimary"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention><Intervention type="InterventionPrimary"><Name>fluorouracil</Name></Intervention><Intervention type="InterventionPrimary"><Name>goserelin acetate</Name><Drug id="7286">goserelin acetate</Drug></Intervention><Intervention type="InterventionPrimary"><Name>paclitaxel</Name><Drug id="3803">paclitaxel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="combo"><Interventions><Intervention type="InterventionControl"><Name>anthracycline</Name></Intervention><Intervention type="InterventionControl"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionControl"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention><Intervention type="InterventionControl"><Name>fluorouracil</Name></Intervention><Intervention type="InterventionControl"><Name>paclitaxel</Name><Drug id="3803">paclitaxel</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2953">docetaxel</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039932">Peking Union Medical College Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3803">paclitaxel</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039932">Peking Union Medical College Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="7286">goserelin acetate</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039932">Peking Union Medical College Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3803" type="Drug"><TargetEntity id="101438" type="siDrug">Paclitaxel</TargetEntity></SourceEntity><SourceEntity id="2953" type="Drug"><TargetEntity id="140605" type="siDrug">Docetaxel</TargetEntity></SourceEntity><SourceEntity id="7286" type="Drug"><TargetEntity id="90110" type="siDrug">Goserelin</TargetEntity></SourceEntity><SourceEntity id="1039932" type="Company"><TargetEntity id="5041082090" type="organizationId">Peking Union Medical College Hospital</TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1092" type="Action"><TargetEntity id="590" type="Mechanism">GnRH (LHRH) Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1039932">Peking Union Medical College Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1092">GNRH receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2575">Microtubule inhibitor</Class><Class id="2576">Microtubule stabilizer</Class><Class id="2660">Vasoprotectant</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="80">Peptide</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="658">Subcutaneous drug implant</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>98</PatientCountEnrollment><DateStart>2015-06-30T00:00:00Z</DateStart><DateEnd type="actual">2016-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:33:15Z</DateChangeLast><DateAdded>2015-08-01T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The patients signed the written informed consent&lt;/li&gt;&lt;li&gt;Histologically proven stage I, II, or III breast cancer&lt;/li&gt;&lt;li&gt;Must be candidates for adjuvant or neoadjuvant chemotherapy&lt;/li&gt;&lt;li&gt;Must be premenopausal&lt;/li&gt;&lt;li&gt;Trastuzumab is permitted in patients with human epidermal growth factor receptor 2 (HER2) overexpressing tumors&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;The patients were previous chemotherapy&lt;/li&gt;&lt;li&gt;Evidence of distant metastases&lt;/li&gt;&lt;li&gt;Other malignancies in the previous five years&lt;/li&gt;&lt;li&gt;The patients were using GnRHa, progesterone, stimulate ovulation drugs, oral contraceptives, aromatase inhibitors, intrauterine device with hormone, subcutaneous preparations contraceptive drugs such as hormone drugs and instruments during 3 month preceding the start of chemotherapy&lt;/li&gt;&lt;li&gt;Pregnancy or lactation&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Ovarian failure: ovarian failure is defined as amenorrhea for the preceding 6 months and follicle-stimulating hormone (FSH)  and E2 levels in the post -menopausal range two year after the end of chemotherapy</Description><Timeframe>Two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>DFS OS: disease free survival (DFS) and overall survival (OS) will be assessed at five years after the end of chemotherapy</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>FSH,E2,AMH: FSH, estradiol, and anti-Mullerian hormone (AMH) levels in the postmenopausal range will be assessed at 3 months,one and two years after  the end of chemotherapy</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Ovarian dysfunction: ovarian dysfunction is defined as amenorrhea for the preceding 3 months and follicle-stimulating hormone (FSH)  and E2 levels in the post -menopausal range one or two year after the end of chemotherapy</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Time to the resumption of menstrual activity: time to the resumption of menstrual activity will be assessed at 3 months,one and two years after  the end of chemotherapy</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>pregnancy: whether pregnancy will be accessed at one, two, three, four, and five years after the end of chemotherapy</Description><Timeframe>Five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this  prospective, randomized, control, clinical trial  was to determine the effectiveness of      gonadotropin-releasing hormone agonist on ovarian function for premenopausal breast cancer      patients during chemotherapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The premenopausal breast cancer patients would be randomly      (1:1) enrolled to receive standard chemotherapy with the GnRH agonist &lt;ulink linkType="Drug" linkID="7286"&gt;goserelin&lt;/ulink&gt; (goserelin      group) or standard chemotherapy without goserelin (chemotherapy alone group). Standard chemotherapy (anthracyclines/cyclophosphamide) would be followed by &lt;ulink linkType="Drug" linkID="75471"&gt;paclitaxel&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;; docetaxel/cyclophosphamide; docetaxel or paclitaxel/anthracyclines; fluorouracil/anthracyclines/cyclophosphamide followed by docetaxel or paclitaxel; doxetaxel/anthracyclines/cyclophosphamide; anthracyclines/cyclophosphamide.&lt;/para&gt;&lt;para&gt;All patients      would be stratified according to age (&amp;lt; 35 years versus 36 to 44years), hormone receptor status (HR+ or      ER+ versus HR- and ER-), chemotherapy regimen(3 to 4 cycles versus 6 to 8 cycles, and      cyclophosphamide-based versus noncyclophosphamide).The follow-up time would be at least two years.      The ovarian failure, follicle-stimulating hormone, estradiol and anti-Mullerian hormone,      pregnancy outcomes and disease-free and overall survival would be compared between two groups      to evaluate the effectiveness of protect against ovarian failure.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02483767</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Breast tumor" id="8971"><Endpoint>Assessment of Hormone Levels</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8972">Assessment of steroid hormones</SubEndpoint><SubEndpoint disease="Breast tumor" id="8973">Assessment of pituitary hormones</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Breast tumor" id="9043"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Breast tumor" id="8712"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8714"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8971"><Endpoint>Assessment of Hormone Levels</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8972">Assessment of steroid hormones</SubEndpoint><SubEndpoint disease="Breast tumor" id="8973">Assessment of pituitary hormones</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="9043"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4816"><Criterion>Premenopausal Breast Cancer Women</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4823"><Criterion>TNM Stage I Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4824"><Criterion>TNM Stage II Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4827"><Criterion>TNM Stage III Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="34443"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4955">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6294"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6328"><Criterion>Subjects with History of/Scheduled for Anti-neoplastic Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6350">Subjects with history of/scheduled for Gonadotropin-releasing hormone (GnRH) antagonists</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6393"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6331">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6415"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6474">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26375"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6246">Metastatic/TNM Stage IV Breast Cancer</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-11-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-06-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-08-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-10-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="263002"><TitleDisplay>Impact of cherry consumption on acute exercise-induced inflammation in well-trained cyclists</TitleDisplay><TitleOfficial>The impact of sweet cherry consumption on acute inflammation following high-intensity exercise in trained cyclists - a randomized, double-blind, placebo-controlled, crossover study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">ACTRN12616000765426p</Identifier><Identifier type="Secondary Organisational">U1111-1183-9969</Identifier><Identifier type="Secondary Organisational">ANZCTR370857</Identifier></Identifiers><Indications><Indication id="188">Inflammatory disease</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="130" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 2</BiomarkerName><BiomarkerName id="159" role="Therapeutic effect marker" type="Biochemical">Lactic Acid</BiomarkerName><BiomarkerName id="175" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-10</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="364" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-1 beta</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="2265" role="Therapeutic effect marker" type="Physiological">Maximal oxygen uptake</BiomarkerName><BiomarkerName id="2623" role="Therapeutic effect marker" type="Biochemical">Lipid peroxides</BiomarkerName><BiomarkerName id="8024" role="Therapeutic effect marker" type="Genomic;Proteomic">Creatine kinase</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sweet cherry drink</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1125336" type="Company"><TargetEntity id="5037932272" type="organizationId">Essential Oils of Tasmania Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="1125341" type="Company"><TargetEntity id="5051005710" type="organizationId">Reid Fruits Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="30556" type="Company"><TargetEntity id="4296948569" type="organizationId">University of Tasmania</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="30556">University of Tasmania</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1125336">Essential Oils of Tasmania</Company><Company id="1125341">Reid Fruits Pty Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2016-07-01T00:00:00Z</DateStart><DateEnd type="estimated">2016-08-01T00:00:00Z</DateEnd><DateChangeLast>2016-06-15T16:00:10Z</DateChangeLast><DateAdded>2016-06-19T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>Melanie.Blackhall@utas.edu.au</Email><Name>Melanie Blackhall</Name><Phone>+61 03 62267638</Phone></Contact><Contact type="Scientific contact"><Email>J.Walls@utas.edu.au</Email><Name>Justin Walls</Name><Phone>+61 03 62262662</Phone></Contact><Contact type="Scientific contact"><Email>Melanie.Blackhall@utas.edu.au</Email><Name>Melanie Blackhall</Name><Phone>+61 03 62267638</Phone></Contact><Contact type="Public contact"><Email>Rachael.Berry@utas.edu.au</Email><Name>Rachael Berry</Name><Phone>+61 03 62266993</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Competitive cyclists training for a minimum of 7 h per week; endurance training history of at least three years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Cardiovascular history; history of fainting; diabetes; history of allergy/reaction to stone fruit&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Changes in plasma IL-6 concentration assessed by venous blood analysis</Description><Timeframe>Baseline (familiarization session), immediately and 24 h post cycling trial 1, immediately and 24 h post cycling trial 2</Timeframe></Measure><Measure><Description>Change in plasma IL-10 concentration assessed by venous blood analysis</Description><Timeframe>Baseline (familiarization session), immediately and 24 h post cycling trial 1, immediately and 24 h post cycling trial 2</Timeframe></Measure><Measure><Description>Change in plasma TNFalpha concentration assessed by venous blood analysis</Description><Timeframe>Baseline (familiarization session), immediately and 24 h post cycling trial 1, immediately and 24 h post cycling trial 2</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in blood glucose levels assessed by finger-prick blood test</Description><Timeframe>Every 2 min of VO2max testing, in each active recovery phase of cycling trial 1 (approximately every 2 min), in each active recovery phase of cycling trial 2 (approximately every 2 min)</Timeframe></Measure><Measure><Description>Change in blood lactate levels assessed by finger-prick blood test</Description><Timeframe>Every 2 min of VO2max testing, in each active recovery phase of cycling trial 1 (approximately every 2 min), in each active recovery phase of cycling trial 2 (approximately every 2 min)</Timeframe></Measure><Measure><Description>Change in exercise performance, determined by the number of intervals performed (primary outcome)</Description><Timeframe>Cycling trial 1 and 2</Timeframe></Measure><Measure><Description>Change in perceived muscle soreness measured via a 10 cm visual analog scale (primary outcome</Description><Timeframe>24 hours post cycling trial 1 and 24 hours post cycling trial 2</Timeframe></Measure><Measure><Description>Change in plasma CRP concentration (primary outcome) assessed by venous blood analysis</Description><Timeframe>Baseline (familiarization session), immediately and 24 h post cycling trial 1, immediately and 24 h post cycling trial 2</Timeframe></Measure><Measure><Description>Change in plasma IL-1beta concentration (primary outcome) assessed by venous blood analysis</Description><Timeframe>Baseline (familiarization session), immediately and 24 h post cycling trial 1, immediately and 24 h post cycling trial 2</Timeframe></Measure><Measure><Description>Change in plasma LOOH levels assessed by venous blood analysis</Description><Timeframe>Baseline (familiarization session), immediately and 24 h post cycling trial 1, immediately and 24 h post cycling trial 2</Timeframe></Measure><Measure><Description>Change in plasma MCP-1 concentration (primary outcome) assessed by venous blood analysis</Description><Timeframe>Baseline (familiarization session), immediately and 24 h post cycling trial 1, immediately and 24 h post cycling trial 2</Timeframe></Measure><Measure><Description>Change in serum creatine kinase level assessed by venous blood test</Description><Timeframe>Baseline (familiarization session), immediately and 24 h post cycling trial 1, immediately and 24 h post cycling trial 2</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study will utilize a randomized, double-blind, placebo-controlled, crossover design to investigate the following aims:&lt;br/&gt;To determine if consumption of sweet cherries attenuates exercise-induced inflammation.&lt;br/&gt;To determine if consumption of sweet cherries improves post-exercise recovery.&lt;br/&gt;To determine if consumption of sweet cherries improves exercise performance.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Participants will be asked to refrain from ingesting dietary anthocyanins or flavonoids and will be provided with a food and exercise plan and diary to complete in the week prior to both the familiarization and trial sessions.  Participants will undergo an initial familiarization session, at each time baseline blood samples will be taken. Participants will undertake a ramp incremental VO2max test to ascertain their level of cardiovascular fitness.  Lactate and blood glucose measurements will be taken every 2 min via finger prick.  Participants with a VO2max of between 4.5 and 5.0 l/min will be included in the supplementation and trial sessions.  Participants will be randomly assigned to the cherry or placebo group. Participants will be given blended cherry drinks containing cherries, water and lemon juice (at a ratio of 10 : 5 : 1) with an anthocyanin content of 540 mg/drink or carbohydrate-matched, blended pear drinks containing 0% anthocyanin (placebo).  Participants will be asked to consume one drink at 8 pm for the 3 days prior to the cycling trial, and one drink 1 h immediately prior to the commencement of the trial. To monitor adherence to the intervention, drinks were provided in opaque bottles which were returned the day following provision.  The cycling trial consisted of 60 s intervals of cycling on a cycle ergometer at a workload equivalent to 100% VO2max followed by 75 s of active recovery at 50% VO2max, until the 100%VO2max workload is unable to be maintained.  &lt;/para&gt;&lt;para&gt;A 10 min warm-up and cool-down at 50% VO2max will be undertaken prior to and following the trial.    Venous blood samples will be collected immediately following exercise and at 24 h post exercise.  At 24 h post exercise, participants indicated perceived muscle soreness via a 10 cm visual analog scale. Following a washout period of at least 2 weeks, participant groups crossed over and the supplementation and cycling trial will be repeated.  Blood samples will be tested for levels of the circulating inflammatory mediators IL-6, IL-10, TNF-alpha, IL-1beta, CRP and MCP-1 using ELISA kits, and LOOH levels and creatine kinase levels will be monitored. Participants will be asked to refrain from ingesting dietary anthocyanins or flavonoids and will be provided with a food and exercise plan and diary to complete in the week prior to both the familiarization and trial sessions.  Participants underwent an initial familiarization session, at which time baseline blood samples will be taken.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Address2>TAS</Address2><CountrySubDivision>TAS</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1004">WHO ICTRP</Name><Identifiers><Identifier type="Secondary Organisational">U1111-1183-9969</Identifier></Identifiers></Registry><Registry><Name id="1011">Australian New Zealand Clinical Trials Registry (ANZCTR)</Name><Identifiers><Identifier type="Secondary Organisational">ACTRN12616000765426p</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-06-19T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="270482"><TitleDisplay>Comparison of the effects of bazedoxifene and eldecalcitol on the health screening results of postmenopausal women</TitleDisplay><TitleOfficial>Comparison of the effects of bazedoxifene and eldecalcitol on the health screening results of postmenopausal women</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000023659</Identifier></Identifiers><Indications><Indication id="2549">Postmenopausal osteoporosis</Indication></Indications><BiomarkerNames><BiomarkerName id="3374" role="Therapeutic effect marker" type="Physiological">Bone mineral density</BiomarkerName><BiomarkerName id="48953" role="Therapeutic effect marker" type="Physiological">Lumbar spine bone mineral density</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bazedoxifene</Name><Drug id="16311">bazedoxifene</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>eldecalcitol</Name><Drug id="8241">eldecalcitol</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="16311">bazedoxifene</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1084931">Hitachinaka General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="28247">Tokyo Medical and Dental University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="16311" type="Drug"><TargetEntity id="257955" type="siDrug">Bazedoxifene acetate</TargetEntity></SourceEntity><SourceEntity id="1084931" type="Company"><TargetEntity id="5040043717" type="organizationId">Hitachinaka General Hospital</TargetEntity></SourceEntity><SourceEntity id="28247" type="Company"><TargetEntity id="4298187527" type="organizationId">Tokyo Medical and Dental University</TargetEntity></SourceEntity><SourceEntity id="2549" type="ciIndication"><TargetEntity id="M81.0" type="ICD10"></TargetEntity><TargetEntity id="10031285" type="MEDDRA"></TargetEntity><TargetEntity id="D015663" type="MeSH"></TargetEntity><TargetEntity id="-67845500" type="omicsDisease"></TargetEntity><TargetEntity id="966" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4078" type="Action"><TargetEntity id="1286" type="Mechanism">Estrogen Receptor (ER) alpha Antagonists</TargetEntity></SourceEntity><SourceEntity id="846" type="Action"><TargetEntity id="857" type="Mechanism">Selective Estrogen Receptor Modulators (SERM)</TargetEntity><TargetEntity id="1283" type="Mechanism">Drugs Acting on Estrogen Receptors (ER) </TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1084931">Hitachinaka General Hospital</Company><Company id="28247">Tokyo Medical and Dental University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4078">Estrogen receptor alpha antagonist</Action><Action id="846">Estrogen receptor modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="89">Bone resorption inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2016-09-01T00:00:00Z</DateStart><DateChangeLast>2017-04-03T06:37:06Z</DateChangeLast><DateAdded>2016-09-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tokyo Medical and Dental University ; Department of Women's Health
</Affiliation><Email>teragyne@tmd.ac.jp</Email><Name>Masakazu Terauchi</Name><Phone>03-5803-4605</Phone></Contact><Contact type="Scientific contact"><Affiliation>Tokyo Medical and Dental University ; Department of Women's Health
</Affiliation><Name>Masakazu Terauchi</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who need medical treatment of osteoporosis, with one or less spinal fractures&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Past history of arterial/venous thromboembolism&lt;/li&gt;&lt;li&gt;Past history of urollithiasis&lt;/li&gt;&lt;li&gt;Use of aromatase inhibitors for the adjuvant treatment of breast cancer&lt;/li&gt;&lt;li&gt;Renal dysfunction with eGFR&amp;lt; 50 ml/min&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Changes in lumbar spine/hip BMD</Description><Timeframe>After 12 months of treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Changes in bone metabolism markers, health-related QOL, and the results of a health screening program</Description><Timeframe>After 12 months of treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to compare the effects and safety of a SERM and an activated vitamin D on lumbar spine/hip BMD, bone metabolism markers, health-related QOL, and the results of a health screening program in women diagnosed with postmenopausal osteoporosis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive 12-month treatment with 20 mg of &lt;ulink linkType="Drug" linkID="16311"&gt;bazedoxifene&lt;/ulink&gt; or 0.75 microg of &lt;ulink linkType="Drug" linkID="8241"&gt;eldecalcitol&lt;/ulink&gt;.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Hitachinaka General Hospital</Name><Address1>Ibaraki Prefecture</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Osteoporosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7657">Subjects with Postmenopausal Osteoporosis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000023659</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Osteoporosis" id="13772"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Osteoporosis" id="13771">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Osteoporosis" id="13782"><Endpoint>Assessment of Markers of Bone/Cartilage/Collagen Turnover</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Osteoporosis" id="13846"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Osteoporosis" id="36802">Assessment by Health Related Quality of Life (HRQOL)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Osteoporosis" id="13839"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Osteoporosis" id="8685"><Criterion>Subjects with Postmenopausal Osteoporosis</Criterion></Inclusion><Inclusion disease="Osteoporosis" id="8711"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion><Inclusion disease="Osteoporosis" id="13261"><Criterion>Subjects with Fracture</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Osteoporosis" id="10247"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Osteoporosis" id="10268"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Osteoporosis" id="26328"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Osteoporosis" id="10260">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-09-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-04-06T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="272666"><TitleDisplay>Hypofractionated Versus Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer</TitleDisplay><TitleOfficial>Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02912312</Identifier><Identifier type="Organisational Study">2016-0142</Identifier><Identifier type="Other">NCI-2016-01941</Identifier><Identifier type="Other">P30CA016672</Identifier><Identifier type="Trial Acronym">SAPHIRE</Identifier></Identifiers><Indications><Indication id="49">Breast tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="119" role="Therapeutic effect marker" type="Biochemical">Homocysteine</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName><BiomarkerName id="36136" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytokines</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>shorter regional nodal irradiation (37.5 Gy)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>standard regional nodal irradiation (45 Gy)</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="23382" type="Company"><TargetEntity id="4296619331" type="organizationId">University of Texas MD Anderson Cancer Center</TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23382">MD Anderson Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>290</PatientCountEnrollment><DateStart>2017-02-23T00:00:00Z</DateStart><DateEnd type="estimated">2031-02-28T00:00:00Z</DateEnd><DateChangeLast>2019-06-04T02:12:53Z</DateChangeLast><DateAdded>2016-09-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>M D Anderson Cancer Center</Affiliation><Email>khoffman1@mdanderson.org</Email><Name>Karen Hoffman</Name><Phone>713-563-2331</Phone></Contact><Contact type="Scientific contact"><Affiliation>M.D. Anderson Cancer Center</Affiliation><Name>Karen Hoffman, MD</Name></Contact><Contact type="Public contact"><Email>khoffman1@mdanderson.org</Email><Name>Karen Hoffman, MD</Name><Phone>713-563-2331</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Postoperativeradiationtherapy: radiation oncologist recommends radiation treatment to the supraclavicular and infraclavicular fossa (ie, RNI)&lt;/li&gt;&lt;li&gt;Postoperative radiation therapy: pathologically-confirmed invasive breast cancer. If patients undergo upfront surgery, the pathologic stage must be T0 to T3, N0 to N2a or N3a. If patients receive neoadjuvant chemotherapy prior to surgery, the clinical stage must be T0 to T3, N0 to N2a or N3a&lt;/li&gt;&lt;li&gt;Postoperative radiation therapy: treatment with mastectomy or segmental mastectomy and axillary evaluation (sentinel node evaluation, axillary sampling, or axillary lymph node dissection); if the patient has T0 disease, breast surgery is not required&lt;/li&gt;&lt;li&gt;Postoperative radiation therapy: age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Postoperative radiation therapy: documentation of arm volume measurement by perometer prior to axillary surgery&lt;/li&gt;&lt;li&gt;Postoperative radiation therapy: if the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration, and the patient must have no evidence of disease for this prior non-breast cancer&lt;/li&gt;&lt;li&gt;Postoperative radiation therapy: patients must be enrolled on the trial within 12 weeks of the later of two dates: the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy&lt;/li&gt;&lt;li&gt;Preoperative radiation therapy: surgeon and radiation oncologist recommend preoperative radiation therapy&lt;/li&gt;&lt;li&gt;Preoperative radiation therapy: radiation oncologist recommends radiation treatment to the supraclavicular and infraclavicular fossa (ie, RNI)&lt;/li&gt;&lt;li&gt;Preoperative radiation therapy: pathologically-confirmed invasive breast cancer. The clinical stage must be T0 to T3, N0 to N3a&lt;/li&gt;&lt;li&gt;Preoperative radiation therapy: planned treatment with mastectomy and axillary evaluation (sentinel node evaluation, axillary sampling, or axillary lymph node dissection)&lt;/li&gt;&lt;li&gt;Preoperative radiation therapy: if the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration, and the patient must have no evidence of disease for this prior non-breast cancer&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pathological or clinical evidence for a stage T4 breast cancer&lt;/li&gt;&lt;li&gt;Pathological or clinical evidence for a stage N2b, N3b,  or N3 breast cancer (supraclavicular, or internal mammary lymph node involvement)&lt;/li&gt;&lt;li&gt;Clinical or pathologic evidence for distant metastasis&lt;/li&gt;&lt;li&gt;Any prior diagnosis of invasive or ductal carcinoma in situ breast cancer in either breast&lt;/li&gt;&lt;li&gt;Current diagnosis of bilateral breast cancer&lt;/li&gt;&lt;li&gt;History of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breast&lt;/li&gt;&lt;li&gt;Patient is pregnant&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Lymphedema rate as assessed by perometry: will compare between patients randomized to short versus standard regional nodal irradiation (RNI). Will use a two-sided chi-squared test with a significance level of 0.05</Description><Timeframe>Up to 24 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Volume of affected and unaffected arm as assessed by perometry: the Shapiro-Wilk test will be used to objectively assess the normality of the data and these findings will be visually confirmed by inspecting normal probability quantile-quantile plots. If the data are not normally distributed, a normalizing transformation before using t-test or a non-parametric method such as the Wilcoxon rank sum test to compare the standardized difference between the two arms at each time point may be used</Description><Timeframe>Up to 126 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Investigators are conducting a clinical trial to compare two different treatment schedules for women who need radiation therapy to their lymph nodes as part of their breast cancer treatment. The main purpose of the trial is to see if the newer radiation treatment schedule will lower the risk of developing arm swelling, also known as lymphedema, after radiation treatment. Investigators will also be studying the impact of the innovative, shorter, treatment on patient-reported arm function and quality of life.&lt;/para&gt;&lt;para&gt;Primary objectives:&lt;br/&gt;To compare the risk of developing lymphedema, defined as a 10% difference in volume between the affected and unaffected arm, within 24 months of regional nodal irradiation (RNI) between patients assigned to short versus standard RNI.&lt;/para&gt;&lt;para&gt;Secondary objectives:&lt;br/&gt;To compare the maximum standardized difference in arm volume between the affected arm and the unaffected arm within 24 months after completion of RNI between the two treatment arms.&lt;br/&gt;To compare maximal acute (within 6 weeks of treatment) and late (&gt; 6 weeks after treatment) skin and soft tissue toxicities using the &lt;ulink linkType="Company" linkID="20519"&gt;National Cancer Institute&lt;/ulink&gt; Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v)4.0 scale between patients assigned to short versus standard RNI.&lt;br/&gt;To compare patient-reported arm and shoulder function for the two treatment arms using the 9-item Disabilities Arm Shoulder and Hand questionnaire (QuickDASH-9).&lt;br/&gt;To compare patient quality of life for the two treatment arms using EQ-5D-3L and the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue SF 6a.&lt;br/&gt;To compare the peripheral blood cytokine profile at the end of radiation between patients assigned to short versus standard RNI.&lt;br/&gt;To evaluate the effect of the peripheral blood cytokine profile at the end of radiation on developing lymphedema.&lt;br/&gt;To evaluate the effect of homocysteine levels prior to radiation on developing lymphedema.&lt;br/&gt;To evaluate time to locoregional recurrence, time to distant metastasis, disease-free survival and overall survival for patients assigned to short versus standard RNI.&lt;br/&gt;To evaluate the effect of lipid profiles prior to radiation on the time to locoregional recurrence.&lt;br/&gt;To evaluate if deoxyribonucleic acid (DNA) repair capacity contributes to the presence of acute radiation related toxicity and patient-reported quality of life decrements including fatigue and arm and shoulder symptoms.&lt;br/&gt;To evaluate changes in echocardiography global longitudinal strain measurements and cardiac serum biomarkers, based on measurements performed before and after radiation therapy (RT), in patients assigned to short versus standard RNI.&lt;br/&gt;In a separate cohort of 30 patients who will receive RNI before surgery, to collect information on number of patients developing lymphedema within 24 months of RNI on reconstructive complications, and on patient reported quality of life, in those assigned to short versus standard RNI.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized to one of two arms.&lt;br/&gt;Arm I: patients will undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks.&lt;br/&gt;Arm II: patients will undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks.&lt;br/&gt;In both arms, patients will undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.&lt;/para&gt;&lt;para&gt;Patient evaluation: patients participating in the trial will have their arm measured prior to radiation, during the final week of radiation and when they return for follow-up visits. Patients will be checked for any arm swelling that may develop. Patients will also fill out questionnaires before treatment and when they return for follow-up visits. Patients return 3 and 6 months after radiation, then every 6 months through two and a half years after radiation and then on a yearly basis until ten and a half years after finishing radiation. At some of the follow-up visits, investigators measure arm volume and ask participants to complete questionnaires.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>M D Anderson Cancer Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Karen E. Hoffman, MD</Name><Phone>713-563-2331</Phone></Contact><Contact type="Facility investigator"><Name>Karen E. Hoffman, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3943">Subjects with Stage I Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3944">Subjects with Stage II Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3945">Subjects with Stage III Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3967">Others</PatientSegment><SubSegments><SubSegment id="3970">Subjects with node positive breast cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="12005">Subjects with invasive breast cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02912312</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Breast tumor" id="9432"><Endpoint>Assessment of Lymphedema</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Breast tumor" id="37159"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4823"><Criterion>TNM Stage I Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4824"><Criterion>TNM Stage II Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4827"><Criterion>TNM Stage III Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4870"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4871">Subjects history/scheduled for mastectomy</SubCriterion><SubCriterion disease="Breast tumor" id="4874">Subjects history/scheduled for sentinel lymphadenectomy</SubCriterion><SubCriterion disease="Breast tumor" id="4875">Subjects history/scheduled for axillary lymphadenectomy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4893"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4894">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Breast tumor" id="4904">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4924"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="33170">Subjects with a cytological diagnostic and/or pathology of breast cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="6702"><Criterion>TNM Stage 0 Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22399"><Criterion>Subjects with Invasive Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22423"><Criterion>Subjects with Node Positive Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="34443"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4955">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="34920"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4928">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6215"><Criterion>Subjects with Other forms of Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6217">Subjects with bilateral breast cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6377"><Criterion>Subjects with history of/planned radiotherapy</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6415"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6474">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26375"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6227">Subjects with ductal carcinoma in situ (DCIS)</SubCriterion><SubCriterion disease="Breast tumor" id="6251">Subjects with Supraclavicular lymph node metastases</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2030-02-28T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-09-19T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-09-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-03-01T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="278595"><TitleDisplay>Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma</TitleDisplay><TitleOfficial>Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02959463</Identifier><Identifier type="Organisational Study">2015-0856</Identifier><Identifier type="Other">NCI-2016-01923</Identifier><Identifier type="Other">P30CA016672</Identifier></Identifiers><Indications><Indication id="1240">Mesothelioma</Indication></Indications><BiomarkerNames><BiomarkerName id="36136" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytokines</BiomarkerName><BiomarkerName id="46506" role="Therapeutic effect marker" type="Cellular">T-Lymphocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>hemithoracic radiation therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>palliative radiation therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pembrolizumab</Name><Drug id="70667">pembrolizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="70667">pembrolizumab</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23382">MD Anderson Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="70667" type="Drug"><TargetEntity id="729094" type="siDrug">Pembrolizumab</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="23382" type="Company"><TargetEntity id="4296619331" type="organizationId">University of Texas MD Anderson Cancer Center</TargetEntity></SourceEntity><SourceEntity id="1240" type="ciIndication"><TargetEntity id="C45" type="ICD10"></TargetEntity><TargetEntity id="163" type="ICD9"></TargetEntity><TargetEntity id="10027406" type="MEDDRA"></TargetEntity><TargetEntity id="D008654" type="MeSH"></TargetEntity><TargetEntity id="50251" type="ORPHANET"></TargetEntity><TargetEntity id="-666440137" type="omicsDisease"></TargetEntity><TargetEntity id="2015" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23382">MD Anderson Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="67136">Programmed cell death protein 1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1589">Apoptosis stimulator</Class><Class id="393">Immunostimulant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="7761">T-lymphocyte stimulator</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="852">Intravesical formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>24</PatientCountEnrollment><DateStart>2017-05-01T00:00:00Z</DateStart><DateEnd type="estimated">2021-05-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-20T05:16:10Z</DateChangeLast><DateAdded>2016-11-10T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>dgomez@mdanderson.org</Email><Name>Daniel Gomez, MD</Name><Phone>713-563-2300</Phone></Contact><Contact type="Scientific contact"><Affiliation>M.D. Anderson Cancer Center</Affiliation><Name>Daniel Gomez</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must have a histological diagnosis of malignant pleural mesothelioma, with histological diagnosis from the pleura or relevant lymph node stations, including mediastinal, hilar, or supraclavicular lymph nodes&lt;/li&gt;&lt;li&gt;Be willing and able to provide written informed consent/assent for the trial&lt;/li&gt;&lt;li&gt;Have measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. However, note that patients in Cohort 1 that have undergone an R0 resection will be eligible for the trial&lt;/li&gt;&lt;li&gt;Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale&lt;/li&gt;&lt;li&gt;Absolute neutrophil count (ANC) &gt;/= 1,500/microl (within 10 to 15 days of treatment initiation)&lt;/li&gt;&lt;li&gt;Platelets &gt;/= 100,000/microl (within 10 to 15 days of treatment initiation)&lt;/li&gt;&lt;li&gt;Hemoglobin &gt;/= 9 g/dl or &gt;/= 5.6 mmol/l without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (within 10 to 15 days of treatment initiation)&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt;/= 1.5 x  upper limit of normal (ULN) or measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) &gt;/= 60 ml/min for subject with creatinine levels &gt; 1.5 x  institutional ULN (within 10 to 15 days of treatment initiation)&lt;/li&gt;&lt;li&gt;Serum total bilirubin&amp;lt;/= 1.5 x ULN or direct bilirubin &amp;lt;/= ULN for subjects with total bilirubin levels &gt; 1.5 ULN (within 10 to 15 days of treatment initiation)&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT)&amp;lt;/= 2.5 x ULN or &amp;lt;/= 5 x  ULN for subjects with liver metastasis (within 10 to 15 days of treatment initiation)&lt;/li&gt;&lt;li&gt;Albumin &gt;/= 2.5 mg/dl (within 10 to 15 days of treatment initiation)&lt;/li&gt;&lt;li&gt;International Normalized Ratio (INR) or Prothrombin Time (PT)&amp;lt;/= 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 10 to 15 days of treatment initiation)&lt;/li&gt;&lt;li&gt;Activated Partial Thromboplastin Time (aPTT)&amp;lt;/= 1.5 x  ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 10 to 15 days of treatment initiation)&lt;/li&gt;&lt;li&gt;Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 h prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required&lt;/li&gt;&lt;li&gt;Female subjects of childbearing potential should be willing to use two methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for &gt; 1 year&lt;/li&gt;&lt;li&gt;Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy&lt;/li&gt;&lt;li&gt;Cohort 1 (Patients Receiving Hemithoracic Radiation Therapy):&lt;ul&gt;&lt;li&gt;Patients must not have evidence of metastatic disease per positron emission tomography (PET)/ computed tomography (CT) scan; mediastinal lymph node involvement is acceptable&lt;/li&gt;&lt;li&gt;Patients will have received at least two cycles of induction chemotherapy with pemetrexed/cisplatin or pemetrexed/carboplatin&lt;/li&gt;&lt;li&gt;Forced expiratory volume in 1 s (FEV1) &gt;/= 30% of predicted postoperative (ppoFEV1, as if patient underwent a pneumonectomy)&lt;/li&gt;&lt;li&gt;Diffusing capacity of the lungs for carbon monoxide (DLCO) &gt; 35% predicted&lt;/li&gt;&lt;li&gt;Patients must be assessed to be a suitable candidate for hemithoracic radiation therapy per the treating radiation oncologist; if the patient undergoes pleurectomy/decortication, they must initiate hemithoracic radiation therapy within 4 months of the surgery date; patients that do not meet the dose constraints outlined below will be removed from the study prior to radiation therapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Cohort 2 (inclusion criteria):&lt;ul&gt;&lt;li&gt;Patients must be assessed to be a suitable candidate for radiation therapy by the treating radiation oncologist; patients that do not meet the dose constraints outlined below will be removed from the study prior to radiation therapy&lt;/li&gt;&lt;li&gt;Any prior number of prior therapies, including prior immunotherapy, is allowed&lt;/li&gt;&lt;li&gt;Patient must have prior treatment with a platinum plus pemetrexed regimen&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment&lt;/li&gt;&lt;li&gt;Has a diagnosis of immunodeficiency. Note that patients should not receive steroids during pembrolizumab administration&lt;/li&gt;&lt;li&gt;Has a known history of active tuberculosis (TB) (Bacillus tuberculosis)&lt;/li&gt;&lt;li&gt;Hypersensitivity to pembrolizumab or any of its excipients&lt;/li&gt;&lt;li&gt;Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (ie, grade&amp;lt;/= 1 or at baseline) from adverse events due to agents administered &gt; 4 weeks earlier&lt;/li&gt;&lt;li&gt;Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 and who have not recovered adequately from this treatment (grade&amp;lt;/= 2 toxicity at the time of enrollment)&lt;/li&gt;&lt;li&gt;Has a known additional malignancy that is progressing or requires active treatment. Patients with a stage I to III cancer that has been cured over two years ago are not excluded in the study&lt;/li&gt;&lt;li&gt;Has known active central nervous system (CNS) metastasis and/or carcinomatous meningitis. Subjects with previously treated brain metastasis may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastasis, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability&lt;/li&gt;&lt;li&gt;Has active autoimmune disease that has required systemic treatment in the past two years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment&lt;/li&gt;&lt;li&gt;Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis&lt;/li&gt;&lt;li&gt;Has an active infection requiring systemic therapy&lt;/li&gt;&lt;li&gt;Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial&lt;/li&gt;&lt;li&gt;Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment&lt;/li&gt;&lt;li&gt;Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)&lt;/li&gt;&lt;li&gt;Has known active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (eg, hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)&lt;/li&gt;&lt;li&gt;Has received a live vaccine within 30 days of planned start of study therapy. Note: seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (eg, Flu-Mist) are live attenuated vaccines, and are not allowed&lt;/li&gt;&lt;li&gt;Evidence of interstitial lung disease&lt;/li&gt;&lt;li&gt;Cohort 1 exclusion criteria:&lt;ul&gt;&lt;li&gt;Patients undergoing an extrapleural pneumonectomy (EPP); lung sparing surgeries, such as pleurectomy/decortication, are acceptable&lt;/li&gt;&lt;li&gt;Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Cohort 2 exclusion criteria:&lt;ul&gt;&lt;li&gt;Patients in which hemithoracic radiation therapy is planned&lt;/li&gt;&lt;li&gt;Patients who have received EPP for mesothelioma&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Cohort 1 and 2 exclusion criteria:&lt;ul&gt;&lt;li&gt;Patients with inherited syndromes associated with hypersensitivity to ionizing radiation, specifically patients with known history of ataxia-telengiectasia, Nijmegen breakage syndrome&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Incidence of treatment-related adverse events: for each study cohort, will tabulate toxicities by dose, severity, and relationship to the treatment plan. If treatment-related toxicity rate is &gt; 30%, the trial will stop</Description><Timeframe>Up to at least 4 months from start of radiation therapy</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Progression-free survival assessed according to Response Evaluation Criteria for Solid Tumors version 1.1: estimated using the method of Kaplan and Meier</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Overall survival assessed according to Response Evaluation Criteria for Solid Tumors version 1.1: estimated using the method of Kaplan and Meier</Description><Timeframe>Up to five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This phase I trial studies the side effects and best way to give &lt;ulink linkType="Drug" linkID="70667"&gt;pembrolizumab&lt;/ulink&gt; after radiation therapy in treating patients with pleural malignant mesothelioma.&lt;/para&gt;&lt;para&gt;Primary objective:&lt;br/&gt;To determine the safety and tolerability of pembrolizumab administered after radiation therapy in patients with malignant pleural mesothelioma (MPM) who have not undergone extrapleural pneumonectomy.&lt;/para&gt;&lt;para&gt;Secondary objectives:&lt;br/&gt;To assess progression-free and overall survival (progression free survival [PFS] and overall survival [OS], respectively) in patients receiving pembrolizumab after radiation therapy for malignant pleural mesothelioma (MPM).&lt;/para&gt;&lt;para&gt;Exploratory objectives:&lt;br/&gt;To evaluate biomarkers of interest, including cytokines, measurements of T-cell activation, and serum exosome micro ribonucleic acid (RNA)s with the delivery of pembrolizumab after radiation therapy for MPM.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients are assigned to one of two cohorts:&lt;br/&gt;Cohort 1: patients undergo hemithoracic radiation therapy.&lt;br/&gt;Cohort 2: patients undergo palliative radiation therapy over 1 to 3 weeks to only the region of palliation (a region that does not include the entire side of the chest or thorax).&lt;/para&gt;&lt;para&gt;After radiation therapy, both cohorts receive pembrolizumab intravenously (IV) over about 30 min on day 1. Courses repeat every 3 weeks for up to two years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, every 6 weeks for 48 weeks, then every 12 weeks for up to five years.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>M D Anderson Cancer Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Daniel Gomez</Name><Phone>713-563-2300</Phone></Contact><Contact type="Facility investigator"><Name>Daniel Gomez</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Mesothelioma</Disease><PatientSegments><PatientSegment><PatientSegment id="8132">Subjects with Malignant Pleural Mesothelioma</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02959463</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Mesothelioma" id="12541"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Mesothelioma" id="12542">Assessment of toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Mesothelioma" id="12491"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Mesothelioma" id="12497">Assessment of tumor response rate</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Mesothelioma" id="8531"><Criterion>Subjects with Malignant Pleural Mesothelioma</Criterion></Inclusion><Inclusion disease="Mesothelioma" id="8543"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Mesothelioma" id="8555"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8556">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Mesothelioma" id="8557">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="8564"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8565">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="8574"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8575">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Mesothelioma" id="8576">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Mesothelioma" id="8579">Subjects with normal/acceptable pulmonary function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="8581"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8589">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="8601"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Mesothelioma" id="34042"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8577">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="34070"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8590">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="34357"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8584">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="34805"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8586">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Mesothelioma" id="10094"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="10095"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="10096"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="10097">Subjects co-morbid with HIV infection</SubCriterion><SubCriterion disease="Mesothelioma" id="10098">Subjects co-morbid with hepatitis virus infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Mesothelioma" id="10114"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="10115">Subjects with hypersensitivity/contraindication to chemotherapeutic agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Mesothelioma" id="10130"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="10131"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="25585"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="10141">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Mesothelioma" id="26829"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="10125">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Mesothelioma" id="29330"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="10148">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-11-07T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-11-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-05-10T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-20T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-20T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-20T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-05-20T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="added"><Date>2019-05-20T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-05-20T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change></ChangeHistory></Trial><Trial id="280664"><TitleDisplay>A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency</TitleDisplay><TitleOfficial>TRITON3: A Multicenter, Randomized, Open-Label, Phase III Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02975934</Identifier><Identifier type="Organisational Study">CO-338-063</Identifier><Identifier type="Other">2016-003163-20</Identifier><Identifier type="Other">129,840</Identifier><Identifier type="Trial Acronym">TRITON3</Identifier></Identifiers><Indications><Indication id="3246">Hormone refractory prostate cancer</Indication><Indication id="3664">Metastatic prostate cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="22" role="Disease marker" type="Genomic;Proteomic">Breast cancer type 1 susceptibility protein</BiomarkerName><BiomarkerName id="38" role="Therapeutic effect marker" type="Genomic;Proteomic">Prostate-specific antigen</BiomarkerName><BiomarkerName id="41" role="Disease marker" type="Genomic">Breast cancer type 2 susceptibility protein</BiomarkerName><BiomarkerName id="1763" role="Disease marker" type="Genomic;Proteomic">Serine-protein kinase ATM</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rucaparib camsylate (oral, solid tumors), Clovis</Name><Drug id="75079">rucaparib camsylate (oral, solid tumors), Clovis</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>abiraterone</Name><Drug id="10309">abiraterone</Drug></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>enzalutamide</Name><Drug id="53981">enzalutamide</Drug></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="combo"><Interventions><Intervention type="InterventionControl"><Name>abiraterone</Name><Drug id="10309">abiraterone</Drug></Intervention><Intervention type="InterventionControl"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention><Intervention type="InterventionControl"><Name>prednisolone</Name></Intervention><Intervention type="InterventionControl"><Name>prednisone</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="75079">rucaparib camsylate (oral, solid tumors), Clovis</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1047565">Clovis Oncology Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1056444">Foundation Medicine Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1124765">Strata Oncology</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="75079" type="Drug"><TargetEntity id="292526" type="siDrug">Rucaparib phosphate</TargetEntity></SourceEntity><SourceEntity id="1047565" type="Company"><TargetEntity id="4298504105" type="organizationId">Clovis Oncology Inc</TargetEntity></SourceEntity><SourceEntity id="1056444" type="Company"><TargetEntity id="5000714889" type="organizationId">Foundation Medicine Inc</TargetEntity></SourceEntity><SourceEntity id="1124765" type="Company"><TargetEntity id="5050648527" type="organizationId">Strata Oncology Inc</TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3664" type="ciIndication"><TargetEntity id="10036909" type="MEDDRA"></TargetEntity><TargetEntity id="639" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2507" type="Action"><TargetEntity id="477" type="Mechanism">NAD+ ADP-Ribosyltransferase (poly(ADP-ribose) Polymerase; PARP) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="38283" type="Action"><TargetEntity id="2212" type="Mechanism">Poly(ADP-ribose) Polymerase 1 (PARP-1; ARTD1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="38286" type="Action"><TargetEntity id="2475" type="Mechanism">Poly(ADP-ribose) Polymerase 2 (PARP-2; ARTD2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="38289" type="Action"><TargetEntity id="4487" type="Mechanism">Poly(ADP-ribose) Polymerase 3 (PARP-3; ARTD3) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>140</NumberOfSites><CompaniesSponsor><Company id="1047565">Clovis Oncology Inc</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1056444">Foundation Medicine Inc</Company><Company id="1124765">Strata Oncology</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="2507">PARP inhibitor</Action><Action id="38283">Poly ADP ribose polymerase 1 inhibitor</Action><Action id="38286">Poly ADP ribose polymerase 2 inhibitor</Action><Action id="38289">Poly ADP ribose polymerase 3 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="90">Steroid</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>400</PatientCountEnrollment><DateStart>2017-06-13T00:00:00Z</DateStart><DateEnd type="estimated">2022-04-30T00:00:00Z</DateEnd><DateChangeLast>2019-07-02T02:05:45Z</DateChangeLast><DateAdded>2016-11-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Clovis Oncology UK Ltd</Affiliation><Email>info@clovisoncology.com</Email><Name>Chief Medical Officer</Name><Phone>+44 01223 370037</Phone></Contact><Contact type="Public contact"><Email>clovistrials@emergingmed.com</Email><Name>Clovis Oncology Clinical Trial Navigation Service</Name><Phone>1-855-262-3040 (USA)</Phone></Contact><Contact type="Public contact"><Email>clovistrials@emergingmed.com</Email><Name>Clovis Oncology Clinical Trial Navigation Service</Name><Phone>1-303-625-5160 (ex-USA)</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Be 18 years old at the time the informed consent is signed&lt;/li&gt;&lt;li&gt;Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate that is metastatic&lt;/li&gt;&lt;li&gt;Be surgically or medically castrated, with serum testosterone levels of&amp;lt;/=  50 ng/dl (1.73 nM)&lt;/li&gt;&lt;li&gt;Be eligible for treatment with physician's choice of comparator treatment (abiraterone acetate, enzalutamide or docetaxel)&lt;/li&gt;&lt;li&gt;Experienced disease progression after having received one prior next generation androgen receptor-targeted therapy for castration-resistant disease&lt;/li&gt;&lt;li&gt;Have a deleterious germline or somatic mutation in a BRCA1/2 or ATM gene&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Active second malignancy, with the exception of curatively treated non melanoma skin cancer, carcinoma in situ, or superficial bladder cancer&lt;/li&gt;&lt;li&gt;Prior treatment with any PARP inhibitor&lt;/li&gt;&lt;li&gt;Prior treatment with chemotherapy for metastatic castration-resistant prostate cancer&lt;/li&gt;&lt;li&gt;Symptomatic and/or untreated central nervous system metastasis&lt;/li&gt;&lt;li&gt;Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Radiographic progression-free survival (rPFS), assessed using modified RECIST version 1.1 or PCWG3 criteria</Description><Timeframe>From enrollment to primary completion of study (up to approximately five years)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in patient-reported outcome (PRO)</Description><Timeframe>From enrollment to primary completion of study (up to approximately five years)</Timeframe></Measure><Measure><Description>Clinical Benefit Rate (CBR), defined as the percentage of patients with a complete response (CR), partial response (PR), and stable disease (SD) according to modified RECIST Version 1.1 with no progression in bone per PCWG3 criteria</Description><Timeframe>From enrollment to primary completion of study (up to approximately five years)</Timeframe></Measure><Measure><Description>Duration of response (DOR)</Description><Timeframe>From enrollment to primary completion of study (up to approximately five years)</Timeframe></Measure><Measure><Description>Objective response rate (ORR)</Description><Timeframe>From enrollment to primary completion of study (up to approximately five years)</Timeframe></Measure><Measure><Description>Overall survival</Description><Timeframe>From enrollment to primary completion of study (up to approximately five years)</Timeframe></Measure><Measure><Description>PSA response &gt;/= 50% (all patients) and &gt;/= 90% (all patients)</Description><Timeframe>From enrollment to primary completion of study (up to approximately five years)</Timeframe></Measure><Measure><Description>Time to Prostate Specific Antigen (PSA) progression</Description><Timeframe>From enrollment to primary completion of study (up to approximately five years)</Timeframe></Measure><Measure><Description>Trough plasma PK (Cmin) of rucaparib based on sparse sampling</Description><Timeframe>From enrollment to primary completion of study (up to approximately five years)</Timeframe></Measure><Measure><Description>Number of participants with adverse events (AEs) as a measure of safety and tolerability. Composite assessment of treatment-emergent AEs, including laboratory abnormalities, vital sign abnormalities, electrocardiogram (ECG) abnormalities, physical examination abnormalities and ECOG abnormalities</Description><Timeframe>From enrollment to primary completion of study (up to approximately five years)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this comparativestudy was to determine how patients with metastatic castration-resistant      prostate cancer and evidence of a homologous recombination gene deficiency, respond to      treatment with &lt;ulink linkType="Drug" linkID="75079"&gt;rucaparib&lt;/ulink&gt; versus treatment with physician's choice of &lt;ulink linkType="Drug" linkID="10309"&gt;abiraterone acetate&lt;/ulink&gt;,      &lt;ulink linkType="Drug" linkID="53981"&gt;enzalutamide&lt;/ulink&gt;, or &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="2088697"&gt;2088697&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Secondary objectives of the trial:&lt;br/&gt;To assess objective response rate (ORR) using modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in patients with measurable (nodal or visceral) disease.&lt;br/&gt;To assess duration of response (DOR) using modified RECIST Version 1.1 in patients with measurable (nodal or visceral) disease.&lt;br/&gt;To assess time to PSA progression.&lt;br/&gt;To assess PSA response &gt;/= 50% (all patients).&lt;br/&gt;To assess PSA response &gt;/= 90% (all patients).&lt;br/&gt;To evaluate Patient-reported Outcome (PRO) using the EuroQol 5 dimensions 5 level questionnaire (EQ-5D-5L), Functional Assessment of Cancer TherapyProstate (FACT-P), analgesic drug score, and Brief Pain InventoryShort Form (BPI-SF) instruments.&lt;br/&gt;To assess clinical benefit rate (CBR).&lt;br/&gt;To assess overall survival (OS).&lt;br/&gt;To assess sparse pharmacokinetics (PK).&lt;br/&gt;To assess safety and tolerability  [&lt;ulink linkType="Reference" linkID="1897124"&gt;1897124&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1946206"&gt;1946206&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1957590"&gt;1957590&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1960642"&gt;1960642&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As of February 2017, &lt;ulink linkType="Company" linkID="1047565"&gt;Clovis Oncology Inc&lt;/ulink&gt; in collaboration with &lt;ulink linkType="Company" linkID="1124765"&gt;Strata Oncology Inc&lt;/ulink&gt; decided to accelerate patient identification and enrollment of the study [&lt;ulink linkType="Reference" linkID="1897124"&gt;1897124&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this study, patients would be randomized (2 : 1) to two arms:&lt;br/&gt;Arm 1: patients would receive po rucaparib (monotherapy; 600 mg bid) administered daily.&lt;br/&gt;Arm 2:  patients would receive physician's choice, oral abiraterone acetate (monotherapy or given in combination with prednisone), oral enzalutamide (monotherapy) and intravenous docetaxel (monotherapy or given in combination with prednisone or prednisolone) [&lt;ulink linkType="Reference" linkID="1946206"&gt;1946206&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1960642"&gt;1960642&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients in physician's choice arm might crossover to rucaparib on radiographic progression confirmed by independent radiology review[&lt;ulink linkType="Reference" linkID="1946206"&gt;1946206&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1960642"&gt;1960642&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Name>Barwon Health, University Hospital Geelong</Name><Address1>Geelong</Address1><Address3>3220</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Northern Cancer Insitute, St. Leonards</Name><Address1>Saint Leonards</Address1><Address2>New South Wales</Address2><Address3>2065</Address3><CountrySubDivision>New South Wales</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Orange Health Service</Name><Address1>Orange</Address1><Address2>New South Wales</Address2><Address3>2800</Address3><CountrySubDivision>New South Wales</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Peninsula &amp; Southeast Oncology</Name><Address1>Frankston</Address1><Address3>3199</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Riverina Cancer Care Centre</Name><Address1>Wagga Wagga</Address1><Address3>2650</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Royal Hobart Hospital</Name><Address1>Hobart</Address1><Address3>7000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>St John of God Hospital, Subiaco</Name><Address1>Subiaco</Address1><Address2>Western Australia</Address2><Address3>6008</Address3><CountrySubDivision>Western Australia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Belgium"><Sites><Site><Name>AZ Groeninge</Name><Address1>Kortrijk</Address1><Address3>8500</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>CHU Sart-Tilman</Name><Address1>Lige</Address1><Address3>4000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Clinique et Maternit Sainte-Elisabeth</Name><Address1>Namur</Address1><Address3>5000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>ZNA Middelheim</Name><Address1>Antwerp</Address1><Address3>2020</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Canada"><Sites><Site><Name>Cancer Care Manitoba</Name><Address1>Winnipeg</Address1><Address2>Manitoba</Address2><Address3>R3E 0V9</Address3><CountrySubDivision>Manitoba</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Centre Hospitalier Universitaire Dr-Georges-L.-Dumont</Name><Address1>Moncton</Address1><Address2>New Brunswick</Address2><Address3>E1C 8X3</Address3><CountrySubDivision>New Brunswick</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Lakeridge Health Medical Specialty Medical Oncology</Name><Address1>Oshawa</Address1><Address3>L1G 2B9</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>London Health Sciences Centre</Name><Address1>London</Address1><Address2>Ontario</Address2><Address3>N6A 4L6</Address3><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Princess Margaret Cancer Centre</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M5G 2M9</Address3><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Sunnybrook Odette Cancer Centre</Name><Address1>Toronto</Address1><Address3>M4N3M5</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>The Ottawa Hospital</Name><Address1>Ottawa</Address1><Address2>Ontario</Address2><Address3>K1H8L6</Address3><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Name>Charite - Universitaetsmedizin Berlin</Name><Address1>Berlin</Address1><Address3>12200</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Die GesundheitsUnion (DGU)</Name><Address1>Wuppertal</Address1><Address3>42103</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Gemeinschaftspraxis fr Hmatologie&amp;Onkologie</Name><Address1>Augsburg</Address1><Address3>86150</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Medizinischen Fakultt Mannheim der Universitt Heidelberg</Name><Address1>Mannheim</Address1><Address3>68167</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Studienpraxis Urologie</Name><Address1>Nurtingen</Address1><Address3>72622</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Universitaetsklinikum Hamburg-Eppendorf (UKE)</Name><Address1>Hamburg</Address1><Address3>20246</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Universitatsklinikum Dusseldorf</Name><Address1>Dusseldorf</Address1><Address3>40225</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Universitatsklinikum Jena</Name><Address1>Jena</Address1><Address3>07747</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University Hospital Carl Gustav Carus</Name><Address1>Dresden</Address1><Address3>01307</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University of Tuebingen</Name><Address1>Tuebingen</Address1><Address3>72076</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Universittsklinikum Kln</Name><Address1>Kln</Address1><Address3>50937</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Universittsklinikum Schleswig-Holstein</Name><Address1>Lubeck</Address1><Address3>23538</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Urologische Gemeinschaftspraxis</Name><Address1>Emmendingen</Address1><Address3>79312</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Denmark"><Sites><Site><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Chief Medical Officer</Name></Contact></Contacts></Site><Site><Name>Copenhagen University Hospital</Name><Address1>Copenhagen</Address1><Address3>2100</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Herlev Hospital</Name><Address1>Herlev</Address1><Address3>2730</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Vejle Sygehus</Name><Address1>Vejle</Address1><Address3>7100</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><Name>Corporacio Sanitaria Parc Tauli</Name><Address1>Sabadell</Address1><Address3>08208</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital 12 de Octubre</Name><Address1>Madrid</Address1><Address3>28041</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Clinico Universitario Virgen de la Victoria</Name><Address1>Mlaga</Address1><Address3>29010</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Universitari Germans Trias i Pujol</Name><Address1>Barcelona</Address1><Address3>08916</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Universitario Central de Asturias</Name><Address1>Oviedo</Address1><Address3>33011</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Universitario La Paz</Name><Address1>Madrid</Address1><Address3>28046</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Universitario Lucus Augusti.</Name><Address1>Lugo</Address1><Address3>27004</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Universitario Ramn y Cajal</Name><Address1>Madrid</Address1><Address3>28034</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Universitario Virgen del Roco</Name><Address1>Sevilla</Address1><Address3>41013</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Instituto Valenciano de Oncologa</Name><Address1>Valencia</Address1><Address3>46009</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>MD Anderson Cancer Center - Madrid</Name><Address1>Madrid</Address1><Address3>28033</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Marques de Valdecilla University Hospital (HUMV)</Name><Address1>Santander</Address1><Address3>39008</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>CRLCC Eugene Marquis</Name><Address1>Rennes</Address1><Address3>35042</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Centre Armoricain de Radiotherapie, Imagerie medicale et Oncologie, CARIO</Name><Address1>Plrin</Address1><Address3>22190</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Centre Georges Franois Leclerc</Name><Address1>Dijon</Address1><Address3>21079</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Centre Lon Brard</Name><Address1>Lyon</Address1><Address3>69008</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Clinique Victor Hugo Centre Jean Bernard</Name><Address1>Le Mans</Address1><Address3>72000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hpital Priv La Louvire</Name><Address1>Lille</Address1><Address3>59000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Institut Curie</Name><Address1>Paris</Address1><Address3>75248</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Institut Gustave-Roussy</Name><Address1>Villejuif</Address1><Address3>94805</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Polyclinique de Gentilly (Centre D'Oncologie De Gentilly)</Name><Address1>Nancy</Address1><Address3>54000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><Name>Guy's and St Thomas' NHS Foundation Trust</Name><Address1>London</Address1><Address2>England</Address2><Address3>SE1 9RT</Address3><CountrySubDivision>England</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Musgrove Park Hospital</Name><Address1>Taunton</Address1><Address3>TA15DA</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Oxford Cancer Centre, Medical Oncology Unit</Name><Address1>Oxford</Address1><Address2>England</Address2><Address3>OX3 7LE</Address3><CountrySubDivision>England</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Royal Marsden Hospital</Name><Address1>London</Address1><Address3>SM2 5PT</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Royal Marsden Hospital</Name><Address1>London</Address1><Address2>England</Address2><Address3>SM2 5PT</Address3><CountrySubDivision>England</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Royal Preston Hospital</Name><Address1>Preston</Address1><Address2>England</Address2><Address3>PR2 9HT</Address3><CountrySubDivision>England</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>The Clatterbridge Cancer Centre NHS Foundation Trust</Name><Address1>Wirral</Address1><Address3>CH63 4JY</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Velindre Hospital</Name><Address1>Cardiff</Address1><Address3>CF14 2TL</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Wexham Park Hospital</Name><Address1>Slough</Address1><Address2>England</Address2><Address3>SL2 4HL</Address3><CountrySubDivision>England</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Ireland"><Sites><Site><Name>Adelaide &amp; Meath Hospital, Incorporating the National Children's Hospital</Name><Address1>Dublin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Cork University Hospital</Name><Address1>Cork</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Mater Misericordiae University Hospital</Name><Address1>Dublin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Mater Private Hospital (MPH)</Name><Address1>Dublin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>St James's Hospital</Name><Address1>Dublin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>St. Vincent's University Hospital</Name><Address1>Dublin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Israel"><Sites><Site><Name>Chaim Sheba Medical Center</Name><Address1>Tel Hashomer</Address1><Address3>5262000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hadassah University Hospital</Name><Address1>Jerusalem</Address1><Address3>91120</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Meir Medical Center</Name><Address1>Kfar Saba</Address1><Address3>4428164</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Rambam Health Care Campus (RHCC), Rambam Medical Center</Name><Address1>Haifa</Address1><Address3>3109601</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>The Tel Aviv Sourasky Medical Center (Ichilov Hospital)</Name><Address1>Tel Aviv</Address1><Address3>6423</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Name>Azienda Opsedaliera S. Maria di Terni</Name><Address1>Terni</Address1><Address3>05100</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Azienda Ospedaliera San Camillo-Forlanini</Name><Address1>Roma</Address1><Address3>00152</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>IEO Instituto Europeo di Oncologia</Name><Address1>Milano</Address1><Address3>20141</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Ospedale San Donato, Azienda USLSUDEST</Name><Address1>Arezzo</Address1><Address3>52100</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Ospedale Santa Maria delle Croci</Name><Address1>Faenza</Address1><Address3>48018</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Presidio Ospedaliero Santa Chiara di Trento</Name><Address1>Trento</Address1><Address3>38122</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Romagnolo per lo Studio e la Cura dei Tumori IRST-IRCCS - Oncologia medica</Name><Address1>Meldola</Address1><Address3>47014</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University of Modena and Reggio Emilia</Name><Address1>Modena</Address1><Address3>41124</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Clovis Oncology Clinical Trial Navigation Service</Name><Contacts></Contacts></Site><Site><Name>Alegent Health Bergan Mercy Hospital , GU Research Network</Name><Address1>Omaha</Address1><Address2>Nebraska</Address2><Address3>68130</Address3><CountrySubDivision code="NE">Nebraska</CountrySubDivision><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Alliance Research Centers</Name><Address1>Laguna Hills</Address1><Address2>California</Address2><Address3>92653</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Arizona Oncology Associates - USOR</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><Address3>85704</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Atlanta Urological Group</Name><Address1>Atlanta</Address1><Address2>Georgia</Address2><Address3>30312</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Boca Raton Community Hospital, Inc.</Name><Address1>Boca Raton</Address1><Address2>Florida</Address2><Address3>33486</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Carolina Urology Partners</Name><Address1>Concord</Address1><Address2>North Carolina</Address2><Address3>28025</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Clinical Research Solutions</Name><Address1>Middleburg Heights</Address1><Address2>Ohio</Address2><Address3>44130</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Comprehensive Cancer Centers of Nevada</Name><Address1>Las Vegas</Address1><Address2>Nevada</Address2><Address3>89169</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Durham VA Medical Center</Name><Address1>Durham</Address1><Address2>North Carolina</Address2><Address3>27705</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Henry Ford Hospital</Name><Address1>Detroit</Address1><Address2>Michigan</Address2><Address3>48202</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Kaiser Permanente Medical Group</Name><Address1>Honolulu</Address1><Address2>Hawaii</Address2><Address3>96819</Address3><CountrySubDivision code="HI">Hawaii</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Kaiser Permanente, Northern CA</Name><Address1>Vallejo</Address1><Address2>California</Address2><Address3>94589</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Knight Cancer Institute</Name><Address1>Portland</Address1><Address2>Oregon</Address2><Address3>97239</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Massachusetts General Hospital</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02114</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Mayo Clinic - Arizona</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85054</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Memorial Sloan Kettering CC</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10065</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Minnesota Oncology Hematology, P.A.</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55404</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Minnesota Veterans Research Institute</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55417</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>MultiCare Regional Cancer Center - Gig Harbor</Name><Address1>Gig Harbor</Address1><Address2>Washington</Address2><Address3>98335</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>NYU Perlmutter Cancer Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Nebraska Cancer Specialists</Name><Address1>Omaha</Address1><Address2>Nebraska</Address2><Address3>68130</Address3><CountrySubDivision code="NE">Nebraska</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Northwest Cancer Specialist DBA Compass Oncology</Name><Address1>Portland</Address1><Address2>Oregon</Address2><Address3>97227</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Ochsner Medical Center</Name><Address1>New Orleans</Address1><Address2>Louisiana</Address2><Address3>70121</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Pacific Hematology Oncology Associates</Name><Address1>San Francisco</Address1><Address2>California</Address2><Address3>94115</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Premier MEdical Group of the Hudson Valley PC</Name><Address1>Poughkeepsie</Address1><Address2>New York</Address2><Address3>12601</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Premier Urology Associates</Name><Address1>Lawrenceville</Address1><Address2>New Jersey</Address2><Address3>08648</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Rocky Mountain Cancer Centers</Name><Address1>Aurora</Address1><Address2>Colorado</Address2><Address3>80012</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Roswell Park</Name><Address1>Buffalo</Address1><Address2>New York</Address2><Address3>14263</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>SUNY Upstate Medical University</Name><Address1>Syracuse</Address1><Address2>New York</Address2><Address3>13210</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>San Bernardino Urological Associates</Name><Address1>San Bernardino</Address1><Address2>California</Address2><Address3>92404</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>San Francisco VA Health Care System</Name><Address1>San Francisco</Address1><Address2>California</Address2><Address3>94121</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Sharp Memorial Hospital</Name><Address1>San Diego</Address1><Address2>California</Address2><Address3>92123</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>St. Joseph Heritage Healthcare</Name><Address1>Santa Rosa</Address1><Address2>California</Address2><Address3>95403</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Texas Oncology Cancer Center-Round Rock</Name><Address1>Round Rock</Address1><Address2>Texas</Address2><Address3>78681</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>The Urology Group</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><Address3>45212</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>UCSF Helen Diller Family Comprehensive Cancer Center</Name><Address1>San Francisco</Address1><Address2>California</Address2><Address3>94158</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>UT Health Science Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>UT Southwestern Medical Center</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75390</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University of Alabama at Birmingham</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><Address3>35233</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University of Florida Health Cancer Center</Name><Address1>Orlando</Address1><Address2>Florida</Address2><Address3>32806</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University of Maryland Greenebaum Cancer Center</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><Address3>21201</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University of Minnesota</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55455</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University of North Carolina Lineberger Cancer Center</Name><Address1>Chapel Hill</Address1><Address2>North Carolina</Address2><Address3>27599</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University of Rochester</Name><Address1>Rochester</Address1><Address2>New York</Address2><Address3>14642</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University of Southern California</Name><Address1>Beverly Hills</Address1><Address2>California</Address2><Address3>90210</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>University of Washington Fred Hutchinson Cancer Research Center</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98109</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Urology Associates Clinical Research</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37209</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Urology Clinics of North Texas</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75231</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Urology of Virginia</Name><Address1>Virginia Beach</Address1><Address2>Virginia</Address2><Address3>23462</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>VA Ann Arbor Healthcare System</Name><Address1>Ann Arbor</Address1><Address2>Michigan</Address2><Address3>48105</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>VA Greater Los Angeles Healthcare System</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90073</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>VA Portland Health Care System</Name><Address1>Portland</Address1><Address2>Oregon</Address2><Address3>97219</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>VA Puget Sound HCS</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98108</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Walter Reed National Military Medical Center</Name><Address1>Bethesda</Address1><Address2>Maryland</Address2><Address3>20889</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Weill Cornell Medical College</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10065</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Yale University School of Medicine</Name><Address1>New Haven</Address1><Address2>Connecticut</Address2><Address3>06510</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3564">Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3565">Subjects with Stage IV Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3581">Subjects with Hormone Sensitive Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3583">Subjects with Castrate Resistant Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3586">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12009">Subjects With Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12018">Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12907">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-1085079355" id="15724">BRCA1_HUMAN_Mutation</SubSegment><SubSegment genevariantId="-613688363" id="15725">BRCA2_HUMAN_Mutation</SubSegment><SubSegment genevariantId="-314354798" id="18851">ATM_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02975934</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2016-003163-20</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="7049"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Prostate tumor" id="7179"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7188">Assessments by radiography/imaging</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate tumor" id="7045"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7076"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7067">Assessment of Overall/Objective Response (ORR)</SubEndpoint><SubEndpoint disease="Prostate tumor" id="7074">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Prostate tumor" id="7075">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Prostate tumor" id="7077">Assessment of Stable Disease</SubEndpoint><SubEndpoint disease="Prostate tumor" id="7080">Assessment of clinical benefit/disease control rate</SubEndpoint><SubEndpoint disease="Prostate tumor" id="7086">Assessment of duration of response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7088"><Endpoint>Assessment of Disease Progression</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7129"><Endpoint>Assessment of Prostate Specific Antigen(PSA) Dependent Variables</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7130">Assessment of PSA response</SubEndpoint><SubEndpoint disease="Prostate tumor" id="7138">Assessment of time to PSA  progression</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7179"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7188">Assessments by radiography/imaging</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7189"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7191">Assessment of treatment emergent adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7217"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7222"><Endpoint>Assessment of Physical Examination</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="26571"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3695"><Criterion>Subjects with Stage IV Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3704"><Criterion>Subjects with Progressive Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3709">Subjects with progressive disease despite therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3714"><Criterion>Subjects with Histologically/Cytologically Confirmed Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3715">Subjects with adenocarcinoma of prostate</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3716"><Criterion>Subjects with Prostate Specific Laboratory Values</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3717">Subjects with castrate level of testosterone</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3745"><Criterion>Subjects on Prior/Concurrent Therapy for Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3746">Subjects on prior/concurrent hormone therapy</SubCriterion><SubCriterion disease="Prostate tumor" id="3749">Subjects with prior/concurrent surgery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3755"><Criterion>Subjects with Castrate Resistant Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3757"><Criterion>Subjects with Hormone Sensitive Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3762"><Criterion>Treatment Refractory Prostate Cancer Subjects</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3771"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="7091"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4845"><Criterion>Subjects with Advanced/Metastatic Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4847">Subjects with brain metastasis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4876"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4909"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4965"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4967">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="5004"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="5015">Subjects unsuitable to participate as per investigator</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="25640"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="5009">Subjects unable to give informed consent</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2022-02-28T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-11-19T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-11-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-01-12T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-20T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-05-02T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change></ChangeHistory></Trial><Trial id="281687"><TitleDisplay>EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC</TitleDisplay><TitleOfficial>A Prospective, Multicenter Study to Investigate the EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02988141</Identifier><Identifier type="Organisational Study">CCTC1601</Identifier><Identifier type="Trial Acronym">PRECENT</Identifier></Identifiers><Indications><Indication id="3665">Metastatic non small cell lung cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="8" role="Disease marker" type="Genomic;Proteomic">Epidermal growth factor receptor</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1048195" type="Company"><TargetEntity id="5035546712" type="organizationId">First Affiliated Hospital of Guangzhou Medical University</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"></TargetEntity><TargetEntity id="613" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1048195">The First Affiliated Hospital of Guangzhou Medical College</Company></CompaniesSponsor><CompaniesCollaborator><Company id="14190">AstraZeneca plc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2017-03-31T00:00:00Z</DateStart><DateEnd type="estimated">2021-02-28T00:00:00Z</DateEnd><DateChangeLast>2017-10-08T17:04:09Z</DateChangeLast><DateAdded>2016-12-20T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>China</Affiliation><Email>yxy701@126.com</Email><Extension>0</Extension><Name>Jian Xing HE, MD</Name><Phone>86-20-83062338</Phone></Contact><Contact type="Scientific contact"><Affiliation>China</Affiliation><Email>yxy701@126.com</Email><Extension>0</Extension><Name>Jian Xing HE, MD</Name><Phone>86-20-83062338</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Provision of informed consent prior to any study specific procedures&lt;/li&gt;&lt;li&gt;Male or female patients age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Histological confirmation of stage IIIB/IV NSCLC&lt;/li&gt;&lt;li&gt;Documented EGFR mutation positive&lt;/li&gt;&lt;li&gt;WHO Performance Status 0, 1 or 2&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study.&lt;/li&gt;&lt;li&gt;Previous (within 6 months) or current treatment with AZD-9291&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The biomarker profile of EGFR-TKI resistance</Description><Timeframe>Baseline</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The concordance, sensitivity and specificity in paired blood and tissue samples</Description><Timeframe>Baseline</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;A prospective, multicenter study to investigate the EGFR-TKI resistance profile in Chinese      patients with advanced EGFRm + NSCLC.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with EGFR mutation and presented secondary resistance to prior first-generation      EGFR-TKI should have received biopsy of at least on progressed lesions and are able to      provide tissues for pathological examination and NGS testing. All enrolled patients will be      followed up to clinical outcome (treatments, tumor response, survival, etc). &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lung tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3617">Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3623">Subjects with Advanced Stage Lung Cancer</PatientSegment><SubSegments><SubSegment id="3634">Subjects with metastatic/stage IV lung cancer</SubSegment><SubSegment id="10295">Subjects with locally advanced/stage III lung cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3647">Subjects with Treatment Resistant Disease</PatientSegment><SubSegments><SubSegment id="3649">Subjects with EGFR tyrosine kinase inhibitor resistant disease</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="10129">Subjects with EGFR Positive Lung Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12810">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-939494421" id="14656">EGFR_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02988141</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lung tumor" id="8629"><Endpoint>Assessment of Biomarkers</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Lung tumor" id="8635"><Endpoint>Assessment of markers of drug resistance/metabolism</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lung tumor" id="8651"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Lung tumor" id="8500"><Endpoint>Assessment of Survival</Endpoint></OtherEndpoint><OtherEndpoint disease="Lung tumor" id="8529"><Endpoint>Assessment of Clinical Response</Endpoint></OtherEndpoint><OtherEndpoint disease="Lung tumor" id="44828"><Endpoint>Assessment of Response Rates (RR)</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lung tumor" id="3900"><Criterion>Subjects with Non Small Cell Lung Cancer (NSCLC)</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3925"><Criterion>Subjects with Protocol Specified Stages of Lung Cancer(TNM staging)</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3935">Subjects with stage IIIB lung cancer</SubCriterion><SubCriterion disease="Lung tumor" id="3936">Subjects with stage IV lung cancer</SubCriterion><SubCriterion disease="Lung tumor" id="3938">Subjects with advanced stage lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3940"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3956"><Criterion>Subjects Confirmed of Lung Cancer by Specific Modes</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3957">Subjects with cytologically/histologically confirmed diagnosis of lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3959"><Criterion>Subjects with Lung Cancer Expressing Mutations</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3960">Subjects with EGFR (epidermal growth factor mutations) mutations</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3975"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3976">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Lung tumor" id="3977">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Lung tumor" id="3978">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3997"><Criterion>Subjects with Treatment Resistant Disease</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3999">Lung cancer subjects refractory/resistant to targeted therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34344"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="32043">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lung tumor" id="5269"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5345">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="5344"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5347">Subjects with abnormal laboratory values</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20281"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-12-07T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-12-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="297306"><TitleDisplay>A phase Ib, open-label, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of HM-95573 in combination with cobimetinib in patients with KRAS-, NRAS-, and BRAF-mutational locally advanced or metastatic solid tumors</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="3713">Advanced solid tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="52" role="Disease marker" type="Genomic;Proteomic">GTPase KRas</BiomarkerName><BiomarkerName id="82" role="Disease marker" type="Genomic;Proteomic">B-Raf proto-oncogene serine/threonine-protein kinase</BiomarkerName><BiomarkerName id="2062" role="Disease marker" type="Genomic;Proteomic">GTPase NRas</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>belvarafenib</Name><Drug id="84332">belvarafenib</Drug></Intervention><Intervention type="InterventionPrimary"><Name>cobimetinib</Name><Drug id="56544">cobimetinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="56544">cobimetinib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="16611">Hanmi Pharmaceutical Co Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="84332">belvarafenib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="16611">Hanmi Pharmaceutical Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="56544" type="Drug"><TargetEntity id="441013" type="siDrug">Cobimetinib</TargetEntity><TargetEntity id="669604" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="84332" type="Drug"><TargetEntity id="808940" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="16611" type="Company"><TargetEntity id="5000805170" type="organizationId">Hanmi Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="4542" type="Action"><TargetEntity id="1212" type="Mechanism">Raf Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4760" type="Action"><TargetEntity id="1215" type="Mechanism">Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4762" type="Action"><TargetEntity id="1226" type="Mechanism">Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 (MAP2K1; MEK1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4764" type="Action"><TargetEntity id="1227" type="Mechanism">Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2; MEK2) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1b Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="16611">Hanmi Pharmaceutical Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4542">Raf protein kinase inhibitor</Action><Action id="4760">MEK protein kinase inhibitor</Action><Action id="4762">MEK-1 protein kinase inhibitor</Action><Action id="4764">MEK-2 protein kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><DateChangeLast>2017-05-09T16:00:46Z</DateChangeLast><DateAdded>2017-05-10T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with KRAS-, NRAS-, and BRAF-mutational locally advanced or metastatic solid tumors&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety, tolerability</Description></Measure><Measure><Description>Pharmacokinetics</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this phase Ib, open-label, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of &lt;ulink linkType="Drug" linkID="84332"&gt;HM-95573&lt;/ulink&gt; in combination with &lt;ulink linkType="Drug" linkID="56544"&gt;cobimetinib&lt;/ulink&gt; in patients with KRAS-, NRAS-, and BRAF-mutational locally advanced or metastatic solid tumors [&lt;ulink linkType="Reference" linkID="1924791"&gt;1924791&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive HM-95573 in combination with cobimetinib [&lt;ulink linkType="Reference" linkID="1924791"&gt;1924791&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="301676"><TitleDisplay>Comparing the relaxation effect of diazepam of oral administration of single and divided dose in patients with limited mouth opening origin of masticatory muscles</TitleDisplay><TitleOfficial>Comparing the relaxation effect of diazepam of oral administration of single and divided dose in patients with limited mouth opening origin of masticatory muscles</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2017032933167N1</Identifier><Identifier type="Secondary Organisational">IR.mums.sd.REC.1394.213</Identifier></Identifiers><Indications><Indication id="1038">Muscle disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>diazepam</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1053601" type="Company"><TargetEntity id="5035560314" type="organizationId">Mashhad University of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="1038" type="ciIndication"><TargetEntity id="G71" type="ICD10"></TargetEntity><TargetEntity id="728" type="ICD9"></TargetEntity><TargetEntity id="10028300" type="MEDDRA"></TargetEntity><TargetEntity id="-1952423694" type="omicsDisease"></TargetEntity><TargetEntity id="3505" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1053601">Mashhad University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>48</PatientCountEnrollment><DateStart>2017-04-30T00:00:00Z</DateStart><DateChangeLast>2017-06-22T11:53:08Z</DateChangeLast><DateAdded>2017-06-19T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Dental Faculty of Mashhad University</Affiliation><Email>jarrahin921@mums.ac.ir</Email><Name>Neda Jarahi</Name><Phone>009838067117 00989155205446</Phone></Contact><Contact type="Scientific contact"><Affiliation>Dental Faculty of Mashhad</Affiliation><Email>madania@mums.ac.ir</Email><Name>Azam Sadat Madani</Name><Phone>00985137685758 00989155111408</Phone></Contact><Contact type="Public contact"><Affiliation>Mashhad University of Medical Science</Affiliation><Email>jarrahin921@mums.ac.ir</Email><Name>Neda Jarrahi</Name><Phone>0098515220729 00989155205446</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with limitation in mouth opening by the source of masticatory muscle&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pregnancy: breastfeeding&lt;/li&gt;&lt;li&gt;Using drugs have interactions with diazepam (such as cimetidine, amvprazvl, phenytoin, erythromycin and fungicides)&lt;/li&gt;&lt;li&gt;Liver and kidney disfunctions (with tests SGOT, SGPT, ALP, bun-creatinine)&lt;/li&gt;&lt;li&gt;Alcoholism&lt;/li&gt;&lt;li&gt;Glaucoma&lt;/li&gt;&lt;li&gt;Severe difficulty breathing&lt;/li&gt;&lt;li&gt;Sleep apnea&lt;/li&gt;&lt;li&gt;Epilepsy&lt;/li&gt;&lt;li&gt;Consumers of other benzodiazepines&lt;/li&gt;&lt;li&gt;Other muscle relaxants and anti-inflammatory drugs&lt;/li&gt;&lt;li&gt;Close lock&lt;/li&gt;&lt;li&gt;The joint disorders&lt;/li&gt;&lt;li&gt;Chronic slow mandible&lt;/li&gt;&lt;li&gt;Patients with submucosal fibrosis&lt;/li&gt;&lt;li&gt;Patients radiotherapy&lt;/li&gt;&lt;li&gt;Sensitivity to diazepam&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Range of mouth opening: the distance between inscisal edge of two right centrals in milimeter</Description><Timeframe>Before Intervention and in 3, 5 and 7 days after Intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Drug complications: patient's discription</Description><Timeframe>Before Intervention and in 3, 5 and 7 days after Intervention</Timeframe></Measure><Measure><Description>Pain through opening: VAS (visual analog scale)</Description><Timeframe>Before Intervention and in 3, 5 and 7 days after Intervention</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to compare muscle relaxation in patients with limitation in mouth opening that use single or divided dose of diazpam.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 48 patients with limitation in mouth opening in the range of 8 to 10 mm with the origin of masticatory muscles will be  assigned to three groups randomly. The first group will receive  a dose of 10 mg, the second group will receive two dose of 5 mg and the third group will  receive four dose of 2.5 mg diazpam daily. The rage of mouth opening (from incisal edge of the right centrals) will be measured in millimeter and the pain during the mouth opening will be scaled on the VAS before and after using the drugs in the third, fifth and seventh days.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Dental Faculty of Mashhad</Name><Address1>Khorasan Razavi</Address1><Contacts><Contact type="Facility contact"><Name>Neda Jarahi</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other musculoskeletal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18266">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="18771">Subjects with muscle disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2017032933167N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other musculoskeletal disease" id="42991"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other musculoskeletal disease" id="42923"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="45597"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46477"><Endpoint>Assessment by Global Assessment Scales</Endpoint><SubEndpoints><SubEndpoint disease="Other musculoskeletal disease" id="46375">Visual analogue scales (VAS) for local and general pain/overall disease activity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other musculoskeletal disease" id="32681"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other musculoskeletal disease" id="24023"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24093"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24173"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24176">Subjects with elevated Alanine aminotransferase (ALT)</SubCriterion><SubCriterion disease="Other musculoskeletal disease" id="24177">Subjects with elevated Aspartate aminotransferase (AST)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24183"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24962"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24043">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2018-05-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>13.06 Months</EnrollmentPeriod><EnrollmentRate>3.68 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-06-19T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="303178"><TitleDisplay>Measurement of blood glucagon levels in glucose tolerance and meal tolerance test</TitleDisplay><TitleOfficial>Evaluation of change in blood glucagon levels in response to orally glucose loading and food intake</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000027852</Identifier></Identifiers><Indications><Indication id="97">Diabetes mellitus</Indication></Indications><BiomarkerNames><BiomarkerName id="435" role="Disease marker" type="Genomic;Proteomic">Glucagon</BiomarkerName><BiomarkerName id="808" role="Disease marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="38237" role="Disease marker" type="Genomic;Proteomic">Incretins</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>oral glucose loading</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1013118" type="Company"><TargetEntity id="4298181964" type="organizationId">Gunma University</TargetEntity></SourceEntity><SourceEntity id="1043555" type="Company"><TargetEntity id="5037124911" type="organizationId">Cosmic Corporation Co Ltd</TargetEntity></SourceEntity><SourceEntity id="97" type="ciIndication"><TargetEntity id="10012601" type="MEDDRA"></TargetEntity><TargetEntity id="D003920" type="MeSH"></TargetEntity><TargetEntity id="-203480060" type="omicsDisease"></TargetEntity><TargetEntity id="506" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1013118">Gunma University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1043555">Cosmic Corp</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><PatientCountEnrollment>70</PatientCountEnrollment><DateStart>2017-06-30T00:00:00Z</DateStart><DateChangeLast>2017-12-25T05:53:53Z</DateChangeLast><DateAdded>2017-07-07T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Institute for Molecular and Cellular Regulation, Gunma University ; Metabolic Signal Research Center
</Affiliation><Email>hos-webmaster@ml.gunma-u.ac.jp</Email><Name>Tadahiro Kitamura</Name><Phone>+81-27-220-8845</Phone></Contact><Contact type="Scientific contact"><Affiliation>Institute for Molecular and Cellular Regulation, Gunma University ; Metabolic Signal Research Center
</Affiliation><Name>Tadahiro Kitamura</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Normal subjects&lt;ul&gt;&lt;li&gt;20 to 69 years old&lt;/li&gt;&lt;li&gt;HbA1c is&amp;lt; 6.2%&lt;/li&gt;&lt;li&gt;Person who do not regularly use medicine&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Diabetes patients&lt;ul&gt;&lt;li&gt;20 to 69 years old&lt;/li&gt;&lt;li&gt;Patients who are not receiving medication for diabetes&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Abnormal in liver or renal function test&lt;/li&gt;&lt;li&gt;A woman within 12 weeks expected to give birth&lt;/li&gt;&lt;li&gt;Impaired cardiopulmonary function&lt;/li&gt;&lt;li&gt;Anemia symptoms&lt;/li&gt;&lt;li&gt;Chronic or acute infections according to the judgment of doctor&lt;/li&gt;&lt;li&gt;Persons who are participating in other clinical trials at the start of this study&lt;/li&gt;&lt;li&gt;Subjects judged by investigator as inappropriate&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The time course (0, 30, 60, 120, 180 min after loading) of blood glucagon levels in diabetes patients in response to glucose loading or food intake will be compared with those in normal glucose tolerant subjects</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>In addition, blood glucose, insulin, and incretin levels will be measured and analyzed in accordance with kinetic changes in blood glucagon levels</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of the study is  to examine change in blood glucagon levels of normal glucose tolerant subjects and diabetes subjects in response to orally glucose loading and food intake.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this observational study the subjects  recieve oral glucose loading and food intake. The investigators  will measure blood glucagon levels using relatively glucagon-specific new ELISA method. They will also    measure blood glucagon levels by using conventional RIA kits to clarify which kit of sandwich ELISA or conventional RIA is more suitable to attain the objectives. &lt;br/&gt;This study is categorized into observational study, in which collected blood samples are assayed for glucagon by commercially available glucagon test kits. &lt;br/&gt;Glucagon test kits:&lt;br/&gt;Glucagon ELISA (Cosmic), &lt;br/&gt;Glucagon RIA KIT (&lt;ulink linkType="Company" linkID="CM28288"&gt;Merck Millipore&lt;/ulink&gt;), &lt;br/&gt;Glucagon RIA SML (Sceti Medical Lab). &lt;br/&gt;Study subjects:&lt;br/&gt;20 healthy subjects &lt;br/&gt;50 diabetes patients &lt;br/&gt;Blood sampling &lt;br/&gt;Blood will be  intravenously collected using P800 blood sampling tube (&lt;ulink linkType="Company" linkID="14596"&gt;Becton Dickinson&lt;/ulink&gt;).&lt;br/&gt;Test schedule:&lt;br/&gt;Fasting subjects (Healthy subjects and diabetes paitients) take Torelan G or Sanet SA. Blood samples of 10 mL are collected at 0, 30, 60, 120, 180 min after glucose or food intake. A subject participates both glucose tolerance and meal tolerance tests on separate days on the interval of 1 to 4 weeks. &lt;br/&gt;Prohibited treatments:&lt;br/&gt;Pharmaceuticals and herbal medicine without previous experience of use &lt;br/&gt;Treatments that can be done together with this study: None.&lt;br/&gt;Data extraction from medical record: sex, date of birth, age, height, weight, blood pressure, liver and renal function test results, lipid metabolism data, and HbA1c. &lt;br/&gt;Examination and evaluation items:&lt;br/&gt;Just before tolerance test: &lt;br/&gt;HbA1c (healthy subject), blood glucose, glucagon, insulin, incretin, subjective symptom, objective symptom , 30, 60, 120, 180 min after glucose or meal intake:  blood glucose, glucagon, insulin, incretin, subjective symptom, objective symptom, adverse event.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Institute for Molecular and Cellular Regulation, Gunma University</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="7646">Subjects with Good Glycemic Control</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="102">Subjects with Good Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19156">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000027852</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1385"><Endpoint>Assessment of Glucagon Secretion/Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="43963"><Endpoint>Assessment of Hormone Levels</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1362"><Endpoint>Assessment of Insulin Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1377"><Endpoint>Assessment of Incretins</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1385"><Endpoint>Assessment of Glucagon Secretion/Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18118"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18158"><Endpoint>Assessment of Insulin Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18284"><Endpoint>Assessment of Incretins</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="43963"><Endpoint>Assessment of Hormone Levels</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="639"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="1047"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16356"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33510"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="606">Subjects with Good Glycemic Control</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="33656"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35051"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16355">Subjects with Good Glycemic Control</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35101"><Criterion>Subjects with Diabetes Mellitus</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="837"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="891"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="928"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="936">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="995"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1030">Participating in another trial/administration of any investigational drug before wash out period</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="1594">Not suitable to take part in the trial as per the physician/investigator</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5072"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5074"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5078"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5620">Abnormal liver function test</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13757"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13785"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13812"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13815"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13835"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13839">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13850"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13852">Abnormal liver function test</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13886"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13902">Not suitable to take part in the trial as per the physician/investigator</SubCriterion><SubCriterion disease="Insulin dependent diabetes" id="13903">Participating in another trial/administration of any investigational drug before wash out period</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="25726"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="25727"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-07-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-12-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="344964"><TitleDisplay>Comparison of the efficacy two drugs which are routinely added to local anaesthetics in hand surgeries</TitleDisplay><TitleOfficial>Comparison of Anesthetic efficacy of nalbuphine and dexmedetomidine as an adjuvant to 0.5% ropivacaine and 2% lignocaine for supraclavicular block in upper limb surgeries</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2018/06/014678</Identifier></Identifiers><Indications><Indication id="19">Anesthesia</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>dexmedetomidine</Name><Drug id="8783">dexmedetomidine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lidocaine (endometriosis), Isifer</Name><Drug id="76327">lidocaine (endometriosis), Isifer</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>nalbuphine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ropivacaine</Name><Drug id="4271">ropivacaine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4271">ropivacaine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1082257">ESI Post Graduate Institute of Medical Science and Research (PGIMSR)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="76327">lidocaine (endometriosis), Isifer</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1082257">ESI Post Graduate Institute of Medical Science and Research (PGIMSR)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8783">dexmedetomidine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1082257">ESI Post Graduate Institute of Medical Science and Research (PGIMSR)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4271" type="Drug"><TargetEntity id="129999" type="siDrug">Ropivacaine</TargetEntity><TargetEntity id="150269" type="siDrug">Ropivacaine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="8783" type="Drug"><TargetEntity id="145584" type="siDrug">Dexmedetomidine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1082257" type="Company"><TargetEntity id="5059975537" type="organizationId">ESI Post Graduate Institute of Medical Science and Research</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"></TargetEntity><TargetEntity id="D000758" type="MeSH"></TargetEntity><TargetEntity id="-564538434" type="omicsDisease"></TargetEntity><TargetEntity id="23" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="33" type="Action"><TargetEntity id="54" type="Mechanism">alpha2-Adrenoceptor Agonists</TargetEntity></SourceEntity><SourceEntity id="498" type="Action"><TargetEntity id="358" type="Mechanism">Sodium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1082257">ESI Post Graduate Institute of Medical Science and Research (PGIMSR)</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="33">Alpha 2 adrenoceptor agonist</Action><Action id="498">Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1669">Local anesthetic</Class><Class id="2942">Anxiolytic</Class><Class id="2946">Analgesic</Class><Class id="2953">Anti-inflammatory</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="654">Intrathecal formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="767">Rectal formulation</Technology><Technology id="622">Rectal formulation local</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="630">Stereochemistry</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2018-06-29T00:00:00Z</DateStart><DateChangeLast>2018-07-31T22:04:13Z</DateChangeLast><DateAdded>2018-07-10T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>ESICMC PGIMSR</Affiliation><Email>rsuma@yahoo.com</Email><Name>R Uma</Name><Phone>9840822288</Phone></Contact><Contact type="Public contact"><Affiliation>ESICMC PGIMSR</Affiliation><Email>drsowmyaashan@gmail.com</Email><Name>Sowmya Shanmugam</Name><Phone>9444413647</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient willing&lt;/li&gt;&lt;li&gt;ASA 1 and 2&lt;/li&gt;&lt;li&gt;Upper limb surgeries&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patient not willing&lt;/li&gt;&lt;li&gt;Bleeding disorders&lt;/li&gt;&lt;li&gt;Infection at site of injection&lt;/li&gt;&lt;li&gt;Patients on anticoagulants&lt;/li&gt;&lt;li&gt;Patients with musculoskeletal disorders&lt;/li&gt;&lt;li&gt;Patients with history of allergy to local anaesthetics&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To compare the anaesthetic efficacy of Nalbuphine and dexmedetomidine as an adjuvant to 0.5% ropivacaine and 2% lignocaine for supraclavicular block in upper limb surgeries</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Time of onset of sensory and otor block duration of sensory and otor block level of sedation and side effets such as pruritis, bradycardia, respiratory dpression</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim is to compare two adjuvants &lt;ulink linkType="Drug" linkID="8783"&gt;dexmedetomidine&lt;/ulink&gt; and nalbuphine in terms of their efficacy in hastening the motor and sensory blockade and also in terms of prolonging both the sensory and motor blockade in supraclavicular brachial plexus block for patients undergoing upper limb surgeries using ultrasound guidance.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized into two arms:&lt;br/&gt;Arm A: will receive nalbuphine vesus dexmedetomidine as adjuvants to ropivacaine in supraclavicular brachial pexus block.&lt;br/&gt;Arm B: will receive supraclavicular brachial plexus block using 0.5% &lt;ulink linkType="Drug" linkID="4271"&gt;ropivacaine&lt;/ulink&gt; and 2% &lt;ulink linkType="Drug" linkID="76327"&gt;lignocaine&lt;/ulink&gt;.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>ESICMC and PGIMSR</Name><Address1>Chennai</Address1><Address2>TAMIL NADU</Address2><Address3>600078</Address3><CountrySubDivision>TAMIL NADU</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2018/06/014678</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-07-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="345105"><TitleDisplay>A study to evaluate the effect of tofacitinib on peripheral blood leukocyte phenotype and function and reversal effects with treatment withdrawal in healthy volunteers</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications></Indications><BiomarkerNames><BiomarkerName id="125" role="Therapeutic effect marker" type="Cellular">Leukocyte count</BiomarkerName><BiomarkerName id="252" role="Therapeutic effect marker" type="Genomic;Proteomic">Interferon gamma</BiomarkerName><BiomarkerName id="1857" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD4</BiomarkerName><BiomarkerName id="2706" role="Therapeutic effect marker" type="Cellular">Natural killer cells</BiomarkerName><BiomarkerName id="3447" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD8 alpha chain</BiomarkerName><BiomarkerName id="6663" role="Therapeutic effect marker" type="Cellular">B-lymphocytes</BiomarkerName><BiomarkerName id="8097" role="Therapeutic effect marker" type="Cellular">Monocytes</BiomarkerName><BiomarkerName id="10204" role="Therapeutic effect marker" type="Cellular">Granulocytes</BiomarkerName><BiomarkerName id="11580" role="Therapeutic effect marker" type="Cellular">T-lymphocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tofacitinib (oral modified release), Pfizer</Name><Drug id="83185">tofacitinib (oral modified release), Pfizer</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="83185">tofacitinib (oral modified release), Pfizer</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="3562" type="Action"><TargetEntity id="1506" type="Mechanism">Jak1 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3566" type="Action"><TargetEntity id="1390" type="Mechanism">Jak3 Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="18767">Pfizer Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3562">Jak1 tyrosine kinase inhibitor</Action><Action id="3566">Jak3 tyrosine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="641">Controlled release formulation</Technology><Technology id="805">Daily dosing</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateChangeLast>2018-07-31T22:04:41Z</DateChangeLast><DateAdded>2018-07-06T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Cytomegalovirus (CMV)-seropositive healthy subjects&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Determine the effects of tofacitinib on peripheral blood leukocyte phenotype and function</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study was to evaluate the short-term effects of treatment with&lt;ulink linkType="Drug" linkID="83185"&gt;tofacitinib&lt;/ulink&gt; onperipheralbloodleukocytephenotype and function and evaluate thereversibilityof any such effects following withdrawal of treatmentinhealthyvolunteers [&lt;ulink linkType="Reference" linkID="2051302"&gt;2051302&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2018, results were published. During treatment with tofacitinib, a slight increase in total lymphocyte and total T-cell counts, and B-cell counts rised by up to 26%. No significantchange was observedin granulocyte  counts or function or monocyte count. During treatment, there was an increase in naive and central memory T-cell lymphocyte counts, while all subsets of activated T cells were reduced by up to 69%. T-cell subsets other than activated naive cluster of differentiation (CD)4+, effector memory CD4+, and effector CD8+ T-cell counts and B-cell counts had normalized 4weeksafter treatmentwithdrawal. Following ex vivo activation, measures of cytomegalovirus-specific T-cell responses, and antigen non-specific T-cell-mediated cytotoxicity and interferon-gamma production, reduced slightly. T-cellfunctionalchangeswere observed to be most pronounced at Day 15, partially normalized while still ontofacitinibtreatment and had returned to baselineafterdrugwithdrawal. Total natural killer (NK)-cell counts reduced by 33%, returning towards baselineafterdrugwithdrawal. NK-cell function reduced duringtofacitinibtreatment, but there was no consistent time course across measured parameters. However, markers of antibody-dependent cellular cytotoxicity, NK-cell-mediated cytotoxicity and  interferon-gamma  production were reduced up to 42% 1monthafterdrugwithdrawal. Cytomegalovirus DNA was not detectable in wholeblood, and there were no observed cases of herpes zoster reactivation. There were no new safety concerns [&lt;ulink linkType="Reference" linkID="2051302"&gt;2051302&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects received tofacitinib10mg po bid for 4weeks and  followed up for 4weeksafterdrugwithdrawal [&lt;ulink linkType="Reference" linkID="2051302"&gt;2051302&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="824666">tofacitinib (oral modified release), Pfizer</Intervention><Treatments><Treatment><Dose>10 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-07-06T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="349909"><TitleDisplay>Effects of Walking Training on Different Surfaces on Walking Ability in Ambulatory Patients With Spinal Cord Injury</TitleDisplay><TitleOfficial>Effects of Walking Training on Different Surfaces on Walking Ability, Balance Control, Lower Limb Muscle Strength, and Falls in Ambulatory Patients With Spinal Cord Injury</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03622710</Identifier><Identifier type="Organisational Study">PHD57I0062</Identifier></Identifiers><Indications><Indication id="1258">Spinal cord injury</Indication></Indications><BiomarkerNames><BiomarkerName id="147" role="Therapeutic effect marker" type="Physiological">Six-minute walk distance</BiomarkerName><BiomarkerName id="48952" role="Therapeutic effect marker" type="Physiological">Lower limb strength</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>walking training on different surfaces</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>walking training overground</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1037042" type="Company"><TargetEntity id="5035541531" type="organizationId">Khon Kaen University</TargetEntity></SourceEntity><SourceEntity id="1258" type="ciIndication"><TargetEntity id="10041552" type="MEDDRA"></TargetEntity><TargetEntity id="D013119" type="MeSH"></TargetEntity><TargetEntity id="90058" type="ORPHANET"></TargetEntity><TargetEntity id="-1980782964" type="omicsDisease"></TargetEntity><TargetEntity id="178" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1037042">Khon Kaen University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>72</PatientCountEnrollment><DateStart>2017-07-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-04-15T00:00:00Z</DateEnd><DateChangeLast>2019-03-13T07:24:34Z</DateChangeLast><DateAdded>2018-08-16T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>mai_en@windowslive.com</Email><Name>Donlaya Promkeaw</Name><Phone>+66-83-4177516</Phone></Contact><Contact type="Scientific contact"><Affiliation>School of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University Affiliation: Khon Kaen University</Affiliation><Name>Sugalya Amatachaya</Name></Contact></Contacts><MeasuresOutcome><MeasuresPrimary><Measure><Description>A 10-meter walk test (10MWT): subjects walk at a comfortable pace along a 10 m walkway. The test records the time use over the middle 4m of the walkway in order to minimize acceleration and deceleration effects. Then the average time over the 3 trials is converted to walking speed using the formula v=distance (m) /time (s)</Description><Timeframe>Change over 4 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>A 6-minute walk test (6MWT): subjects walk along a rectangular walkway as long as possible in 6 minutes. Every minute during the test, they are informed the time left and encouraged to continue in a good manner. Subjects are able to take a period of rest as needed and continued walking as soon as they can. The distance covered after 6 min are recorded</Description><Timeframe>Change over 4 weeks</Timeframe></Measure><Measure><Description>Five times sit-to-stand test (FTSST): the time taken to complete 5 chair-rise cycles at a fastest and safe speed is measured for each subject. Then the average time over the 3 trials is used for data analysis</Description><Timeframe>Change over 4 weeks</Timeframe></Measure><Measure><Description>Incidence of fall: then subject will be monthly monitored for the fall data during 6 months using a fall diary and telephone</Description><Timeframe>6 months after completing the training program</Timeframe></Measure><Measure><Description>Timed up and go test (TUGT): subjects stand up from a standard armchair, walk around a traffic cone that is located 3m away from the chair, and return to sit down on the chair at a maximum and safe speed. The test records the time taken from the command "Go" until the subject's back against the backrest of the chair. Then the average times finding over the three trials is used for data analysis</Description><Timeframe>Change over 4 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study compares effects of 4-week walking training program on a walking track with      difference surface (WTDS) and a firm ground on functional ability of ambulatory individuals      with incomplete spinal cord injury (iSCI), using within- and between-group comparisons.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consist of two groups:&lt;br/&gt;Group 1: subjects will be trained to walk over a walking track with different surfaces (WTDS) for 5 days over 4 weeks.&lt;br/&gt;Group 2: subjects will be trained to walk overground for 5 days over 4 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Thailand"><Sites><Site><Name>Srinagarind hospital</Name><Address1>Khon Kaen</Address1><Address3>40000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other neurological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16683">Others</PatientSegment><SubSegments><SubSegment id="18692">Healthy Subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="17728">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="15871">Subjects with spinal cord injury</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03622710</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other neurological disease" id="43422"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="44193"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other neurological disease" id="43422"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="44193"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Other neurological disease" id="43423">Six-minute walk test (6MWT)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other neurological disease" id="32685"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="33192"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="33214">Subjects with spinal cord injury</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other neurological disease" id="33283"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="32746">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other neurological disease" id="24024"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24094"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="25821"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-12-10T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-01-10T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-08-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="3561"><TitleDisplay>Effect of Chronic PDE5-Inhibition on Endothelial Function in Diabetics</TitleDisplay><TitleOfficial>Effect of Chronic Administration of Sildenafil on Endothelial Function in Men With Diabetes</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">HSRRM1999/4</Identifier><Identifier type="NCT">NCT00420901</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sildenafil citrate</Name><Drug id="8713">sildenafil citrate</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8713">sildenafil citrate</Drug><IndicationsPioneer><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsPioneer><Companies><Company><Company id="25126">Istituto Scientifico H San Raffaele</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8713" type="Drug"><TargetEntity id="184491" type="siDrug">Sildenafil citrate</TargetEntity></SourceEntity><SourceEntity id="25126" type="Company"><TargetEntity id="5035524231" type="organizationId">Ospedale San Raffaele Srl</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25126">Istituto Scientifico H San Raffaele</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="778">PDE 5 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2657">Antihypertensive</Class><Class id="388">Vasodilator</Class><Class id="882">5-HETE modulator</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>1999-01-31T00:00:00Z</DateStart><DateEnd type="actual">2000-03-31T00:00:00Z</DateEnd><DateChangeLast>2013-12-02T16:36:38Z</DateChangeLast><DateAdded>2007-08-09T08:54:22Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>San Raffaele EUR</Affiliation><Name>Giuseppe rosano</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Type 2 diabetes&lt;/li&gt;&lt;li&gt;Males&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Females, nitrate use, PDE5-Inhibitors intolerance&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Endothelial function responders - Improvement in endothelial function</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Changes in vascular inflammatory markers</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective of this study was to determine if chronic inhibition  of phosphodiesterase type 5 (PDE5) with &lt;ulink linkType="Drug" linkID="8713"&gt;sildenafil&lt;/ulink&gt; improves endothelial function in diabetics.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study was to  evaluate endothelial function at baseline and after chronic administration of &lt;ulink linkType="Drug" linkID="8713"&gt;sildenafil&lt;/ulink&gt; in male subjects with diabetes.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Italy"><Sites><Site><Name>San Raffaele EUR</Name><Address1>Roma</Address1><Address3>00144</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00420901</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1572"><Endpoint>Assessment of Vascular Endothelial Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1423"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Non-insulin dependent diabetes" id="1423"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1427">Assessment of C reactive protein (CRP)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1430">Intercellular adhesion molecule-1 (ICAM-1)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1433">Interleukin-6 (IL-6)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1450">Assessment of vascular cell adhesion molecule-1 (VCAM-1)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Non-insulin dependent diabetes" id="1572"><Endpoint>Assessment of Vascular Endothelial Function</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1574">Flow-mediated dilatation (FMD)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="963"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="983"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="990">Hypersensitivity/contraindications to study medication/device</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2007-08-09T08:54:22Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="358597"><TitleDisplay>MSAPN study</TitleDisplay><TitleOfficial>Therapy with macrolide in severe asthmatic patients with peripheral blood neutrophilia: a non-blinded, crossover trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000034699</Identifier><Identifier type="Trial Acronym">MSAPN</Identifier></Identifiers><Indications><Indication id="1984">Neutrophilia</Indication><Indication id="31">Asthma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>clarithromycin</Name><Drug id="2829">clarithromycin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>standard therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2829">clarithromycin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1009840">Kyorin University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2829" type="Drug"><TargetEntity id="121880" type="siDrug">Clarithromycin</TargetEntity></SourceEntity><SourceEntity id="1009840" type="Company"><TargetEntity id="5035562525" type="organizationId">Kyorin University</TargetEntity></SourceEntity><SourceEntity id="1984" type="ciIndication"><TargetEntity id="10029379" type="MEDDRA"></TargetEntity><TargetEntity id="3537" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1009840">Kyorin University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="15187">Systemic dermatological antibacterial product</Class><Class id="1538">Bacterial protein synthesis inhibitor</Class><Class id="1540">Macrolide antibiotic</Class><Class id="1594">Antibacterial</Class><Class id="463">Ribosome binding agent</Class></Class><Technologies><Technology id="66">Antibiotic</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="743">Granule</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2018-12-01T00:00:00Z</DateStart><DateChangeLast>2018-11-05T10:46:27Z</DateChangeLast><DateAdded>2018-11-02T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Kyorin University Faculty of Medicine ; First Department of Internal Medicine (Respiratory Medicine)
</Affiliation><Email>masato@ks.kyorin-u.ac.jp</Email><Name>Masato Watanabe</Name><Phone>0422-47-5511</Phone></Contact><Contact type="Scientific contact"><Affiliation>Kyorin University Faculty of Medicine ; First Department of Internal Medicine (Respiratory Medicine)
</Affiliation><Name>Masaki Tamura</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who are diagnosed with asthma according to guidelines of The Japanese Respiratory Society and Japanese Society of Allergy&lt;/li&gt;&lt;li&gt;Patients who meet our criteria of severe asthma with peripheral blood neutrophilia (white blood cell count&amp;gt;/= 8000/microl, neutrophil count &amp;gt;/= 6000 /microl, or eosinophil count &amp;gt;/= 72/microl)&lt;/li&gt;&lt;li&gt;Patients who understand the purpose of the study and gave written informed consent&lt;/li&gt;&lt;li&gt;Patients who are &gt;/= 20 years old&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with chronic obstructive lung disease&lt;/li&gt;&lt;li&gt;Patient who smoked within 3 months&lt;/li&gt;&lt;li&gt;Patients whose attending physician recommends not to participate the study because of comorbidities (ie, respiratory infection, heart disease, liver disease, and kidney disease)&lt;/li&gt;&lt;li&gt;Patients with non-tuberculotic mycobacterial infection&lt;/li&gt;&lt;li&gt;Patients who cannot use clarithromycin: with history of hypersensitivity to clarithromycin; using presently pimozide, ergotamine tartrate, dihydroergotamine mesylate, tadalafil, asunaprevir, vaniprevir, or suvorexant; with liver or kidney disease and using presently colchicine&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Exacerbation of asthma</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this is to evaluate efficacy of macrolide in severe asthmatic participants with peripheral blood neutrophilia.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study consist of two groups:&lt;br/&gt;Group 1: standard therapy (the participants have used before participating the study) plus &lt;ulink linkType="Drug" linkID="2829"&gt;clarithromycin&lt;/ulink&gt; 200 mg/day for 12 weeks, followed by standard therapy alone for 12 weeks.&lt;br/&gt;Group 2: standard therapy (the participants have used before participating the study) alone for 12 weeks, followed by standard therapy plus clarithromycin 200 mg/day for 12 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Kyorin University Faculty of Medicine</Name><Address1>Tokyo</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other hematological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18261">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000034699</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Asthma" id="5983"><Endpoint>Assessment of Exacerbations</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Asthma" id="2849"><Criterion>Subjects with Other Abnormal Lab Parameters</Criterion></Inclusion><Inclusion disease="Asthma" id="2875"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Asthma" id="4266"><Criterion>Subjects Included based on Diagnostic/Therapeutic Guidelines for Asthma</Criterion></Inclusion><Inclusion disease="Asthma" id="4322"><Criterion>Subjects with Diagnosis of Asthma</Criterion></Inclusion><Inclusion disease="Other hematological disease" id="33056"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other hematological disease" id="34317"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other hematological disease" id="33114">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Asthma" id="34346"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Asthma" id="33515">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other hematological disease" id="35075"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Asthma" id="3839"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Asthma" id="3855"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Asthma" id="3877"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Asthma" id="20242"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Asthma" id="20245"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Asthma" id="20247"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Asthma" id="20252"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Asthma" id="20253">Subjects with contraindication to drugs or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Asthma" id="20256"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other hematological disease" id="24000"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other hematological disease" id="24304"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other hematological disease" id="24624"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Asthma" id="25070"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Asthma" id="3954">Smokers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Asthma" id="25434"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Other hematological disease" id="25612"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-11-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="360733"><TitleDisplay>Effect of Modified 45-Degree Head-Up Tilt Position in Cesarean Operation to the Success of Spinal Anesthesia</TitleDisplay><TitleOfficial>Effect of Modified 45-Degree Head-Up Tilt Position in Cesarean Operation to the Success of Spinal Anesthesia</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03740399</Identifier><Identifier type="Organisational Study">TTF-BAEK 2018/79</Identifier><Identifier type="Trial Acronym">cesarean</Identifier></Identifiers><Indications><Indication id="19">Anesthesia</Indication></Indications><BiomarkerNames><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="12385" role="Therapeutic effect marker" type="Structural (imaging)">Cerebrospinal fluid</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Spinal anesthesia</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1054835" type="Company"><TargetEntity id="5035560098" type="organizationId">Trakya Universitesi</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"></TargetEntity><TargetEntity id="D000758" type="MeSH"></TargetEntity><TargetEntity id="-564538434" type="omicsDisease"></TargetEntity><TargetEntity id="23" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1054835">Trakya University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>180</PatientCountEnrollment><DateStart>2018-04-19T00:00:00Z</DateStart><DateEnd type="estimated">2019-06-28T00:00:00Z</DateEnd><DateChangeLast>2018-11-21T22:02:02Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Trakya University</Affiliation><Email>sevtaphekimoglu@mynet.com</Email><Name>Sevtap Hekimoglu Sahin, Professor</Name><Phone>+90-284-235-76-41</Phone></Contact><Contact type="Scientific contact"><Affiliation>Trakya University</Affiliation><Email>sevtaphekimoglu@mynet.com</Email><Name>Sevtap Hekimoglu Sahin, Proffesor</Name><Phone>+90-284-235-76-41</Phone></Contact><Contact type="Public contact"><Affiliation>Trakya University</Affiliation><Email>beykar@mynet.com</Email><Name>Beyhan Karamanloglu</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Caesarean section&lt;/li&gt;&lt;li&gt;Age 18 to 50 years old&lt;/li&gt;&lt;li&gt;ASA I to II risk&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Heart failure&lt;/li&gt;&lt;li&gt;Patient's refusal&lt;/li&gt;&lt;li&gt;Thrombocytopenia&lt;/li&gt;&lt;li&gt;Coagulation disorder&lt;/li&gt;&lt;li&gt;Heart valve diseases&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Spinal anesthesia success: the free flow of clear cerebrospinal fluid (CSF) upon first attempt was considered to be evidence of a successful LP</Description><Timeframe>Spinal anesthesia success will be 15 min in intraoperative</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study is to evaluate the effect of modified 45-degree head-up tilt position in cesarean operation to the success of spinal anesthesia. The success of the application of spinal block in three different application as the      sitting position, side decubitus position and 45 degrees head upside side decubitus position      will be evaluated.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study includes 180 patients in ASA I to II risk group between the ages of 18 to 50. Anatomical features of height, weight, block application of the patients      will be recorded. Spinal anesthesia will be performed in sitting position pregnant patients,lateral decubitus position pregnant patients, and modified 45-degree head-up tilt position pregnant patients.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Turkey"><Sites><Site><Name>Trakya University</Name><Address1>Edirne</Address1><Address2>Centrum</Address2><Address3>22030</Address3><CountrySubDivision>Centrum</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>sevtaphekimoglu@mynet.com</Email><Name>Sevtap Hekimoglu Sahin, Professor</Name></Contact><Contact type="Facility contact"><Email>beykar@mynet.com</Email><Name>Beyhan Karamanloglu, Professor</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03740399</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Anticipated">2019-03-28T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-10-19T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="369278"><TitleDisplay>A trial to assess HerpeCide for treatment of HSV-2 genital ulcers</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="157">Herpes simplex virus infection</Indication><Indication id="165">HSV-2 infection</Indication><Indication id="3842">Genital ulcer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>HSV-1-binding nanomicelle therapeutics (cream/lotion, cold sores), NanoViricides</Name><Drug id="105353">HSV-1-binding nanomicelle therapeutics (cream/lotion, cold sores), NanoViricides</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="105353">HSV-1-binding nanomicelle therapeutics (cream/lotion, cold sores), NanoViricides</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1014809">NanoViricides Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1014809" type="Company"><TargetEntity id="4297100266" type="organizationId">NanoViricides Inc</TargetEntity></SourceEntity><SourceEntity id="157" type="ciIndication"><TargetEntity id="B00" type="ICD10"></TargetEntity><TargetEntity id="054" type="ICD9"></TargetEntity><TargetEntity id="10019948" type="MEDDRA"></TargetEntity><TargetEntity id="D006561" type="MeSH"></TargetEntity><TargetEntity id="-1360288263" type="omicsDisease"></TargetEntity><TargetEntity id="858" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3842" type="ciIndication"><TargetEntity id="10018180" type="MEDDRA"></TargetEntity><TargetEntity id="2633" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="15">Planned</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1014809">NanoViricides Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="59620">Unspecified drug target</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="611">Dermatological formulation</Technology><Technology id="612">Emulsion dermatological</Technology><Technology id="1667">Nanoparticle formulation dermatological</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><DateChangeLast>2019-02-07T22:01:18Z</DateChangeLast><DateAdded>2019-02-07T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects with HSV-2 genital ulcers&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This ia a trial to assess &lt;ulink linkType="Drug" linkID="105353"&gt;HerpeCide&lt;/ulink&gt; for treatment of HSV-2 genital ulcers [&lt;ulink linkType="Reference" linkID="2116326"&gt;2116326&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-02-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="374583"><TitleDisplay>A Open-Labeled, Non-Controlled Study for Formestane Cream in Healthy Volunteers</TitleDisplay><TitleOfficial>A Open-Labeled, Non-Controlled Study for Formestane Cream in Healthy Volunteers</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1900022068</Identifier></Identifiers><Indications><Indication id="49">Breast tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>formestane</Name><Drug id="3163">formestane</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3163">formestane</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1137837">The Affiliated Hospital Of Southwest Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3163" type="Drug"><TargetEntity id="117636" type="siDrug">Formestane</TargetEntity></SourceEntity><SourceEntity id="1137837" type="Company"><TargetEntity id="5052145739" type="organizationId">Affiliated Hospital of Southwest Medical University</TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="76" type="Action"><TargetEntity id="393" type="Mechanism">Aromatase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1137837">The Affiliated Hospital Of Southwest Medical University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="76">Aromatase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class></Class><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Female</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><PatientCountEnrollment>8</PatientCountEnrollment><DateStart>2019-04-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-03-28T08:40:43Z</DateChangeLast><DateAdded>2019-03-27T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>The Affiliated Hospital of Southwest Medical University</Affiliation><Email>923397671@qq.com</Email><Name>Wang Guilin</Name><Phone>+86 18215601131</Phone></Contact><Contact type="Scientific contact"><Affiliation>The Affiliated Hospital of Southwest Medical University</Affiliation><Email>1843320672@qq.com</Email><Name>Wu Bin</Name><Phone>+86 15282477373</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Eight postmenopausal healthy women&lt;/li&gt;&lt;li&gt;BMI between 18.5 to 32&lt;/li&gt;&lt;li&gt;No medical treatment was received within the past month before the trail (including but not limited to essential oilscontaining hormones, drugs, etc,)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Blood routine:&lt;ul&gt;&lt;li&gt;If WBC, RBC, HB, PLT, N% and L% are significantly abnormal&lt;/li&gt;&lt;li&gt;If the WBC is elevated or lowered, slightly elevated or decreased parameters are acceptable&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Urine routine: a number of indicators are significantly abnormal&lt;/li&gt;&lt;li&gt;Blood biochemistry (liver and kidney function)are significantly abnormal:&lt;ul&gt;&lt;li&gt;Total protein reduction&lt;/li&gt;&lt;li&gt;Liver function (ALT, AST) and elevated creatinine (Crea)&lt;/li&gt;&lt;li&gt;Those with abnormal c-reactive protein&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;ECG: Sinus bradycardia (heart rate&amp;lt; 55 times/min), and other abnormal ECG&lt;/li&gt;&lt;li&gt;Chest X-ray: lung lesions&lt;/li&gt;&lt;li&gt;Ultrasound of breast: BI-RADS-0, 2, 3, 4, 5 or 6&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Formestane and its metabolites</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this open-labeled, non-controlled study is to evaluate the safety of &lt;ulink linkType="Drug" linkID="3163"&gt;formestane&lt;/ulink&gt; cream, including local tolerance and systemic adverse reactions. &lt;br/&gt;Secondary study goal:  metabolic kinetic (PK) analysis of the formestane cream.&lt;br/&gt;To demonstrate the absorption capacity of skin with formestane.&lt;br/&gt;To determine the content of formestane and its metabolites in plasma and urine.&lt;br/&gt;To examine the half-life, clearance rate, apparent volume of distribution, bioavailability, etc,&lt;br/&gt;To performe pharmacodynamic analysis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this  study, subjects (n = 8) who receive formestane cream will be observed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>The Affiliated Hospital of Southwest Medical University</Name><Address1>Chengdu</Address1><Address2>Sichuan</Address2><CountrySubDivision>Sichuan</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3967">Others</PatientSegment><SubSegments><SubSegment id="20169">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1900022068</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><SecondaryEndpoints><SecondaryEndpoint disease="Breast tumor" id="9024"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="9026"><Endpoint>Assessment of Renal Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="9122"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="46751">Assessment of half life of drug (t1/2)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Breast tumor" id="8996"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Breast tumor" id="8998"><Endpoint>Assessment of adverse events</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4924"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Breast tumor" id="34129"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Inclusion><Inclusion disease="Breast tumor" id="34697"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4936">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6252"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6261">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6258"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6267"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Breast tumor" id="17557"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Breast tumor" id="28399"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-03-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="375102"><TitleDisplay>A Study to Evaluate the Effect of Patterns of Chemotherapy and Radiotherapy in the Treatment of Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="2273">Oligodendroglioma</Indication><Indication id="2453">Astrocytoma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Chemotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Radiotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1038311" type="Company"><TargetEntity id="5000350822" type="organizationId">Allegheny General Hospital</TargetEntity></SourceEntity><SourceEntity id="2273" type="ciIndication"><TargetEntity id="10030286" type="MEDDRA"></TargetEntity><TargetEntity id="D009837" type="MeSH"></TargetEntity><TargetEntity id="251627" type="ORPHANET"></TargetEntity><TargetEntity id="-457865669" type="omicsDisease"></TargetEntity><TargetEntity id="1237" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2453" type="ciIndication"><TargetEntity id="10003571" type="MEDDRA"></TargetEntity><TargetEntity id="D001254" type="MeSH"></TargetEntity><TargetEntity id="94" type="ORPHANET"></TargetEntity><TargetEntity id="-1843024614" type="omicsDisease"></TargetEntity><TargetEntity id="582" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1038311">Allegheny General Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Small molecule</Category><Category>Radiation therapy</Category></TrialCategories><PatientCountEnrollment>225</PatientCountEnrollment><PatientCountEvaluable>225</PatientCountEvaluable><DateChangeLast>2019-03-29T22:01:34Z</DateChangeLast><DateAdded>2019-03-29T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with newlydiagnosed anaplasticoligodendrogliomas andanaplasticoligoastrocytomas&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Compare the overall survival between cohorts by using Kaplan-Meier methodology. Univariate and multivariate Cox proportional hazards modeling will evaluate factors associated with overall survival</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to evaluate the practice patterns and outcomes between the approaches of radiotherapyfollowed bychemotherapy (RT-CT) and chemotherapy was followed by radiotherapy (CT-RT) [&lt;ulink linkType="Reference" linkID="2135839"&gt;2135839&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In March 2019, results were published. Median overall survival in the CT-RT and RT-CT cohort was 93 and 107 months (p = 0.709).Therapysequence was observed to be not associated with overall survival on univariate (p = 0.709) or multivariate (p = 0.257) assessment [&lt;ulink linkType="Reference" linkID="2135839"&gt;2135839&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who received treatment with postoperative sequential radiotherapyfollowed bychemotherapy (RT-CT; n = 206) and chemotherapy  followed by radiotherapy (CT-RT;  n = 19) were enrolled and observed [&lt;ulink linkType="Reference" linkID="2135839"&gt;2135839&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-03-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="375134"><TitleDisplay>Forecasting capacity of circulating free DNA to assess treatment results in patients with oral cancer</TitleDisplay><TitleOfficial>Predictive Value of Circulating Free DNA to assess Clinical Outcome in Patients with Oral Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2019/03/018136</Identifier></Identifiers><Indications><Indication id="1069">Metastasis</Indication><Indication id="793">Mouth tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="1827" role="Therapeutic effect marker" type="Genomic">Cell-free DNA</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>chemoradiation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>induction chemotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1162359" type="Company"><TargetEntity id="5063164599" type="organizationId">Dr Ram Manohar Lohia Institute of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="1069" type="ciIndication"><TargetEntity id="10062194" type="MEDDRA"></TargetEntity><TargetEntity id="D009362" type="MeSH"></TargetEntity><TargetEntity id="-1423187778" type="omicsDisease"></TargetEntity><TargetEntity id="618" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="793" type="ciIndication"><TargetEntity id="10061325" type="MEDDRA"></TargetEntity><TargetEntity id="D009062" type="MeSH"></TargetEntity><TargetEntity id="-538098431" type="omicsDisease"></TargetEntity><TargetEntity id="625" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1162359">Dr. Ram Manohar Lohia Institute of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biomarker identification</Category></TrialCategories><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2017-04-22T00:00:00Z</DateStart><DateEnd type="estimated">2018-12-14T00:00:00Z</DateEnd><DateChangeLast>2019-04-15T11:39:40Z</DateChangeLast><DateAdded>2019-03-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>RMLIMS</Affiliation><Email>akku5658@gmail.com</Email><Name>Dr akhlak Hussain</Name><Phone>9555963451</Phone></Contact><Contact type="Public contact"><Affiliation>RMLIMS</Affiliation><Email>ashishpgi@yahoo.co.in</Email><Name>Dr Ashish Singhal</Name><Phone>9555963451</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Treatment naive cases with early andlocally advanced cancer of oral cavity, confirmed by biopsy (histopathology will be gold standard for diagnosis)&lt;/li&gt;&lt;li&gt;Potential candidate for surgery&lt;/li&gt;&lt;li&gt;Performance status: ECOG 0 to 2&lt;/li&gt;&lt;li&gt;Patient consent to be part of study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients having a history of any other malignancy from which the patient has been disease-free for&amp;lt; 2 years, with the exception of adequately treated basal or squamous cell carcinoma of skin&lt;/li&gt;&lt;li&gt;Metastatic cancer of oral cavity&lt;/li&gt;&lt;li&gt;Performance status: ECOG: &gt;/= 3&lt;/li&gt;&lt;li&gt;Presence of second malignancy&lt;/li&gt;&lt;li&gt;Patients unwilling to take active treatment or to join the study&lt;/li&gt;&lt;li&gt;A serious co-existing medical condition likely to interfere with lab results including a potentially serious infection&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The proposed study is to assess the level of cfDNA in peripheral blood of early and locally advanced cases of oral cavity cancers initially before treatment</Description><Timeframe>Two years from the start of the study</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To evaluate cfDNA as response assessment tool in the patients receiving induction chemotherapy</Description><Timeframe>1.5 years</Timeframe></Measure><Measure><Description>To correlate cfDNA level with clinical and histo-pathological prognostic parameters</Description><Timeframe>1.5 years</Timeframe></Measure><Measure><Description>To correlate cfDNA with subsequent recurrence in a 18 months</Description><Timeframe>1.5 years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study was to  evaluate the usefulness of cfDNA as prognostic and predictive marker in oral cancer. The proposed study was  to assess the level of cfDNA in peripheral blood of early (stage I and II, T3N0M0) and locally advanced (III and IVa) cases of oral cavity cancers initially before treatment, during the course of chemotherapy and after completion of the treatment.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;All patients who are potential candidates for surgery would  be included in the study. Those, who are considered to be borderline operable (viz.disease reaching up to the zygoma, soft tissue involvement reaching up to the hyoid cartilage and skin infiltration not amenable for reconstruction and involvement of the infratemporal fossa above sigmoid notch) would  receive  three cycles of induction chemotherapyfollowed by surgery, if it becomes resectable, otherwise they would  be referred for chemoradiations.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>RML institute of medical sciences</Name><Address1>Lucknow</Address1><Address2>UTTAR PRADESH</Address2><Address3>226010</Address3><CountrySubDivision>UTTAR PRADESH</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Head and neck tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3773">Subjects with Early Stage Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3775">Subjects with Locally Advanced Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3785">Subjects with Resectable Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7278">Subjects with Oral Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10285">Subjects with TNM Stage I Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10286">Subjects with TNM Stage II Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10289">Subjects with TNM Stage III Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10290">Subjects with TNM Stage IV Head and Neck Cancer</PatientSegment><SubSegments><SubSegment id="10291">Subjects with TNM stage IVa HNC</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="19046">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2019/03/018136</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Head and neck tumor" id="7335"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Head and neck tumor" id="7339"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Head and neck tumor" id="7263"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7270"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7281"><Endpoint>Assessment of Biopsy/Cytology/Histology</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7339"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="45203"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Head and neck tumor" id="4359"><Criterion>Subjects with Oral Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4381"><Criterion>Subjects with TNM Stage I Head and Neck Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4382"><Criterion>Subjects with TNM Stage II Head and Neck Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4385"><Criterion>Subjects with TNM Stage III Head and Neck Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4386"><Criterion>Subjects with TNM Stage IV Head and Neck Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4387">Subjects with TNM stage IV A HNC</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4391"><Criterion>Subjects with Resectable Head and Neck Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4396"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4397">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Head and neck tumor" id="4398">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Head and neck tumor" id="4399">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4455"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4462">Subjects with history of excisional biopsy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="7087"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="7088"><Criterion>Subjects with Early Stage Head and Neck Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="34360"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4460">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="35580"><Criterion>Treatment Naive Subjects</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Head and neck tumor" id="5738"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5744"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5751"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5752"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5760"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5761">Subjects with specific ECOG/WHO/Zubrod performance status</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="5792"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="26437"><Criterion>Subjects with Evidence of Metastasis</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="27843"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="6478">Subjects unable to comply with protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-03-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="380914"><TitleDisplay>Globifer Forte in Heart Failure</TitleDisplay><TitleOfficial>Globifer Forte Oral Hem and Non-hem Iron Supplementation in Heart Failure: A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Part Mechanistic</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">2013-004704-19</Identifier><Identifier type="Secondary Organisational">3200</Identifier><Identifier type="Trial Acronym">GLOBIFER HF</Identifier></Identifiers><Indications><Indication id="3191">Iron deficiency anemia</Indication><Indication id="55">Cardiac failure</Indication></Indications><BiomarkerNames><BiomarkerName id="106" role="Therapeutic effect marker" type="Proteomic">N-terminal Pro Brain Natriuretic Peptide</BiomarkerName><BiomarkerName id="147" role="Therapeutic effect marker" type="Physiological">Six-minute walk distance</BiomarkerName><BiomarkerName id="1051" role="Disease marker" type="Genomic;Proteomic">Ferritin</BiomarkerName><BiomarkerName id="1945" role="Disease marker" type="Physiological">Left ventricular ejection fraction</BiomarkerName><BiomarkerName id="2700" role="Therapeutic effect marker" type="Genomic;Proteomic">Centromere protein F</BiomarkerName><BiomarkerName id="4877" role="Therapeutic effect marker" type="Genomic;Proteomic">Solute carrier family 40 member 1</BiomarkerName><BiomarkerName id="8885" role="Therapeutic effect marker" type="Genomic">Feline leukemia virus subgroup C receptor-related protein 2</BiomarkerName><BiomarkerName id="9421" role="Therapeutic effect marker" type="Genomic;Proteomic">Natural resistance-associated macrophage protein 2</BiomarkerName><BiomarkerName id="10139" role="Disease marker" type="Physiological">Transferrin saturation</BiomarkerName><BiomarkerName id="17319" role="Therapeutic effect marker" type="Genomic;Proteomic">Heme transporter HRG1</BiomarkerName><BiomarkerName id="36136" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytokines</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Globifer Forte</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>ferrous sulphate</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1014674" type="Company"><TargetEntity id="5035534471" type="organizationId">Kings College Hospital Nhs Trust</TargetEntity></SourceEntity><SourceEntity id="23507" type="Company"><TargetEntity id="4296365401" type="organizationId">King's College London</TargetEntity></SourceEntity><SourceEntity id="3191" type="ciIndication"><TargetEntity id="D50" type="ICD10"></TargetEntity><TargetEntity id="10022972" type="MEDDRA"></TargetEntity><TargetEntity id="D018798" type="MeSH"></TargetEntity><TargetEntity id="-533542915" type="omicsDisease"></TargetEntity><TargetEntity id="1249" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"></TargetEntity><TargetEntity id="10007554" type="MEDDRA"></TargetEntity><TargetEntity id="D006333" type="MeSH"></TargetEntity><TargetEntity id="-1323949873" type="omicsDisease"></TargetEntity><TargetEntity id="237" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1014674">Kings College Hospital NHS Trust</Company><Company id="23507">King's College London</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2016-01-14T00:00:00Z</DateStart><DateChangeLast>2019-05-20T10:55:23Z</DateChangeLast><DateAdded>2019-05-17T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>King's College London</Affiliation><Email>darlington.okonko@kcl.ac.uk</Email><Name>Dr Darlington Okonko</Name><Phone>+44207848 5017</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt;/= 30 years of age&lt;/li&gt;&lt;li&gt;Signed written informed consent&lt;/li&gt;&lt;li&gt;Stable symptomatic CHF; NYHA II,III or ambulatory IV and LVEF&amp;lt;/= 45% as assessed within the last 6 months using echocardiographic or magnetic resonance imaging techniques&lt;/li&gt;&lt;li&gt;On optimal conventional therapy for at least 4 weeks prior to recruitment and without dose changes for at least 2 weeks&lt;/li&gt;&lt;li&gt;Ferritin&amp;lt; 100 ug/l (absolute iron deficiency) or 100 to 300 ug/l with TSAT &amp;lt; 20% (functional iron deficiency) within 4 weeks of initial screening visit&lt;/li&gt;&lt;li&gt;Red cell folate and Vitamin B12 levels above the lower limit of normal according to local lab reference range within 4 weeks of initial screening visit (even if achieved with folate or vitamin B12 supplements)&lt;/li&gt;&lt;li&gt;Negative pregnancy test in women of child-bearing age&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of acquired iron overload, known haemochromatosis or first relatives with haemochromatosis&lt;/li&gt;&lt;li&gt;Known hypersensitivity to oral iron preparations&lt;/li&gt;&lt;li&gt;Patients with rare hereditary galactose intolerance or fructose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption or sucrase-isomaltase insufficiency&lt;/li&gt;&lt;li&gt;Religious or other objections to bovine/animal products&lt;/li&gt;&lt;li&gt;Known active infection, inflammation, bleeding, malignancy and hemolytic anemia&lt;/li&gt;&lt;li&gt;History of chronic liver disease and/or AST&amp;gt; 3 times the upper limit of the normal range within 4 weeks of initial screening visit, chronic lung disease with FEV1 &amp;lt; 50% predicted, myelodysplastic disorder, and known HIV/AIDS disease&lt;/li&gt;&lt;li&gt;Known gastrointestinal disorder or malabsorption syndrome&lt;/li&gt;&lt;li&gt;Prior gastric surgery&lt;/li&gt;&lt;li&gt;Recipient of immunosuppressive therapy or renal dialysis&lt;/li&gt;&lt;li&gt;Diabetes with estimated glomerular filtration rate&amp;lt; 30 ml/min/1.73m2 within 4 weeks of initial screening visit&lt;/li&gt;&lt;li&gt;History of erythropoietin therapy in previous 30 days or scheduled for erythropoietin therapy or blood transfusion during duration of the study&lt;/li&gt;&lt;li&gt;Unstable angina pectoris as judged by the investigator, severe uncorrected non-functional valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, uncontrolled fast atrial fibrillation or flutter (&amp;gt; 110 bpm), uncontrolled symptomatic brady- or tachyarrhythmias&lt;/li&gt;&lt;li&gt;Musculoskeletal limitation that, in the investigators judgement, would impair exercise testing&lt;/li&gt;&lt;li&gt;Pregnant, breast-feeding, or planning to get pregnant&lt;/li&gt;&lt;li&gt;Inability to comprehend study protocol&lt;/li&gt;&lt;li&gt;Parallel participation in another clinical trial&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>A 6MWD at week 12 between patients randomized to Globifer Forte and those allocated to placebo</Description><Timeframe>Week 12</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>A 6MWD at week 12 between patients randomized to Globifer Forte and those allocated to FeSO4</Description><Timeframe>Week 12</Timeframe></Measure><Measure><Description>Blood tests (eg, iron status, NT-BNP, cytokines) at week 12</Description><Timeframe>Week 12</Timeframe></Measure><Measure><Description>Cardiac structure and function on echo at week 12</Description><Timeframe>Week 12</Timeframe></Measure><Measure><Description>DMT-1, FPN, and FLVCR2 expression on Caco-2 cells with sera from CHF patients</Description><Timeframe>Week 12</Timeframe></Measure><Measure><Description>Serum iron levels at 3 h after oral Globifer Forte, FeSO4, and placebo tablets</Description><Timeframe>Week 12</Timeframe></Measure><Measure><Description>Symptom status and quality of life (NYHA class, Kansas City Cardiomyopathy questionnaire [KCCQ], visual analogue fatigue scale) at week 12</Description><Timeframe>Week 12</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main objective of the trial is:  &lt;br/&gt;To evaluate the effect of 3 months of Globifer Forte treatment on exercise capacity, as quantified by the 6 min walk distance (6MWD), in chronic heart failure (CHF) patients with functional or absolute iron deficiency. &lt;/para&gt;&lt;para&gt;Secondary objectives of the trial are:  &lt;br/&gt;To evaluate the effect of sera from CHF patients on DMT-1, FPN, HCP-1, HRG-1, and FLVCR2 protein expression on Caco-2 duodenal cell lines. &lt;br/&gt;To compare the change in serum iron levels 3 h after oral FeSO4, Globifer Forte or placebo tablets (oral absorption test). &lt;br/&gt;To evaluate the effect of 3 months of Globifer Forte treatment on iron status, symptoms and quality of life in CHF patients with functional or absolute iron deficiency.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive either 	ferrous sulphate (FeSO4), Globifer Forte or placebo oral tablets.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Dr Darlington Okonko</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cardiac failure</Disease><PatientSegments><PatientSegment><PatientSegment id="61">Subjects with Symptomatic Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="72">Chronic Heart Failure Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="13416">Subjects with NYHA Functional Class	</PatientSegment><SubSegments><SubSegment id="76">Mild /NYHA Functional Class II Heart Failure Subjects</SubSegment><SubSegment id="77">Moderate/NYHA Functional Class III Heart Failure Subjects</SubSegment><SubSegment id="78">Severe/NYHA Functional Class IV Heart Failure Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Anemia</Disease><PatientSegments><PatientSegment><PatientSegment id="19884">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="7525">Subjects with Iron Deficiency Anemia</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2013-004704-19</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cardiac failure" id="732"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="753">Six-minute walk test (6MWT)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Anemia" id="45063"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Anemia" id="45610"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cardiac failure" id="609"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="641"><Endpoint>Assessment of Cardiac Markers</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="656">Plasma NT-pro-BNP</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="662"><Endpoint>Assessment of Cardiac Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="732"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="753">Six-minute walk test (6MWT)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="764"><Endpoint>Assessment of Fatigue</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="848"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="1031"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="1060">Echocardiographic parameter - unspecified</SubEndpoint><SubEndpoint disease="Cardiac failure" id="1143">Serum iron</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="6790"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="762">Change in NYHA functional class</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17205"><Endpoint>Assessment of iron status</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17207">Assessment of serum iron</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17219"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17244"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17257"><Endpoint>Assessment of Cardiac Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17273"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17282">Assessment using imaging modalities</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17328"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="32781">Kansas City Cardiomyopathy Questionnaire (KCCQ)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="28679"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="28692">Kansas city cardiomyopathy questionnaire(KCCQ)</SubEndpoint><SubEndpoint disease="Cardiac failure" id="28717">Assessment by Visual Analog Scale (VAS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="44786"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="45041"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="45063"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="45576"><Endpoint>Assessment of Fatigue</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="45610"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="45895"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Cardiac failure" id="1321"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Anemia" id="17353"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cardiac failure" id="270"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="272"><Criterion>Subjects with Chronic Heart Failure</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="290"><Criterion>Subjects with Poor Ejection Fraction</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="291">LVEF &lt; 45% (Below normal)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="447"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="456">Subjects with stable medical conditions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="14372"><Criterion>Subjects with Iron Deficiency Anemia</Criterion></Inclusion><Inclusion disease="Anemia" id="14455"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14465">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="14471"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="31870"><Criterion>Inclusion of Subjects Based on NYHA Class</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="275">Subjects with heart failure, NYHA class II</SubCriterion><SubCriterion disease="Cardiac failure" id="276">Subjects with heart failure, NYHA class III</SubCriterion><SubCriterion disease="Cardiac failure" id="277">Subjects with heart failure, NYHA class IV</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="33681"><Criterion>Subjects Diagnosed by Specific Methods</Criterion></Inclusion><Inclusion disease="Anemia" id="34101"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="34145"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="577">Women with adequate contraception/Negative pregnancy test/Non-lactating women</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="34405"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14456">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="34444"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="485">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="34526"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="451">Ambulatory subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cardiac failure" id="448"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="449">Subjects co-morbid with atrial fibrillation</SubCriterion><SubCriterion disease="Cardiac failure" id="502">Tachycardia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="456"><Criterion>Subjects with Valvular Heart Diseases</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="460"><Criterion>Subjects with specific type of cardiomyopathy</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="464"><Criterion>Subjects with Left Ventricular Dysfunction</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="468">Left ventricular outflow obstruction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="481"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="800">Recent blood product/blood transfusion or donation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="503"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="518">Subjects with history of/scheduled to receive immunosuppressants</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="525"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="543"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="623"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="628">Acute/chronic bleeding or bleeding diathesis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="635"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="640"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="644">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="679"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="592">Receiving/scheduled to receive dialysis</SubCriterion><SubCriterion disease="Cardiac failure" id="691">Any condition that limit exercise performance/Limitations to exercise testing</SubCriterion><SubCriterion disease="Cardiac failure" id="820">Unsuitable to participate as per the investigator's opinion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="681"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="574">Lung function tests</SubCriterion><SubCriterion disease="Cardiac failure" id="582">Abnormal liver function test</SubCriterion><SubCriterion disease="Cardiac failure" id="588">Renal function tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11802"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Anemia" id="11815"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11823">Subjects with premalignant/malignant condition</SubCriterion><SubCriterion disease="Anemia" id="11825">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11817"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11819"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11821"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11777">Subjects on dialysis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11822"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11824"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11848"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11851">Subjects with hypersensitivity/contraindication to iron supplementation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11855"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11864">Subjects with history of blood donation/transfusions</SubCriterion><SubCriterion disease="Anemia" id="12934">Subjects with history of immunotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11878"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11881">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="13183"><Criterion>Subjects with Iron Overload</Criterion></Exclusion><Exclusion disease="Anemia" id="24940"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Anemia" id="24792">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25073"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="581">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Cardiac failure" id="660">Subjects co-morbid with chronic inflammatory disorders</SubCriterion><SubCriterion disease="Cardiac failure" id="670">Muscular dystrophies/skeletal muscle disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25137"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="24205">Subjects co-morbid with type 1 diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="25384"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11793">Subjects with Hemolytic Anemia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="25429"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11885">Subjects not suitable to participate as per investigator's discretion</SubCriterion><SubCriterion disease="Anemia" id="11890">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25524"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="795">Subjects with history of/current participation in other clinical trials</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25725"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="740">Lactating women</SubCriterion><SubCriterion disease="Cardiac failure" id="792">Pregnant women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25881"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="671">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="26014"><Criterion>Subjects with Angina/Chest Pain</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="447">Subjects with unstable angina</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="26067"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11820">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="26321"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11843">Subjects with abnormal/unacceptable lung function</SubCriterion><SubCriterion disease="Anemia" id="11844">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Anemia" id="11845">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="26609"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Anemia" id="26636"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Anemia" id="26735"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11880">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27060"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="572">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="27098"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11818">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27844"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="823">Unwillingness/inability to comply with study requirements/protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-05-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="38607"><TitleDisplay>First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer</TitleDisplay><TitleOfficial>Prospective Randomized Phase II Trial With Gemcitabine Plus Sunitinib Versus Gemcitabine Alone in First-Line Therapy of Metastatic or Locally Advanced Pancreatic Cancer</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">C-II-004 / 2007-005022-71</Identifier><Identifier type="NCT">NCT00673504</Identifier></Identifiers><Indications><Indication id="249">Pancreas tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>gemcitabine + sunitinib</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>sunitinib</Name><Drug id="12973">sunitinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12973">sunitinib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1044286">Central European Society for Anticancer Drug Research</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1117382">Pfizer Deutschland</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3199">gemcitabine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1044286">Central European Society for Anticancer Drug Research</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1117382">Pfizer Deutschland</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3199" type="Drug"><TargetEntity id="102180" type="siDrug">Gemcitabine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="12973" type="Drug"><TargetEntity id="309144" type="siDrug">Sunitinib malate</TargetEntity></SourceEntity><SourceEntity id="1044286" type="Company"><TargetEntity id="5035544842" type="organizationId">Cesar Central European Society for Anticancer Drug Research EWIV</TargetEntity></SourceEntity><SourceEntity id="1117382" type="Company"><TargetEntity id="5000175098" type="organizationId">Pfizer Deutschland GmbH</TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3154" type="Action"><TargetEntity id="2314" type="Mechanism">CSF1R (c-FMS) Inhibitors</TargetEntity><TargetEntity id="4836" type="Mechanism">Anti-Colony Stimulating Factor 1 Receptor (CSF1R)</TargetEntity><TargetEntity id="4956" type="Mechanism">Anti-M-CSF</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity></SourceEntity><SourceEntity id="48489" type="Action"><TargetEntity id="1650" type="Mechanism">PDGFRalpha Inhibitors</TargetEntity><TargetEntity id="2517" type="Mechanism">Anti-CD140a (PDGFRalpha)</TargetEntity><TargetEntity id="5666" type="Mechanism">PDGFRalpha (Asp842Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="48492" type="Action"><TargetEntity id="1651" type="Mechanism">PDGFRbeta Inhibitors</TargetEntity><TargetEntity id="1831" type="Mechanism">Anti-CD140b (PDGFRbeta)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>11</NumberOfSites><CompaniesSponsor><Company id="1044286">Central European Society for Anticancer Drug Research</Company><Company id="1117382">Pfizer Deutschland</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3154">CSF-1 antagonist</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="3816">RET tyrosine kinase receptor family inhibitor</Action><Action id="3846">VEGF-1 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="48489">PDGF receptor alpha antagonist</Action><Action id="48492">PDGF receptor beta antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>105</PatientCountEnrollment><PatientCountEvaluable>106</PatientCountEvaluable><DateStart>2008-04-30T00:00:00Z</DateStart><DateEnd type="actual">2011-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-05-09T05:25:34Z</DateChangeLast><DateAdded>2008-12-16T09:25:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Goethe University Frankfurt</Affiliation><Email>l.bergmann@em.uni-frankfurt.de</Email><Name>L Bergmann</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who suffer from locally advanced or metastatic pancreatic cancer&lt;/li&gt;&lt;li&gt;Patients with measurable disease (at least one uni-dimensionally measurable target
             lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors
             (RECIST)&lt;/li&gt;&lt;li&gt;ECOG performance status 0 to 1&lt;/li&gt;&lt;li&gt;Signed written informed consent&lt;/li&gt;&lt;li&gt;White blood cell count (WBC)&amp;gt;/= 3 x 10(9)/l with neutrophils &amp;gt;/= 1.5 x 10(9)/l, platelet
             count &amp;gt;/= 100 x 10(9)/l, hemoglobin &amp;gt;/= 5.6 mmol/l (9 g/dl)&lt;/li&gt;&lt;li&gt;Total bilirubin&amp;lt; 2 x upper limit of normal&lt;/li&gt;&lt;li&gt;AST and ALT&amp;lt; 2.5 x upper limit of normal, or &amp;lt; 5 x upper limit of normal in case of
             liver metastases&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt; 1.5 x upper limit of normal
&lt;/li&gt;&lt;li&gt;Normal ECG without QT prolongation&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Resectable pancreatic cancer&lt;/li&gt;&lt;li&gt;Previous chemotherapy (for adjuvant or metastatic disease)&lt;/li&gt;&lt;li&gt;Any investigational drug within the 30 days before inclusion&lt;/li&gt;&lt;li&gt;Prior use of sunitinib or other multitarget tyrosine kinase inhibitor&lt;/li&gt;&lt;li&gt;Pregnancy (absence to be confirmed by beta-hCG test) or lactation period&lt;/li&gt;&lt;li&gt;Men or women of child-bearing potential who are sexually active and unwilling to use a
             medically acceptable method of contraception during the trial&lt;/li&gt;&lt;li&gt;Clinically symptomatic brain or meningeal metastasis. (known or suspected)&lt;/li&gt;&lt;li&gt;Cardiac arrhythmias requiring anti-arrhythmics (excluding beta blockers or digoxin)&lt;/li&gt;&lt;li&gt;History of any of the following cardiac events within the past 6 months: myocardial
             infarction (including severe/unstable angina; coronary/peripheral artery bypass graft;
             symptomatic congestive heart failure (CHF) &amp;gt; NYHA Class II; cerebrovascular accident
             or transient ischemic attack; pulmonary embolism&lt;/li&gt;&lt;li&gt;Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 90
             mmHg despite the use of up to three anti-hypertensive drugs&lt;/li&gt;&lt;li&gt;Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or
             chronic diarrhea&lt;/li&gt;&lt;li&gt;Previous malignancy (other than pancreatic cancer) in the last five years except basal
             cell cancer of the skin, pre-invasive cancer of the cervix or superficial bladder
             tumor [Ta, Tis and T1]&lt;/li&gt;&lt;li&gt;History of organ allograft&lt;/li&gt;&lt;li&gt;Patients requiring long-term cortisone therapy&lt;/li&gt;&lt;li&gt;Patients requiring oral anticoagulation treatment (such as marcoumar)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Time to Progression</Description><Timeframe>Once all patients completed treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Response Rate (RR)</Description><Timeframe>Once all patients completed treatment</Timeframe></Measure><Measure><Description>overall survival</Description><Timeframe>At study end</Timeframe></Measure><Measure><Description>Safety</Description><Timeframe>At study end</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In January 2015, results were published. SAEs were reportedin53.7%inthe GEM arm and 71.2%inthe SUNGEM arm. Grade 3 and 4 neutropenia was statistically significantly higherinthe SUNGEM arm with48.1%versus27.8%inthe GEM arm (p = 0.045, two sided log-rank)[&lt;ulink linkType="Reference" linkID="1721901"&gt;1721901&lt;/ulink&gt;]&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Primary objective of this study was to evaluate whether the addition of &lt;ulink linkType="Drug" linkID="12973"&gt;sunitinib&lt;/ulink&gt; prolongates the
      Progression-Free Survival (PFS) in patients with advanced pancreatic cancer receiving
      first-line &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; chemotherapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2015, results were published. The median PFS was 13.3 weeks (95% confidence interval (95%-CI): 10.4-18.1 weeks) for Gemcitabine and 11.6 weeks for SUNGEM regimen (95%-CI: 7.0-18.0 weeks; p = 0.78 one-sided log-rank). The ORR was 6.1% (95%-CI: 0.7-20.2%) for Gemcitabine and for 7.1% (95%-CI: 0.9-23.5%) for SUNGEM (p = 0.87). The median time to progression (TTP) was 14.0 weeks (95%-CI: 12.4-22.3 weeks) for Gemcitabine and 18.0 weeks (95%-CI: 11.3-19.3 weeks) for SUNGEM regimen (p = 0.60; two-sided log-rank). The median OS was 36.7 weeks (95%-CI: 20.6-49.0 weeks) for the Gemcitabine arm and 30.4 weeks (95%-CI: 18.1-37.6 weeks) for SUNGEM regimen (p = 0.78, one-sided log-rank)[&lt;ulink linkType="Reference" linkID="1721901"&gt;1721901&lt;/ulink&gt;]&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients (n=106) were randomized to receive &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; at a adosage of 1.000 mg/m(2) d1, 8, 15 q28versusacombination of SUNGEM atadosage of &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;, 1.000 mg/m(2) d1 + 8 and&lt;ulink linkType="Drug" linkID="12973"&gt;sunitinib&lt;/ulink&gt;50 mg p.o. d1-14, q21d[&lt;ulink linkType="Reference" linkID="1721901"&gt;1721901&lt;/ulink&gt;]&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>gemcitabine + sunitinib</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="1991">Neutropenia</Indication><CountPatientsAffectedPercentage>48.1</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="1991">Neutropenia</Indication><CountPatientsAffectedPercentage>27.8</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="80477">gemcitabine</Intervention><Treatments><Treatment><Dose>1000 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="80384">sunitinib</Intervention><Treatments><Treatment><Dose>50 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Switzerland"><Sites><Site><Name>Kantonsspital St. Gallen</Name><Address1>St. Gallen</Address1><Address3>9007</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Name>Internistisches Facharztzentrum</Name><Address1>Frankfurt</Address1><Address3>60596</Address3><Contacts></Contacts></Site><Site><Name>Klinikum der J. W. Goethe Universitt; Zentrum der Inneren Medizin</Name><Address1>Frankfurt</Address1><Address3>60590</Address3><Contacts></Contacts></Site><Site><Name>Martin-Luther-Universitt Halle-Wittenberg; Medizinische Fakultt</Name><Address1>Halle (Saale)</Address1><Address3>06097</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Robert-Bosch-Krankenhaus</Name><Address1>Stuttgart</Address1><Address3>70376</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Universittsklinikum Essen</Name><Address1>Essen</Address1><Address3>45122</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Klinikum Nrnberg Nord</Name><Address1>Nrnberg</Address1><Address3>90419</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Facharztpraxis</Name><Address1>Heidelberg</Address1><Address3>69115</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Klinikum Ldenscheid</Name><Address1>Luedenscheid</Address1><Address3>58515</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Krankenhaus</Name><Address1>Frankfurt</Address1><Address3>60488</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Stdtisches Klinikum Braunschweig</Name><Address1>Braunschweig</Address1><Address3>38114</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pancreas tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8072">Subjects with Locally Advanced Pancreatic Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8073">Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00673504</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="2">BP control rate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pancreas tumor" id="13354"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13351">Assessment of time to disease progression (TTP)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="2">BP control rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13344"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13356"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13433"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pancreas tumor" id="13352"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></OtherEndpoint><OtherEndpoint disease="Pancreas tumor" id="13354"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13351">Assessment of time to disease progression (TTP)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Pancreas tumor" id="13356"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13360">Assessment of Complete Response</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Pancreas tumor" id="13433"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13444">Assessment of treatment induced toxicity</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pancreas tumor" id="8816"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8817"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8822"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8824">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8834"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8835">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Pancreas tumor" id="8836">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8854"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8855">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Pancreas tumor" id="8856">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="34028"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8857">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pancreas tumor" id="10370"><Criterion>Subjects with Advanced/Metastatic/Stage IV Pancreatic Cancer</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="11231">Subjects with CNS/brain metastasis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10374"><Criterion>Subjects with Resectable Tumor</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10377"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10378"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10397"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10399">Subjects with hypersensitivity/contraindication to targeted therapy agents</SubCriterion><SubCriterion disease="Pancreas tumor" id="10400">Subjects with hypersensitivity/contraindication to biological therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10405"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10406">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Pancreas tumor" id="10410">Patient with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10412"><Criterion>Subjects with History of Treatment with Non-anticancer Drugs</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-10-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2008-05-06T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-12-16T09:25:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2015-12-16T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="44346"><TitleDisplay>Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer</TitleDisplay><TitleOfficial>Randomized, Phase III Trial Comparing in a Preoperative Schedule the Result of Two Concurrent Chemoradiation Schemes (45 Gy + Capecitabine versus 50 Gy + Capecitabine - Oxaliplatin) on the Rate of Sterilization of the Operative Specimen in Resectable Rectal Carcinomas T3-4 No-2 Mo</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">ACCORD 12/0405-Prodige 2</Identifier><Identifier type="Other">ACCORD 12/0405</Identifier><Identifier type="Other">ACCORD 12/0405-PRODIGE 02</Identifier><Identifier type="Organisational Study">CDR0000445034</Identifier><Identifier type="NCT">NCT00227747</Identifier><Identifier type="Secondary Organisational">FRE-FNCLCC-ACCORD-12/0405</Identifier><Identifier type="Secondary Organisational">EU-20522</Identifier><Identifier type="Trial Acronym">ACCORD</Identifier></Identifiers><Indications><Indication id="1055">Rectal tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="1135" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-2 receptor alpha chain </BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>capecitabine</Name><Drug id="12205">capecitabine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>capecitabine + oxaliplatin + radiotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>capecitabine + radiotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>mesorectal excision</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>radiotherapy (45/50 Gy)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>capecitabine</Name><Drug id="12205">capecitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>oxaliplatin</Name><Drug id="3792">oxaliplatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12205">capecitabine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1069320">The UNICANCER Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12205">capecitabine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1069320">The UNICANCER Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3792">oxaliplatin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1069320">The UNICANCER Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3792" type="Drug"><TargetEntity id="108094" type="siDrug">Oxaliplatin</TargetEntity></SourceEntity><SourceEntity id="12205" type="Drug"><TargetEntity id="211639" type="siDrug">Capecitabine</TargetEntity><TargetEntity id="211639" type="siDrug">Capecitabine</TargetEntity></SourceEntity><SourceEntity id="1069320" type="Company"><TargetEntity id="5037432364" type="organizationId">Unicancer</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="1055" type="ciIndication"><TargetEntity id="C20" type="ICD10"></TargetEntity><TargetEntity id="154.1" type="ICD9"></TargetEntity><TargetEntity id="10038038" type="MEDDRA"></TargetEntity><TargetEntity id="D012004" type="MeSH"></TargetEntity><TargetEntity id="-796050081" type="omicsDisease"></TargetEntity><TargetEntity id="640" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>69</NumberOfSites><CompaniesSponsor><Company id="1069320">The UNICANCER Group</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="372">Thymidylate synthase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="50">Anticancer alkylating agent</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>590</PatientCountEnrollment><PatientCountEvaluable>598</PatientCountEvaluable><DateStart>2005-07-31T00:00:00Z</DateStart><DateChangeLast>2018-01-17T07:22:40Z</DateChangeLast><DateAdded>2009-02-09T09:30:13Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Centre Antoine Lacassagne</Affiliation><Name>Jean-Pierre Gerard</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Disease characteristics:&lt;ul&gt;&lt;li&gt;Histologically confirmed adenocarcinoma of the rectum&lt;/li&gt;&lt;li&gt;T3 to 4, N0 to 2, M0 disease by endorectal ultrasound&lt;/li&gt;&lt;li&gt;T2 disease located in the low rectum allowed provided lower pole is&amp;lt;/= 6 cm from the anal verge
&lt;/li&gt;&lt;li&gt;Tumor must be accessible to digital rectal examination (ie, tumor located at low- or mid-rectum)&lt;/li&gt;&lt;li&gt;Resectable disease treatable with chemoradiotherapy&lt;/li&gt;&lt;li&gt;No unresectable disease (ie, T4 disease with high risk for incomplete gross resection [ie, R2])&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient characteristics:&lt;ul&gt;&lt;li&gt;Age: 
18 to 80
years&lt;/li&gt;&lt;li&gt;Performance status: ECOG 0 to 2&lt;/li&gt;&lt;li&gt;Life expectancy: not specified&lt;/li&gt;&lt;li&gt;Hematopoietic:&lt;ul&gt;&lt;li&gt;WBC &gt;/= 1500/mm3&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 100,000/mm3&lt;/li&gt;&lt;li&gt;Hemoglobin&amp;gt; 10 g/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Hepatic:&lt;ul&gt;&lt;li&gt;Alkaline phosphatase normal&lt;/li&gt;&lt;li&gt;Bilirubin normal&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Renal:&lt;ul&gt;&lt;li&gt;Creatinine&amp;lt;/= 130 micromol/l&lt;/li&gt;&lt;li&gt;No severe renal insufficiency&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Cardiovascular:&lt;ul&gt;&lt;li&gt;No cardiac insufficiency&lt;/li&gt;&lt;li&gt;No symptomatic coronary artery disease&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;Not pregnant or nursing&lt;/li&gt;&lt;li&gt;Negative pregnancy test&lt;/li&gt;&lt;li&gt;Fertile patients must use effective contraception&lt;/li&gt;&lt;li&gt;No contraindication to study treatment&lt;/li&gt;&lt;li&gt;Prior acute intestinal obstruction allowed provided patient underwent surgical diversion with stoma&lt;/li&gt;&lt;li&gt;No history of other cancer except basal cell skin cancer or carcinoma in situ of the cervix&lt;/li&gt;&lt;li&gt;No peripheral neuropathy&lt;/li&gt;&lt;li&gt;No uncontrolled diabetes&lt;/li&gt;&lt;li&gt;No other uncontrolled severe disease&lt;/li&gt;&lt;li&gt;No geographical, social, or psychological condition that would preclude study follow-up&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior concurrent therapy:&lt;ul&gt;&lt;li&gt;Biological therapy: 
not specified&lt;/li&gt;&lt;li&gt;Chemotherapy:&lt;ul&gt;&lt;li&gt;No prior chemotherapy for cancer&lt;/li&gt;&lt;li&gt;No other concurrent chemotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Endocrine therapy: not specified&lt;/li&gt;&lt;li&gt;Radiotherapy: no prior radiotherapy for cancer&lt;/li&gt;&lt;li&gt;Surgery: not specified&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;No concurrent phenytoin&lt;/li&gt;&lt;li&gt;No concurrent participation in another clinical trial of an experimental medical treatment&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;No evidence of distant metastases&lt;/li&gt;&lt;li&gt;Written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Tumor response according to the Dworak score in each arm</Description></Measure><Measure><Description>Rate of complete surgical resection</Description></Measure><Measure><Description>Complete sterilization of the operative specimen (ypCR)</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Circumferential rectal margin</Description></Measure><Measure><Description>Local control</Description></Measure><Measure><Description>Overall survival</Description></Measure><Measure><Description>Disease-free survival</Description></Measure><Measure><Description>Sphincter preservation</Description></Measure><Measure><Description>Sphincter function</Description></Measure><Measure><Description>Biological parameters that predict tumor response and treatment-related toxicity</Description></Measure><Measure><Description>Acute and late toxicity</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results published in April 2010 demonstrated that more preoperative grade 3 to 4 toxicity occurred in the       &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;   plus   &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;   plus radiotherapy group when compared to      &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;   plus radiotherapy  group (25 versus 11%; p &amp;lt; 0.001) [&lt;ulink linkType="Reference" linkID="1091290"&gt;1091290&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 2011, results were published. Patients who received &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; immediately showed increased side effects, which includes severe diarrhea, and increased the odds of local tumor sterilization.  &lt;ulink linkType="Drug" linkID="3792"&gt;Oxaliplatin&lt;/ulink&gt; has not been shown to improve survival [&lt;ulink linkType="Reference" linkID="1536115"&gt;1536115&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1536116"&gt;1536116&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were published in December 2012. The toxicities were mainly digestive or sexual. At the three-year evaluation, grade 3 toxicities (no grade 4) were reported in four patients in the CAP45 group and two patients in the CAPOX50 group. Patients equally distributed between groups at the time of inclusion, and 8 and 9% of patients in the CAP45 (13 of 165) and CAPOX50 (16 of 182) groups, respectively, experienced some bowel incontinence, declaring losing some solid stool. At  three years, 41 patients were analyzed, and 71% reported erectile dysfunction (ED), equally distributed between both groups. Social life disturbance was analyzed in 347 patients undergoing a sphincter-saving procedure (CAP45, n = 165; CAPOX50, n = 182); mean scores at time of inclusion were 3.33 and 3.25, respectively [&lt;ulink linkType="Reference" linkID="1364366"&gt;1364366&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, results of the exploratory analysis aims to assess the benefit of neoadjuvant chemotherapy between the elderly (&gt; 70 years; n=142) and younger patients (&amp;lt; 70years; n = 442). Preoperative chemoradiotherapy which lead to more severe grade 3/4 toxicities in elderly and younger patients were 25.6 and 15.8% respectively (p = 0.01)  [&lt;ulink linkType="Reference" linkID="1536099"&gt;1536099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2017, results were published from a meta-analysis of eight randomized controlled trials (NSABP R-04, STAR-01, FOWARC, ADORE, ACCORD 12/0405, CAO/ARO/AIO-04, and PETACC-6) which compared oxaliplatin-based with fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer). Greater toxicity (p &amp;lt; 0.00001) was observed in oxaliplatin-based regimen group compared to fluorouracil-based regimen group [&lt;ulink linkType="Reference" linkID="1964177"&gt;1964177&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2017, results were published. Latetoxicitieswere acceptable with 1.6% grade 3 anal incontinence, and &amp;lt;1% grade 3 diarrhea, grade 3rectalbleeding, grade 3 stenosis, grade 3 to 4 pain, grade 3 urinary incontinence, grade 3 urinary retention and grade 3 skeletal toxicity. At five years, a slight increase of erectile dysfunction was reported over time with a 63% rate of erectile dysfunction. There was no significant statistical difference noticed for thesetoxicitiesbetween treatment arms [&lt;ulink linkType="Reference" linkID="1997763"&gt;1997763&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, controlled, multicenter, phase III trial was to assess radiation therapy, &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;, and &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; to see how well they work compared to radiation therapy and &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; in treating patients who are undergoing surgery for stage II or  III rectal cancer.&lt;/para&gt;&lt;para&gt;The hypothesis of this study was to increase ypCR from 11% in the Cap 45 group to 20% in the Capox 50 group [&lt;ulink linkType="Reference" linkID="1767270"&gt;1767270&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The primary objective was to compare the efficacy of neoadjuvant chemoradiotherapy comprising radiotherapy and &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; with versus without &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; followed by total mesorectal excision, in terms of the rate of complete surgical resection, in patients with resectable stage II or III rectal cancer.
The secondary objectives were to:&lt;br/&gt;Compare overall and disease-free survival of patients treated with these regimens.
&lt;br/&gt;Compare clinical tumor response in patients treated with these regimens.
&lt;br/&gt;Compare acute and late toxicity of these regimens in these patients.
&lt;br/&gt;Determine biological parameters that predict tumor response and treatment-related toxicity in patients treated with these regimens.
&lt;br/&gt;Compare sphincter preservation and function in patients treated with these regimens.
&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results in April 2010, showed that  surgery was performed in 98% of patients in both groups. There were no differences between groups in the rate of conservative surgery (75%) or postoperative deaths at 60 days (0.3%). The ypCR rate was 13.9% with   &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;    plus radiotherapy (CAP45) and 19.2% with   &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;   plus   &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;   plus radiotherapy (CAPOX50) (p = 0.09).  The rates of positive circumferential rectal margins (between 0 and 2 mm) were 19.3 and 9.9% with    &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;   plus radiotherapy  and      &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;   plus   &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;   plus radiotherapy, respectively  (p = 0.02) [&lt;ulink linkType="Reference" linkID="1091290"&gt;1091290&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Similar results were published in December 2012. The rate of complete and nearly complete response (no cancer cells or few residual cancer cells detected in operative specimen) was 28.9% for CAP45 versus 39.4% for CAPOX50 (p = 0.008). Cumulative incidence rates were 6.1% (CAP45) and 4.4% (CAPOX50). In T2, T3, and T4 tumors in the CAPOX50 group, cumulative rates were 5, 4.2, and 7.1%, respectively. When full dose of RT was administered in the CAPOX50 group (264 patients), cumulative incidence rate of local recurrence was 4.1%. A three-year overall and DFS in the CAP45 and CAPOX50 groups were 87.6 versus 88.3% and 67.9 versus 72.7%, respectively [&lt;ulink linkType="Reference" linkID="1364366"&gt;1364366&lt;/ulink&gt;] [&lt;ulink linkType="Reference" linkID="1536116"&gt;1536116&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, results were published. Score for supple rectal wall (cCR), partial response (PR), stable disease (ST) + progressive disease  (PROG), PROG were 8, 68, 24, 4% respectively. In the capox 50 arm trends was more for cCR (9.3 versus 6.7%). When cohort of 201 patients were assess early T stage was associated with cCR (T2: 28 versus T34: 6%). cCR was linked with sphincter saving surgery, ypCR, CRM R1, disease free survival. Sphincter Saving Surgery observed for cCR, PR, ST + PG 87, 76, 68 % respectively. yp CR observed were 73 , 15 , 12 %. CRM R1 observed for cCR, PR, ST + PG were 0, 3, 9% respectively DFS 3y observed for cCR , PR , ST + PG were 87.5, 77.6, 65% respectively. Rectal preservation was possible in three patients with cCR and three patients alive and well between 3 and 5 years follow up [&lt;ulink linkType="Reference" linkID="1536105"&gt;1536105&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In January 2013, the results were published. A total of 8% was reported positive for circumferential resection margin (CRM). A 6% rate of positive CRM was reported in patients who received 50 Gy plus &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; while a 10% positive CRM rate was reported in 45 Gy plus &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; (p = 0.128). Abdominoperineal resection (APR) (p = 0.004), vascular tumor invasion (p = 0.026), poor histological response (p = 0.003) were the three independent predictive factors of positive CRM. Positive CRM are related to type of surgery which was APR, and poor histological prognostic factors [&lt;ulink linkType="Reference" linkID="1385118"&gt;1385118&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, results of the exploratory analysis aims to assess the benefit of neoadjuvant chemotherapy between the elderly (&gt; 70 years; n=142) and younger patients (&amp;lt; 70years; n = 442). Permanent stomas reported in elderly and younger patients were 33.3 and 22.8% respectively (p=0.014) and it was in elderly patients who were less often operated when compared to younger patients (95.8 versus 99.0%, p=0.008). For both the catagories, the relative number of interventions per surgery type (p = 0.18), treatment efficacy in terms of R0 resection rate (88.6 versus. 90.6%; p=0.54) and complete pathological response (14.7 versus 16.9%; p=0.55) [&lt;ulink linkType="Reference" linkID="1536099"&gt;1536099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, results were presented. In terms of survival outcomes, there were no significant differences in local recurrence, disease free survival or overall survival at five years. For quality of life, explored with the anal sphincter conservative treatment questionnaire, there was no difference between the two arms, for the 18 items of the questionnaire. A total of 63% of patients having declared erectile dysfunction (ED) at five years, with no significant difference between groups. There was no significant difference in the evolution of the ED score between the two arms (p = 0.893) over the entire period [&lt;ulink linkType="Reference" linkID="1767270"&gt;1767270&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2017, results were published from a meta-analysis of eight randomized controlled trials (&lt;ulink linkType="Protocol" linkID="56163"&gt;NSABP R-04&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="79595"&gt;STAR-01&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="70804"&gt;FOWARC&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="38553"&gt;ADORE&lt;/ulink&gt;, ACCORD 12/0405, &lt;ulink linkType="Protocol" linkID="45951"&gt;CAO/ARO/AIO-04&lt;/ulink&gt;, and &lt;ulink linkType="Protocol" linkID="47955"&gt;PETACC-6&lt;/ulink&gt;) which compared oxaliplatin-based with fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer). A total of 6103 stage II or III rectal cancer patients were analyzed, including 2887 and 3216 patients with oxaliplatin + fluorouracil regimen and fluorouracil alone regimen, respectively. Higher pathological complete response (p = 0.0005) and three-year disease-free survival (p = 0.21) was observed in oxaliplatin-based regimen group compared to fluorouracil-based regimen group. Between two regimens, no significant differences were observed in sphincter-sparing surgery rates (p = 0.33), five-year disease-free survival (p = 0.21) and overall survival (three-year, p = 0.09; five-year, p = 0.70) [&lt;ulink linkType="Reference" linkID="1964177"&gt;1964177&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, results of a pharmacogenetic study were presented. Univariate analysis revealed that two SNPs in IL2RA (rs11256456: odds ratio (OR) = 5.1; rs706781: OR = 4.2) had a significant association with the Dworak score in the CAP45 group (n = 155) and one SNP in the IL2RA (rs2104286: OR = 0.11) was significantly related to the Dworak score in the CAPOX50 group (n = 161), and multivariate analysis confirmed these results. In the CAP45 group, a significant haplotypic effect was noted (p = 0.0001). Interaction was significant for IL2RA rs11256456 (p = 0.03) and rs706781 (p = 0.002) but not for IL2RA rs2104286 (p = 0.722), predicting a deleterious effect of the first two snps for response to oxaliplatin based chemoradiotherapy, and a prognostic effect of the third snp for response to chemoradiotherapy with or without oxaliplatin. In the multivariate analysis, none of three SNPs were associated with survival [&lt;ulink linkType="Reference" linkID="1940487"&gt;1940487&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2017, meta-analysis results of four randomized trials (ACCORD [NCT00227747], CAO/ARO/AIO-04 [&lt;ulink linkType="Protocol" linkID="45951"&gt;NCT00349076&lt;/ulink&gt;], NSAPB R-04 and Chinese study) were published. Compared tostandardchemoradiotherapy, patients treated with oxaliplatin-5-fluoropirimidine chemoradiotherapy had significantly decreased distant failure (p=0.03). Between groups, overall survival, disease free survivaland local failure were not significantly different [&lt;ulink linkType="Reference" linkID="1979038"&gt;1979038&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2017, results were published. After a median follow-up of 60.2months, through multivariate analysis, there were no difference  observed between treatment arms either for disease-free survival or overall survival (OS) (p=0.9 and 0.3, respectively). In univariate analysis, local control showed no difference  (p=0.7) [&lt;ulink linkType="Reference" linkID="1997763"&gt;1997763&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomized to one of two treatment arms:&lt;br/&gt;Arm I: patients would undergo radiotherapy qd 5 days a week and would receive &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; qd 5 days a week in weeks 1 to 5.
&lt;br/&gt;Arm II: patient would undergo radiotherapy and receive &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; as in arm I. Patients would also receive &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; qw in weeks 1 to 5.
&lt;br/&gt;All patients would undergo total mesorectal excision 6 weeks after completion of chemoradiotherapy.
&lt;/para&gt;&lt;para&gt;Patients would receive 5 weeks of treatment with radiotherapy 45 Gy/25 fractions with concurrent  &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;  800 mg/m2 bid for 5 days per week (n = 299)   or radiotherapy 50 Gy/25 fractions with  &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;  800 mg/m2 bid for 5 days per week and  &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;  50 mg/m2 qw (n = 299)    [&lt;ulink linkType="Reference" linkID="1091290"&gt;1091290&lt;/ulink&gt;] [&lt;ulink linkType="Reference" linkID="1364366"&gt;1364366&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients would receive 5 weeks of treatment with radiotherapy 45 Gy/25 fractions with concurrent  capecitabine  800 mg/m2 bid for 5 days per week (n = 299)   or radiotherapy 50 Gy/25 fractions with  capecitabine  800 mg/m2 bid for 5 days per week and  oxaliplatin  50 mg/m2 qw (n = 299). After 6 weeks, mesorectal excision  was performed [&lt;ulink linkType="Reference" linkID="1091290"&gt;1091290&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1364366"&gt;1364366&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1385118"&gt;1385118&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1536105"&gt;1536105&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1536115"&gt;1536115&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1767270"&gt;1767270&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1940487"&gt;1940487&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1997763"&gt;1997763&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>capecitabine + oxaliplatin + radiotherapy</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="186">Erectile dysfunction</Indication></AdverseEvent><AdverseEvent><Indication id="599">Intestine disease</Indication><CountPatientsAffectedPercentage>9.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>capecitabine + radiotherapy</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="186">Erectile dysfunction</Indication></AdverseEvent><AdverseEvent><Indication id="599">Intestine disease</Indication><CountPatientsAffectedPercentage>8.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="97266">capecitabine</Intervention><Treatments><Treatment><Dose>800 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="96896">oxaliplatin</Intervention><Treatments><Treatment><Dose>50 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>Centre Hospitalier</Name><Address1>Pau</Address1><Address3>64046</Address3><Contacts></Contacts></Site><Site><Name>Clinique Clementville</Name><Address1>Montpellier</Address1><Contacts></Contacts></Site><Site><Name>Clinique Saint - Pierre</Name><Address1>Perpignan</Address1><Contacts></Contacts></Site><Site><Name>C.H.U. de Nimes - Groupe Hospitals-Universitaire Caremeau</Name><Address1>Nimes</Address1><Address3>30029</Address3><Contacts></Contacts></Site><Site><Name>Centre Alexis Vautrin</Name><Address1>Vandoeuvre-les-Nancy</Address1><Address3>54511</Address3><Contacts></Contacts></Site><Site><Name>Centre Antoine Lacassagne</Name><Address1>Nice</Address1><Address3>06189</Address3><Contacts></Contacts></Site><Site><Name>Centre d'Oncologie Saint-Yves</Name><Address1>Vannes</Address1><Address3>56001</Address3><Contacts></Contacts></Site><Site><Name>Centre Eugene Marquis</Name><Address1>Rennes</Address1><Address3>35062</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospital Regional Universitaire de Limoges</Name><Address1>Limoges</Address1><Address3>87042</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier d'Abbeville</Name><Address1>Abbeville</Address1><Address3>80101</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier de Blois</Name><Address1>Blois</Address1><Address3>41016</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier de Mulhouse</Name><Address1>Mulhouse</Address1><Address3>68051</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier de Rodez</Name><Address1>Rodez</Address1><Address3>12027</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier Departemental</Name><Address1>La Roche Sur Yon</Address1><Address3>F-85025</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier Docteur Duchenne</Name><Address1>Boulogne Sur Mer</Address1><Address3>62200</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier General Andre Boulloche</Name><Address1>Montbeliard</Address1><Address3>25209</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier General</Name><Address1>Longjumeau</Address1><Address3>91164</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier Lyon Sud</Name><Address1>Pierre Benite</Address1><Address3>69495</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier Pierre Oudot</Name><Address1>Bourgoin-Jallieu</Address1><Address3>38300</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier</Name><Address1>Altkirch</Address1><Address3>68134</Address3><Contacts></Contacts></Site><Site><Name>Centre Leon Berard</Name><Address1>Lyon</Address1><Address3>69373</Address3><Contacts></Contacts></Site><Site><Name>Centre Oscar Lambret</Name><Address1>Lille</Address1><Address3>59020</Address3><Contacts></Contacts></Site><Site><Name>Centre Paul Strauss</Name><Address1>Strasbourg</Address1><Address3>67065</Address3><Contacts></Contacts></Site><Site><Name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</Name><Address1>Montpellier</Address1><Address3>34298</Address3><Contacts></Contacts></Site><Site><Name>Centre Regional Francois Baclesse</Name><Address1>Caen</Address1><Address3>14076</Address3><Contacts></Contacts></Site><Site><Name>Centre Regional Rene Gauducheau</Name><Address1>Nantes-Saint Herblain</Address1><Address3>44805</Address3><Contacts></Contacts></Site><Site><Name>Centre Rene Huguenin</Name><Address1>Saint Cloud</Address1><Address3>92210</Address3><Contacts></Contacts></Site><Site><Name>CHU - Robert Debre</Name><Address1>Reims</Address1><Address3>51092</Address3><Contacts></Contacts></Site><Site><Name>CHU de Caen</Name><Address1>Caen</Address1><Address3>14033</Address3><Contacts></Contacts></Site><Site><Name>CHU de la Timone</Name><Address1>Marseille</Address1><Address3>13385</Address3><Contacts></Contacts></Site><Site><Name>CHU Pitie-Salpetriere</Name><Address1>Paris</Address1><Address3>75651</Address3><Contacts></Contacts></Site><Site><Name>Clinique Armoricaine De Radiologie</Name><Address1>Saint Brieuc</Address1><Address3>F-22015</Address3><Contacts></Contacts></Site><Site><Name>Clinique Hartmann</Name><Address1>Neuilly sur Seine</Address1><Address3>92200</Address3><Contacts></Contacts></Site><Site><Name>Clinique J. B. Menis</Name><Address1>Macon</Address1><Address3>71000</Address3><Contacts></Contacts></Site><Site><Name>Clinique Pasteur - Toulouse</Name><Address1>Toulouse</Address1><Address3>31076</Address3><Contacts></Contacts></Site><Site><Name>Clinique Sainte Marie</Name><Address1>Chalon Sur Saone</Address1><Address3>71100</Address3><Contacts></Contacts></Site><Site><Name>Clinique Sainte-Marguerite</Name><Address1>Hyeres</Address1><Address3>83400</Address3><Contacts></Contacts></Site><Site><Name>Clinique Tivoli</Name><Address1>Bordeaux</Address1><Address3>F-33000</Address3><Contacts></Contacts></Site><Site><Name>Clinique Victor Hugo</Name><Address1>Le Mans</Address1><Address3>F-72000</Address3><Contacts></Contacts></Site><Site><Name>Hopital Bichat - Claude Bernard</Name><Address1>Paris</Address1><Address3>75018</Address3><Contacts></Contacts></Site><Site><Name>Hopital de Beziers</Name><Address1>Beziers</Address1><Address3>34525</Address3><Contacts></Contacts></Site><Site><Name>Hopital Drevon</Name><Address1>Dijon</Address1><Address3>21000</Address3><Contacts></Contacts></Site><Site><Name>Hopital Du Bocage</Name><Address1>Dijon</Address1><Address3>21034</Address3><Contacts></Contacts></Site><Site><Name>Hopital Duffaut</Name><Address1>Avignon</Address1><Address3>84902</Address3><Contacts></Contacts></Site><Site><Name>Hopital Europeen Georges Pompidou</Name><Address1>Paris</Address1><Address3>75015</Address3><Contacts></Contacts></Site><Site><Name>Hopital Jean Bernard</Name><Address1>Limoges</Address1><Address3>87042</Address3><Contacts></Contacts></Site><Site><Name>Hopital Louis Pasteur</Name><Address1>Colmar</Address1><Address3>68024</Address3><Contacts></Contacts></Site><Site><Name>Hopital Notre-Dame de Bon Secours</Name><Address1>Metz</Address1><Address3>57038</Address3><Contacts></Contacts></Site><Site><Name>Hopital Robert Boulin</Name><Address1>Libourne</Address1><Address3>33500</Address3><Contacts></Contacts></Site><Site><Name>Hopital Saint Andre</Name><Address1>Bordeaux</Address1><Address3>33075</Address3><Contacts></Contacts></Site><Site><Name>Hopital Saint-Louis</Name><Address1>Paris</Address1><Address3>75475</Address3><Contacts></Contacts></Site><Site><Name>Hopital Tenon</Name><Address1>Paris</Address1><Address3>75970</Address3><Contacts></Contacts></Site><Site><Name>Institut Bergonie</Name><Address1>Bordeaux</Address1><Address3>33076</Address3><Contacts></Contacts></Site><Site><Name>Institut Claudius Regaud</Name><Address1>Toulouse</Address1><Address3>31052</Address3><Contacts></Contacts></Site><Site><Name>Institut de Cancerologie de la Loire</Name><Address1>Saint Priest en Jarez</Address1><Address3>42270</Address3><Contacts></Contacts></Site><Site><Name>Institut Gustave Roussy</Name><Address1>Villejuif</Address1><Address3>F-94805</Address3><Contacts></Contacts></Site><Site><Name>Institut Jean Godinot</Name><Address1>Reims</Address1><Address3>51056</Address3><Contacts></Contacts></Site><Site><Name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</Name><Address1>Marseille</Address1><Address3>13273</Address3><Contacts></Contacts></Site><Site><Name>Polyclinique De Courlancy</Name><Address1>Reims</Address1><Address3>F-51100</Address3><Contacts></Contacts></Site><Site><Name>Polyclinique des Quatre Pavillons</Name><Address1>Lormont</Address1><Address3>33310</Address3><Contacts></Contacts></Site><Site><Name>Polyclinique du Val de Loire</Name><Address1>Nevers</Address1><Address3>58000</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier de Gap</Name><Address1>Gap</Address1><Address3>05007</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier Universitaire Henri Mondor</Name><Address1>Creteil</Address1><Address3>94000</Address3><Contacts></Contacts></Site><Site><Name>CHR D'Orleans - Hopital de la Source</Name><Address1>Orleans</Address1><Address3>45067</Address3><Contacts></Contacts></Site><Site><Name>Clinique Plein Ciel</Name><Address1>Mougins</Address1><Address3>06250</Address3><Contacts></Contacts></Site><Site><Name>Hopital Louis Pasteur</Name><Address1>Chartres</Address1><Address3>28018</Address3><Contacts></Contacts></Site><Site><Name>Polyclinique Bordeaux Nord Aquitaine</Name><Address1>Bordeaux</Address1><Address3>33300</Address3><Contacts></Contacts></Site><Site><Name>Institut Sainte Catherine</Name><Address1>Avignon</Address1><Address3>84000</Address3><Contacts></Contacts></Site><Site><Name>Centre Hospitalier Intercommunal Le Raincy - Montfermeil</Name><Address1>Montfermeil</Address1><Address3>93370</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Colorectal tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3813">Subjects with Rectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3821">Subjects with TNM Stage I/Dukes A Colorectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3822">Subjects with TNM stage II/Dukes B Colorectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3823">Subjects with TNM stage III/Dukes C Colorectal Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00227747</Identifier></Identifiers></Registry><Registry><Name id="1039">Center for Drug Evaluation</Name><Identifiers><Identifier type="Organisational Study">CDR0000445034</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8447">Assessment of tumor resectability</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Colorectal tumor" id="8151"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8172"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8383"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8386">Functional assessment of bowel</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8409"><Endpoint>Assessment of Mortality/Morbidity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8429"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8430">Assessment of adverse events/serious adverse events</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="9147">Assessment of toxicities</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8446">Assessment of surgery rates</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="9370"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8187">Assessment of Objective/Overall Response Rate (ORR)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Colorectal tumor" id="4467"><Criterion>Subjects with Rectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4470"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4480"><Criterion>Subjects with TNM Stage I/Dukes A Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4481"><Criterion>Subjects with TNM Stage II/Dukes B Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4482"><Criterion>Subjects with TNM Stage III/Dukes C Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4509"><Criterion>Subjects with Histologically Confirmed Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4517"><Criterion>Subjects with Resectable Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4526"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4527">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Colorectal tumor" id="4528">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Colorectal tumor" id="4529">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4544"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4545">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Colorectal tumor" id="4546">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="32554"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4564">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Colorectal tumor" id="4569">Subjects with normal/acceptable hematopoetic/marrow function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="33970"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4565">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Colorectal tumor" id="5805"><Criterion>Subjects with Colorectal Cancer</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5808">Subjects with acutely obstructed or perforated colon cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5841"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5860"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5864"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5879"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5887"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5918"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5921">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5949"><Criterion>Subjects with history of/scheduled to receive radiation therapy</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5962"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="20283"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="26894"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5934">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2009-09-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>50.03 Months</EnrollmentPeriod><EnrollmentRate>11.79 Patients/Month</EnrollmentRate><DateFirstReceived>2005-09-26T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-02-09T09:30:13Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="4814"><TitleDisplay>A Study to Develop Additional Safety and Clinical Experience With Natrecor hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels</TitleDisplay><TitleOfficial>A Randomized, Open-Label, Active-Controlled, Multi-Center Phase III Safety Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in the Treatment of Decompensated CHF</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CR005203</Identifier><Identifier type="NCT">NCT00271557</Identifier></Identifiers><Indications><Indication id="1559">Congestive heart failure</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>nesiritide</Name><Drug id="7204">nesiritide</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="7204">nesiritide</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="19831">Scios Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="7204" type="Drug"><TargetEntity id="202811" type="siDrug">Nesiritide</TargetEntity></SourceEntity><SourceEntity id="19831" type="Company"><TargetEntity id="4295907891" type="organizationId">Scios LLC</TargetEntity></SourceEntity><SourceEntity id="1559" type="ciIndication"><TargetEntity id="428.0" type="ICD9"></TargetEntity><TargetEntity id="10007559" type="MEDDRA"></TargetEntity><TargetEntity id="239" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="19831">Scios Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3332">BNP agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2657">Antihypertensive</Class><Class id="388">Vasodilator</Class><Class id="966">Cardiac agent</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="85">Protein recombinant</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>305</PatientCountEnrollment><DateStart>1997-01-31T00:00:00Z</DateStart><DateEnd type="actual">1997-12-31T00:00:00Z</DateEnd><DateChangeLast>2013-12-02T16:08:44Z</DateChangeLast><DateAdded>2007-10-04T08:51:32Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Scios, Inc.</Affiliation><Name>Scios, Inc. Clinical Trial</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with a previous history of chronic congestive heart failure (CHF)&lt;/li&gt;&lt;li&gt;Presenting with symptomatic, decompensated CHF for inpatient iv therapy with medications that influence the tone and caliber of blood vessels (other than, or in addition to, diuretics)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with myocardial ischemia within the past 48 h&lt;/li&gt;&lt;li&gt;Having significant valvular stenosis, obstructive cardiomyopathy, constrictive pericarditis or primary pulmonary hypertension&lt;/li&gt;&lt;li&gt;  Being treated with iv therapy with medications that influence the tone and caliber of blood vessels for&amp;gt; 4 h for this episode of CHF &lt;/li&gt;&lt;li&gt;Already being treated with iv therapy with medications that influence the tone and caliber of blood vessels that cannot be discontinued&lt;/li&gt;&lt;li&gt;Having cardiogenic shock, systolic blood pressure consistently&amp;lt; 90 mmHg or other significant blood circulation instability&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Changes in symptoms and signs of CHF</Description><Timeframe>After 6 h and after 24 h of treatment with Natrecor hBNP</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Adverse events, vital signs</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  purpose of this safety study was to evaluate &lt;ulink linkType="Drug" linkID="7204"&gt;nesiritide&lt;/ulink&gt; (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure), in subjects with worsening congestive heart failure for whom inpatient iv therapy with medications that influence the tone and caliber of blood vessels was deemed appropriate.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The purpose of this safety study was to evaluate &lt;ulink linkType="Drug" linkID="7204"&gt;nesiritide&lt;/ulink&gt; in subjects with symptomatic, decompensated congestive heart failure for whom inpatient iv therapy with medications that influence the tone and caliber of blood vessels (other than, or in addition to, iv diuretics) is deemed appropriate.  This was a multicenter, randomized, open-label, safety study designed to compare two doses of &lt;ulink linkType="Drug" linkID="7204"&gt;nesiritide&lt;/ulink&gt; for the treatment of decompensated congestive heart failure.  One treatment group would receive &lt;ulink linkType="Drug" linkID="7204"&gt;nesiritide&lt;/ulink&gt; fixed-dose infusion iv bolus of 0.3 microg/kg followed by a 0.015 microg/kg/min infusion; group two would receive an iv bolus of 0.6 microg/kg followed by a 0.03 microg/kg/min infusion.  The duration of &lt;ulink linkType="Drug" linkID="7204"&gt;nesiritide&lt;/ulink&gt; therapy was determined by the attending physician.  The study hypothesis was that doses of &lt;ulink linkType="Drug" linkID="7204"&gt;nesiritide&lt;/ulink&gt; in the range of 0.015 to 0.03 microg/kg/min provide an optimal safety/efficacy profile for the treatment of decompensated CHF.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Myocardial disease</Disease><PatientSegments><PatientSegment><PatientSegment id="11229">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="11236">Subjects co-morbid with heart failure</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Cardiac failure</Disease><PatientSegments><PatientSegment><PatientSegment id="59">Acute Decompensated Heart Failure (ADHF) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="61">Subjects with Symptomatic Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="72">Chronic Heart Failure Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="150">Subjects with History of Treatment</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00271557</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cardiac failure" id="6790"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="765">Heart failure symptoms / Clinical signs of heart failure</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myocardial disease" id="24762"><Endpoint>Assessment of Cardiac Markers</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24764">Assessment of BNP or NT-pro-BNP</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myocardial disease" id="24774"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24778">Assessment of heart failure</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cardiac failure" id="557"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="1208"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myocardial disease" id="24770"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Cardiac failure" id="819"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="844">Assessment of rehospitalizations</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Cardiac failure" id="973"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cardiac failure" id="258"><Criterion>Subjects with Congestive Heart Failure (CHF)</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="261"><Criterion>Subjects with Decompensated Heart Failure</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="270"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="272"><Criterion>Subjects with Chronic Heart Failure</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="315"><Criterion>Subjects with History of Hospitalization</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="367"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="378">Subjects with history of/scheduled to receive diuretics</SubCriterion><SubCriterion disease="Cardiac failure" id="381">Intravenous medications</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myocardial disease" id="21416"><Criterion>Subjects co-morbid with heart failure</Criterion></Inclusion><Inclusion disease="Myocardial disease" id="21430"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="21439">Subjects with history /scheduled to receive intravenous therapy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cardiac failure" id="456"><Criterion>Subjects with Valvular Heart Diseases</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="459">Valvular stenosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="460"><Criterion>Subjects with specific type of cardiomyopathy</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="469"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="474">Subjects co-morbid with cardiogenic shock</SubCriterion><SubCriterion disease="Cardiac failure" id="725">Subjects co-morbid with hypotension</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="503"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="640"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="479">Subjects co-morbid with pericarditis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="19162"><Criterion>Subjects with specific disease</Criterion></Exclusion><Exclusion disease="Myocardial disease" id="19163"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19165">Subjects co-morbid with cardiogenic shock</SubCriterion><SubCriterion disease="Myocardial disease" id="19167">Subjects co-morbid with coronary artery disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="19188"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19192">Subjects with abnormal blood pressure values</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="19217"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Myocardial disease" id="26987"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19171">Subjects co-morbid with valvular heart diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27043"><Criterion>Subjects with history of cardiovascular disease/disorder</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="441">Subjects with history of myocardial infarction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27060"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="572">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="27078"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19199">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2007-10-04T08:51:32Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="49122"><TitleDisplay>Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial</TitleDisplay><TitleOfficial>Phase II Study of Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">PROTOCOL NUMBER: OZM-004</Identifier><Identifier type="NCT">NCT00386828</Identifier><Identifier type="Secondary Organisational">A-CORRECT Study</Identifier><Identifier type="Trial Acronym">A-CORRECT</Identifier></Identifiers><Indications><Indication id="3658">Metastatic colorectal cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>bevacizumab</Name><Drug id="8047">bevacizumab</Drug></Intervention><Intervention type="InterventionPrimary"><Name>bevacizumab + oxaliplatin + capecitabine</Name></Intervention><Intervention type="InterventionPrimary"><Name>bevacizumab + oxaliplatin + capecitabine (post-operative)</Name></Intervention><Intervention type="InterventionPrimary"><Name>bevacizumab + oxaliplatin + capecitabine (pre-operative)</Name></Intervention><Intervention type="InterventionPrimary"><Name>capecitabine</Name><Drug id="12205">capecitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>oxaliplatin</Name><Drug id="3792">oxaliplatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12205">capecitabine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1007766">BC Cancer Agency</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3792">oxaliplatin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1007766">BC Cancer Agency</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8047">bevacizumab</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1007766">BC Cancer Agency</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3792" type="Drug"><TargetEntity id="108094" type="siDrug">Oxaliplatin</TargetEntity></SourceEntity><SourceEntity id="12205" type="Drug"><TargetEntity id="211639" type="siDrug">Capecitabine</TargetEntity></SourceEntity><SourceEntity id="8047" type="Drug"><TargetEntity id="223839" type="siDrug">Bevacizumab</TargetEntity></SourceEntity><SourceEntity id="1007766" type="Company"><TargetEntity id="4298147346" type="organizationId">BC Cancer Agency</TargetEntity></SourceEntity><SourceEntity id="3658" type="ciIndication"><TargetEntity id="10052358" type="MEDDRA"></TargetEntity><TargetEntity id="595" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="1007766">BC Cancer Agency</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="12521">VEGF ligand inhibitor</Action><Action id="372">Thymidylate synthase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="2953">Anti-inflammatory</Class><Class id="50">Anticancer alkylating agent</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="61">Angiogenesis inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="751">Film coating</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Historical Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>43</PatientCountEnrollment><PatientCountEvaluable>42</PatientCountEvaluable><DateStart>2006-10-31T00:00:00Z</DateStart><DateEnd type="actual">2009-05-31T00:00:00Z</DateEnd><DateChangeLast>2018-12-19T07:02:48Z</DateChangeLast><DateAdded>2009-03-18T09:45:17Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>BC Cancer Agency -Vancouver Centre</Affiliation><Name>Hagen Kennecke, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histologically confirmed adenocarcinoma of the rectum, stage II to IV, defined as either:&lt;ul&gt;&lt;li&gt;Mid- or upper rectal tumours (&gt;/= 6 to 15 cm): T3 or T4 adenocarcinoma that is fixed or partially fixed or tethered and is potentially resectable; or low rectal tumours (&amp;lt; 6 cm): T3 or T4 adenocarcinoma: or node positive rectal tumours (&amp;lt;/= 15 cm): T1-4N2 or T1-4N+ where pelvic nodes approach or invade the mesorectum&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Appropriate staging investigations of the primary tumour, either endorectal ultrasound or pelvic MRI.&lt;/li&gt;&lt;li&gt;Male or female aged &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Have a performance status ECOG of 0 or 1&lt;/li&gt;&lt;li&gt;Have a life expectancy  &gt; 6 months&lt;/li&gt;&lt;li&gt;Adequate organ function and coagulation parameters as measured by:&lt;ul&gt;&lt;li&gt;ANC &gt;/= 1.5&lt;/li&gt;&lt;li&gt;Platelets &gt;/= 100&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt;/= 1.5 x ULN &lt;/li&gt;&lt;li&gt;AST, ALT&amp;lt;/= 2.5 x ULN &lt;/li&gt;&lt;li&gt;Bilirubin&amp;lt;/= 1.5 x ULN &lt;/li&gt;&lt;li&gt;PTT and INR within normal limits&lt;/li&gt;&lt;li&gt;Albumin &gt;/=  30&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient consent&lt;/li&gt;&lt;li&gt;No neurological diseases that can increase the neurotoxicity of&lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Be willing and able to comply with the protocol for the duration of the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day -14, (ie, patients must have recovered from any major surgery), or anticipation of need for major surgical procedure during or within 7 weeks after chemo-radiotherapy&lt;/li&gt;&lt;li&gt;Evidence of distant metastases based upon imaging of the chest, abdomen and pelvis&lt;/li&gt;&lt;li&gt;Known to have clinical or radiological evidence of CNS metastases&lt;/li&gt;&lt;li&gt;Patients with a past or current history (within last  two  years) of other malignancies, except for the indication under this study and curatively treated basal and squamous skin cancer or in-situ cancer of the cervix&lt;/li&gt;&lt;li&gt;Women of childbearing potential with either a positive or no pregnancy test at baseline or lactating. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential&lt;/li&gt;&lt;li&gt;Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study. Patients of childbearing potential must be willing to use a reliable method of birth control. ie, doublebarrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive, intrauterine device or tubal ligation during the study&lt;/li&gt;&lt;li&gt;Evidence of bleeding diathesis or coagulopathy&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension, defined as SBP &gt; 150/100 on more than one occasion that does not respond to therapy with antihypertensive agents&lt;/li&gt;&lt;li&gt;Clinically significant (ie, active) cardiovascular disease for example:&lt;ul&gt;&lt;li&gt;Cerebrovascular accidents (&amp;lt;/= 6 months), myocardial infarction (&amp;lt;/= 6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes ie, except for anticoagulation for maintenance of patency of permanent indwelling iv catheters&lt;/li&gt;&lt;li&gt;Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or puts the patient at high risk from treatment complications&lt;/li&gt;&lt;li&gt;Ongoing treatment with aspirin (&gt; 325 mg/day) or other medications known to predispose to gastrointestinal ulceration&lt;/li&gt;&lt;li&gt;Any other serious or uncontrolled illnesses&lt;/li&gt;&lt;li&gt;Current or recent serious polyneuropathy&lt;/li&gt;&lt;li&gt;Known hypersensitivity against&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Known peripheral neuropathy &gt;/= NCI CTCAE grade 1. Absence of deep tendon reflexes (DTRs) as the sole neurological abnormality does not render the patient ineligible&lt;/li&gt;&lt;li&gt;Organ allografts requiring immunosuppressive therapy&lt;/li&gt;&lt;li&gt;Serious, non-healing wound, ulcer, or bone fracture&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The primary endpoint is pathologic complete response (pCR) rate</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Rate of sphincter sparing surgery</Description></Measure><Measure><Description>Complete resection rate</Description></Measure><Measure><Description>Post-surgical complication rates</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In January 2012, results were published.  Pain (81%), diarrhea (76%), fatigue (64%), neuropathy sensory (62%), and nausea (50%) were the commonly observed pre-operative adverse events (AEs) in the study. Insomnia (26%), anorexia (21%), constipation (21%), weight loss (55%), and infection (34%) were the commonly observed post-operative AEs in the study. One patient with post-operative grade 2 sensory neuropathy developed grade 3/4 sensory and motor neuropathy of the lower extremities reported by serious AE at month 5. The drug-related AEs observed during pre-operative period were bleeding in seven patients (&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;-related in six patients) and pelvic infection in three patients (&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;-related in one patient). The drug-related AEs observed during post-operative period were bleeding in 4 patients (&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;-related in 2 patients), pelvic infection in 11 patients (&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;-related in 4  patients), fistulae in 3 patients (&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;-related in 2  patients), delayed healing in 7 patients (&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;-related in 6  patients), anastomotic leak in 6 patients (&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;-related in 4  patients), and re-operation in 4 patients (&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;-related in 2  patients) [&lt;ulink linkType="Reference" linkID="1264373"&gt;1264373&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This phase II study was to  evaluate the effect of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; with radiation on rectal cancer. Researchers would  also evaluate the tolerability (how it makes the patient feel) and safety of this combination by watching for harmful side-effects. It was hoped that by adding &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; to the &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; treatment in combination with radiation before surgery would improve response rate.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2012, results from 38 evaluable patients  were published. R0 resection was possible in 92% of patients; the remainder underwent R1 surgery. Among 24 patients with low rectal tumors, 7  had sphincter-sparing surgery. A total of nine patients had  pathological complete response  (pCR) defined by complete regression of the tumor (ypT0; p = 0.104); and pCR defined as ypT0N0 was observed in seven cases.   Nodal metastases were observed in two patients with complete tumor regression (Dworak grade 4) [&lt;ulink linkType="Reference" linkID="1264373"&gt;1264373&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This was a one-armed, multicenter, phase II study in patients with T3/4 locally advanced and T3/4 low lying rectal cancer, to study the efficacy and safety of the addition of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; to a regimen of &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; in combination with pre-operative radiation.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received  &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; 5 mg/kg over 90 min for 2 weeks (day 14)  prior to the start of radiation. Subsequent &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; (5 mg/kg) infusions were given on days 1, 15 and 29 over 30 to 60 min. Patients received &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; 50 mg/m2 over 1 h on days 1, 8, 22 and 29;. &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; 825 mg/m2 po bid on days 1 to 14 and 22 to 35. The first dose was to be taken 2 h prior to radiation in the morning and the second dose 12 h later. Patients received  45 Gy of pelvic radiation on days 1 to 35, followed by an elective boost of 54 Gy to all identifiable disease, with a margin of 2 cm. The total dose  was not exceeded  50.4 Gy (daily fraction size 1.8 Gy). If chemotherapy was interrupted due to toxicity, consideration was given to holding radiation until toxicity resolved to grade 1.   Total mesorectal excision (TME) was done no earlier than 7 weeks following completion of radiation  (8 weeks after last dose of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;) and no later than 9 weeks after completion of radiation. Surgery was required for all patients irrespective of the extent of clinical response [&lt;ulink linkType="Reference" linkID="1264373"&gt;1264373&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>bevacizumab + oxaliplatin + capecitabine (pre-operative)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="552">Bleeding</Indication><CountPatientsTotal>42</CountPatientsTotal><CountPatientsAffected>7</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="746">Infectious disease</Indication><CountPatientsTotal>42</CountPatientsTotal><CountPatientsAffected>3</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>bevacizumab + oxaliplatin + capecitabine (post-operative)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="3054">Fistula</Indication><CountPatientsTotal>42</CountPatientsTotal><CountPatientsAffected>3</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="552">Bleeding</Indication><CountPatientsTotal>42</CountPatientsTotal><CountPatientsAffected>4</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="746">Infectious disease</Indication><CountPatientsTotal>42</CountPatientsTotal><CountPatientsAffected>11</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="113270">bevacizumab</Intervention><Treatments><Treatment><Dose>5 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="113303">oxaliplatin</Intervention><Treatments><Treatment><Dose>50 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>825 milligram/m2</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>BC Cancer Agency - Vancouver Centre</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><Address3>V5Z 4E6</Address3><CountrySubDivision>British Columbia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Cross Cancer Institute</Name><Address1>Edmonton</Address1><Address2>Alberta</Address2><Address3>T6G 1Z2</Address3><CountrySubDivision>Alberta</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Tom Baker Cancer Centre</Name><Address1>Calgary</Address1><Address2>Alberta</Address2><CountrySubDivision>Alberta</CountrySubDivision><Contacts></Contacts></Site><Site><Name>BCCA - Centre for Southern Interior</Name><Address1>Kelowna</Address1><Address2>British Columbia</Address2><CountrySubDivision>British Columbia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>CancerCare Manitoba</Name><Address1>Winnipeg</Address1><Address2>Manitoba</Address2><CountrySubDivision>Manitoba</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sunnybrook Odette Cancer Centre</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Colorectal tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3813">Subjects with Rectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3822">Subjects with TNM stage II/Dukes B Colorectal Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00386828</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Colorectal tumor" id="9370"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="9369">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="9371">Assessment of clinical/pathological response</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Colorectal tumor" id="8429"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8448">Assessment of postoperative complications</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8446">Assessment of surgery rates</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="8447">Assessment of tumor resectability</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Colorectal tumor" id="8429"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8430">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Colorectal tumor" id="4467"><Criterion>Subjects with Rectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4481"><Criterion>Subjects with TNM Stage II/Dukes B Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4509"><Criterion>Subjects with Histologically Confirmed Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4519"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4524">Subjects with life expectancy of six months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4526"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4527">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Colorectal tumor" id="4528">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="32554"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4564">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Colorectal tumor" id="4569">Subjects with normal/acceptable hematopoetic/marrow function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="33970"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4565">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Colorectal tumor" id="5825"><Criterion>Subjects with Metastatic Colorectal Cancer</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5826">Subjects with brain metastases or leptomeningeal carcinomatosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5841"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5860"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5864"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5879"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5885">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5889"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5918"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5921">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion><SubCriterion disease="Colorectal tumor" id="5922">Subjects with hypersensitivity/Contraindication to non steroidal antiinflammatory drugs (NSAIDs)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5928"><Criterion>Subjects with History of/Scheduled to Receive Colorectal Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="20284">Subjects with history of/scheduled to receive intervention/surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5954"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5955">Subjects with history of/scheduled for biopsy</SubCriterion><SubCriterion disease="Colorectal tumor" id="5959">Subjects with history of/scheduled for transplantation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5962"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="20283"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="26894"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5934">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2006-10-11T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-03-18T09:45:17Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="54250"><TitleDisplay>A single-dose, single-blind, placebo-controlled study to evaluate the pharmacokinetic and pharmacodynamic properties of BOF-4272 in healthy male volunteers</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>BOF-4272</Name><Drug id="8527">BOF-4272</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8527">BOF-4272</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8527" type="Drug"><TargetEntity id="188399" type="siDrug">BOF-4272</TargetEntity></SourceEntity><SourceEntity id="18717" type="Company"><TargetEntity id="5000020419" type="organizationId">Otsuka Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="392" type="Action"><TargetEntity id="514" type="Mechanism">Xanthine Oxidase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="18717">Otsuka Pharmaceutical Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="392">Xanthine oxidase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Male</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Placebo Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>8</PatientCountEnrollment><PatientCountEvaluable>8</PatientCountEvaluable><DateStart>1994-12-31T00:00:00Z</DateStart><DateChangeLast>2011-12-29T08:53:06Z</DateChangeLast><DateAdded>2009-05-07T06:36:50Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy male volunteers&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Plasma concentrations of BOF-4272</Description></Measure><Measure><Description>Half-life of BOF-4272</Description></Measure><Measure><Description>Serum UA concentration</Description></Measure><Measure><Description>Tolerability</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results reported that  in healthy subjects, &lt;ulink linkType="Drug" linkID="8527"&gt;BOF-4272&lt;/ulink&gt; was well tolerated [&lt;ulink linkType="Reference" linkID="162957"&gt;162957&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the pharmacokinetic and pharmacodynamic properties of &lt;ulink linkType="Drug" linkID="8527"&gt;BOF-4272&lt;/ulink&gt; in healthy male volunteers [&lt;ulink linkType="Reference" linkID="162957"&gt;162957&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results reported that in proportion to the given dose, the maximal plasma concentrations of &lt;ulink linkType="Drug" linkID="8527"&gt;BOF-4272&lt;/ulink&gt; and its major metabolite (M-4) and their areas under the plasma concentration-time curve increased. Irrespective of the dose, both substances were eliminated from plasma with half-lives of 1.7 to 1.9 and 4.8 to 6.9 h. &lt;ulink linkType="Drug" linkID="8527"&gt;BOF-4272&lt;/ulink&gt; was recovered in the urine at about 1% as unchanged drug and 15% as M-4. There was a dose-dependent decrease in serum UA concentration to about 80% of the predose value [&lt;ulink linkType="Reference" linkID="162957"&gt;162957&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Three doses of &lt;ulink linkType="Drug" linkID="8527"&gt;BOF-4272&lt;/ulink&gt; at 100, 200 and 400 mg po and a placebo were administered to eight subjects on three occasions at more than 1-week intervals in a single-blind and balanced incomplete block design [&lt;ulink linkType="Reference" linkID="162957"&gt;162957&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Three doses of &lt;ulink linkType="Drug" linkID="8527"&gt;BOF-4272&lt;/ulink&gt; at 100, 200 and 400 mg po and a placebo were administered to  subjects on three occasions at more than 1-week intervals in a single-blind and balanced incomplete block design [&lt;ulink linkType="Reference" linkID="162957"&gt;162957&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="128386">BOF-4272</Intervention><Treatments><Treatment><Dose>100 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>200 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>400 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-05-07T06:36:50Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="6216"><TitleDisplay>Phase I clinical study of gadocoletic acid (B-22956) for intravascular contrast enhancement, in healthy volunteers</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="742">Vascular disease</Indication><Indication id="80">Coronary artery disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>gadocoletic acid</Name><Drug id="48959">gadocoletic acid</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="48959">gadocoletic acid</Drug><IndicationsPioneer><Indication id="742">Vascular disease</Indication><Indication id="80">Coronary artery disease</Indication></IndicationsPioneer><Companies><Company><Company id="30218">Bracco Imaging SpA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="30218" type="Company"><TargetEntity id="5000012331" type="organizationId">Bracco Imaging SpA</TargetEntity></SourceEntity><SourceEntity id="742" type="ciIndication"><TargetEntity id="10059245" type="MEDDRA"></TargetEntity><TargetEntity id="D014652" type="MeSH"></TargetEntity><TargetEntity id="-90096021" type="omicsDisease"></TargetEntity><TargetEntity id="1157" type="siCondition"></TargetEntity><TargetEntity id="3754" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"></TargetEntity><TargetEntity id="D003327" type="MeSH"></TargetEntity><TargetEntity id="-1572475765" type="omicsDisease"></TargetEntity><TargetEntity id="221" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="30218">Bracco Imaging SpA</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="4158">MRI imaging agent</Class><Class id="7210">Cardiovascular diagnostic agent</Class></Class><Technologies><Technology id="731">Imaging</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Diagnosis</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><PatientCountEvaluable>12</PatientCountEvaluable><DateStart>2003-09-19T00:00:00Z</DateStart><DateChangeLast>2017-04-06T10:39:23Z</DateChangeLast><DateAdded>2007-12-13T19:58:45Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Clinic of Internal Medicine/Cardiology, German Heart Institute</Affiliation><Email>paetsch@dhzb.de</Email><Name>Ingo Paetsch</Name></Contact><Contact type="Public contact"><Affiliation>Bracco Imaging SpA, Milan, Italy</Affiliation><Name>Friedrich Cavagna</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy volunteers&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Signal-to-noise ratio (SNR)</Description></Measure><Measure><Description>Contrast-to-noise ratio (CNR)</Description></Measure><Measure><Description>Vessel sharpness</Description></Measure><Measure><Description>Visible vessel length</Description></Measure><Measure><Description>Maximal luminal diameter</Description></Measure><Measure><Description>Number of visible side branches</Description></Measure><Measure><Description>Visual score for image quality</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was evaluate the diagnostic efficacy of the intravascular contrast agent, &lt;ulink linkType="Drug" linkID="48959"&gt;gadocoletic acid&lt;/ulink&gt; (B-22956), for contrast-enhanced coronary magnetic resonance angiography (MRA), and to compare the findings with those obtained using a standard non-contrast T2 preparation sequence [&lt;ulink linkType="Reference" linkID="860786"&gt;860786&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;After 5 min of &lt;ulink linkType="Drug" linkID="48959"&gt;B-22956&lt;/ulink&gt; application, a significant increase in signal- and contrast- to-noise ratio (+42% and +86% , respectively) were noted, compared to pre-contrast T2 preparation values (p &amp;lt; 0.01). A significant increase in the contrast-to-noise ratio (+40%, p &amp;lt; 0.05) was also noted 45 min post-contrast. The image quality of the coronary vessels (left anterior descending artery [LAD], left coronary circumflex [LCx], and right coronary artery [RCA]) were also significantly sharper post-contrast (p &amp;lt; 0.05). Significant increases in vessel length were noted for the LAD (p &amp;lt; 0.05) and LCx and RCA (both p &amp;lt; 0.01), while significantly more side branches were noted for the LAD and RCA (both p &amp;lt; 0.05) when compared to precontrast T2 preparation values [&lt;ulink linkType="Reference" linkID="860786"&gt;860786&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The left coronary system was imaged in volunteers before &lt;ulink linkType="Drug" linkID="48959"&gt;B-22956&lt;/ulink&gt; application and 5 (n = 11) and 45 (n = 7) min after application. In addition, imaging of the right coronary system was performed 23 min after &lt;ulink linkType="Drug" linkID="48959"&gt;B-22956&lt;/ulink&gt; application (n = 6). A 3-dimensional gradient echo sequence with T2 preparation (pre-contrast) or inversion recovery (IR) pulse (post-contrast) with real-time navigator correction was used. Assessments of the left and right coronary systems were performed qualitatively (a 4-point visual score for image quality) and quantitatively in terms of signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), vessel sharpness, visible vessel length, maximal luminal diameter, and the number of visible side branches [&lt;ulink linkType="Reference" linkID="860786"&gt;860786&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects were administered an iv dose of &lt;ulink linkType="Drug" linkID="48959"&gt;B-22956&lt;/ulink&gt; (0.075 mmol/kg of body weight) [&lt;ulink linkType="Reference" linkID="860786"&gt;860786&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2007-12-13T19:58:45Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="8390"><TitleDisplay>A Trial of Neupro (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery</TitleDisplay><TitleOfficial>An Explorative, Multicenter, Open-Label, Pilot Trial With Neupro (Rotigotine Transdermal Patch) Once Daily Treatment Administered Perioperatively in Patients With Idiopathic Parkinson's Disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">2006-005438-19</Identifier><Identifier type="Organisational Study">SP882</Identifier><Identifier type="NCT">NCT00594464</Identifier><Identifier type="Trial Acronym">NEUPOS</Identifier></Identifiers><Indications><Indication id="255">Parkinsons disease</Indication></Indications><BiomarkerNames><BiomarkerName id="1904" role="Toxic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2586" role="Toxic effect marker" type="Physiological">Blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Name><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="19821">UCB Pharma GmbH</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20452">UCB SA</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="7971" type="Drug"><TargetEntity id="171120" type="siDrug">Rotigotine</TargetEntity></SourceEntity><SourceEntity id="19821" type="Company"><TargetEntity id="4295869636" type="organizationId">Schwarz Pharma AG</TargetEntity></SourceEntity><SourceEntity id="20452" type="Company"><TargetEntity id="4295859381" type="organizationId">Ucb SA</TargetEntity></SourceEntity><SourceEntity id="255" type="ciIndication"><TargetEntity id="G20" type="ICD10"></TargetEntity><TargetEntity id="10061536" type="MEDDRA"></TargetEntity><TargetEntity id="D010300" type="MeSH"></TargetEntity><TargetEntity id="-342157116" type="omicsDisease"></TargetEntity><TargetEntity id="127" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1" type="Action"><TargetEntity id="219" type="Mechanism">Serotonin Agonists</TargetEntity></SourceEntity><SourceEntity id="1193" type="Action"><TargetEntity id="133" type="Mechanism">Dopamine D4 Agonists</TargetEntity></SourceEntity><SourceEntity id="147" type="Action"><TargetEntity id="130" type="Mechanism">Dopamine D1 Agonists</TargetEntity></SourceEntity><SourceEntity id="149" type="Action"><TargetEntity id="131" type="Mechanism">Dopamine D2 Agonists</TargetEntity></SourceEntity><SourceEntity id="28" type="Action"><TargetEntity id="48" type="Mechanism">Adrenoceptor Agonists</TargetEntity></SourceEntity><SourceEntity id="2959" type="Action"><TargetEntity id="134" type="Mechanism">Dopamine D5 Agonists</TargetEntity></SourceEntity><SourceEntity id="779" type="Action"><TargetEntity id="132" type="Mechanism">Dopamine D3 Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>12</NumberOfSites><CompaniesSponsor><Company id="19821">UCB Pharma GmbH</Company><Company id="20452">UCB SA</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1">5-HT receptor agonist</Action><Action id="1193">Dopamine D4 receptor agonist</Action><Action id="147">Dopamine D1 receptor agonist</Action><Action id="149">Dopamine D2 receptor agonist</Action><Action id="28">Adrenergic receptor agonist</Action><Action id="2959">Dopamine D5 receptor agonist</Action><Action id="779">Dopamine D3 receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2947">Antiparkinsonian</Class></Class><Technologies><Technology id="723">Drug coating</Technology><Technology id="600">Patch formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="558">Transdermal formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>14</PatientCountEnrollment><DateStart>2007-09-30T00:00:00Z</DateStart><DateEnd type="actual">2008-05-31T00:00:00Z</DateEnd><DateChangeLast>2018-02-22T07:16:42Z</DateChangeLast><DateAdded>2008-03-10T15:53:22Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>UCB</Affiliation><Name>UCB Call Center</Name><Phone>+1 877 822 9493</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subject has idiopathic Parkinson's disease (early- or advanced-stage), as defined by
             the cardinal sign bradykinesia, plus the presence of at least one of the following:&lt;ul&gt;&lt;li&gt;Resting tremor&lt;/li&gt;&lt;li&gt;Rigidity&lt;/li&gt;&lt;li&gt;Postural instability  and is without any other known or suspected cause of Parkinsonism&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subject is without any other known or
             suspected cause of Parkinsonism&lt;/li&gt;&lt;li&gt;Subject is scheduled for an operation requiring general anesthesia&lt;/li&gt;&lt;li&gt;Subject is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent&lt;/li&gt;&lt;li&gt;Subject is willing and able to comply with all trial requirements&lt;/li&gt;&lt;li&gt;Subject is male or female &gt;/= 18 years of age and&amp;lt;/= 80 years of age&lt;/li&gt;&lt;li&gt;Female subject is surgically sterile (uterus removed or bilateral tubal ligation), postmenopausal (at least two years without periods), or must practice adequate methods of contraception if of childbearing potential (defined as consistent use of 2 (combined) effective methods of contraception including 1 hormonal method (oral, implant, injections, intrauterine device) and 1 barrier method)&lt;/li&gt;&lt;li&gt;Subject is American Society of Anesthesiologists (ASA) stage II through III as determined by the investigator&lt;/li&gt;&lt;li&gt;Subject is currently taking medication for PD (eg, levodopa, dopamine agonists, anticholinergics, monoamine oxidase B (MAO-B) inhibitors, entacapone, N-methyl-d-aspartate [NMDA] antagonists)&lt;/li&gt;&lt;li&gt;Subject is scheduled for an operation requiring general anesthesia&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subject has previously been treated with&lt;ulink linkType="Drug" linkID="7971"&gt;rotigotine&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Subject has a history of any of the following:&lt;ul&gt;&lt;li&gt;Significant skin hypersensitivity to adhesives or other
             transdermals or recent unresolved contact dermatitis or has a known allergy or hypersensitivity to rotigotine or to other components of the patch&lt;/li&gt;&lt;li&gt;Unresolved contact dermatitis&lt;/li&gt;&lt;li&gt;Allergy or
             hypersensitivity to&lt;ulink linkType="Drug" linkID="7971"&gt;rotigotine&lt;/ulink&gt; or to other components of the patch&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subject is scheduled for a surgical procedure (SPP) that requires magnetic resonance
             imaging or cardioversion&lt;/li&gt;&lt;li&gt;Subject has a high probability to require extended postoperative ventilation (&amp;gt; 24
             h)&lt;/li&gt;&lt;li&gt;Subject has any medical condition that (in the opinion of the investigator) could
             jeopardize or compromise the subject's ability to participate in this trial&lt;/li&gt;&lt;li&gt;Subject has participated in another trial of an investigational drug within the last 28 days prior to Screening or is currently participating in another trial using an investigational drug&lt;/li&gt;&lt;li&gt;Female subject is pregnant or nursing, or is of childbearing potential and is not practicing adequate methods of contraception&lt;/li&gt;&lt;li&gt;Subject has atypical Parkinsonian syndromes (including drug-induced Parkinsonian syndromes), metabolic neurodegenerative disorders (eg, Wilson's disease), encephalitis, cerebrovascular disease or degenerative disease (eg, progressive supranuclear palsy)&lt;/li&gt;&lt;li&gt;Subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to Baseline (Visit 2): reserpine, alpha-methyldopa, metoclopramide, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, quetiapine), monoamine oxidase A (MAO-A) inhibitors, methylphenidate, budipine or amphetamine&lt;/li&gt;&lt;li&gt;Presence of clinically relevant hepatic or renal dysfunction (as defined as an ALT and/or AST greater than 5 times the upper limit of the reference range or Child/Pugh B and C, and/or creatinine clearance of&amp;lt;30ml/min)&lt;/li&gt;&lt;li&gt;Subject has any medical condition that, in the opinion of the investigator, could jeopardize or compromise the subject's ability to participate in this trial&lt;/li&gt;&lt;li&gt;Subject with psychosis requiring therapy in the medical history&lt;br/&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Feasibility assessment questionnaire by the anesthesiologist</Description></Measure><Measure><Description>Feasibility assessment questionnaire by the neurologist</Description></Measure><Measure><Description>Feasibility assessment questionnaire by the subject</Description></Measure><Measure><Description>Apparent dose</Description></Measure><Measure><Description>Observation and assessment of AEs</Description></Measure><Measure><Description>Laboratory parameters</Description></Measure><Measure><Description>Vital sign measurements (blood pressure, pulse)</Description></Measure><Measure><Description>Physical examination findings</Description></Measure><Measure><Description>12-lead ECG</Description></Measure><Measure><Description>Efficacy and safety of rotigotine used during surgery under general anesthesia assessed by Anesthesiologist: Questionnaire including four items Range of sum score: 4 to 24 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Patient did not show unexpected symptoms Item 2: Handling was simple Item 3: Handling wasn't time-consuming Item 4: patch is a considerable option</Description><Timeframe>After subject wakes up from general anesthesia</Timeframe></Measure><Measure><Description>Efficacy and safety of rotigotine used during surgery under general anesthesia assessed by neurologist: Questionnaire including four items Range of sum score: 4 to 24 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Switch to patch was easily feasible Item 2: Re-switch was easily feasible Item 3: Patient did not show unexpected symptoms Item 4: patch is a feasible option</Description><Timeframe>2 weeks after surgery</Timeframe></Measure><Measure><Description>Efficacy and safety of rotigotine used during surgery under general anesthesia assessed by patient: Questionnaire including 3 items Range of sum score: 3 to 18 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Therapy with patch was easily feasible Item 2: symptoms of Parkinson's Disease were well controlled Item 3: I felt safe with the Parkinson patch</Description><Timeframe>2 weeks after surgery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Plasma concentration of rotigotine after use</Description><Timeframe>24 h</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  purpose of this study was to evaluate  safety  and efficacy on the use of  &lt;ulink linkType="Drug" linkID="7971"&gt;rotigotine&lt;/ulink&gt;  in patients suffering from Parkinson's disease (PD) during and after surgery requiring general anesthesia.&lt;/para&gt;&lt;para&gt;Main objective of the trial: this pilot study is designed to provide exploratory information on the feasibility of perioperative rotigotine treatment in a limited number of subjects with PD. In addition, efficacy and safety information on the use of rotigotine as part of the perioperative management of Parkinson's Disease will be collected.&lt;/para&gt;&lt;para&gt;Secondary objectives of the trial: other variables in this trial are plasma concentration of rotigotine and apparent dose. These variables will be analyzed using descriptive methods only. The variables including summary statistics will be displayed (n, arithmetic mean, standard deviation, minimum, median, and maximum).&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive  &lt;ulink linkType="Drug" linkID="7971"&gt;rotigotine&lt;/ulink&gt; 2, 4 ,6, 8 mg/day patch; single patches and a combination of two of these patches for a dosage of up to 16 mg/day; one regimen on day of surgery, but exceptionally extended for up to 2 weeks if the patient requires unexpected ventilation after surgery.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Address1>Dresden</Address1><Contacts></Contacts></Site><Site><Address1>Bonn</Address1><Contacts></Contacts></Site><Site><Address1>Hanau</Address1><Contacts></Contacts></Site><Site><Address1>Kiel</Address1><Contacts></Contacts></Site><Site><Address1>Ulm</Address1><Contacts></Contacts></Site><Site><Address1>Bochum</Address1><Contacts></Contacts></Site><Site><Address1>Augsburg</Address1><Contacts></Contacts></Site><Site><Address1>Ingolstadt</Address1><Contacts></Contacts></Site><Site><Address1>Bremerhaven</Address1><Contacts></Contacts></Site><Site><Address1>Dortmund</Address1><Contacts></Contacts></Site><Site><Address1>Schwerin</Address1><Contacts></Contacts></Site><Site><Address1>Stralsund</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Parkinsons disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7366">Subjects with Early Stage Parkinson's Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7367">Subjects with Advanced/Late Stage Parkinson's Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7368">Subjects with Motor Symptoms of Parkinson's Disease</PatientSegment><SubSegments><SubSegment id="7369">Subjects with bradykinesia</SubSegment><SubSegment id="7370">Subjects with tremors</SubSegment><SubSegment id="7371">Subjects with rigidity</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00594464</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Parkinsons disease" id="10217"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Parkinsons disease" id="10229"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Parkinsons disease" id="10230">Assessment of efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Parkinsons disease" id="10214"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Parkinsons disease" id="10217"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Parkinsons disease" id="10219">Assessment of serious adverse events</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Parkinsons disease" id="10218"><Endpoint>Assessment of adverse events</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Parkinsons disease" id="6052"><Criterion>Subjects with Early Stage Parkinson's Disease</Criterion></Inclusion><Inclusion disease="Parkinsons disease" id="6056"><Criterion>Subjects with Advanced/Late Stage Parkinson's Disease</Criterion></Inclusion><Inclusion disease="Parkinsons disease" id="6068"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="6069">Subjects with bradykinesia</SubCriterion><SubCriterion disease="Parkinsons disease" id="6070">Subjects with tremors</SubCriterion><SubCriterion disease="Parkinsons disease" id="6071">Subjects with rigidity</SubCriterion><SubCriterion disease="Parkinsons disease" id="6072">Subjects with postural instability</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Parkinsons disease" id="6124"><Criterion>Subjects scheduled to receive disease specific therapy</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="6132">Subjects scheduled for brain surgery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Parkinsons disease" id="6168"><Criterion>Subjects with Idiopathic Parkinson's Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Parkinsons disease" id="7726"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="7749"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="7756">Hypersensitivity/Contraindications to adhesives or other transdermal products </SubCriterion></SubCriteria></Exclusion><Exclusion disease="Parkinsons disease" id="7769"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="7776">Subjects with history of major surgical procedure</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2008-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2007-12-21T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-03-10T15:53:22Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="89734"><TitleDisplay>Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab (5/160 mg) in Healthy Male Subjects</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">HL-LDV-101</Identifier><Identifier type="NCT">NCT01652339</Identifier><Identifier type="Other">KCT0000489</Identifier><Identifier type="Other">12-105</Identifier><Identifier type="Other">HL-LDV</Identifier></Identifiers><Indications><Indication id="178">Hypertension</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>S-amlodipine + valsartan (hypertension), Hanlim</Name><Drug id="77628">S-amlodipine + valsartan (hypertension), Hanlim</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>valsartan + amlodipine besylate (oral), Novartis</Name><Drug id="54288">valsartan + amlodipine besylate (oral), Novartis</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="77628">S-amlodipine + valsartan (hypertension), Hanlim</Drug><IndicationsPioneer><Indication id="178">Hypertension</Indication></IndicationsPioneer><Companies><Company><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="77628" type="Drug"><TargetEntity id="784405" type="siDrug">S(-)-amlodipine nicotinate/valsartan</TargetEntity></SourceEntity><SourceEntity id="1004564" type="Company"><TargetEntity id="5000831397" type="organizationId">Hanlim Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"></TargetEntity><TargetEntity id="D006973" type="MeSH"></TargetEntity><TargetEntity id="-369992864" type="omicsDisease"></TargetEntity><TargetEntity id="240" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="64" type="Action"><TargetEntity id="3578" type="Mechanism">Anti-Angiotensin II</TargetEntity></SourceEntity><SourceEntity id="93" type="Action"><TargetEntity id="361" type="Mechanism">Calcium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="64">Angiotensin II receptor antagonist</Action><Action id="93">Calcium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2657">Antihypertensive</Class></Class><Technologies><Technology id="175">Drug combination</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2012-07-31T00:00:00Z</DateStart><DateEnd type="actual">2012-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-06-22T06:20:08Z</DateChangeLast><DateAdded>2012-08-01T10:17:21Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Inje University Busan Paik Hospital</Affiliation><Name>Myeong Kim</Name></Contact><Contact type="Scientific contact"><Affiliation>Inje University</Affiliation><Name>Jae Gook Shin, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy volunteers aged 20 to 45 years&lt;/li&gt;&lt;li&gt;Body weight &gt;/= 50 kg and BMI&amp;lt;/= 29 kg/m2&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subject with serious active cardiovascular, respiratory, hepatologic, renal,
             hematological, gastrointestinal, immunological, dermal, neurological, or psychological
             disease or history of such disease
&lt;/li&gt;&lt;li&gt;Subject with symptoms of acute disease within 28 days prior to study medication dosing&lt;/li&gt;&lt;li&gt;Subject with known for history which affect on the absorption, distribution,
             metabolism or excretion of drug&lt;/li&gt;&lt;li&gt;Subject with clinically significant active chronic disease&lt;/li&gt;&lt;li&gt;Subject with any of the following conditions in laboratory test:&lt;ul&gt;&lt;li&gt;AST(sGOT) or
             ALT(sGPT)&amp;gt; upper normal limit x 1.5 &lt;/li&gt;&lt;li&gt;Total bilirubin&amp;gt; upper normal limit x 1.5
             &lt;/li&gt;&lt;li&gt;Renal failure with creatinine clearance&amp;lt; 50 ml/min
&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Clinically significant hypotension when screening period (SBP&amp;lt; 100 mmHg, DBP &amp;lt;
             60 mmHg)
&lt;/li&gt;&lt;li&gt;Positive test results for HBs Ab, HCV Ab, Syphilis regain test&lt;/li&gt;&lt;li&gt;Use of any prescription medication within 14 days prior to study medication dosing&lt;/li&gt;&lt;li&gt;Use of any medication such as over-the-counter medication including oriental
             medication within 7 days prior to study medication dosing&lt;/li&gt;&lt;li&gt;Subject with clinically significant allergic disease (except for mild allergic
             rhinitis and mild allergic dermatitis that are not needed to administer drug)&lt;/li&gt;&lt;li&gt;Subject with known for hypersensitivity reaction to S-amlodipine, amlodipine and
             valsartan and dihydropyridine derivatives&lt;/li&gt;&lt;li&gt;Subject who is not able to taking the institutional standard meal&lt;/li&gt;&lt;li&gt;Subjects with whole blood donation within 60 days, component blood donation within
             20 days&lt;/li&gt;&lt;li&gt;Subjects receiving blood transfusion within 30 days prior to study medication dosing&lt;/li&gt;&lt;li&gt;Participation in any clinical investigation within 60 days prior to study medication
             dosing&lt;/li&gt;&lt;li&gt;Continued excessive use of caffeine (caffeine&amp;gt; 5 cups/day),
             alcohol(alcohol &amp;gt; 30 g/day) and severe heavy smoker (cigarette &amp;gt; 10 cigarettes per day)&lt;/li&gt;&lt;li&gt;Subject who has been taken meal which affect on the absorption, distribution,
             metabolism, excretion of drug, especially grapefruit juice&lt;/li&gt;&lt;li&gt;Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within
             28days prior to study medication dosing&lt;/li&gt;&lt;li&gt;Continued serum potassium concentration abnormal status (on baseline visit,&amp;lt;
             3.5 or &amp;gt; 5.5 mEq/l)&lt;/li&gt;&lt;li&gt;Subjects with decision of nonparticipation through investigator's review due to
             laboratory test results or other excuse such as non-responding to request or
             instruction by investigator&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Cmax (maximum concentration)</Description><Timeframe>Valsartan evaluation : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 h (14 points) - S-Amlodipine : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168 h (17 points)</Timeframe></Measure><Measure><Description>AUC (area under curve)</Description><Timeframe>Valsartan evaluation : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 h (14 points) - S-Amlodipine : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168 h (17 points)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of participants with adverse events</Description><Timeframe>Participants will be followed for the duration of hospital stay, an expected average of 3 days and follow-up period for maximum 6 days from the discharge</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to evaluate the pharmacokinetic and safety characteristics of &lt;ulink linkType="Drug" linkID="77628"&gt;Lodivixx&lt;/ulink&gt; tablet (5/160 mg) in healthy male
      subjects.
&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects will receive either &lt;ulink linkType="Drug" linkID="77628"&gt;Lodivixx&lt;/ulink&gt; (S-amlodipine nicotinate/valsartan; 5/160 mg) or &lt;ulink linkType="Drug" linkID="54288"&gt;Exforge&lt;/ulink&gt; (amlodipine besylate/valsartan; 10/160 mg). &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Inje University Busan Paik Hospital</Name><Address1>Busan</Address1><Address3>614-735</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01652339</Identifier></Identifiers></Registry><Registry><Name id="1010">Korea Clinical Research Information Service (CRiS)</Name><Identifiers><Identifier>KCT0000489</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2012-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-07-19T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-08-01T10:17:21Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="93177"><TitleDisplay>Vitamin A and Response to Endotoxin</TitleDisplay><TitleOfficial>The Effect of Vitamin A on the Response to Endotoxin</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">9583-2625-VITA-LPS</Identifier><Identifier type="NCT">NCT00168649</Identifier><Identifier type="Secondary Organisational">9583-2625</Identifier></Identifiers><Indications></Indications><BiomarkerNames><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="2170" role="Therapeutic effect marker" type="Biochemical">Vitamin A</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Vitamin A</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1038964" type="Company"><TargetEntity id="5035559567" type="organizationId">Bandim Health Project</TargetEntity></SourceEntity><SourceEntity id="1073588" type="Company"><TargetEntity id="5037853101" type="organizationId">Institut for Human Ernaering</TargetEntity></SourceEntity><SourceEntity id="22324" type="Company"><TargetEntity id="5001205357" type="organizationId">Uppsala University</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1038964">Bandim Health Project</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1073588">Institute for Human Nutrition</Company><Company id="22324">Uppsala University</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2005-06-30T00:00:00Z</DateStart><DateChangeLast>2013-11-18T09:09:01Z</DateChangeLast><DateAdded>2012-10-04T12:28:11Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Rigshospitalet, Denmark</Affiliation><Name>Bente K Pedersen, MD, DMSc</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy, male, between 18 and 35 years of age&lt;/li&gt;&lt;li&gt;Non-smoker&lt;/li&gt;&lt;li&gt;No medicine&lt;/li&gt;&lt;li&gt;No infections in preceding 14 days&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Endotoxin levels</Description></Measure><Measure><Description>TNF-alfa levels</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Measures of oxidative injury and stress</Description></Measure><Measure><Description>Retinol and beta-caroten levels</Description></Measure><Measure><Description>Haematological values</Description></Measure><Measure><Description>Clinical markers</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study is to  examine the effect of vitamin
      A as pre-treatment on the response to endotoxin in humans.The investigators  will also examine the
      long-term effects of vitamin A on the response to endotoxin and it is also  hypothesise that vitamin A
      decreases endotoxin levels and TNF-alfa responses.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The investigators  intend to examine the effect of vitamin
      A as pre-treatment on the response to endotoxin in humans. This  study is    done in an established model using infusion with endotoxin to male
      human volunteers. It is hypothesise that vitamin A decreases endotoxin levels and TNF-alfa
      responses and it can also  reduces oxidative stress and injury.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Denmark"><Sites><Site><Name>Rigshospitalet, Department M7641</Name><Address1>Copenhagen</Address1><Address3>2100</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00168649</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-10-04T12:28:11Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="99980"><TitleDisplay>Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study</TitleDisplay><TitleOfficial>Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">SU-12012009-4443</Identifier><Identifier type="NCT">NCT01171794</Identifier><Identifier type="Trial Acronym">PAINS</Identifier></Identifiers><Indications><Indication id="3810">Altitude anoxia</Indication></Indications><BiomarkerNames><BiomarkerName id="11700" role="Therapeutic effect marker" type="Structural (imaging)">Optic nerve</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ibuprofen (motrin)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20679" type="Company"><TargetEntity id="4297085592" type="organizationId">Leland Stanford Junior University</TargetEntity></SourceEntity><SourceEntity id="25451" type="Company"><TargetEntity id="4296621839" type="organizationId">University of California San Diego</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20679">Stanford University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="25451">University of California San Diego</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>89</PatientCountEnrollment><DateStart>2010-07-31T00:00:00Z</DateStart><DateEnd type="actual">2010-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-12-14T02:06:20Z</DateChangeLast><DateAdded>2012-11-30T10:17:59Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Stanford University</Affiliation><Name>Grant S Lipman</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy Male or female volunteer&lt;/li&gt;&lt;li&gt;Age 18 to 65
years&lt;/li&gt;&lt;li&gt;Sea-level dwelling&lt;/li&gt;&lt;li&gt;Non pregnant&lt;/li&gt;&lt;li&gt;Have not been to high altitude in the past week&lt;/li&gt;&lt;li&gt;Can arrange for their own transportation to WMRS by friday evening the weekend of
             their study enrollment and are available the duration of the weekend of their study
             enrollment
&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;lt; 18 or &amp;gt; 65
years&lt;/li&gt;&lt;li&gt;Live at altitude&amp;gt; Sea Level +/- 1000'&lt;/li&gt;&lt;li&gt;Pregnant&lt;/li&gt;&lt;li&gt;Taking NSAIDs, Acetazolamide, or Corticosteroids&lt;/li&gt;&lt;li&gt;Allergic to NSAIDs or Aspirin, or have had adverse reaction to them in the past&lt;/li&gt;&lt;li&gt;Traveled or planning to travel to high altitude in the week prior to their
             enrollment&lt;/li&gt;&lt;li&gt;Medical history of Brain Tumor, increased intercranial pressure, pseudotumor cerebri,
             ventricular shunts, loss of an eye, Asthma, HACE or HAPE&lt;/li&gt;&lt;li&gt;Cannot arrange for their own transportation to WMRS or are unavailable for the
             duration of the weekend of their study enrollment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Acute mountain sickness : Lake Louise Criteria scores range from 0 to 15 with higher scores representing more severe symptoms; scores of &gt;/= 3 with presence of a headache considered a positive diagnosis of acute mountain sickness</Description><Timeframe>2 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Acute mountain sickness severity : Lake Louise Criteria scores range from 0 to 15 with higher scores representing more severe symptoms</Description><Timeframe>2 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a research study on Altitude Illness.  In
      this project the investigators  would hope to learn more about Altitude Illness, including factors that might affect
      and prevent the development and progression of this condition.The investigators would hope to learn if the
      commonly used non-steroidal anti-inflammatory medication, ibuprofen  could prevent altitude
      illness.  Possible participants in this study would be  healthy adults who would
      like to participate, learn about altitude illness, and desire to hike Barcroft Peak.
      &lt;ulink linkType="Company" linkID="20679"&gt;Stanford University&lt;/ulink&gt; researchers would  hope to enroll about 100 participants.&lt;/para&gt;&lt;para&gt;Primary hypothesis: Ibuprofen 600 mg TID would  be superior to placebo in decreasing both the incidence and severity of AMS in high altitude travel.&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would be  designed to bring together elements of prior studies and go one step further
      for definitive data on several points. The trial would  employ two pharmaceutical intervention
      arms, which would compare placebo (the standard of care - information on prevention of
      altitude sickness) with the widely used NSAID ibuprofen. The investigators  would also determine optic nerve
sheath diameter (ONSD) measurements via ultrasound in both the control and interventional
      arms. The investigators would  accomplish these objectives with a prospective, double-blinded view of a large
      population of hikers who would be  ascending at their own rate in a true hiking environment. Participants would receive ibuprofen (motrin) 600 mg tid one dosing on the subsequent day ( four doses total) or visually identical placebo.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Stanford University School of Medicine</Name><Address1>Stanford</Address1><Address2>California</Address2><Address3>94305</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01171794</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2010-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2010-07-27T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-30T10:17:59Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>